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The United States (U.S.) is in the midst of an opioid overdose epidemic. In the 
U.S., overdose deaths related to opioid exposure are the leading cause of accidental 
death, yet life-saving treatments, such as methadone or buprenorphine (opioid agonist 
therapy [OAT]), are underused. OAT underuse is due, in part, to complex regulatory and 
health services delivery environments. Public health officials and policymakers have 
focused on expanding OAT access in the community (e.g. office-based buprenorphine 
treatment, and opioid treatment programs); however, an often-overlooked component 
of the treatment pathway is the acute care delivery setting, in particular hospitals. 
Opioid use disorder (OUD)-related hospitalizations are increasing, and incurring 
significant costs; care delivered in this setting is likely sub-optimal. This study examined 
hospital-based services for OUD using a conceptual framework based on an 
interdisciplinary review of policy, organizational behavior, systems science, economics, 
and health services delivery scholarship. The study’s primary research question was: 
How do supply-side attributes influence hospital OAT delivery, health outcomes, and 
health services utilization for persons hospitalized with OUD? Supply-side attributes 
refer to the contextual elements inside and outside of a hospital that may be associated 
with hospital OAT delivery performance, such as social structures (e.g., hospital 
standards of care, societal values) and resources and technologies (e.g., hospital 




A mixed methods study described, explored, and identified how patients with 
OUD are cared for in the hospital and the barriers and facilitators to delivering OAT 
during hospitalization. The sequential mixed methods approach (i.e., qualitative 
followed by quantitative analyses) included analysis of 17 key informant interviews with 
addiction medicine physicians from 16 non-federal U.S. hospitals, 25 hospital guidance 
documents from 10 non-federal U.S. hospitals, and administrative data from 12,407 
OUD-related hospital admissions from the Veterans Health Administration (VHA) health 
system.  
The findings from the study’s three aims and 16 research sub-questions were 
integrated to reach seven conclusions: 1) OAT is underused in the hospital; 2) OAT 
delivery varies within and across hospitals; 3) OAT is used ineffectively; 4) non-OAT 
modalities are inappropriately used during and after hospitalization; 5) supply-side 
attributes inside and outside the hospital facilitate and impede hospital OAT delivery; 6) 
demand-side attributes facilitate and impede hospital OAT delivery; and 7) the hospital 
is an important service delivery mechanism in the OUD care continuum.  
The study’s findings could be extrapolated to improve policy and practice by 
implementing education and health service delivery interventions through regulatory 
and allocative policy mechanisms focused on physicians, medical trainees, and hospital 
and health system administrators. Understanding how OAT delivery may be improved 
within the acute care delivery system is an important element to support efforts to curb 
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Chapter 1: Introduction 
 This dissertation explores the influence of supply-side attributes (e.g., social, 
financial, and policy-related) contributing to opioid agonist therapy (OAT) delivery for 
hospitalized patients with opioid use disorder (OUD). This chapter provides a broad 
overview of the foundational issues related to OAT delivery that guided the rationale 
and design of this dissertation study, presented in six sections: 
1. Section 1.1 introduces the contemporary issues and action related to the 
opioid overdose epidemic. 
2. Section 1.2 provides background for the dissertation including defining and 
describing opioids, OUD, and OUD treatments. 
3. Section 1.3 outlines the study’s problem statement. 
4. Section 1.4 states the study’s research question and three aims. 
5. Section 1.5 describes the study’s purpose and significance. 
6. Section 1.6 articulates this chapter’s conclusion. 
Following Chapter 1, Chapter 2 provides an interdisciplinary literature review 
and describes the conceptual framework proposed for the study. Study methods are 
detailed in Chapter 3 and results are presented in Chapter 4 (qualitative) and Chapter 5 
(quantitative). Chapter 6 discusses and integrates study findings to extract seven 
primary results, details the limitations and assumptions of the research, updates the 
study’s conceptual framework, provides strategies for policy change, and concludes with 




Section 1.1. Contemporary Issues and Action 
The undertreatment and subsequent preventable suffering and deaths of 
persons with OUD are pressing public health issues. An estimated 33 million people 
globally use opioids (United Nations [UN] Office on Drugs and Crime, 2016), 2.3 million 
people in the United States (U.S.) live with an OUD (Center for Behavioral Health 
Statistics and Quality, 2016), and in 2017, opioids were involved in nearly 48,000 
overdose deaths (Centers for Disease Control and Prevention [CDC], 2018). In addition 
to mortality, OUD incurs total annual costs of $78.5 billion related to loss of 
productivity, crime, and health care (Florence, Zhou, Luo, & Xu, 2016). The largest 
contributor to annual costs is health care service delivery (33%), which starkly contrasts 
with the costs of providing OUD treatment (4%) (Florence et al., 2016).  
OUD related hospitalizations likely drive health care costs for persons with OUD. 
Between 2005 and 2014 the national rate of OUD-related hospitalizations increased 
64% (Weiss et al., 2016). As compared with hospitalizations for other conditions, 
persons with OUD were admitted for almost a day longer (4.5 days vs. 5.2 days) and had 
nearly triple the costs ($10,400 vs. $28,543) (Ronan & Herzig, 2016; Weiss & Elixhauser, 
2014). Moreover, for persons with OUD with a concurrent drug-use related infection 
(e.g., endocarditis, osteomyelitis), the length of stay more than tripled (14.6 days) and 
the costs rose to $107,217 (Ronan & Herzig, 2016). Hospitalization costs for persons 
with OUD are estimated at $15 billion annually, the majority of which are associated 




The loss of life and the financial costs attributed to OUD may be mitigated with 
treatment, specifically using OAT: methadone and buprenorphine. The Food & Drug 
Administration (FDA) approved methadone for OUD treatment in 1972 (Institute of 
Medicine Committee on Federal Regulation of Methadone, 1995) and buprenorphine in 
2002 (FDA, 2002). Despite decades of FDA approval and years of robust research 
(Mattick, Breen, Kimber, & Davoli, 2009, 2014; Nielsen et al., 2016), the number of 
treatment facilities offering OAT is lower than the growing need. Only 34% of substance 
use disorder (SUD) treatment facilities in the U.S. offer OAT or antagonist therapy (i.e., 
naltrexone) (Knudsen, Abraham, & Roman, 2011) and only 10% of patients in these 
clinical settings received OUD pharmacotherapy (Knudsen & Roman, 2012). 
Explanations for OAT underuse are well described in outpatient and addiction treatment 
facility settings, and are attributed to financial, regulatory, geographic, and health care 
professional attitudinal factors (Sharma, Lamba, Cauderella, Guimond, & Bayoumi, 
2017). Systemic and institutionalized structural and sociologic elements (e.g., racism, 
criminal justice status, insurance benefits) further exacerbate OAT underuse (Cummings, 
Wen, & Ko, 2016; Grogan et al., 2016; Merrall et al., 2010; Saloner, Bandara, McGinty, & 
Barry, 2016; Saloner & Cook, 2013).  
The nationwide opioid overdose crisis has sparked the attention, action, and 
collaboration of policymakers in federal and state government offices, legislative bodies, 
and agencies. In the past decade, legislation has shaped OUD treatment practices, such 




the 2018 SUPPORT for Patients and Communities Act. During President Barak Obama’s 
administration, the Office of the Surgeon General launched the Turn the Tide RX 
Campaign (Surgeon General of the United States, n.d.) and published the first Surgeon 
General’s Report on SUDs (U.S. Department of Health & Human Services, 2016). 
President Donald Trump issued an executive order establishing the President’s 
Commission on Combating Drug Addiction and the Opioid Crisis recommending actions 
to address the opioid crisis (White House, 2017). The policy efforts and awareness 
campaigns contributed to the Presidential declaration of the opioid crisis as a federal 
public health emergency on October 26, 2017 (Substance Abuse and Mental Health 
Services Administration [SAMHSA], 2017a). 
Federal agencies (e.g., Centers for Medicare & Medicaid Services (CMS) and 
SAMHSA) and state Governor’s offices have supported initiatives to address the opioid 
overdose epidemic. In 2015 and 2016, CMS provided opportunities for state Medicaid 
agencies to redesign their SUD delivery systems to expand access to treatment using 
§1115 waivers, and updated the Medicaid managed care rules to allow for treatment in 
Institutions for Mental Diseases (Priest, Leof, McCarty, & King, 2017). SAMHSA’s Center 
for Substance Abuse Treatment and Center for Substance Abuse Prevention provided 
additional treatment funding opportunities for single state agencies through the State 
Targeted Response to the Opioid Crisis Grants program (SAMHSA, 2017b). An 
assessment of program funding allocation observed that 71% of grantees used the 




included declarations of emergency by the Governor’s Offices of Alaska, Arizona, 
Florida, Maryland, Massachusetts, and Virginia, which allowed for increased access to 
state funds and resources to expand addiction services and to develop prescribing 
guidelines (Baker-White, 2017).  
Although policymakers are acting, many public health officials and clinical 
leaders are calling urgently for a more robust national public health strategy to decrease 
mortality and morbidity associated with the opioid overdose epidemic (Saloner et al., 
2018). In 2018, experts identified seven key priorities for U.S. policymakers: 1) improved 
data collection; 2) safer opioid prescribing; 3) stigma reduction; 4) harm reduction; 5) 
criminal justice reform; 6) regulatory changes; and 7) treatment expansion (Saloner et 
al., 2018). Treatment expansion, in the hospital setting, is the focus of this dissertation. 
Section 1.2. Background 
The U.S. has a long and complex history with opioids, OUD, and OUD treatment. 
Health professionals and society more broadly may simultaneously view opioids as legal 
medicine for patients and as an illegal drug used by criminals. This dissertation considers 
the existence of these different perspectives, the influence of these perspectives on 
system design, and the institutionalization of these perspectives through policy. 
1.2.1. Opioids. Throughout history, healers and medical professionals used 
opioids to decrease pain (Benyamin et al., 2008). The term opioid is attributed to 
Professor George Acheson, who was the first to use this nomenclature to categorize 




Opioids are produced endogenously, within the body, and may be ingested exogenously 
from sources external to the body (Feng et al., 2012). Exogenous opioids may be 
environmentally derived (e.g., opium from the plant Papaver Somniferum) (Hurley et al., 
2007) or synthesized through pharmaceutical manufacturing (e.g., hydrocodone). Upon 
ingestion of opioids—oral, intravenous, inhalation, nasal insufflation—the compound 
binds to mu, kappa, and delta opioid receptors located predominantly in the limbic 
areas of the brain (Hurley et al., 2007). Opioid receptors are involved in a variety of 
physiologic processes such as, but not limited to: pain modulation; emotional response; 
feeding; the regulation of membrane ionic homeostasis; cell proliferation; immune 
function; respiratory and cardiovascular control; and pathophysiological processes (e.g., 
epileptic seizures, obesity, addiction) (Feng et al., 2012). 
Individuals may obtain opioids through legal and illegal markets. The allowable 
possession and manufacturing of opioids is statutorily defined by the Controlled 
Substances Act of 1970 and monitored by the Drug Enforcement Administration (DEA). 
In 1970, Congress established a scheduling system to categorize legal and illegal opioids. 
Illegal opioids, Schedule I substances, such as diacetylmorphine (also known as heroin), 
are deemed by the U.S. federal government to not have a currently accepted medical 
use (DEA, n.d.). The government categorizes legal FDA-approved opioids (e.g., 
morphine) as Schedule II, III, IV, or V (DEA, n.d.). These opioids have medically accepted 
uses and are manufactured through legal manufacturing processes, but their use is 




The U.S. is the world’s largest consumer of opioids (University of Wisconsin, 
2017). Between 1999 and 2012 the number of U.S. opioid prescriptions tripled, and in 
2012 opioid prescription expenditures across all payers, including self-insured, totaled 
$7.4 billion dollars (Zhou, Florence, & Dowell, 2016). Opioid overconsumption is not 
limited to the last 25 years. The current opioid overdose epidemic follows a succession 
of past epidemics, such as the morphine crisis post-civil war in the 1870s (Courtwright, 
2015), the youth heroin epidemic of the 1950s (Campbell, Olsen, & Walden, 2008), and 
the Vietnam war veteran heroin emergency of the 1970s (Schmidt, 1971). 
It is also important to recognize the changes in the contemporary opioid supply, 
which has been coined the “triple epidemic” and features a “rising waves of deaths due 
to separate types of opioids each building on top of the prior wave” (Ciccarone, 2017, p. 
107). The first wave of overdose deaths in the 1990s was predominantly from 
prescription opioids (Ciccarone, 2017). The second wave, starting in 2010, was due to 
heroin (Warner, Trinidad, Bastian, Miniño, & Hedegaard, 2016), and the third and 
current wave is attributed to the growing supply of synthetic opioids, including illicitly 
manufactured fentanyl and fentanyl analogues (R. G. Frank & Pollack, 2017; Gladden, 
Martinez, & Seth, 2016; Warner et al., 2016). The shift in the illegal drug supply from 
heroin to fentanyl has already happened in parts of Canada. In Vancouver, British 
Columbia, recent data reflects that 90% of presumed heroin tested positive for fentanyl 
(Tupper, McCrae, Garber, Lysyshyn, & Wood, 2018). The shift in the Vancouver supply is 




1.2.2. Opioid use disorder. Health experts are concerned with the excessive use 
of opioids because of the association with increased morbidity and mortality, in 
particular for men and early onset users (Cottler et al., 2016). When taken in excess, 
opioids can cause central nervous system depression leading to respiratory failure and 
death (Bollinger et al., 2012), shortened life expectancy (Hayes et al., 2011), and 
increase the risk of addiction (Compton & Volkow, 2006). In 2016, the CDC published 
recommendations on the safety of consuming opioids for the treatment of chronic non-
cancer pain (Dowell, Haegerich, & Chou, 2016). The CDC prescription opioid guidelines 
specified that prescribers should avoid prescription opioids for chronic non-cancer pain 
and stated that opioid consumption is not safe at any dose (Dowell et al., 2016). In 2017, 
the National Academy of Sciences published Pain Management and the Opioid 
Epidemic: Balancing Societal and Individual Benefits and Risks Of Prescription Opioid Use 
and recommended that the FDA and other organizations take action to reduce OUD-
related harms (Committee on Pain Management and Regulatory Strategies to Address 
Prescription Opioid Abuse, 2017). 
For the purpose of this dissertation OUD is conceptualized as a brain disease that 
is treated through the medical model. The diagnosis of opioid addiction follows the 
criteria from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
(American Psychiatric Association [APA], 2013). The diagnosis criteria characterize OUD 
as a problematic pattern of opioid use that leads to clinically significant impairment or 




states that a patient must have at least two of 11 symptoms, and that the severity of 
illness is to be categorized as mild (2 to 3 symptoms), moderate (4 to 5 symptoms), or 
severe (6 or more symptoms). The symptom criteria are listed in Appendix A (APA, 
2013). The DSM also requires clinicians to distinguish among early remission, sustained 
remission, the use of pharmacotherapy, or if the patient is receiving care in a controlled 
environment (APA, 2013). Other definitions of addiction do exist. The American Society 
of Addiction Medicine [ASAM] (2011) defines addiction as: 
A primary, chronic disease of brain reward, motivation, memory and related 
circuitry. Dysfunction in these circuits leads to characteristic biological, 
psychological, social and spiritual manifestations. This is reflected in an individual 
pathologically pursuing reward and/or relief by substance use and other 
behaviors. Addiction is characterized by inability to consistently abstain, 
impairment in behavioral control, craving, diminished recognition of significant 
problems with one’s behaviors and interpersonal relationships, and a 
dysfunctional emotional response. Like other chronic diseases, addiction often 
involves cycles of relapse and remission. Without treatment or engagement in 
recovery activities, addiction is progressive and can result in disability or 
premature death. 
 
1.2.3. Treatment. The gold standard treatment for OUD is OAT because it is well 
studied, safe, and effective (Mattick, Breen, Kimber, & Davoli, 2003; Mattick et al., 
2014). There are three FDA-approved OATs, with multiple formulations: 1) 
buprenorphine (sublingual tablet, implant, extended-release, injection, and implant); 2) 
buprenorphine/naloxone (sublingual tablet and buccal film); and 3) methadone (liquid, 
tablet). The World Health Organization (WHO) lists OAT on their essential medication 
list (WHO, 2017) and recommends that all national health systems provide widespread 




constrained because of special federal regulations that govern where, when, and who 
may administer or prescribe OAT. 
1.2.3a. Opioid treatment programs. Methadone administration for OUD, a 
Schedule II controlled substance, is governed by the Certification of Opioid Treatment 
Programs (OTPs), 42 Code of Federal Regulations (CFR) 8 (SAMHSA, 2015). Under these 
rules, methadone must be administered daily under direct observation in a federally-
licensed OTP with two exceptions: 1) during hospitalization; and 2) approved take 
home-doses (Priest et al., 2019). OTPs may also administer buprenorphine, offer other 
services such as recovery fellowship (e.g., 12-Step), and require patient participation in 
non-pharmacotherapy services such as counseling (SAMHSA, 2015). 
1.2.3b. Community treatment programs. Currently, the only FDA-approved OAT 
that may be legally prescribed by federally-certified prescribers is buprenorphine (with 
and without naloxone), a Schedule III controlled substance (SAMHSA, 2016). To become 
a certified prescriber, a health professional must meet the requirements of the Drug 
Addiction Treatment Act of 2000, including: licensed to practice under state law, 
registered with the DEA, and completed prescriber training (SAMHSA, 2016). A variety 
of primary care models for buprenorphine delivery have emerged (e.g., office-based 
opioid treatment programs, the Buprenorphine HIV Evaluation and Support 
Collaborative Model) (Korthuis et al., 2017).  
1.2.3c. Integrated health systems. There is much to learn about the delivery of 




of the U.S. addiction treatment system. The largest integrated health system in the U.S. 
is the Veterans Health Administration (VHA), which has a long-standing history of 
providing services for OUD. The VHA is facing a growing OUD patient population (Finlay 
et al., 2016; Oliva, Trafton, Harris, & Gordon, 2013) that is twice as likely to die from 
accidental overdose than non-veterans (Bohnert, Ilgen, Galea, McCarthy, & Blow, 2011). 
The VHA OUD treatment services system began nearly 60 years ago, with the 
creation of the Alcohol and Drug Dependence Service, to meet the needs of veterans 
returning from the Vietnam War (Wyse et al., 2018). Since that time, the VHA has 
implemented policy, educational, and quality improvement initiatives to increase OAT 
capacity across the system (Wyse et al., 2018). The VHA added OAT, specifically 
buprenorphine, to the VHA formulary in 2006, and in 2008, mandated the use of OAT as 
a “minimum clinical requirement” for OUD treatment (Wyse et al., 2018). Further, in 
2015, the VHA published system-wide clinical guidance documents on OAT delivery 
(Wyse et al., 2018). Despite these system-wide initiatives, recent utilization data reports 
that only 38% of OUD patients receive pharmacotherapy and that there is significant 
variation in facility pharmacotherapy performance (3% to 74% delivery) (Finlay et al., 
2018). 
 Data from outside the VHA suggests similar or worse OAT delivery performance. 
In 2016, a national survey of U.S. SUD facilities observed that only 36% of facilities 
offered all three types of OUD pharmacotherapy (OAT or opioid antagonist). 




10% of patients received some form of OUD pharmacotherapy (Knudsen & Roman, 
2012). These studies suggest there is still a need to improve access to and the delivery 
of OAT in the community, both inside and outside the VHA. Although warranted and 
important, VHA research and system-wide initiatives to date have focused on outpatient 
OAT delivery, and research on hospital OAT delivery has not yet occurred. 
 1.2.3d. Hospital OAT delivery. There is historic precedent for hospital-based 
OUD treatment. Similar to contemporary outpatient OAT delivery systems informed by 
public policy, hospital OAT delivery was born out of necessity. In the mid-1920s, the 
Supreme Court ruled that it was illegal for physicians to provide opioids to patients with 
OUD in the outpatient setting (Hohenstein, 2001) and care shifted to the hospital 
(White, 2002). This care delivery trend lasted for about 10 years, falling out of favor 
because of the ineffectiveness of the approach (White, 2002). In its place, the federal 
government created two addiction hospitals called “narcotic farms” managed by the 
U.S. Public Health Service and the U.S. Bureau of Prisons (White, 2002). The narcotic 
hospitals, one in Lexington, Kentucky, and the other in Fort Worth, Texas, were the 
primary source of addiction treatment until the advent of outpatient methadone 
maintenance therapy in the late 1960s (White, 2002). The addiction hospitals closed in 
the 1970s (White, 2002). 
 Nearly 40 years later, there is a renewed interest in hospital-based services for 
OUD, likely inspired by the ongoing opioid overdose epidemic and the subsequent 




evidence suggesting that hospital-based OUD treatment services are urgently needed, 
care for this population is feasible and effective, and potential barriers to care in this 
setting should be explored. 
 1.2.3d.1. The need. The national rate of OUD-related hospitalizations increased 
64% between 2005 and 2014 (Weiss et al., 2016). Moreover, between 2013 and 2015, 
opioid-related admissions (217 per 100,000 people) were the second most common 
SUD admission behind alcohol (558 per 100,000) (Fingar et al., 2018). In 2015, the 
cumulative costs for OUD-related hospitalizations were estimated at $15 billion annually 
(Ronan & Herzig, 2016). Costs for OUD-related hospitalizations were higher ($28,543 vs. 
$10,400 days), and stays were longer (5.2 days vs. 4.5 days), in contrast with non-OUD 
related admissions (Ronan & Herzig, 2016; Weiss & Elixhauser, 2014). The distribution of 
costs by payer for OUD-related hospitalizations disproportionately burdens public 
payers—72% of admissions were paid for by Medicaid (40%) and Medicare (32%) (Weiss 
& Heslin, 2018).  
Persons with OUD-related hospital admissions have a relatively low rate of 
hospital death, although the in-hospital mortality rates are increasing for patients who 
receive higher levels of care during admission. In 2012, 1% of OUD-related hospital 
admission patients and 3% of OUD-related co-infection admissions patients died (Ronan 
& Herzig, 2016). There was a significant increase in hospital deaths in the ICU for opioid 




(Stevens et al., 2017). However, little is known about OUD-related health outcomes that 
occur after discharge, a potentially vulnerable time for overdose. 
A limited literature base characterizes the sub-optimal and potentially 
inappropriate care received during and after hospital admission for patients with OUD. 
Sub-optimal care for OUD may be reflected in three ways: 1) elevated rates of leaving 
the hospital against medical advice (Ronan & Herzig, 2016; Stranges, Wier, Merrill, & 
Steiner, 2009); 2) low OAT use during admission (Rosenthal, Karchmer, Theisen-Toupal, 
Castillo, & Rowley, 2015); and 3) low OAT use in the 30 days after hospital discharge 
(Frazier et al., 2017; Naeger, Ali, Mutter, Mark, & Hughey, 2016). Inappropriate care 
may be further reflected in the increased use of short-acting opioids during (Herzig et 
al., 2014) and after admission (Larochelle, Liebschutz, Zhang, Ross-Degnan, & Wharam, 
2016; Naeger, Mutter, Ali, Mark, & Hughey, 2016). 
1.2.3d.2. The solution. A growing evidence base supports the use of 
interventions to enhance services for patients hospitalized with OUD, including: a 
clinical trial on OAT delivery (Liebschutz et al., 2014); several hospital practice checklists 
and recommendations based on narrative reviews (Noska, Mohan, Wakeman, Rich, & 
Boutwell, 2015; Sharma et al., 2017; Thakarar, Weinstein, & Walley, 2016; Theisen-
Toupal, Ronan, Moore, & Rosenthal, 2017; Weinstein, Wakeman, & Nolan, 2018); 
federal guidance documents (SAMHSA, 2018; Institute of Medicine Committee on 




evaluations of addiction medicine consult (AMC) services (Nordeck et al., 2018; Suzuki, 
2016; Trowbridge et al., 2017; Wakeman, Metlay, Chang, Herman, & Rigotti, 2017).  
1.2.3d.3. The barriers. A limited literature base describes how supply-side 
attributes, inside and outside the hospital, may contribute to hospital OAT underuse. 
Potential barriers outside the hospital include treatment coverage policies imposed by 
third-party payers (Hassamal et al., 2017) and broader federal treatment regulations 
(Hassamal et al., 2017). Not explored explicitly in the literature is the potential 
misinterpretation of specific federal regulations that dictate practice for opioid 
withdrawal in the hospital setting (i.e., 21 CFR 1306.07, sections b and c) (Nagel, 2002).  
Within the hospital, potential barriers to OAT delivery are likely connected to a 
number of factors, including: 1) provider knowledge deficits related to OAT and OUD 
treatment; 2) the perpetuation of stigmatizing behavior by providers towards patients 
with OUD because of knowledge deficits; 3) concerns about external federal regulations 
(e.g. DEA audits); 4) concerns about outside perceptions (e.g., worried about attracting 
OUD patients); 5) a lack of support staff and institutional support; 6) frequent laboratory 
testing; and 7) an inadequate referral network (Hassamal et al., 2017). Another 
potential barrier is whether the hospital has the correct staff employed. Patients with 
OUD and other SUDs, for example, have expressed interest in receiving services from 
peer support providers (i.e., professional with lived experience) during hospitalization 
(Velez, Nicolaidis, Korthuis, & Englander, 2017). Despite this, peer support providers are 




Section 1.3. Problem Statement  
 Limited information exists describing hospital OAT care delivery patterns and 
why hospital OAT is likely underused. This dissertation seeks to enhance the 
understanding of supply-side attributes on hospital OAT delivery by considering the 
broader contextual elements that shape practice through an interdisciplinary research 
lens grounded in theories, models, and frameworks from policy theory (Ingram & 
Schneider, 1990, 1991; MacCoun, Saiger, Kahan, & Reuter, 1993; Pierson, 1993; A. L. 
Schneider & Ingram, 1988, 1993; Skocpol, 1992), organizational behavior (DiMaggio & 
Powell, 1983, 1991; Katz & Kahn, 1978; Leavitt, 1962; Scott, 2003; Scott & Meyer, 1991; 
Thompson, 1967), systems science (Basole & Rouse, 2008; Ferlie & Shortell, 2001; 
Lipsitz, 2012; Perrow, 1986; Plsek & Greenhalgh, 2001; Sallis, Owen, & Fisher, 2015), 
economic theory (Alchian & Demsetz, 1972; Allison & Zelikow, 1999; Eisenhardt, 1989; 
Friedman, 2002; Jensen & Meckling, 1976; Simon, 1985; Williamson, 1979, 1985, 1994; 
Williamson & Ouchi, 1981; Zeckhauser & Pratt, 1985), and health services delivery 
(Levesque, Harris, & Russell, 2013). 
Section 1.4. Research Purpose and Questions 
An integrated mixed methods design (i.e., qualitative followed by quantitative), 
comprised of three aims and 16 research sub-questions, explored this broad research 
question: How do supply-side attributes influence hospital OAT delivery, health 
outcomes, and health services utilization for persons hospitalized with OUD? The data 
for Aim 1, the qualitative aim, were 17 key informant interviews from 16 non-VHA U.S. 




quantitative aims, were deidentified administrative data from a retrospective national 
sample of patients with OUD from the VHA health system in the fiscal year of 2017. Aim 
1 examined how addiction medicine experts and their hospitals delivered OAT for 
patients with OUD and Aims 2 and 3 described current OAT delivery practices in VHA 
hospitals:  
• Aim 1: Examine the influence of supply-side attributes inside and outside of non-
VHA hospitals that shape hospital OAT delivery; 
• Aim 2: Describe and test variation in VHA hospital OAT delivery;  
• Aim 3: Test associations among patient and hospital characteristics on VHA 
hospital OAT delivery.  
Section 1.5. Study Purpose and Significance 
This study sought to describe and understand the patterns and determinants of 
evidence-based hospital OAT delivery, a first step towards ensuring that hospitalized 
patients with OUD receive effective treatments, and that treatment policies are crafted 
and systems are designed to support the delivery of these modalities. This study has the 
potential to contribute to health services delivery improvement because it explores the 
potential contributory contextual elements (e.g., policy, organization, system, and 
economic factors) and analyzes administrative data from an integrated health system to 
describe current practice. This study addresses public health, clinical practice, and 
health system delivery knowledge gaps by connecting the research domains of public 




Section 1.6. Conclusion 
Hospital OAT underuse engages issues of care quality, safety, and cost. 
Understanding the barriers and facilitators to hospital OAT delivery is a first step 
towards informing interventions inside and outside the hospital to ensure that OUD 
hospitalized patients receive effective treatments. Obtaining a greater understanding of 
where and how OAT delivery may be improved across the health services delivery 
system is especially important due to the current opioid overdose epidemic. 




Chapter 2: Literature Review 
The ongoing opioid overdose epidemic has increased the number of persons in 
the United States (U.S.) with opioid use disorder (OUD) and OUD-related 
hospitalizations. A limited literature base describes hospital OAT underuse and nearly no 
literature exists exploring why OAT is underused in the inpatient setting. OAT is a well-
studied life-saving treatment for persons with OUD. Hospitals may play an important 
role in the contemporary OUD treatment pathway. Policy, regulatory, and system-level 
factors likely complicate hospital-based OAT delivery, therefore this dissertation seeks 
to understand the influence of these attributes on the underuse and variation of 
hospital OAT delivery. Chapter 2 includes a comprehensive literature review organized 
into 15 sections: 
1. Section 2.1 provides study definitions for drugs, drug use disorders, and OAT. 
2. Section 2.2 explains how drug use disorders and drugs are socially 
constructed and the two frames dominating the narrative in health policy 
and practice. 
3. Section 2.3 outlines policy frameworks (the Social Construction Framework; 
the Comparative Drug Policy Analytic Framework; and the Policy Feedback 
Theory) to support the rationale that national, state, and local health care 
policies influence hospital OAT delivery. 
4. Section 2.4 provides a 150-year historical overview of OUD treatment 




5. Section 2.5 describes the contemporary drug policy environment, including 
the policy regimes, laws, and regulations informing OAT delivery. 
6. Section 2.6 reviews organizational behavior scholarship relevant to 
understanding hospital OAT delivery. 
7. Section 2.7 examines systems science models and theory that may affect 
hospital OAT delivery. 
8. Section 2.8 discusses economic theory relevant to understanding and 
exploring deficits in hospital OAT delivery. 
9. Section 2.9 contextualizes hospitals in the broader health services delivery 
market. 
10. Section 2.10 summarizes a health services delivery research framework that 
contributes to the study’s conceptual framework (the Health Care Access 
Framework). 
11. Section 2.11 outlines how OAT is delivered outside the hospital. 
12. Section 2.12 describes how OAT is delivered within an integrated health 
services delivery system, the Veterans Health Administration (VHA). 
13. Section 2.13 provides an overview of hospital OAT delivery. 
14. Section 2.14 synthesizes and integrates the literature reviewed in this 
chapter to construct the study’s conceptual framework. 




Section 2.1. Defining Drugs, Drug Use Disorders, and Treatment 
For the purpose of this dissertation, drugs are defined as legal or illegal 
psychoactive substances (e.g., opioids, cocaine) that are “capable of influencing brain 
systems linked to reward and pleasure” (Babor et al., 2010, p. 9). This dissertation is 
focused on a psychoactive class of substances called opioids. Opioids are endogenous 
and exogenous pain-relieving substances that humans have used for thousands of years 
(Trescot, Datta, Lee, & Hansen, 2008). Opioid is a broad contemporary term describing 
compounds with pharmacological effects at opioid receptors primarily in the central 
nervous system (mu, delta, kappa) (Trescot et al., 2008). An outdated term, frequently 
used in policy, is the word “narcotic”, originating from the Greek word for stupor 
(Trescot et al., 2008). The term initially described any medication that promoted sleep, 
then referred more specifically to opioid products, and finally became used in laws and 
regulations the describe drugs of abuse (Trescot et al., 2008). 
All opioids have similar pharmacological effects, such as the capacity to relieve 
pain, produce euphoria, induce respiratory depression, drowsiness, and impair 
judgment (Babor et al., 2010). Continued use of opioids leads to tolerance and may 
result in an OUD. According to the American Psychiatric Association (APA) (APA, 2013), 
OUD occurs when a person has: “A problematic pattern of opioid use leading to clinically 
significant impairment or distress,” and the person meets at least two of the 11 listed 
criteria (e.g., craving, unsuccessful efforts to cut down) within a 12-month period. A full-




The recommended first-line treatment for OUD is OAT (World Health 
Organization, 2009, 2017). OATs are long-acting opioids that occupy the mu-opioid 
receptors in the central nervous system to prevent withdrawal and reduce cravings 
associated with OUD (Schuckit, 2016). OAT decreases mortality risk and improves 
treatment outcomes (Sordo et al., 2017). The two FDA approved OATs, available in a 
variety of formulations, are buprenorphine (with and without naloxone; sublingual 
tablet, sublingual film, long-acting injectable, and implant) and methadone (oral 
solution).  
Section 2.2. Social Construction of Drugs 
This section introduces and applies social constructionism as it relates to the 
historical and contemporary discourse of drug use disorders. Social constructionism 
draws upon the foundational scholarship of Spector and Kitsuse (1977), Foucault (1966), 
and Turner (1992). Social construction is broadly understood as the “multiplicity of 
social forces that combine to create and modify [a] phenomenon” (Brown, 1995, p. 37). 
In the context of health services delivery, medical historian Charles Rosenberg states 
“[a] disease does not exist until we have agreed that it does” (Rosenberg, 1989, p. 1). 
Disease creation, moreover, occurs through the generation of specific verbal constructs 
reflecting the intellectual and institutional history of medicine within the era’s social and 
political context (Rosenberg, 1989). From this approach, the disease is a “social actor” 




the narrative and thereby rearrange how we understand the person or behavior” 
(Reinarman & Granfield, 2014, p. 2). 
In medical sociology, a social construction lens critically evaluates the illness 
identification process through the influence of social stratification and an assessment of 
the contributions of health professionals, health service delivery facilities, the 
government, the media, pharmaceutical companies, other industry profit makers, 
people with the illness, and their families (Brown, 1995). This approach is useful for 
studying interactions among the micro (i.e., individual), the meso (i.e., the institutional), 
and the macro (i.e., the governmental) levels (Brown, 1995). A social construction 
analysis begins with an exploration of five underlying assumptions about the problem: 
1) What are the origins of problem representation?; 2) What elements are missing from 
the problem?; 3) Are there other ways of thinking about the problem?; 4) In what 
context does the production, dissemination, and defense of the problem occur?; and 5) 
What are alternatives to thinking about the problem? (Bacchi, 2012). 
For drug use disorders, two common social constructions reflected in historical 
and contemporary discourse, institutionalized through research, policy, and practice are 
the moral and the addiction as disease models. The foundational premise of each 
model, respectively, is that addiction is a deviant behavior or an illness. From a social 
construction frame, deviant behavior includes the acts, beliefs, and characteristics that 
violate predominant social norms and attract condemnation, stigma, social isolation, 




Sociologists argue that it is “not a quality of the acts the person commits, but rather a 
consequence of the application or rules and sanction to an ‘offender’” (Pfohl, 1994, p. 
345) and that certain behaviors are categorized as deviant because of the “political and 
social artifacts of human activity” (Boyd, Carter, & Macpherson, 2016, p. 8). These 
scholars reject the premise that punishment deters crime and question how the 
inequitable exercise of power in society produces crime and deviance (Boyd et al., 
2016). A summary of the two socially constructed drug use disorder models, and a third, 
less common and emergent model, a multi-sourced model of addiction, is presented in 
the following sub-sections. 
 2.2.1. The moral model. The central thesis of the moral model is that addiction is 
a disease of will (Valverde, 1998). Moralists assert that the use of illegal drugs is 
inherently bad, that drug use and dependency is a consequence of poor decision-making 
and a lack of personal discipline (Boyd et al., 2016). The moral model is intertwined with 
the criminal model, which associates substance use disorders (SUDs) with deviance and 
criminality (Boyd et al., 2016). The moral model came into popular thinking in the 19th 
century bolstered by the proponents of alcohol prohibition (Reinarman & Granfield, 
2014). Temperance advocates popularized the idea that the deviant behavior behind 
every excessive drinker was a corrupt moral character and that anyone who drank 
alcohol was at risk of succumbing to this evilness (Reinarman & Granfield, 2014). This 




discourse until the early to mid-20th century (Reinarman & Granfield, 2014), informing 
and shaping contemporary policies and practices related to drug use. 
2.2.2. Addiction as disease model. Scholars assert that the development of the 
addiction as disease model represents a historical shift from one system of social control 
to another (i.e., church and state to science and medicine) (J. Schneider, 2014). This shift 
occurred in parallel with the consolidation and accumulation of power by physicians and 
the growing dominance of the health care industry (Boyd et al., 2016). In contrast with 
the moral model, the addiction as disease model explains the loss of self-control that 
occurs with addiction as a pathophysiological process versus a byproduct of the moral 
failing of the spirit (Reinarman & Granfield, 2014). The addiction as disease model 
emerged during the mid-20th century, a time in which the medicalization of deviant 
behavior was common (e.g., mental illness) (Reinarman & Granfield, 2014). The 
invention of brain imaging technology in the 1990s led to the latest iteration of the 
addiction as disease model: the brain disease model (Reinarman & Granfield, 2014). 
Founders of the brain disease model assert that SUDs are explained by the changes in 
brain structure and function; addiction is, therefore a chronic progressive, permanent, 
relapsing brain disorder (Leshner, 1997; Volkow & Collins, 2017; Volkow, Koob, & 
McLellan, 2016).  
2.2.3. Multi-sourced model of addiction. An emergent field of scholarship, 
critical addiction studies, posits that the historical, cultural, and contextual specificity of 




2014). This scholarship emerged in the latter half of the 20th century to challenge the 
dominant brain disease model discourse (Reinarman & Granfield, 2014). Emerging from 
the critical addiction studies approach was the multi-source model of addiction (Kovac, 
2014). This model is grounded in theory across disciplines (i.e., philosophy, sociology, 
biochemistry, neurobiology, physiology, genetics, political science, economics, and 
psychology) and asserts that there are five interacting contributory processes at the 
macro and micro-level leading to addictive behaviors: 1) past actions and current 
choices; 2) pre-dispositions; 3) social, historical, and cultural environment; 4) 
neurobiology; and 5) underlying processes (Kovac, 2014). This model does not favor one 
mechanism as the primary cause of addiction and emphasizes that every case is a 
unique combination of circumstances (Kovac, 2014). This broader lens of addiction 
etiology is further supported in forthcoming sections in this chapter that include the 
macro-level historical, cultural, and contextual perspectives.  
Recognizing that different socially constructed models of addiction exist 
facilitates a nuanced interpretation of contemporary opioid control policies and 
regulations, and explains, in part, contemporary OUD care. As aptly stated by Dr. Walter 
Ling: “From the very beginning our policy has been: Addicts are sick, they need help; but 
they also sin and must suffer a little. So, we built treatment programs and put up 
barriers making it difficult for patients to get into treatment” (Ling, 2016). Relevant to 
this dissertation is the influence of the social construction of opioids (e.g., illicit drug or 




of drug use disorders is the meta-influencer of the dissertation’s rationale and research 
design. The next section explores the theoretical connection between social 
construction and policy design.  
Section 2.3. Policy Frameworks 
This section provides complementary and additive theoretical support that social 
construction and contextual phenomena influence contemporary policy and practice 
related to hospital OAT delivery. Three policy frameworks are reviewed: The Social 
Construction Framework, the Policy Feedback Theory, and the Comparative Drug Policy 
Analytic Theory.  
2.3.1. The Social Construction Framework. The underlying assumption of the 
Social Construction Framework (Ingram & Schneider, 1990, 1991; A. L. Schneider & 
Ingram, 1988, 1993) is that policies define and determine who receives societal benefits 
or burdens (A. L. Schneider, Ingram, & deLeon, 2014). Policymakers use socially 
constructed target populations as justification for policy design and do this through the 
presentation of powerful images or stereotypes that become embedded within the 
policy (A. L. Schneider et al., 2014). 
This framework has five propositions. First, benefit or burden allocation depends 
on the target population’s political power, which may be positive or negative and high-
power or low-power (A. L. Schneider et al., 2014). The power typology for substance 
users is low-power and negative; thus, under this framework people who use drugs are 




and symbolic effects on the target population (A. L. Schneider et al., 2014). Policy design 
may impact a group’s attitude and political participation through the creation of 
structures that influence life opportunities (A. L. Schneider et al., 2014). Third, 
emotional and intuitive reactions (i.e., biases) are at the origins of social construction, 
and these biases justify the selection of evidence to support policy design (A. L. 
Schneider et al., 2014). The fourth proposition is that social construction may change 
frequently through “unanticipated or unintended consequences of previous policy 
designs” (A. L. Schneider et al., 2014, p. 124). Note, that changing the narrative for a 
negatively constructed group of people is challenging, and frequently the target 
population continues to exist as “a negative degenerative social memory” (A. L. 
Schneider et al., 2014, p. 125). The fifth proposition is that future policy change is 
dependent on the social construction of the target population (A. L. Schneider et al., 
2014).  
2.3.2. Policy Feedback Theory. The grounding premise of the Policy Feedback 
Theory (Pierson, 1993; Skocpol, 1992) is that other policies influence policy design. This 
theory asserts that policy creation is “deeply influenced” by the existence of other 
policies that shape political landscapes, foster partisan identities, provide precedent, 
build governmental capacities affecting policymaker choice, and the dictation of 
administrative arrangements (Mettler & SoRelle, 2014). This theory is grounded in 




of formal institutions; thus, policies may bestow resources, impose coercive rules, and 
convey messages and norms (Mettler & SoRelle, 2014). 
The Policy Feedback Theory’s four proposed mechanisms that lead to policy 
adaptation over time include that policies: 1) can shape the meaning of citizenship; 2) 
can affect the form of governance; 3) can influence the power of groups; and 4) can 
affect political agendas and policy problem definition (Mettler & SoRelle, 2014). 
Moreover, policies can have resource effects (e.g., increased education increases civic 
engagement) and interpretative effects (e.g., constructed identities may be normative 
and evaluative or positive or negative) (Mettler & SoRelle, 2014).  
2.3.3. Comparative Drug Policy Analytic Framework. The Comparative Drug 
Policy Analytic Framework, like the Policy Feedback Theory, proposes that drug policy is 
influenced through dynamic and interactive relationships with other social phenomena 
(MacCoun et al., 1993). Scholars of this framework identified three influencers: 1) the 
social context (i.e., the attitudes, norms, economics, demographics of a community); 2) 
the ongoing drug problem (i.e., community rates of addiction, overdose, criminality, and 
drug-related accidents); and 3) the existence of other social policies (i.e., health policy, 
welfare policy, and citizenship rights) (MacCoun et al., 1993). 
2.3.4. Summary. These frameworks, as a collective, support the assertion that 
the social construction of drug users and other contextual phenomena influence the 
design, implementation, and enforcement of contemporary opioid and OUD-related 




benefit or burden to persons with OUDs through delivery system design (e.g., 
methadone clinics), the distinction of criminal versus patient (e.g., federal drug 
scheduling laws), and access to treatment (e.g., insurance coverage).  
Section 2.4. History of OUD Treatment: Policy and Practice 
This section highlights the influence of historical policies and practice on 
contemporary opioid-related policies and treatment systems. The review begins in the 
19th century because prior to this time opioid importation and consumption occurred 
with public indifference and little government involvement. Over the course of the 19th 
and 20th centuries, specific opioid products were designated as legitimate or illegitimate 
through policies attributed to different groups of people. These shifting regulatory 
designations determined that some opioids were taxable and tradeable (e.g., raw 
opium), that some opioids were medicine (e.g., morphine), and that some opioids were 
illegal (e.g., smoking opium, diacetylmorphine).  
2.4.1. Opium, morphine, and diacetylmorphine. Prior to the advent of modern 
chemistry and the pharmacy distribution system, there was opium. Opium was sold in 
general stores and groceries as a medicinal product (Aurin, 2000). Opium was the first 
federally regulated opioid. Beginning in the late 19th century, smoking opium was 
banned from importation from China (1880), was taxed domestically (1890), and 
eventually designated an illegal substance (1909) with criminal sanctions for possession 




product from taxable good to a socially menacing illicit substance as primarily due to 
racist anti-Chinese sentiment (J. P. Hoffmann, 1990).  
As smoking opium became illegal, the legitimation of opioids through medical 
practice was flourishing, specifically the use of morphine. In the 19th century opioid 
medicalization was possible because of the advent of modern chemistry, which allowed 
for the compounding, production, and marketing of opioid products to druggists and 
physicians. In 1803, a German pharmacist isolated morphine from the juice of the opium 
poppy (Musto, 2002), and 30 years later, in 1832, morphine manufacturing and 
distribution began (Musto, 1973). By mid-century, morphine was a common medical 
treatment (Musto, 2002) ingested either orally or intravenously (Musto, 1999). 
From 1870 to 1880, the U.S. per capita opioid consumption nearly tripled 
(Courtwright, 2015). Increased use was attributed to self-medication, the advent of 
opioid-laced patent medications, disease and trauma from the Civil War, the spread of 
opium smoking, the promotion of new drugs, and physicians providing and 
compounding opioids (Courtwright, 2015). The result of increased opioid access and use 
culminated in the 1870s morphine crisis primarily afflicting affluent white women 
(Courtwright, 2015). 
Although this opioid crisis was discussed in the public discourse, federal policies 
were not implemented to delegitimize morphine or to support the treatment of persons 
with morphine addiction. During this era, the late 19th century and early 20th century, 




physicians, rest homes, private hospitals, or state asylums (White, 2002). The primary 
treatment provided in those facilities were withdrawal protocols using other 
psychoactive substances, such as cannabis, cocaine, alcohol, other opioids, and 
sedatives (White, 2002). The most common approaches were: 1) abrupt opioid 
withdrawal over 24 to 36 hours; 2) rapid opioid withdrawal over four to 10 days; or 3) 
gradual withdrawal over a period of weeks or months (White, 2002). Generally, these 
modalities were ineffective and return to use was common (White, 2002). 
Ironically, the morphine crisis may have contributed, in part, to diacetylmorphine 
development at the end of the 19th century. Chemists sought to reduce the negative 
side effects of morphine (e.g., dependency, constipation) and expand the positive 
effects (e.g., cough suppression) (Musto, 2002). Scientists at Bayer Pharmaceuticals 
extracted and manufactured diacetylmorphine as a morphine derivative in 1898 
(Moynihan, 2002). It was imported to the U.S. as a cough suppressant for pneumonia 
and tuberculosis (Musto, 2002), and also as a treatment for morphine dependence 
(White, 2002). 
2.4.2. The 1906 Pure Food and Drugs Act. At the turn of the 19th century 
medicalized opioids were largely unregulated and widely available, and druggists and 
physicians became concerned (Spillane & McAllister, 2003). Health professionals feared 
“becoming slaves to an industry whose desire for profit would overwhelm care for 
public health and safety” and sought to protect the drug supply by proposing the 




physician for the use of opioids and other substances (Spillane & McAllister, 2003, p. 6). 
The powerful coalition of physicians and druggists contributed to the political support 
necessary to pass the 1906 Pure Food and Drug Act (Spillane & McAllister, 2003).  
The 1906 Pure Food and Drug Act established the U.S. domestic prescription 
drug policy regime. The Act regulated drug promotion, packaging, distribution of specific 
compounds, and created the first list of restricted “dangerous drugs” including 
morphine, opium, and diacetylmorphine (Spillane & McAllister, 2003). In addition, 
enforcement of the Act occurred under the authority of the Federal Bureau of 
Chemistry, an organization that would later become an important opioid treatment 
regulator: the U.S. Food & Drug Administration (FDA) (Swann, 1998). The authority of 
the FDA grew with the 1938 Food, Drug, and Cosmetic Act, expanding the agency’s 
authority to oversee cosmetics and medical devices, and mandated labeling for drugs 
with directions for safe use, and the pre-market approval of all new drugs (Swann, 
1998). Under this new regulatory system manufacturers had to prove to the FDA that a 
drug was safe before it could enter the market (Swann, 1998).  
2.4.3. The narcotic clinics. At the same time as the development of the 
pharmaceutical regulatory system a more robust addiction treatment system began to 
form without the support of the federal government, the narcotic clinics (White, 2002). 
The narcotic clinics, created by physicians, were the first community-based facilities 
dedicated to providing OAT for patients with OUD (White, 2002). Patients with severe 




“able-bodied” would undergo gradual outpatient withdrawal (White, 2002). The 
purpose of the clinics was to provide consistent medical management of OUD, to 
suppress the illegal drug market, and to prevent “drug peddlers” from selling opioids to 
people with addiction (White, 2002). The clinics ranged from effective and reputable to 
ineffective and disorganized (White, 2002). 
2.4.4. The 1914 Harrison Narcotic Act. In 1912, international delegates 
convened at the Hague Convention to establish a worldwide supply control standard for 
the manufacturing and trade of raw opium, morphine, diacetylmorphine, and cocaine 
(Martin, 1977). U.S. policymakers used the momentum and policy design from the 1912 
Hague Convention to enact the 1914 Harrison Narcotic Act. The 1914 Harrison Narcotic 
Act regulated the importation, manufacturing, and distribution of psychoactive 
substances as determined by the 1912 Hague Convention (Sacco, 2014). The Act 
required persons involved in any part of the drug distribution processes to register with 
the U.S. Department of the Treasury, pay special taxes, and to track all transactions 
(Sacco, 2014). The Act technically allowed physicians to prescribe opioids and cocaine 
for treating persons with OUD; however, in contravention of the text, many physicians 
were arrested, prosecuted, and incarcerated for providing diacetylmorphine or 
morphine as a treatment for OUD (Sacco, 2014). 
A series of three U.S. Supreme Court cases reviewed in 1916 and 1919 
challenged the Act’s legality: Jin Fuey Moy v. United States (1916); Webb et al. v. United 




v. United States, the Supreme Court overruled a lower court ruling that Dr. Moy, a 
physician who provided opium for a non-registered patient did not violate the 
provisions of the Act (Hohenstein, 2001). Three years later in Webb et al., v. United 
States and United States v. Doremus the U.S. Supreme Court affirmed the rulings of the 
lower courts finding the physicians in violation of the Act because the doctors had 
provided opioids to “dope fiends” (Hohenstein, 2001). Hereinafter, according to the 
Supreme Court, only physicians who prescribed opioids to their patients as medical 
treatment, versus for their addiction, could avoid the provisions of the Act (Hohenstein, 
2001). Contemporary OAT policies reflect this foundational ruling—it is illegal, in most 
clinical scenarios, for health care professionals to prescribe opioids for OUD treatment, 
unless a specific product has received FDA approval for that indication. In addition to 
federal action to delegitimize the use of specific opioids, in 1920 the American Medical 
Association’s (AMA) House of Delegates passed a resolution banning the use and 
importation of diacetylmorphine for medical purposes (Courtwright, 2002).  
The culmination of these policies and resolutions resulted in the destruction of 
the narcotic clinics (AMA: Council on Mental Health, 1966). By the end of 1920, all 
narcotic clinics were closed because of prosecutorial threat; as a result, in less than a 
decade the “fledging specialty of addiction medicine was all but obliterated” (White, 
2002, p. 136). It is at this point in history that many subsequent opioid-related federal 
policies shifted from taxable product to the criminal sanctions policy regime (White, 




importing, manufacturing, and possessing diacetylmorphine, including for medical use, 
and criminalized all persons who used, sold, or administered diacetylmorphine (Musto, 
1973).  
2.4.5. Early treatment in hospitals. From 1924 to 1935, after diacetylmorphine 
distribution and use became illegal, and the community-based narcotic clinic system 
collapsed, OUD treatment resources were limited (White, 2002). Treatment access was 
dependent on the race and social class of the patient. Affluent middle-aged patients 
sought discreet withdrawal management in private hospitals. Young people with heroin 
addiction, in contrast, were more likely to undergo opioid withdrawal in a correctional 
facility (White, 2002). Physicians practicing in private and community-based hospitals 
continued to focus on opioid withdrawal management resulting in the development of 
several withdrawal regimens, such as the “Towns-Lambert Treatment,” the “Pettey 
Method,” and the “Nellens and Masse Method” (White, 2002). Eventually, the health 
care professional community recognized that these protocols were ineffective for curing 
addiction (White, 2002), and hospitals began denying OUD patients access, resulting in a 
substantial increase in people with OUD entering the criminal justice system (White, 
2002).  
Moreover, a eugenics movement successfully lobbied for the inclusion of 
“addicts” in state mandatory sterilization laws, and inebriate commitment laws were 
expanded to provide for the involuntary commitment of persons addicted to opioids to 




targets of the 1924 Heroin Act, which dictated that persons who used specific opioids 
(i.e., diacetylmorphine) were criminals and immoral. One of the consequences of this 
shifting discourse was the invention of cruel and invasive interventions for OUD such as 
“serum therapies,” which created blisters on a person’s body and withdrew fluid and 
reinjected it into the blisters (Reddish, 1931) or “bromide sleep treatments” that had a 
20% death rate (Church, 1900).  
2.4.6. The 1929 Porter Act and the narcotic farms. By 1928, persons with 
addiction comprised nearly two-thirds of federally incarcerated persons, because of 
facility crowding Congress legislated the creation of specialized addiction treatment 
hospitals (White, 2002). The Porter Act, with support from Dr. Lawrence Kolb of the U.S. 
Public Health Service, approved the construction of two “narcotic farms” one in 
Lexington, Kentucky, and the other in Fort Worth, Texas (White, 2002). Together, these 
facilities had the capacity to treat 2,400 criminally-justice involved persons and 
voluntary patients (White, 2002). The hospitals divided treatment into three phases: 
withdrawal, convalescence, and rehabilitation (White, 2002). Interprofessional teams of 
physicians, nurses, social workers, chaplains, and recreational therapists administered 
treatment modalities within the hospitals (White, 2002). Once patients completed their 
opioid withdrawal protocol they spent their time working on the farm (White, 2002). 
There was limited programmatic success as 90 to 95% of patients returned to drug use 
upon leaving the farms (Maddux, 1978).  




methadone, occurred at the farms as part of the Addiction Research Center (ARC) 
(Campbell et al., 2008). However, most of the research practices would be considered 
unethical by 21st century human subjects research protection standards. Until 1955, for 
example, patients would receive drugs in return for their participation in experimental 
studies (Campbell et al., 2008) and these studies were conducted primarily on 
incarcerated individuals. The narcotic farms, up until the 1960s, were the primary 
addiction treatment facilities in the U.S. (White, 2002). Operations changed significantly 
with the passage of the 1966 Narcotic Addict Rehabilitation Act (Campbell, 2010), and in 
1974, the hospitals were closed and converted into minimum security prisons (White, 
2002). The history of the ARC post-narcotic farm is convoluted but the research program 
was eventually absorbed as part of the broader intramural research program at the 
National Institute on Drug Abuse (Campbell et al., 2008). 
During the narcotic farm era, some states experimented with state-operated 
addiction treatment hospitals or created “addict wards” in community hospitals (White, 
2002). These experimental delivery systems, however, failed to spread across the U.S. 
Subsequently, two other outpatient treatment delivery approaches emerged: the 
therapeutic community and methadone maintenance therapy (White, 2002). The 
therapeutic community model started in 1958 with the creation of a mutual aid group 
called Synanon (White, 2002). This model required participants to commit to one to two 
years of “re-socialization” through authoritarian surrogate families (White, 2002). By 




& Ofshe, 1980; Yablonsky, 1967). 
German scientists synthesized methadone during World War II (Kleber, 2002) 
and it was FDA approved for the treatment of pain 1947 (Institute of Medicine 
Committee on Federal Regulation of Methadone, 1995). Methadone has a longer 
duration of action than other opioids and a single dose is sufficient to prevent opioid 
withdrawal for up to 24 hours. Methadone maintenance in community-based treatment 
centers emerged in the 1960s (Kleber, 2002). Drs. Marie Nyswander and Vincent Dole 
pioneered this treatment delivery mechanism and conceptualized OUD as a metabolic 
disease that necessitated the daily oral administration of methadone to stabilize the 
metabolism (Kleber, 2002).  
During the 1960s, the social construction of drug use disorders shifted towards 
the addiction as disease model. In 1961, a joint committee of the American Bar 
Association and the AMA questioned the long-standing repressive drug policies of the 
prior forty-years and encouraged OAT research (Musto, 1987). In 1962, the U.S. 
Supreme Court in Robinson v. California declared that narcotic addiction was a disease 
and that persons with addiction should be “proper subjects for medical treatment” 
(White, 2002). The 1966 Narcotic Addict Rehabilitation Act reflected this change in the 
social construction of drug users. The Act authorized, treatment of “narcotics addicts” in 
lieu of incarceration for federal drug offenses and promoted the development of 
community-based outpatient services (Besteman, 1992). 




of contemporary U.S. opioid regulations. In 1925, at the International Opium 
Convention delegates created the first psychoactive regulatory mechanism for opioids 
and other drugs (League of Nations, 1925). These efforts were expanded upon with the 
1931 Manufacturing Convention (League of Nations, 1931), which was strongly 
influenced by a turbulent social environment. First, the convention occurred during a 
worldwide economic recession, the European banks were failing, countries were 
experiencing currency destabilization, and foreign trade had “imploded” (McAllister, 
2004). Thus, delegates did not want to impose limits on the export of profitable 
medicalized opioids (e.g., codeine in Germany) because countries needed the revenue 
(McAllister, 2004). Second, international delegates received conflicting pressure from 
scientists, who were concerned about policies limiting research capabilities; and 
temperance advocates, who wanted the strictest limits on drugs (McAllister, 2004). 
Third, the moral model dominated the social construction of drug users at this time; 
thus, delegates believed if the illicit drug supply was eliminated drug misuse would end 
(McAllister, 2004). The delegates created a two-tiered regulatory structure for 
psychoactive substances to meet the needs of all of their stakeholders and to adhere to 
the socially constructed narrative of drug users at the time: Group I (e.g., morphine, 
heroin, cocaine) and Group II (e.g., codeine) (League of Nations, 1931). The policy 
required that countries track Group I drugs during retail transaction and distribution 
(McAllister, 2004).  




Drugs, delegates from 97 nations extended prior regulatory efforts from the 
Manufacturing Convention and designed and ratified the contemporary prescription 
policy regime (UN, 2013). The treaty’s primary intention was to create worldwide opioid 
prohibition, except for medical and research purposes (UN, 2013). Convention 
representatives crafted the regulations with two assumptions: 1) limiting the worldwide 
opioid supply would eradicate illicit use; and 2) opioid control and prohibition would be 
imposed until evidence demonstrated that a drug did not have addictive potential 
(Spillane & McAllister, 2003). The treaty created four drug schedules with different 
levels of regulation; provided definitions for legal and illegal trade; provided definitions 
for medical and research purposes; and created penalties for recreational consumption 
(Spillane & McAllister, 2003). 
2.4.8. Summary. Over the course of the 19th and 20th centuries drug policies 
institutionalized opioids as a taxable product (e.g., the 1914 Harrison Narcotic Act), 
illegal substance (e.g., the 1924 Heroin Act), or pharmaceutical treatment (e.g., the UN 
Conventions) and subsequently categorized specific opioid users as patients or 
criminals. These policies shape the contemporary treatment policy regimes, dictating 
how, when, and where persons with OUD can access treatment. 
Section 2.5. Contemporary Drug Policy: Regimes, Law, and Regulations 
This section provides an overview of the contemporary drug policy regimes, and 




2.5.1. Drug policy regimes. Policy regimes are collections of policies intended to 
achieve a broad goal (Birkland, 2015). Drug policies are trans-disciplinary (Babor et al., 
2010; Boyd et al., 2016; MacCoun et al., 1993) and enact a broad range of administrative 
actions related to substance use. Babor et al. (2010) identified five drug policy regimes: 
1) criminal sanctions; 2) health and social services; 3) prescription; 4) prevention; and 5) 
supply control. Policies may exist in multiple regimes or sub-regimes. The purpose of 
drug policies is to achieve three goals: 1) prevalence reduction (i.e., decreasing the 
number of users); 2) quantity reduction (i.e., reducing the amount consumed); and 3) 
micro-harm reduction (i.e., reducing the average harm per dose to users and non-users) 
(MacCoun & Martin, 2008). Each micro-goal contributes to the broader overarching goal 
of macro-harm reduction, which is to decrease the total harm of drug use to society 
(MacCoun & Martin, 2008).  
2.5.1a. Criminal and punitive sanctions regime. The criminal and punitive 
sanctions policy regime includes policies intended to deter drug use, to prevent the 
normalization and spread of drug use, and to prevent the negative effects of 
criminalizing less harmful forms of drug use (Babor et al., 2010). This regime includes 
policy strategies such as deterrence (e.g., threatening to arrest), incapacitation (e.g., 
incarceration), rehabilitation (e.g., coercive treatment), and penalty modification (e.g. 
decriminalization, depenalization) (Babor et al., 2010). 
2.5.1b. Health and social services regime. The health and social services policy 




with SUDs from a non-punitive approach (Babor et al., 2010). Treatment policies, a 
policy sub-regime, affect treatment access through planning, financing, and monitoring 
of addiction services, as well as the development of the professional workforce 
(Klingemann, Holder, & Gutzwiller, 1993; Klingemann & Klingemann, 1999). Regulatory 
and allocative treatment policies; moreover, may determine the structural resources 
available to treat SUDs, such as the number of facilities, the types of programs (e.g., 
opioid treatment programs [OTP]), the delivery setting (e.g., hospitals), and the health 
care professionals who can deliver services (e.g., prescribers). Additionally, treatment 
policies may affect where services are located, and the organization and integration of 
services (Klingemann et al., 1993; Klingemann & Klingemann, 1999). 
2.5.1c. The prescription regime. For opioids, the prescription policy regime is 
“the major control structure through which these substances are made legally available 
for consumption in the modern world” (Babor et al., 2010, p. 179). The two goals of this 
regulatory system are to permit opioid use for approved medical purposes and to 
prevent non-approved use (Babor et al., 2010). The prescription regime, although less 
than a century old, is the normative approach for pharmaceutical regulation globally 
(Babor et al., 2010). The prescription regime is influenced by consumer groups, 
international conventions, government regulations, and professional associations 
(Babor et al., 2010). 
2.5.1d. The prevention regime. The prevention policy regime includes policies 




changing attitudes and improving health literacy (Babor et al., 2010). Prevention efforts 
to decrease OUD and opioid exposure may include policies to support educational 
programming for prescribers, patients, families, and the public. For example, some 
states (e.g., Iowa, Kentucky, Massachusetts, Ohio, Tennessee, and Utah) mandate 
provider opioid education (Executive Office of the President of the United States, 2014). 
Another prevention policy approach is to decrease the number of opioids in circulation 
with the purpose to reduce long-term exposure and new exposure to opioids (Kolodny 
et al., 2015).  
2.5.1e. The supply-control regime. The primary goal of the supply-control policy 
regime is to keep illegal drug prices high and to reduce illegal drug availability (Babor et 
al., 2010). Commonly used supply control approaches include polices for alternative 
crop development, crop eradication, precursor chemical control, interdiction, high-level 
enforcement through criminal investigations, street-level enforcement, and 
imprisonment (Babor et al., 2010). 
2.5.2. Contemporary laws and regulations. The 20th and 21st century opioid-
related policies germane to this dissertation cross all drug policy regimes and build upon 
the foundations of previously reviewed historic policies. The result is a complex 
contemporary regulatory environment comprised of discordant rules for specific opioids 
that is shaped by social construction. This section includes a summary of contemporary 




2.5.2a. The 1970 Comprehensive Drug Abuse Prevention and Control Act. This 
Act is the cornerstone of contemporary opioid regulations with elements from all five 
policy regimes (Babor et al., 2010). The enactment of this legislation reflected assorted 
interrelated social phenomena including the actions taken by President Richard Nixon. 
As a candidate, Nixon ran on a platform of domestic crime control and, in his view, the 
primary cause of increased crime was SUDs (Courtwright, 2004). Within the first six 
months of his presidency, in July 1969, President Nixon submitted to Congress the 
legislative architecture of what would eventually become the 1970s Comprehensive 
Drug Abuse Prevention and Control Act (Courtwright, 2004). The proposed legislation, 
addressed multiple aspects of SUDs through supply control, education, research, 
treatment, and training (Courtwright, 2004). 
At the time, methadone was the only medication available for persons with 
OUD. Patients received methadone at experimental treatment centers. To circumvent 
the federal prohibition of treating persons with OUD with opioids, methadone 
maintenance treatment centers operated as research facilities using Investigational New 
Drug (INDs) waivers from the FDA (Jaffe & O'Keeffe, 2003). Between 1967 and 1970 
several thousand patients received methadone in these research programs (Institute of 
Medicine Committee for the Substance Abuse Coverage Study, 1990; Jaffe, 1975; 
Jonnes, 1996; Kreek & Vocci, 2002). In June of 1970, the FDA proposed a new rule for 
methadone IND applications with strict requirements on entry into treatment, dosage, 




allowed methadone to be more restrictively used but still “thinly disguised as research” 
(Jaffe & O'Keeffe, 2003). Other interventions for OUD in the 1960s and 1970s included 
civil commitment, narcotic antagonists, non-opiate withdrawal medications (e.g., 
clonidine), and drug testing as a form of treatment monitoring (White, 2002). 
On October 27, 1970, President Nixon signed the Comprehensive Drug Abuse 
Prevention and Control Act of 1970 into law repealing and replacing the long-standing 
1914 Harrison Narcotic Act. This omnibus bill included three titles. Title I authorized the 
Department of Health, Education, and Welfare to engage in drug use prevention and 
treatment through community mental health centers and public service hospitals, and 
authorized increased research funding through the National Institute of Mental Health. 
Title II, named the 1970 Controlled Substance Act, provided the regulatory framework 
for opioids and other psychoactive drugs. Title III addressed importation and 
exportation of controlled substances.  
The 1970 Controlled Substances Act, informed by the scheduling structure 
created in the earlier international conventions, provided a regulatory mechanism for 
categorizing “controlled substances” into five schedules based on acceptable medical 
use and the potential for abuse, which is in place today: 
• Schedule I substances have no currently accepted medical use in the U.S. and 
have a high potential for abuse (e.g., diacetylmorphine);  
 
• Schedule II substances are considered dangerous, have a high potential for abuse 





• Schedule III substances have less potential for abuse than Schedule I or II, but 
more than Schedule IV, with a moderate to low potential for physical and 
psychological dependence (e.g., buprenorphine);  
 
• Schedule IV substances have a low potential for abuse and risk of dependence 
(e.g., lorazepam); and 
 
• Schedule V substances have a lower abuse potential as compared to Schedule IV 
and consist of preparations containing limited quantities of certain opioids (e.g., 
Phenergan® with codeine) (DEA, n.d.). 
 
The Act does not describe how drug abuse potential is determined, but does 
provide a legislated review mechanism for scheduling additional drugs and rescheduling 
or decontrolling already regulated substances (Courtwright, 2004). At the time, the 1970 
Controlled Substances Act was seen as “an overdue and noncontroversial piece of 
legislation” designed to tighten and clarify a statutory and administrative “mess” 
because the regulatory system prior to that time was unstable and rapidly changing 
(Courtwright, 2004, p. 10). The major contribution of the Act was the creation of a 
common regulatory process that shifted drug control from Congressional action to 
administrative control (Spillane, 2004). 
2.5.2b. The 1972 Drug Abuse Office and Treatment Act. After the enactment of 
the 1970 Controlled Substances Act, the treatment and prescription policy regime 
expanded rapidly along with access to OUD treatment. In June of 1971, the Nixon 
administration decided to mainstream methadone, which led to a 1972 revision of the 
1970 FDA regulations (Jaffe & O'Keeffe, 2003). These regulations created a closed 
treatment system restricting methadone administration to federally approved facilities 




Methadone, 1995; Jaffe, 1975, 1997; Kreek & Vocci, 2002). The policy was supposed to 
tightly control methadone distribution until the treatment became less controversial 
and more well-studied (Jaffe, 1975, 1997). The regulations were in full effect by 1973, 
and today, are largely in the same form. Methadone is considered to be “the most 
highly regulated of all medical treatments” (Strain & Stoller, 1999). 
The 1972 Drug Abuse Office and Treatment Act legislatively empowered the 
Special Action Office for Drug Abuse Prevention and required this new federal office to 
support the development of opioid antagonist therapy for OUD treatment (Julius, 1976). 
Moreover, this Act enacted a federal-state-local partnership requiring shared 
responsibility in the design, implementation, operation, and evaluation of community-
based opioid addiction treatment programs (White, 2002). In the same year, the Social 
Security Act Amendment addressed addiction-related conditions and stated that both 
alcoholism and drug addiction would not qualify as a disability unless the person was 
receiving “appropriate available treatment in an approved facility” (Ball, 1973). Shortly 
following that amendment, in July 1973, President Nixon established the Drug 
Enforcement Administration (DEA) through Executive Order 11727, merging together 
the Office for Drug Abuse Law Enforcement and the Office of National Narcotics 
Intelligence in the Department of Justice (Nixon, 1973).  
2.5.2c. The 1974 Narcotic Addict Treatment Act. This Act amended the 1970 
Controlled Substances Act to legislate DEA authority over the storage and security of 




treatment sites to annually register with the DEA (Jaffe & O'Keeffe, 2003) .The Secretary 
of Health, Education, and Welfare (now the Department of Health and Human Services) 
retained the responsibility for setting standards for proper professional practice in the 
medical treatment of addiction (Jaffe & O'Keeffe, 2003), and today, that responsibility is 
with SAMHSA.  
2.5.2d. The 2000 Drug Addiction Treatment Act. This law is the most important 
OUD treatment policy of the 21st century because it expanded OAT access. Prior to 
enactment, federal legislation prohibited the prescribing of opioids for OUD treatment, 
a holdover from the Supreme Court rulings related to the 1914 Harrison Narcotic Act 
(McCarty, Priest, & Korthuis, 2018). The 2000 Drug Addiction Treatment Act permits 
physicians, after registering with the DEA and completing eight of hours of SAMHSA-
verified training, to prescribe Schedule III, IV, or V controlled substances that are FDA 
approved for OUD treatment. Currently, buprenorphine (Schedule III) is the only opioid 
that meets these requirements. Although buprenorphine was approved by the FDA in 
2002, it was discovered more than 40 years ago in the United Kingdom (Courtwright, 
2004) and its treatment efficacy was hypothesized in the late 1970s (Jasinski, Pevnick, & 
Griffith, 1978). The delay in the use of buprenorphine to treat OUD was due primarily to 
policymakers obtaining the necessary amendments to the 1970 Controlled Substances 
Act and the 1974 Narcotic Addict Treatment Act (Jaffe & O'Keeffe, 2003). 
2.5.2e. The 2016 Comprehensive Addiction and Recovery Act and the 21st 




expansion of SUD treatment services and overdose reversal medications, including 
prevention, OAT, and other non-pharmacological recovery supports. This Act also 
authorized nurse practitioners and physician assistants to become buprenorphine 
prescribers through the federal waiver program. Importantly, the 21st Century Cures Act, 
which was passed a few months later, provided $1 billion in funding for the treatment 
expansion efforts outlined in the 2016 Comprehensive Addiction and Recovery Act 
(ASAM, 2016), including the State Targeted Response to the Opioid Crisis Grants 
program (SAMHSA, 2017b). 
2.5.2f. The 2018 SUPPORT for Patients and Communities Act. This law 
authorized a variety of interventions (e.g., programs and demonstration projects) to 
address the opioid overdose epidemic through treatment, prevention, recovery, and 
enforcement (Musumeci & Tolbert, 2018). Treatment and recovery highlights germane 
to this dissertation include (Musumeci & Tolbert, 2018): A limited repeal of the 
Institutions for Mental Diseases exclusion; the authorization of grants to academic 
health centers to develop curricula to support provider buprenorphine waiver 
attainment; and codifying the ability of qualified physicians to prescribe OAT for up to 
275 patients. 
2.5.6. Summary. The contemporary federal OAT policy regime, created over the 
last 45 years, dictates where and when persons with OUD can access OAT, and further, 
how health professionals and health facilities may prescribe or administer OAT. The OAT 




with OUD are treated during hospitalization. How health services delivery organizations 
are shaped by internal and external elements (e.g., policies) are explored in the next 
section. 
Section 2.6. Organizational Behavior Scholarship 
Organizations are “social structures created by individuals to support the 
collaborative pursuit of specified goals” (Scott, 2003, p. 11). The core operational 
requirements of an organization, include: 1) defining their objectives; 2) inducing 
participants to contribute; 3) controlling and coordinating participant contributions; 4) 
participant selection, training, and replacing; and 5) working with neighbors (Scott, 
2003). Organizations must also devote resources to maintain the organization (Scott, 
2003).  
2.6.1. Leavitt’s Diamond. Four central, inter-related organizational elements are 
included in Leavitt’s Diamond (Leavitt, 1962). This model, recently modified by Scott 
(2003), asserts that organizations are influenced by the environment and comprised of 
social structures, goals, technology, and participants (Leavitt, 1962; Scott, 2003). 
2.6.1a. Social structures. Social structures are the patterned, regularized 
interactions or relationships among participants in an organization (Scott, 2003). Social 
structures may be formal (e.g., specified roles) or informal (e.g., indistinguishable roles) 
(Scott, 2003) and embody a “duality” (Giddens, 1979), meaning they exist as a medium 




Scott, 2003); cultural-cognitive (Berger & Luckmann, 1966; Scott, 2003; Weick, 1995); 
and behavioral (Davis, 1949; Homans, 1950; Scott, 2003). 
Normative social structures include organizational values, norms, and role 
expectations (Davis, 1949; Scott, 2003). Normative structures impose constraints on 
behavioral structures, shaping, and channeling behavior through mutually held 
expectations and obligations (Davis, 1949; Scott, 2003). Organizational values are the 
criteria that inform the selection of goals and behavior; norms are the generalized rules 
governing behaviors; and roles are the behavior expectations for occupants of specific 
social positions (Davis, 1949; Scott, 2003).  
Cultural-cognitive structures are the beliefs and understandings that participants 
in an organization share about the nature of their situation, providing a common 
interpretative framework (Scott, 2003)—an organizational culture. Organizational 
culture formation occurs through the interaction of observable artifacts, espoused 
values, and basic assumptions (Kinicki & Kreitner, 2009; Ostroff, Kinicki, & Tamkins, 
2003) and is passed on to new employees through socialization (Kinicki & Kreitner, 
2009). Organizational culture is structuralized through the creation of reward systems, 
and enacted through socialization, mentoring, group dynamics, decision-making, 
communication, influence and empowerment, and leadership (Kinicki & Kreitner, 2009; 
Ostroff et al., 2003).  
Behavioral social structures are the actual behaviors that occur within an 




sentiments (Homans, 1950). The repetition of actual behaviors into patterns or 
networks, within an organization, provides rich insight into the understanding of the 
organizational power structures and the sociometric structure (i.e., who is attracted to 
whom, and who is rejected by whom) of the group (Scott, 2003). 
2.6.1b. Participants. Participants are individuals who, in exchange for 
inducements, make contributions to an organization (Scott, 2003). Participants are 
usually involved in multiple organizations, and these outside involvements may 
constrain or influence the behavior of participants (Scott, 2003). Participants are social 
actors; thus, it is their energy, ideas, conformity or non-conformity that constitute the 
shape and structure of organizations and resulting functions (Scott, 2003). The 
demographic characteristics of participants (e.g., age, gender, ethnicity) may have 
important consequences for organizational structure and function (Scott, 2003). From 
an organizational perspective, organizations must be able to relate to a range of 
participant interests and demands. This broader collection of individuals is often called 
stakeholders. Stakeholders are affected by the organization and have “legitimate claims 
on an organization” (Scott, 2003, p. 21). 
2.6.1c. Goals. Organizational goals are defined as the desired ends that 
participants attempt to achieve through task performance that involve cultural-
cognitive and normative elements (Scott, 2003). From a resource dependency 
perspective, goals and actions are intended to minimize environmental uncertainties 




mergers, vertical integration, creation of joint ventures and other interorganizational 
relationships, board of director actions, political action, and executive succession 
(Pfeffer & Salancik, 1978). Another approach to understanding organizational goals is 
through the use of Chandler’s (1962) definition of strategy: “Strategy is the 
determination of the basic long-term goals and objectives of an enterprise, and the 
adoption of courses of action and the allocation of resources necessary for carrying out 
these goals” (p. 13). This approach includes integrated decisions, actions, or plans that 
will set and achieve organizational goals; the setting of goals and the achievement of 
goals are the results of strategic decisions (Chaffee, 1985). 
2.6.1c. Technology. Technology may be a place where a specific type of work is 
conducted, a location in which energy transforms materials (Scott, 2003). Every 
organization does “work” and has a technology for completing the work (Scott, 2003). In 
the context of health care delivery, health systems “process people” and the product is 
healthier or healed individuals (Scott, 2003). Technology may be embedded in physical 
machines, but importantly, it is also the technical knowledge and skills of participants 
(Scott & Davis, 2015). Finally, similar to the “duality” of social structures (Giddens, 
1979), technology influences and shapes organizational design, by attempting to match 
the complexity of an organization’s structure with the complexity of its environment and 
technology (Galbraith, 1982). 
2.6.1d. The environment. The physical, technological, cultural, and social milieu 




organization is completely self-sufficient; thus, it depends on relationships established 
with the larger external system (Scott, 2003). The environment influences the 
comprising elements of an organization, the social structures, the participants, the 
goals, and the technology (Scott, 2003).  
Few organizations assume responsibility for training and socialization of their 
participants; thus, employees join organizations with “heavy cultural and social baggage 
obtained from interactions in other social contexts” (Scott, 2003, p. 23). Further, few 
organizations create their own technologies; most are imported from other 
organizations, including employee rules and professional norms (Scott, 2003). Goals may 
be influenced by the external environment through societal support and informed by 
societal values (Scott, 2003). Social structures are also borrowed from the environment, 
as organizations frequently follow models that already exist (Scott, 2003). It is, 
therefore, an imperative that studies of organizational behavior include considerations 
of the larger environment.  
Another approach to understanding the influence of the external environment 
on organizational behavior is institutional theory. This theory asserts that there are 
three mechanisms in the environment that shape organizations towards homogeneity 
through a process called isomorphism (DiMaggio & Powell, 1983). There are three 
isomorphic mechanisms: coercive, mimetic, and normative (DiMaggio & Powell, 1983). 
Coercive isomorphism is caused by external political influence, legitimacy, formal and 




Mimetic isomorphism occurs when an organization mimics another in the environment 
due to environmental uncertainty (DiMaggio & Powell, 1983). Normative isomorphism is 
associated with professionalization, which is the collective struggle by occupational 
members to define the conditions and methods of their work, control the number of 
persons entering the profession, and establish a cognitive base and legitimate 
occupational autonomy (DiMaggio & Powell, 1983). 
Section 2.7. Systems Science Scholarship 
Organizations are coordinated systems producing controlled activities embedded 
within complex networks participating in technical and boundary-spanning exchanges 
(Meyer & Rowan, 1977). There are a variety of system typologies and sub-typologies: 
rational; natural; open; closed; or a combination (Scott, 2003). For this dissertation, 
health service delivery organizations are conceptualized as sociotechnical and complex 
adaptive systems. Sociotechnical systems function as closed (i.e., technical) and open 
systems (i.e., institutional) (DiMaggio & Powell, 1991; Scott & Meyer, 1991; Thompson, 
1967). A closed, technical system produces a product or service within a contained 
environment that is exchanged in a market that rewards the organization for effective 
and efficient control of the production systems (Scott & Meyer, 1991). An open system 
is comprised of inputs, the inflow of external energy and information, throughputs, the 
energies inside the system, outputs, the exported product, cycles of events, the 
repeated activities to exchange and transform energy, and negative feedback, the 




definition of an open system is “Congeries of interdependent flows and activities linking 
shifting coalitions of participants embedded in a wider material-resource and 
institutional environments” (Scott, 2003, p. 29). Complex adaptive systems are “A 
collection of individual agents with freedom to act in ways that are not always totally 
predictable, and whose actions are interconnected so that one agent’s actions changes 
the context for other agents” (Plsek & Greenhalgh, 2001, p. 625).  
There is unresolvable tension and paradox within a complex adaptive system 
reflected in the amalgamation of contradictory properties, which are found in health 
service delivery settings, including:  
• The system has unclear and fuzzy boundaries; 
• The system has non-linear behaviors; 
• The system has unpredictable outcomes; 
• The system has inherent patterning; 
• The system has embedded co-evolving systems; 
• The agents within the system are adaptive; or 
• The agents within the system act based on internalized rules (Plsek & 
Greenhalgh, 2001). 
Complex systems are comprised of functional units that interact non-linearly 
with other units within a system (Lipsitz, 2012). Hospitals exist as functional units within 
the nested context of a larger complex health services delivery systems, including: the 




the relationships among multiple hospitals and health systems, a system of hospitals, 
hospital networks, all hospitals, the industry, the region, the nation, and the global 
community (Ferlie & Shortell, 2001; Perrow, 1986). The nesting phenomena causes 
continuous evolution and interaction within each level; thus, theoretical multilevel 
frameworks examine health behavior interventions (Sallis et al., 2015), health care 
improvement leverage points (Ferlie & Shortell, 2001), the health care delivery 
enterprise, health service utilization (Andersen, Davidson, & Baumeister, 2013; 
Levesque et al., 2013) and health care value-networks (Basole & Rouse, 2008). 
Scholars describe the production of health services as existing within a nested 
context—patient, care team (e.g., frontline health professionals), organization (e.g., 
facility infrastructure and resources), and the environment (e.g., regulatory, market, and 
policy frameworks (Fanjiang, Grossman, Compton, & Reid, 2005; Ferlie & Shortell, 
2001); thus environmental attributes (e.g., regulatory pressures and statutory 
requirements) may influence hospital structures and hospital attributes (Covaleski, 
Dirsmith, & Michelman, 1993; Goodrick & Salancik, 1996; Ruef & Scott, 1998). 
Section 2.8. Economics Scholarship 
Economic theories and analyses attempt to predict and explain human behavior 
through the modeling of agents (e.g., individuals, organization) and resources (e.g., 
labor, monetary) (Feldstein, 2005; Friedman, 2002). A neoclassical economics approach 
assumes that individual agents are rational, that transactions are governed by market 




of efficiency, and that efficiency benefits society (Perrow, 1986). Rationality is 
articulated as either procedural (i.e., bounded) or substantive (i.e., objective) (Simon, 
1985). In bounded rationality, three elements are necessary to understand decision-
making: 1) the individual’s goal; 2) the information and conceptualization of the 
situation; and 3) the individual’s ability to draw inferences from information in 
possession (Simon, 1985). In objective rationality, only two elements are necessary for 
understanding choice: the individual’s goals and the objective situational characteristics 
(Simon, 1985). Thus, bounded rationality accounts for the limits of human cognition and 
recognizes the resources necessary for processing information and making a decision 
(Simon, 1985).  
 A transaction, from an economics perspective, is an exchange that occurs 
between two parties in the market that may incur costs (Friedman, 2002). A market is 
an allocative mechanism and an institutionally specific cultural system that generates 
and measures value (Friedland & Alford, 1991). New market equilibrium situations are 
predicted and explained using supply and demand principles (Feldstein, 2005). Supply is 
the quantity of a good sold at a given price and demand is the quantity of a good 
purchased at a given price (Friedman, 2002). Budget constraints and income level also 
impact the supply and demand curve (Friedman, 2002). When a price changes along the 
supply and demand curves, the quantitative impact is called elasticity (Feldstein, 2005). 
Market equilibrium occurs when consumer quantity demand is equal to supplier 




resources are being used to maximize value to its members (Friedman, 2002). Efficiency 
is the use of a firm’s resources to maximize value to its members through the goods and 
services produced (Friedman, 2002). In the market, resources are scarce; thus, specific 
resource allocation involves an opportunity cost, meaning that resources spent on one 
item are not spent on another (Friedman, 2002). 
Resource allocation is either efficient or inefficient (Friedman, 2002). An efficient 
allocation of resources is one where there is no waste and everyone gains. In reality, 
there is no perfectly efficient allocation; therefore, the concept of relative efficiency 
exists. Relative efficiency compares the efficiency of one allocation to another 
(Friedman, 2002). There is always room to improve efficiency, and efficient allocation 
does not always mean an optimal or equitable allocation of resources (Friedman, 2002). 
Efficiency and allocation are the cornerstones of government economic objectives, 
which are to improve market efficiency and achieve appropriate allocation of resources 
(Feldstein, 2005). 
2.8.1. Agency theory. Agency theory is based on the premise that relationships 
are represented by contracts between principals and agents (Perrow, 1986). The 
principal (e.g., the hospital) delegates work to the agent (e.g., the physician) who 
performs the work (Eisenhardt, 1989). Agency theory has several assumptions. First, 
people are self-interested, bounded rationally, and risk averse (Eisenhardt, 1989). 
Second, the principal-agent relationship is fraught with goal conflict and information 




(Eisenhardt, 1989). Agency theory explores conflicts in contract design (Alchian & 
Demsetz, 1972; Jensen & Meckling, 1976; Zeckhauser & Pratt, 1985), particularly the 
influence of third-party enforcers (Scott, 1995). Third-party contract enforcers have 
their own utility functions (North, 1990) and monitoring costs (Zeckhauser & Pratt, 
1985). 
2.8.2. The rational actor model. The rational actor model uses the utility 
maximizing model as a theoretical base, is frequently applied in political analysis, and 
describes unitary decision-makers (Allison & Zelikow, 1999). The utility maximizing 
model is a common framework for understanding resource allocation choices. The utility 
maximizing model makes four assumptions about the consumer: 1) she has consistent 
preferences and preference-ordering; 2) she is non-satiable; 3) she prefers a specific 
proportion of goods; and 4) she makes choices based on information and her self-
interest (Friedman, 2002). 
2.8.3. Transaction cost theory. Transaction cost theory explains and explores 
economic transaction design associated with organizations (Williamson, 1994). The 
transaction cost theory assumptions include two elements: 1) humans will behave 
opportunistically with guile under a frame of bounded rationality; and 2) there are 
exchange characteristics that may determine design, such as asset specificity, 
uncertainty, and frequency of transactions (Williamson, 1979, 1985; Williamson & 




Section 2.9. The U.S. Health Services Delivery Market 
This section provides an overview of the U.S. health services production market 
and explores why care delivery variation persists despite advancements in health care 
technology. 
2.9.1. Health services commodification. The construction of the U.S. health 
services delivery system reflects the needs of a political and an economic environment 
that has institutionalized a system of “capitalist relations of production” (Christiansen, 
2017, p. 83). From this lens, capitalists seek to “Augment (and realize) surplus value, as 
well as to increase that portion of surplus value that becomes their profit…while 
simultaneously offering only those ‘benefits’ necessary for retaining their workforce” 
(Christiansen, 2017, p. 83). Under this approach, health service delivery is commodified 
and private enterprise manages a large portion of health care expenditures and profits 
(Christiansen, 2017). The primary goals of the health service delivery system are the 
provision of services and the maximization of profit for shareholders (Christiansen, 
2017). The U.S. health care delivery system is “a loose federation of independent 
enterprises, all trying to optimize the market from their perspective and for their 
benefit” (Basole & Rouse, 2008). In 2015, the delivery of health care services accounted 
for 17.5% of the U.S. Gross Domestic Product (National Center for Health Statistics, 
2017). Out of the total national health expenditure of $3.0 trillion, hospital services 
accounted for 32% of expenditures (National Center for Health Statistics, 2017). 




as previously described, the U.S. economic production system of health services delivery 
influences hospital OAT delivery. 
 The quantification of the economic value of the health services produced in the 
hospital setting is based on the hospital’s self-designated procedure and supply list—the 
“chargemaster” (Reinhardt, 2006). There are two steps in hospital billing and 
reimbursement. First, the hospital bills third-party payers or patients directly using the 
defined prices on the chargemaster; and second, the hospital is reimbursed through a 
unique negotiated payment contract with a third-party payer or the uninsured patient 
(Reinhardt, 2006). Third-party payer contracts with hospitals may be based on steeply 
discounted charges, negotiated per diems, or flat charges per episode dependent on 
negotiations (Reinhardt, 2006). Medicare reimburses hospital-based services using a flat 
fee per case payment structure (Reinhardt, 2006) and Medicaid reimburses hospitals 
using a legislated formula that includes a base payment and a variety of state-
determined supplemental payments (Cunningham, Rudowitz, Young, Garfield, & Foutz, 
2016). One of the most common contractual arrangements in U.S. hospitals, based on 
the Medicare payment model is diagnostic related grouping (DRG). DRG billing is a 
contractually agreed upon amount, set between the hospital and the third-party payer, 
for a specific condition or treatment bundle (Quinn, 2008). 
2.9.2. Variation in service delivery. Health services delivery variation, herein 
referred to as care variation, has been a topic of interest since the first scientific study 




variation perspective, health care services are categorized as: effective (Category I), 
preference-sensitive (Category II), and supply-sensitive care (Category III) (Chandra & 
Skinner, 2012; Skinner, 2011; Wennberg, Fisher, & Skinner, 2002). Category I care 
includes highly effective treatments that are inexpensive and productive across the 
population (e.g., antibiotics for bacterial infections) or are highly productive and 
expensive for a well-defined group of patients (Chandra & Skinner, 2012; Skinner, 2011; 
Wennberg et al., 2002). In general, Category I treatments will eventually diffuse across 
the system to near-universal use, although this process can be slow (Berwick, 2003). 
Category I treatments may have substantial impact on health outcomes, but are not 
likely to play a large role in explaining variation in expenditures (Skinner, 2011) 
Category II care includes preference-sensitive care—treatments that exhibit 
considerable benefit heterogeneity across different populations (Chandra & Skinner, 
2012; Skinner, 2011; Wennberg et al., 2002). An example of this type of care is the use 
of stents, which only benefits a very specific group of people (Hartwell et al., 2005). 
Category II treatment variation is observed in national health systems with salaried 
physicians, which suggests that variation is not solely due to the presence of fee-for-
service or income-maximization by physicians (Skinner, 2011).  
Category III care is supply-sensitive treatments, where there is limited evidence 
of benefit (e.g., knee arthroscopy) or the benefit is unknown (Chandra & Skinner, 2012; 
Skinner, 2011; Wennberg et al., 2002). Skinner (2011) proposes that Category III 




regions. Hospital utilization is considered a Category III treatment because the 
incremental health value of greater hospital capacity is either small, zero or unknown 
(Fisher, Wennberg, Stukel, & Sharp, 1994). Skinner (2011) proposes that patterns of 
geographic variation can be explained in part by the theory of reasoned action (Ajzen & 
Fishbein, 1980). In this model, individual behavior is disaggregated into goals and beliefs 
about how to attain goals (Skinner, 2011). Patients and physicians are assumed to share 
the same goals: better functioning and longer lifespan for the patient. However, local 
health care systems may perceive different approaches for attaining those goals 
(Skinner, 2011). One of the proposed solutions for care variation is to standardize care 
in clinical scenarios with high levels of certainty, clinical agreement, and definitive 
science (Institute of Medicine Committee on Quality of Health Care in America, 2001). 
For the purposes of this dissertation, OAT is a category I treatment.  
Section 2.10. The Health Care Access Framework 
The integration and synthesis of scholarship from sociology, policy, 
organizational behavior, systems science, and economics, supports the proposition that 
supply-side attributes, inside and outside the hospital, influence hospital OAT delivery. 
Levesque et al. (2013) proposed an updated conceptual framework on health services 
access through a synthesis of work from Bashshur, Shannon, and Metzner (1971), 
Donabedian (1974), Salkever (1976), Aday and Andersen (1974), Penchansky and 
Thomas (1981), Dutton (1986), Frenk and White (1992), Haddad and Mohindra (2002), 




Levesque et al. (2013) defined health care access as “the possibility to identify 
healthcare needs, to seek healthcare services, to reach the healthcare resources, to 
obtain or use health care services, and to actually be offered services appropriate to the 
needs for care” (p. 4). The outcomes of achieving access are the utilization of services 
and health care consequences (i.e., economic, satisfaction, and health). From this 
perspective, access enables people to take steps to enter into contracts with health 
professionals and health care facilities to obtain health care services (Levesque et al., 
2013). Levesque et al. (2013) explains that the differences in access (e.g., variation, 
underuse) may be due to either supply-side or demand-side attributes. The supply-side 
attributes include five categories applied to health professionals, facilities, health 
delivery systems, and broader influencing social factors (e.g., health insurance policy) 
(Levesque et al., 2013):  
• Approachability—the articulation that a service exists for treatment; 
• Acceptability—the cultural and social factors for the treatment; 
• Availability and accommodation—the physical and timely manner of treatment; 
• Affordability—the economic capacity to spend resources for treatment; and 
• Appropriateness—the fit of the needs of the patient and service. 
The demand-side determinants, focused largely on the capabilities of individuals, 
families, and communities to access care (Levesque et al., 2013):  




• Seek—the ability for the patient to have the capacity to choose to pursue 
treatment; 
• Reach—the ability for the patient to physically access treatment; 
• Pay—the ability for the patient to generate economic resources to pay for 
treatment; and 
• Engage—the ability for the patient to participate in treatment decision-making. 
The dissertation’s focus is primarily on the supply-side determinants, and uses the 
Levesque et al. (2013) conceptual framework as a scaffold from which to apply the other 
previously described, potential contributors to hospital OAT delivery.  
Section 2.11. OAT Delivery Outside the Hospital 
 This section describes the contemporary U.S. OAT delivery system, specifically, 
the OTP and non-OTP delivery settings informed by the special regulatory frameworks 
overseen by the DEA and SAMHSA described previously. The regulatory frameworks are 
“special” because they are exceptional. No other FDA-approved pharmaceutical 
products require separate federally mandated prescriber registration programs and 
separate systems of delivery (i.e., non-pharmacy based) (Priest et al., 2019). 
 2.11.1. Opioid treatment programs (OTP). The administration of methadone for 
OUD treatment is governed by the Certification of Opioid Treatment Programs, 42 Code 
of Federal Regulations (CFR) 8 (SAMHSA, 2015). Methadone must be administered daily 
under direct observation in a federally licensed OTP. There are only two delivery 




2019). The SAMHSA regulations require OTPs to be certified, accredited, and registered 
with the DEA (SAMHSA, 2015). OTPs are not permitted to prescribe methadone, they 
are only permitted to dispense methadone; thus, most patients are required to 
physically attend the OTP for daily observed dosing (McCarty et al., 2018). OTPs may 
also administer buprenorphine, and they may offer other services, such as recovery 
fellowship (e.g., 12-Step), and they require patient participation in non-
pharmacotherapy services such as counseling (SAMHSA, 2015). In 2016, approximately 
1,500 OTPs operated in the U.S. serving 350,000 people (Alderks, 2017). Patient 
challenges to accessing OTPs are documented and include system-level (e.g., insurance 
policies, program characteristics) and patient-level barriers (e.g., information barriers) 
(Oliva, Maisel, Gordon, & Harris, 2011).   
2.11.2. Non-OTP delivery. At present, buprenorphine, with and without 
naloxone, is the only FDA approved OAT that may be prescribed for OUD treatment. 
Buprenorphine prescribing is only allowed by federally certified prescribers (SAMHSA, 
2016). To become a certified prescriber a health professional must meet the 
requirements of the Drug Addiction Treatment Act of 2000, including: licensed to 
practice under state law; registration with the DEA; and training or certification 
(SAMHSA, 2016). Until recently, certified prescribers only included physicians, nurse 
practitioners, and physician assistants; however, with the passage of the 2018 SUPPORT 
for Patients and Communities Act for Patients Act, clinical nurse specialists, certified 




(American Nurses Association, 2018). 
After the completion of the waiver requirements, and DEA approval, a certified 
provider may prescribe buprenorphine for a certain number of patients depending on 
their clinical licensure. For physicians in the first year they may prescribe to no more 
than 30 patients at a time; in the second year, they may request to prescribe for up to 
100 patients; and in the third year they may request to prescribe for up to 275 patients 
(SAMHSA, 2016). Nurse practitioners and physician assistants are limited to prescribing 
for 30 patients (ASAM, 2018a). Finally, in addition to having the waiver, providers who 
wish to administer non-oral forms of buprenorphine (e.g., implant and long-acting 
injectable) must also become certified by the patent-holding pharmaceutical company 
(SAMHSA, 2018). 
In contrast with the methadone system, a variety of innovative primary care 
models for OAT delivery have emerged (Korthuis et al., 2017). These practice-based 
models include office-based opioid treatment programs, the Buprenorphine HIV 
Evaluation and Support Collaborative Model, the One-stop Shop Model, and the 
Integrated Prenatal Care and Medication Assisted Treatment Model (Korthuis et al., 
2017).  
Section 2.12. OAT Delivery within an Integrated Health System 
 In the U.S. there is a dearth of integrated health systems; thus, there is much to 




patients with OUD. The VHA’s journey with OAT delivery is described below, including 
system design, formulary decisions, and building system-wide treatment capacity. 
2.12.1. VHA system design. The VHA provides insurance coverage and the 
delivery of health services to over 9 million U.S. veterans in 170 VHA-owned and 
operated medical centers and 1,063 outpatient sites (U.S. Department of Veterans 
Affairs, 2016a). The development of the VHA SUD treatment and service delivery system 
began in the late in response to increased OUD prevalence in veterans returning from 
the Vietnam War (Wyse et al., 2018). To meet the needs of these service members, the 
VHA created the Alcohol and Drug Dependence Service and developed specialized OUD 
treatment facilities (Wyse et al., 2018). The program grew rapidly and, by the end of 
1972, 44 VHA Drug Dependency Treatment Centers were operational; by 1973, more 
than half of VHA patients (58%) receiving outpatient OUD services were receiving 
methadone (Cantor, 1974). The original VHA Drug Dependency Treatment Centers 
operated similarly to OTPs (Wyse et al., 2018). In the decades that followed, the number 
of VHA facilities offering methadone declined. By 2008, only 28 VHA medical centers 
had onsite OTPs, and only six of 128 centers offered offsite OTP access through 
community-based programs (Oliva, Harris, Trafton, & Gordon, 2012). As of 2018, the 
VHA operates 32 OTPS and the number of offsite OTPS at present is unknown (Wyse et 
al., 2018).  
 2.12.2. VHA formulary. The VHA’s Pharmacy Benefits Management Service 




additional administrative approvals were necessary prior to prescribing (U.S. 
Department of Veterans Affairs, 2017a). Buprenorphine use during that time was 
limited, and after three years of non-formulary status, in 2006, only 3% of patients with 
OUD received buprenorphine (Gordon et al., 2007). In 2006, the VHA had an internal 
policy change and sublingual buprenorphine was added to the formulary, removing 
administrative prescribing barriers (Wyse et al., 2018). Since that time, buprenorphine 
accessibility has increased in the VHA system; by fiscal year 2011, 88% of VHA facilities 
offered buprenorphine (n = 123 out of 140 eligible facilities) (VA Office of Inspector 
General, 2012).  
 2.12.3. VHA OAT capacity. The VHA used a variety of initiatives to build OAT 
capacity and increase access across the system, including: educational and quality 
improvement initiatives; targeted funding; and national policy and clinical guidelines 
(Wyse et al., 2018). In 2007, the VHA provided $300,000 to institutions without OTPs 
but a high need for care (Gordon et al., 2011) and instituted a national buprenorphine 
consult service, the Buprenorphine in the VA Initiative (Gellad, Good, & Shulkin, 2017). 
In 2008, VHA national clinical guidelines outlined the “minimum clinical requirements” 
to be provided in VHA facilities, which included OAT provision (Wyse et al., 2018). This 
was the first time in VHA history that OAT was mentioned as an OUD clinical 
requirement (Wyse et al., 2018). One year later, in 2009 (updated in 2015), the VHA 




which recommended OAT for OUD treatment (U.S. Department of Veterans Affairs, 
2017b). 
 In spite of all these efforts, OAT is still underused in the VHA system even in the 
midst of increasing need. The number of veterans with OUD increased between 2004 (n 
= 30,093) (Oliva et al., 2013) and 2012 (n = 48,689) (Finlay et al., 2016). Recent data 
from fiscal year 2017 reported that 54,000 VHA patients had an OUD diagnosis, 38% of 
them received some pharmacotherapy (OAT or opioid antagonist), and the OAT facility 
delivery performance ranged from 3% to 74% (Finlay et al., 2018). To date, however, 
little is known specifically about hospital OAT care delivery processes in the VHA. 
Research has focused on the receipt of OAT generally, and discussions of access to OAT 
across the OUD care continuum have not occurred.  
Section 2.13. OAT Delivery within the Hospital 
This section highlights the need for hospital-based OAT delivery, how it can be 
feasibly and effectively delivered, and the potential delivery constraints. To make this 
argument, the presentation of evidence includes an overview of OUD-related 
hospitalization trends, a review of hospital-based OUD treatment interventions, and a 
synopsis of the potential external and internal supply-side attributes informing hospital 
OAT delivery.  
2.13.1. Utilization, costs, and outcomes. This sub-section describes the OUD-
related hospitalization utilization trends (e.g., national rates), health outcomes (e.g., in-




financial implications (e.g., elevated costs of OUD-related admissions). These analyses 
depict the growth of OUD related admissions to support the assertion that hospitals are 
an important part of the OAT delivery system.  
 2.13.1a. Utilization trends. Three descriptive analyses (Fingar et al., 2018; Weiss 
et al., 2017a; Weiss et al., 2016) examined nationwide OUD-related hospitalization 
trends using data from the Healthcare Cost and Utilization Project (HCUP) National 
Inpatient Sample (NIS).1 Between 2005 and 2014 the national rate of OUD-related 
hospitalizations increased 64% (Weiss et al., 2016). The national rate of inpatient stays 
across U.S. states, for OUD-related admissions, averaged across 2013, 2014, and 2015, 
was 217 per 100,000 people, a rate second to alcohol (558 per 100,000 people), and 
ahead of cannabis (193 per 100,000 people) (Fingar et al., 2018). During this time 
period, state-level rates for opioid-related admissions were highest for Maryland (411 
per 100,000 people), West Virginia (201 per 100,00 people), and Massachusetts (373 
per 100,000 people) (Fingar et al., 2018). 
Specific trends across the population were observed for patient gender and 
patient income quartile. In 2014, women had a higher rate of OUD-related inpatient 
stays than men in nearly 75% of jurisdictions (i.e., states and the District of Columbia) 
(Weiss et al., 2017a). In the same year, the OUD-related admission rates were highest 
for patients with the lowest income (297 per 100,000) and were lowest for patients with 
                                                        
1 HCUP NIS is a database of hospital inpatient admissions from a nationally representative of 
community hospitals, from all payers, and uses a hospital sampling frame comprising more than 




the highest income (158 per 100,000) (Weiss et al., 2017b). In contrast, there was 
variation in the highest rates of admission based on patient age and area of residence 
(urban vs. rural) (Weiss et al., 2017a, 2017b).  
2.13.1b. Costs. Using HCUP data, researchers estimated that OUD-related 
hospitalizations in the U.S. cost $15 billion annually and that these costs increased over 
time (Ronan & Herzig, 2016). Costs for OUD-related admissions and OUD-related 
admissions with co-infection increased between 2002 and 2012 (Ronan & Herzig, 2016). 
For OUD-related admissions without an infection, charges more than tripled from $4.6 
billion in 2002 to $14.9 billion in 2012 (p < 0.001) and for patients with a co-occurring 
infection the costs increased from $190.7 million in 2002 to $700.7 million in 2012 (p < 
0.001) (Ronan & Herzig, 2016). In 2012, the estimated total charge per OUD-related 
hospitalization was $28,543 and for OUD-related hospitalization with associated 
infection, the cost was $107,217 (Ronan & Herzig, 2016). Similarly, an analysis of opioid-
associated overdose admissions to the intensive care unit (ICU) between 2009 and 2015 
using data from 162 hospitals in 44 states found the mean cost per ICU overdose 
admission increased from $58,517 (2009) to $92,408 (2015), a 58% increase (p < 0.0001) 
(Stevens et al., 2017). 
Costs for OUD-related hospitalizations were higher and longer than non-OUD 
related admissions. General hospital admissions had a mean length of stay of 4.5 days, 
costing $10,400 per stay (Weiss & Elixhauser, 2014). OUD-related hospital admissions, in 




$28,543 per stay (Ronan & Herzig, 2016). When patients with an OUD-related 
concurrent infection (e.g., endocarditis) were hospitalized, the length of stay more than 
tripled to 14.6 days with costs escalating more than ten times ($107,217 per stay) 
(Ronan & Herzig, 2016). 
Some of these costs may be due to the acuity of services received. The use of ICU 
services for patients with opioid overdose increased between 2009 and 2015. Adjusting 
for covariates, there was a 0.5% per month increase over the study period (RR, 1.005; 
95% CI, 1.003 to 1.006; p < 0.0001) (Stevens et al., 2017). On average, approximately 
10% of ICU overdose patients required mechanical ventilation, 7% required noninvasive 
ventilation, 4% required vasopressors, and 6% required renal replacement (Stevens et 
al., 2017).  
The distribution of costs by payer for OUD-related hospitalizations 
disproportionately burden public payers. An analysis of 2015 HCUP data found that 72% 
of OUD admissions were paid for with public funds (Medicaid 40%; Medicare 32%) 
(Weiss & Heslin, 2018). Between 2010 and 2015, the share of opioid-related inpatient 
stays increased for public payers and decreased for private payers and the uninsured 
(Weiss & Heslin, 2018). Ronan and Herzig (2016) also found that Medicaid was the most 
common payer for patients with an OUD-related diagnosis code or any OUD-related 
infection diagnosis code (i.e., endocarditis, osteomyelitis, septic arthritis, or epidural 




infection and 43% of all admissions with OUD-related co-infections (Ronan & Herzig, 
2016).  
2.13.1c. Health outcomes. Persons with OUD-related hospital admissions have a 
relatively low rate of in-hospital death, although the rates are increasing for persons 
receiving higher levels of care. In 2012, 1% of OUD-related hospital admission patients 
died and 3% of OUD-related co-infection admissions patients died (Ronan & Herzig, 
2016). In the ICU, there was a significant increase in hospital deaths for opioid overdose 
over time: in 2009 the average mortality was 7%; and increased to 10% by 2015 
(Stevens et al., 2017).  
The rates of in-hospital mortality for persons with OUD may depend on the type 
of opioid used and the presence of a co-infection. An analysis of the HCUP data between 
2001 and 2012 found that heroin overdose admissions were twice as likely to lead to in-
hospital death as compared to prescription opioid overdose admissions (Hsu, McCarthy, 
Stevens, & Mukamal, 2017). In multivariate models studying OUD-related ICU 
admissions, the number of hospitalizations with heroin overdose each month was 
associated with an increase in the monthly mortality rate among ICU patients with OUD-
related overdoses (relative rate [RR] 1.25; 95% confidence interval [CI] [1.14, 1.37]; p < 
0.001) and ICU admissions with an overdose during the summer were associated with 
lower mortality (RR, 0.87; 95% CI [0.78, 0.97]; p = 0.012) (Stevens et al., 2017). Finally, 
patients with an OUD-related hospitalization and an associated co-infection were more 




observed at two time points: 2002 and 2012 (p < 0.001 for each comparison) (Ronan & 
Herzig, 2016).  
These analyses suggest that in-hospital mortality is a relatively rare event and 
occurs at a stable rate for aggregated OUD-related admissions. The data also illustrates 
that the use of heroin and the presence of a co-infection were associated with increased 
risk of death. What is not captured is the mortality risk to patients withdrawn from 
opioids or OAT upon discharge. Research in other settings found elevated mortality 
during the first two-weeks following release from U.S. correctional facilities. In one 
study, persons with drug use disorders had a three to eight times increased risk of drug-
related death (Merrall et al., 2010). No research to date has completed an assessment 
of overdose risk upon discharge from the hospital setting. Thus, it is possible that in-
hospital mortality does not fully capture death risk related to OUD-related 
hospitalizations.  
2.13.1d. Sub-optimal and inappropriate care. For hospitalized patients sub-
optimal OUD care may be reflected by three indicators: 1) elevated rates of leaving 
against medical advice; 2) low use of OAT during admission; and 3) low OAT use in the 
30 days after hospital discharge. Inappropriate care may be reflected in the increased 
use of short-acting opioids during and after admission.  
In the 2012 HCUP data, 12% of patients admitted with an OUD-related condition 
left against medical advice (AMA) (Ronan & Herzig, 2016). This rate is elevated when 




five diagnoses with the highest relative rate of leaving AMA included patients with a 
primary diagnosis of: alcohol-related disorders (RR, 11.6), substance-related disorders 
(RR, 10.8), nonspecific chest pain (RR, 3.6), diabetes with complications (RR, 2.7), and 
mood disorders (RR, 1.9) (Stranges et al., 2009). High rates of leaving AMA may be a 
proxy measure for hospital care quality, reflecting that patient’s physical and emotional 
needs are not being met during hospitalization. 
Limited research supports the assertion that OAT initiation and continuation is a 
relatively rare event during OUD-related hospitalizations. In a ten-year (2004 to 2014) 
retrospective chart review of hospitalized patients with injection drug use-associated 
infective endocarditis in Boston, Massachusetts, OAT was documented in 11% of 
admissions (n = 26) (Rosenthal et al., 2015). Upon closer review of the 26 admissions, 
one patient was started on methadone, one was provided a phone number for an 
outpatient buprenorphine clinic, and the other 24 patients were continued on their 
previously initiated OAT-related treatments, none of which were arranged during their 
hospitalization (Rosenthal et al., 2015). 
Even the occurrence of serious OUD-related sentinel events—outpatient and 
inpatient medical attention because of an overdose—does not dramatically increase 
OAT provision upon hospital discharge. A retrospective analysis assessed the association 
between prescription opioid overdose and post-overdose OAT provision using Medicaid 
claims data from 2008 to 2013 in Pennsylvania (Frazier et al., 2017). Among patients 




(95% CI [-0.8, 2.9]; p = 0.27) and a 2% increase in admissions to methadone treatment 
(95% CI [0.7, 3.8]; p = 0.005) (Frazier et al., 2017). For persons with a prescription opioid 
overdose, the use of buprenorphine increased 1% (95% CI [0.5, 2.0]; p = 0.001) and 
methadone use increased 0.1% (95% CI [-0.5, 0.7]; p = 0.75) (Frazier et al., 2017). 
Similarly, the provision of OAT post-OUD related admission discharge for privately 
insured persons was also low. An analysis of claims for privately insured adults with an 
OUD-related diagnosis who were admitted to an acute care hospital or psychiatric 
hospital found low rates of OAT within the first 30 days post-discharge: just one in six 
patients (17%; n = 6,132) received an FDA-approved OUD treatment medication 
(buprenorphine, methadone, naltrexone) and 35% (n = 12,852) did not have any 
prescriptions filled upon discharge (Naeger, Ali, et al., 2016). 
The use of short-acting opioids, instead of OAT, to manage OUD during 
hospitalization is not explicitly described in the literature. A retrospective cohort study 
of adult non-surgical hospital admissions from 286 U.S. non-federal acute care facilities 
found that opioid exposure in the hospital was very common (51% of 1.1 million patient 
admissions). The average opioid exposure in this sample was a mean daily morphine 
milligram equivalent (MME) of 68 ± 185, and 23% of opioid exposed admissions had an 
MME dosage greater than or equal to 100 (Herzig, Rothberg, Cheung, Ngo, & 
Marcantonio, 2014). Moreover, there was substantial variation in opioid exposure 
across hospitals, ranging from 5% of all admissions in a hospital to 72% of admissions 




There is research, however, describing the inappropriate use of opioids in the 
time period post-admission for patients with OUD (Larochelle et al., 2016; Naeger, 
Mutter, et al., 2016). Naeger, Mutter, et al. (2016) observed that in the first 30 days 
after discharge from an OUD-related hospital admission 22% (n = 8,225) of patients 
filled a prescription for a non-OAT opioid pain medication, 14% of patients filled a 
prescription for a benzodiazepine (n = 5,104), and 7% of patients (n = 2,717) filled a 
prescription for a benzodiazepine and a non-OAT opioid. A retrospective cohort study 
from May 2000 to December 2012, using the Optum claims database (a large private 
U.S. health insurer with members in all 50 state), observed that 91% of patients with a 
nonfatal opioid overdose who were receiving long-term opioid therapy prior to their 
opioid overdose continued to receive non-OAT opioids after hospital discharge 
(Larochelle et al., 2016). 
2.13.2. Evidence for OUD treatment. This section summarizes a limited, but 
growing evidence base of interventions to enhance services for patients hospitalized 
with OUD. This narrative review includes a summary of the single clinical trial that exists 
on hospital OAT delivery, a summary of published hospital practice checklists and 
recommendations, and the retrospective and prospective evaluations of addiction 
medicine consult (AMC) services.  
2.13.2a. OAT initiation. A robust literature exists supporting OAT initiation and 
long-term use in community-based settings, including specialty addiction facilities, OTPs, 




assessing hospital-based OAT initiation (Liebschutz et al., 2014). The primary finding 
from this study was that participants who initiated OAT (i.e., buprenorphine) while 
hospitalized were more likely to engage in treatment post-discharge (Liebschutz et al., 
2014). Participants (n = 145) were randomized into either a detoxification protocol (i.e., 
a five-day buprenorphine taper) or a linkage protocol (i.e., buprenorphine induction, 
stabilization and transition to a primary care clinic for continued) (Liebschutz et al., 
2014). Buprenorphine engagement, verified by medical record, and self-reported prior 
30-day use of illicit opioids, was assessed at one, three, and six months (Liebschutz et 
al., 2014). The linkage group was more likely to start buprenorphine (n = 52; 72%) than 
those in the detoxification group (n = 8; 12%; p < 0.001). At six months, 12 linkage 
participants (17%) and two detoxification participants (3%) were still receiving 
buprenorphine (p = 0.007) (Liebschutz et al., 2014). Linkage participants reported less 
illicit opioid use in the 30 days prior to the six-month follow-up interview (incidence rate 
ratio [IRR] 0.60; 95% CI [0.46, 0.73]; p < 0.01) and linkage participants were more likely 
to report no illicit opioid use (n = 24; 38% vs. n = 5; 9%) (Liebschutz et al., 2014). The 
estimated OAT rate among linkage participants was almost 2.4 times higher throughout 
the six-month study period (IRR, 2.44; 95% CI [1.99, 3.36]; p < 0.01) (Liebschutz et al., 
2014). Six participants died over the course of the study, and only one death was related 
to drug overdose (Liebschutz et al., 2014). 
2.13.2b. OUD treatment practice and delivery recommendations. There is a 




delivery for hospitalized patients with OUD and other SUDs (Noska et al., 2015; Sharma 
et al., 2017; Thakarar et al., 2016; Theisen-Toupal et al., 2017; Weinstein et al., 2018) 
and federal guidance documents (SAMHSA, Institute of Medicine Committee on Federal 
Regulation of Methadone, 1995; 2018). The reviews and checklists suggest the 
implementation of a variety of interventions for patients (i.e., psychosocial, medical, and 
harm reduction) and for systems (e.g., AMC services and education on addiction and 
stigma for health professionals), summarized in Table 2.1. The federal guidance 





Table 2.1. Summary of Narrative Review Recommendations for Hospital-Based Treatment of OUD  
Authors Patient-Level Interventions System-Level Interventions 




• Involve social work 
• Involve case 
management 
• Manage opioid withdrawal 
• Initiate OAT or antagonist therapy 
• Treatment of special populations 
(e.g., acute pain/breastfeeding) 
• Discharge checklist 
• Provide opioid overdose 
education 
• Provide safer injection 
education  
• Partnerships between hospitals and 





• Collaborate with 
mental health 
service providers 
• Provide case 
management for 
supportive services 
• Conduct addiction history 
• Assess treatment readiness  
• Provide treatment options (OAT or 
antagonist therapy) 
• Provide opioid overdose 
prevention 
• Provide infection prevention 
• Implement the checklist 
Sharma et 
al. (2017) 
 Future Research Directions 
• Optimal use of peripherally 
inserted central venous catheters 
• Treatment contracts 
• Inpatient supervised injection 
services 
Implementation Research 
• Provide injectable 
diacetylmorphine 
• Provide sterile drug use 
equipment. 
•  Future harm reduction  
For Immediate Implementation 
• Establishment of AMC service  
• Education for health professionals on 
stigma and addiction  
Implementation Research 




 • Establish OUD diagnosis 
• Manage opioid withdrawal 
• Initiate OAT and linkage to care 
 • Educate providers on federal, state, 
and hospital policies 
• Educate providers on medications 




• Referral and linkage • Addiction history 
• Physical examination/laboratory 
tests 
• Withdrawal management 
• Long-term medication titration 
• Provide opioid overdose 
education 
• Provide safer injection 
education 





Federal guidance documents from SAMHSA (SAMHSA, 2018) and the Institute of 
Medicine (Institute of Medicine Committee on Federal Regulation of Methadone, 1995) 
describe the most effective approaches to hospital OAT delivery. The SAMHSA 
document dedicated an entire chapter to the “Medical Management of Patients Taking 
OUD Medications in Hospital Settings” (SAMHSA, 2018, pp. 3-99). The recommendations 
for effective care for patients with OUD who are hospitalized include balancing OUD 
pharmacotherapy with other medical concerns, careful management after discharge, 
and seamless transfer to OAT upon discharge (e.g., either OTP or non-OTP) (SAMHSA, 
2018). The document included clinical management guidance for initiating and 
continuing OAT during admission (SAMHSA, 2018).  
The 1995 Institute of Medicine provided six recommendations on how to care 
for patients already on methadone during an inpatient admission (Institute of Medicine 
Committee on Federal Regulation of Methadone, 1995): 
• Hospital staff should notify the OTP, confirm enrollment, and verify methadone 
dose, and time and date of last dose; 
• Hospital staff should ensure the continuity of methadone pharmacotherapy 
through the hospital's pharmacy or make arrangement for its supply through the 
OTP in the event that the hospital does not stock methadone; 





• Any changes in methadone dose should be made only after consultation with the 
OTP physician and with the informed consent of the patient; 
• Before discharge, the hospital staff should notify the OTP of the time and 
amount of last dose of methadone to ensure that outpatient treatment resumes 
without interruption; and 
• If patients are discharged from acute care to continuing care facilities, 
arrangements for continued provision of methadone should be part of the 
discharge plan.  
The committee also recommended that rule-making agencies modify the federal 
regulations to allow hospitals to continue to provide methadone if the patient is unable 
to get into an OTP or if they need to complete a methadone taper (Institute of Medicine 
Committee on Federal Regulation of Methadone, 1995).  
2.13.2c. The AMC services. A growing literature base suggests that the AMC 
service is an effective health services delivery intervention. The literature on AMCs, 
however, should be interpreted conservatively because it is comprised of non-blinded 
and non-randomized prospective (Trowbridge et al., 2017; Wakeman et al., 2017) and 
retrospective studies (Nordeck et al., 2018; Suzuki, 2016).  
Two prospective AMC service evaluation studies found that patients who 
received AMC services had an increased number of drug free days post-discharge, 
compared with those who did not (Wakeman et al., 2017), and that hospital OAT 




A prospective quasi-experimental evaluation at an urban academic hospital in 
the northeast compared 30-day post-discharge outcomes between hospitalized 
participants who received or did not receive an AMC service (Wakeman et al., 2017). 
The AMC service intervention included a multidisciplinary team offering 
pharmacotherapy initiation, motivational counseling, treatment planning, and direct 
linkage to external addiction treatment resources (Wakeman et al., 2017). The majority 
of patients (61%) had an OUD-related diagnosis (Wakeman et al., 2017). In this non-
randomized intervention, patients who received an addiction consult, compared to 
those who did not, had a mean drug Addiction Severity Index decrease pre-and post (p = 
0.003) and increased days of abstinence at 30-day follow-up (+12.7 days vs. +5.6; p < 
0.001) (Wakeman et al., 2017).  
A prospective evaluation at Boston Medical Center assessed the process and 
care delivery measures of an AMC service (Trowbridge et al., 2017). Over a 26-week 
period the AMC service completed 337 of 367 requested consults for 319 unique 
patients; of those 78% were for persons with an OUD (n = 264) (Trowbridge et al., 2017). 
For those with OUD, methadone was initiated in 27% of patients (n = 70) and 
buprenorphine was initiated in 15% of patients (n = 40), with 42% of patients with OUD 
initiated on OAT (Trowbridge et al., 2017). Of those initiated on methadone, 76% were 
linked to methadone clinics and for buprenorphine, 49% were linked to a clinic 
(Trowbridge et al., 2017). Researchers observed that OAT initiation was feasible in the 




addiction care was challenging, warranting future program development (Trowbridge et 
al., 2017).  
The two retrospective AMC service studies found that most patients were 
interested in receiving AMC services (Nordeck et al., 2018; Suzuki, 2016). The University 
of Maryland Medical Center SUD consultation liaison service—operational for over 
three decades with an interprofessional team of a psychiatrist director, two part-time 
addiction-boarded psychiatrists, a licensed addiction counselor, a licensed social worker, 
nurses, and medical trainees—reported service delivery for 267 patients (Nordeck et al., 
2018). A majority (57%) had a current OUD diagnosis (n = 152) and OAT with 
buprenorphine or methadone was initiated for 14%. Within patients with OUD who 
were referred to an affiliated program during hospitalization (n = 45), 42% of patients 
who initiated hospital OAT kept their intake appointment (Nordeck et al., 2018). A final 
observation was that only 10% of patients expressed no interest in treatment or refused 
a formal consultation (Nordeck et al., 2018); indicating, that hospitalization was a 
reachable moment. 
A retrospective chart review examined the health records for patients with OUD-
related admissions and infective endocarditis who received AMC services between May 
2013 and July 2015 (Suzuki, 2016). Twenty-nine patients were admitted for the 
treatment of infective endocarditis secondary to associated intravenous drug and had a 
request for an addiction psychiatry consultation (Suzuki, 2016). All patients were 




continue treatment, and patients were encouraged to have an initial appointment 
established prior to discharge (Suzuki, 2016). The majority (72%) of hospitalized patients 
in this cohort had previous experience with OAT. Almost two-thirds (62%) of patients 
accepted and received OAT (n = 18), of those, half initiated buprenorphine and half 
initiated methadone maintenance (Suzuki, 2016). 
 2.12.3. External supply-side attributes. External influencers on hospital OAT 
delivery are essentially unstudied. This section is a summary of potential external 
attributes that may facilitate or impede hospital OAT delivery, such as third-party payer 
policies (e.g., pharmacy benefit management strategies) and federal regulations. 
2.12.3a. Payer policies. Payer policies may contribute to limited hospital OAT 
access, although most of hospital billing occurs through bundled payments. Limitations 
imposed by third-party payers on OAT in the outpatient setting may constrain services 
delivered in the hospital setting, particularly when starting people on OAT during 
hospitalization (Hassamal et al., 2017).  
OAT insurance barriers are well-described for public and private third-party 
payers. Medicaid, the most common payer for OUD-related hospitalizations (Weiss & 
Heslin, 2018) imposes a variety of pharmacy benefit management strategies for OAT 
(i.e., prior authorization, quantity limits, and lifetime limits). In an analysis of Medicaid 
Preferred Drug Lists (2011 to 2013), 31 State Medicaid agencies covered methadone 
and all 50 Medicaid agencies covered buprenorphine (SAMHSA, 2014). However, 48 




required evidence that the patient was receiving psychosocial addiction services 
(SAMHSA, 2014). Further, 34 Medicaid programs had buprenorphine quantity limits and 
some states had lifetime treatment limits. Four jurisdictions (District of Columbia, 
Illinois, Michigan, and Washington) established a one-year limit, six states (Arkansas, 
Maine, Mississippi, Montana, Virginia, and Wyoming) established a two-year treatment 
limit, and one state (Utah) established a three-year treatment limit (SAMHSA, 2014). 
Like Medicaid, Medicare coverage of OAT is restrictive. Methadone was not an 
allowable service until the recent passage of the 2018 SUPPORT for Patients and 
Communities Act, and coverage restrictions for buprenorphine are common (Hartung et 
al., 2019). From 2007 to 2018, Medicare coverage for Suboxone® and Subutex® branded 
buprenorphine/naloxone tablets and films declined by 25%, going from 100% plan 
coverage (n = 3,281) to 74% (n = 2,873) (Hartung et al., 2019). Moreover, among plans 
offering coverage, prior authorization requirements for branded buprenorphine/ 
naloxone increased from 16% in 2007 to 58% in 2018. In 2018, moreover, 57% of plans 
required prior authorization for generic buprenorphine/naloxone sublingual tablets 
(Hartung et al., 2019). The proportion of plans covering any buprenorphine product 
without any restriction declined from 89% to 35% in this same time period (Hartung et 
al., 2019).  
Private payers, follow public payer practice, limiting OAT access through 
pharmacy benefit management strategies (Reif et al., 2016). In an analysis of 8,427 plans 




prior authorization requirements, and only 41% of plans covered methadone for OUD 
(Reif et al., 2016).  
 2.12.3b. Federal regulations. It is possible that confusion about federal 
regulations may contribute to limited hospital OAT access. In 2002, the DEA director 
addressed provider uncertainty in a letter reminding hospital providers that it is legal to 
administer OAT during hospitalization (Nagel, 2002). The regulations in 21 CFR 1306.07 
sub-section (b) state: 
(b): Nothing in this section shall prohibit a physician who is not specifically 
registered to conduct a narcotic treatment program from administering (but not 
prescribing) narcotic drugs to a person for the purpose of relieving acute 
withdrawal symptoms when necessary while arrangements are being made for 
referral for treatment. Not more than one day's medication may be administered 
to the person or for the person's use at one time. Such emergency treatment may 
be carried out for not more than three days and may not be renewed or 
extended. (DEA, 2005) 
 
These regulations, known as the three-day rule or 72-hour rule, allow hospital providers 
without a buprenorphine waiver or OTP facility designation, to administer OAT for 72 
hours for patients who have a primary diagnosis of opioid withdrawal. If a patient is 
discharged with a buprenorphine bridge script, a provider with a buprenorphine waiver 
must issue that prescription. Further, if the provider has a buprenorphine waiver, they 
could continue to administer buprenorphine for more than 72 hours as needed.  
 The second part of the rule allows for unconstrained OAT or other non-FDA 
opioid administration for hospital providers without a buprenorphine waiver or OTP 
facility designation for patients who are hospitalized with a non-withdrawal primary 




(c): This section is not intended to impose any limitations on a physician or 
authorized hospital staff to administer or dispense narcotic drugs in a hospital to 
maintain or detoxify a person as an incidental adjunct to medical or surgical 
treatment of conditions other than addiction, or to administer or dispense 
narcotic drugs to persons with intractable pain in which no relief or cure is 
possible or none has been found after reasonable efforts. (DEA, 2005) 
 
This policy is nuanced, but sub-sections b and c in 21 CFR 1306.07 explicitly state 
that federal law allows for the continuation and initiation of OAT in the hospital setting 
within certain parameters. It is possible that this policy constrains hospital OAT delivery, 
Hassamal et al. (2017) described provider concerns about DEA audits. Other federal 
policies that may constrain hospital OAT delivery include the buprenorphine patient 
panel limits and the administrative requirements of the special regulatory system, which 
has been described elsewhere in this dissertation (Sections 2.5 and 2.11).  
 2.13.4. Internal supply-side attributes. A limited literature (Hassamal et al., 
2017; Velez et al., 2017) characterizes the constraints within the hospital environment 
on OAT delivery. This section is a summary of this literature and includes proposed 
internal attributes that may facilitate or impede hospital OAT delivery including hospital 
providers and hospital structures.  
 2.13.4a. Hospital providers. Hassamal et al. (2017), through a clinical case study 
and narrative literature review, describe potential OAT delivery barriers imposed by 
hospital providers, specifically, provider knowledge deficits (e.g., concerns about OAT 
misuse, lack or training), and stigmatizing behavior by providers towards patients with 




would benefit from the inclusion of other non-traditional types of providers in the 
hospital setting, such as peer support providers (Velez et al., 2017).  
 2.13.4b. Hospital attributes. Hassamal et al. (2017) also discussed how hospital 
organizational attributes likely inhibit hospital OAT delivery including concerns about 
outside perceptions (e.g., worried about attracting too many OUD patients), a lack of 
support staff and institutional support, frequent laboratory testing, and inadequate 
referral networks. Patients described hospitalizations as a limited context for treating 
addiction-related issues because hospitalizations generally do not address life stressors, 
trauma, or basic needs (Velez et al., 2017).  
 Other internal hospital delivery structures that may influence hospital OAT 
delivery are the hospital formulary governance body (the Pharmacy & Therapeutics 
Committee [P&T]) and other OAT-related hospital policies, procedures, and guidelines. 
The P&T committee manages the hospital formulary system (American Society of 
Health-System Pharmacists [ASHSP], 2008). Formulary system management is a process 
for making hospital-wide pharmaceutical and therapeutic policies (ASHP, 2000). A 
formulary—a document created and maintained by the P&T committee—includes 
medications, devices, medication-use policies, decision support tools, ancillary drug 
information, and organizational guidelines (ASHP, 2008). P&T committees include 
clinicians (e.g., physicians, pharmacists, nurses) and hospital administrators. The 
committee’s decision-making authority is generally outlined in organizational bylaws, 




2008). Formulary decisions should include the consideration of patient care and an 
unbiased literature review (ASHP, 2008), including the assessments of the 
pharmaceutical evidence-base and pharmaco-economic literature (M. Hoffmann, 2013). 
The existence of P&T committees is nearly universal in hospitals around the 
world (Durán-García, Santos-Ramos, Puigventos-Latorre, & Ortega, 2011). In the U.S., 
the Joint Commission, the primary hospital accrediting body, requires a hospital P&T 
committee (Balu, Connor, & Vogenberg, 2004). P&T committee outputs may include 
policy statements, procedures, and guidelines that provide guidance on service delivery 
within the hospital (O’Donnell & Vogenberg, 2012). These documents are commonly 
created because of accreditation requirements and, to avoid litigation, align hospital 
services with the standard of practice for reasonable and prudent hospital pharmacists 
(O’Donnell & Vogenberg, 2012).  
 2.13.5. Summary. Interest is growing, and the literature base is expanding, to 
support the assertion that hospital OAT delivery is needed, feasible, and effective. OUD-
related hospital admissions and costs are increasing. Communicating and framing 
hospital OAT delivery as a supply-side issue may help motivate hospitals and health 
services administrators to support hospital OAT delivery because people with OUD are 
publicly insured or uninsured. Keeping patients with OUD from readmission by providing 
evidence-based OAT during and after hospitalization could benefit the hospital 




Although, comparative-effectiveness research examining the best way to design 
AMC services has not yet occurred, it seems likely that AMC services are feasible to 
implement and effective in providing evidence-based services. Further, it is possible that 
unexplored internal hospital attributes may influence hospital OAT delivery such as the 
OAT-related decisions made by members of the P&T committee or the adoption of 
hospital guidelines.  
There is limited evidence to suggest that elements within the hospital and 
outside the hospital contribute to hospital OAT delivery. Outside the hospital potential 
external attributes that may impede hospital OAT delivery are third-party payer policies 
(e.g., pharmacy benefit management strategies) and federal regulations, specific to 
hospital delivery, and more broadly, the special OAT regulatory system. Within the 
hospital potential internal attributes informing hospital OAT delivery include the 
behavior and training of hospital providers and hospital structures. This dissertation 
aims to explore these issues and other unidentified facilitating and constraining 
elements. 
Section 2.14. Development of the Conceptual Framework: Synthesis of the Literature  
This section synthesizes the reviewed literature to support the underlying 
premise of this dissertation that OAT provision is influenced by a complex array of 
dynamically related supply-side factors, external and internal to the hospital (see Table 




Table 2.2. Literature Reviewed 
Scholarship 
Domain 
Theory, Model, Framework 
Medical 
Sociology 
• Social Construction Theory (Bacchi, 2012; Brown, 1995; Reinarman & Granfield, 
2014; Rosenberg, 1989)  
• Moral Model (Boyd et al., 2016; Reinarman & Granfield, 2014; Valverde, 1998) 
• Disease Model (Boyd et al., 2016; Reinarman & Granfield, 2014; J. Schneider, 
2014) 
• Multi Model (Kovac, 2014; Reinarman & Granfield, 2014) 
Policy Process • The Social Construction Framework (Ingram & Schneider, 1990, 1991; A. L. 
Schneider & Ingram, 1988, 1993) 
• Policy Feedback Theory (Pierson, 1993; Skocpol, 1992) 
• Comparative Drug Policy Analytic Framework (MacCoun et al., 1993) 
• Drug Policy Regimes (Babor et al., 2010) 
Organization 
Behavior 
• Elements of Leavitt’s Diamond (Berger & Luckmann, 1966; Chaffee, 1985; 
Chandler, 1962; Davis, 1949; Galbraith, 1982; Giddens, 1979; Hillman et al., 2009; 
Homans, 1950; Kinicki & Kreitner, 2009; Leavitt, 1962; Ostroff et al., 2003; Pfeffer 
& Salancik, 1978; Scott, 2003; Weick, 1995) 
• Institutional Theory (DiMaggio & Powell, 1983) 
System Science • Sociotechnical Organizations (DiMaggio & Powell, 1991; Katz & Kahn, 1978; Scott, 
2003; Scott & Meyer, 1991; Thompson, 1967) 
• Multilevel Attributes (Andersen et al., 2013; Basole & Rouse, 2008; Covaleski et 
al., 1993; Fanjiang et al., 2005; Ferlie & Shortell, 2001; Goodrick & Salancik, 1996; 
Levesque et al., 2013; Lipsitz, 2012; Perrow, 1986; Ruef & Scott, 1998; Sallis et al., 
2015) 
• Complex Adaptive System Theory (Lipsitz, 2012; Plsek & Greenhalgh, 2001) 
Economics  • Agency Theory (Alchian & Demsetz, 1972; Eisenhardt, 1989; Jensen & Meckling, 
1976; Perrow, 1986; Zeckhauser & Pratt, 1985) 
• Neo-Classical Economic Principles (Feldstein, 2005; Friedman, 2002; Perrow, 1986) 
• Transaction Cost Theory (Williamson, 1979, 1985, 1994; Williamson & Ouchi, 
1981) 
• Rational Actor Model (Allison & Zelikow, 1999; Simon, 1985) 
Health Services 
Delivery 
• Health Care Access Framework (Levesque et al., 2013) 
2.14.1. Study principles. There are four foundational principles that support the 
study rationale and the development of the conceptual framework. First, the social 
construction (Brown, 1995; Rosenberg, 1989) of opioids and OUD is a meta-influencer of 
external and internal environmental attributes. Second, a hospital is a sociotechnical 
(DiMaggio & Powell, 1991; Katz & Kahn, 1978; Scott & Meyer, 1991; Thompson, 1967), 
complex adaptive (Plsek & Greenhalgh, 2001), economic production system that exists 




(Basole & Rouse, 2008; Ferlie & Shortell, 2001; Perrow, 1986; Sallis et al., 2015). Third, 
an inherent property of this type of system is the influence of external and internal 
environmental factors (Katz & Kahn, 1978; Plsek & Greenhalgh, 2001; Scott, 2003). The 
environment, inside and outside the hospital, includes the physical, technological, 
cultural, and social milieu (Scott & Davis, 2015), and policy, which is frequently both a 
product and an influencer of social phenomena (Ingram & Schneider, 1990, 1991; 
MacCoun et al., 1993; Pierson, 1993; A. L. Schneider & Ingram, 1988, 1993; Skocpol, 
1992). Fourth, hospitals are considered to be rational unitary decision-making bodies 
that select actions with the highest payoff after ranking and understanding the 
consequences (Allison & Zelikow, 1999; Simon, 1985). This perspective suggests a 
hospital’s decision to provide OAT reflects strategic goals, organizational objectives, and 
a value-maximizing activity (Allison & Zelikow, 1999; Simon, 1985). The rational actor 
model application is limited in this context because within the hospital environment 
there are sub-systems of internal stakeholders (e.g., providers, staff, patients) and 
external stakeholders (e.g., payers, regulatory bodies, community, government, 
industry); thus, the ability of a hospital to behave strategically to produce value-
maximizing decisions is in constant tension with the values and needs of stakeholders.  
2.14.2. Supply-side focus. The study’s focus on the supply-side versus demand-
side is because demand-side factors may have a smaller contribution for this specific 
care delivery setting: a) hospitalized persons with OUD will physiologically experience 




can receive OAT in the hospital only if the hospital provides it; and c) OUD patients 
generally do not choose which hospital they are admitted to. 
2.14.3. Conceptual framework. The four foundational study principles and the 
literature review provide the scaffolding of the study’s conceptual framework and how 
the study is operationalized. The conceptual framework (see Figure 2.1) depicts the 
interactions, contributions, and feedback among the nested layers of supply-side 
attributes, inside and outside the hospital, on hospital service delivery, outcomes, and 
demand-side attributes. The elements existing within each nested layer dynamically 
interact across levels shaping and modifying OAT service delivery over time. The 
culmination of these complex interactions results in hospital OAT service delivery, and 
the subsequent clinical and utilization outcomes. The clinical and utilization outcomes, 
in turn, influence the nested supply-side attributes through feedback. The categories are 
interdependent and overlapping in nature. 
2.14.3a. Defining hospital OAT delivery. There are few clinical scenarios that 
would prohibit OAT initiation or continuation for the treatment of OUD in the hospital. 
Clinical experts and the peer-reviewed literature described potential OAT care delivery 
scenarios as: 1) starting OAT in the hospital; 2) continuing OAT in the hospital; and 3) 
linking patients to OAT upon discharge. Part of the exploratory component of this study 
required further defining these care delivery scenarios, and the discovery of others.  
2.14.3b. Internal hospital elements. Categories of potential hospital supply-side 




organizational culture); and 3) technology and resources (e.g., polices, regulations, and 
procedure; and resources and staffing). 
 A hospital’s physical location may affect OAT delivery. Physical location may 
mediate hospital characteristics and processes such as hours of operation, the ability of 
the hospital to match the needs of the patient, and the availability of treatment 
(Levesque et al., 2013). Elements within the proximal physical environment, such as the 
urbanicity or rurality, or being located in an area with elevated or lower opioid 
overdose, or the proximity to other hospitals providing addiction related services, could 
also influence hospital OAT delivery (DiMaggio & Powell, 1983). Other hospital 
attributes such as size and status as a teaching hospital affect quality of care (Keeler et 
al., 1992).  
Hospital social structures could influence OAT delivery (e.g., the organizational 
values, norms, and role expectations) (Davis, 1949; Scott, 2003). Social structures may 
also inform hospital resource allocation. Deciding to invest, or not invest, in addiction-
related treatment technologies within the hospital is based, in part, by the alignment of 
this investment with current organizational strategic goals, objectives, and the 
determination that this is a value-maximizing activity for the hospital (Allison & Zelikow, 
1999; Simon, 1985). Another component of social structures, influencing care delivery, is 
the shared cultural-cognitive elements among hospital staff (Berger & Luckmann, 1966; 
Scott, 2003; Weick, 1995). For example, a hospital that collectively believes in the social 




professionals with similar beliefs, and could be less likely to provide evidence-based 
OAT. In contrast, a hospital with a shared philosophy across staff that addiction is a 
brain disease may be more likely to hire professionals with shared beliefs, and increase 
the likelihood of providing evidence-based OAT.  
 Differences in organizational structures of practice may also change delivery (De 
Jong, 2008). Hospital technologies, in this context, include dedicated resources, staffing, 
and internal policies and regulations. The existence, or lack thereof, of these attributes 
could influence hospital OAT delivery. Staffing technologies of interest include the 
existence of specific staffing structures and models of care for patients with OUD (e.g., 
AMC services to deliver care for patients with OUD), the availability of addiction trained 
specialists (e.g., board-certified addiction medicine physicians), and graduate medical 
education training programs (e.g., addiction medicine fellowships). Other internal 
resources that may influence care include access to OAT on the hospital formulary and 
the existence of hospital policies that either enhance or constrain this practice.  
2.14.3c. Elements outside the hospital. Domains of potential hospital supply-
side attributes external to the hospital include: 1) social structures; 2) the influence of 
other hospitals; 3) polices and regulations; and 4) economic factors. 
The cultural and social contexts outside the hospital environment are also likely 
to influence hospital OAT delivery through communities’ professional values, norms, 
culture, and gender of the health professionals (Levesque et al., 2013; Scott, 2003). The 




employment, from outside the employing hospital (Scott & Davis, 2015). Health care 
professionals who trained during in a different era may not know that hospital OAT 
delivery is evidence-based practice or that only treating withdrawal symptoms is not 
sufficient care. In contrast, a hospital staffed with health care professionals who are 
knowledgeable about OUD treatment may be more likely to provide hospital OAT. It is 
also likely that internal hospital cultural-cognitive elements (Berger & Luckmann, 1966; 
Scott, 2003; Weick, 1995), such as how OUD is conceptualized (moral model vs. brain 
disease model), are informed by the external environment either through public 
discourse (e.g., the media) and values, or the narratives espoused by external health 
professional training programs or organizations (e.g., the Joint Commission).  
Informal and formal coercive isomorphic pressures from other organizations may 
influence hospital OAT delivery (e.g., the government, influential organizations) 
(DiMaggio & Powell, 1983). Other potentially influential elements in the external 
environment (e.g., coercive policies) drive isomorphic hospital behavior (DiMaggio & 
Powell, 1983). Moreover, institutional theory (DiMaggio & Powell, 1983) posits that 
hospitals attempt to mimic each other; thus, hospital OAT delivery could become 
acceptable practice through this process. The proximity to other hospitals is also 
relevant because few organizations create their own technologies (Scott & Davis, 2015). 
Further, other organizations such as third-party contract enforcers (North, 1990; 
Zeckhauser & Pratt, 1985) could influence hospital OAT delivery. Third-party contract 




regulatory bodies (e.g., the Joint Commission), governmental regulatory bodies (e.g., 
CMS), local and state regulatory bodies (e.g., licensing boards), and professional 
associations (e.g., ASAM). These groups could influence hospital behavior because they 
bring their own values and preferences to the contractual relationship (North, 1990; 
Zeckhauser & Pratt, 1985).  
External polices and regulations that affect treatment access through planning, 
financing, and monitoring of addiction services, as well as the development of the 
professional workforce, are likely to influence hospital OAT delivery (Klingemann et al., 
1993; Klingemann & Klingemann, 1999). Influential policies include federal treatment 
regulations that govern allowable treatment in the hospital setting (e.g., the 72-hour 
rule), or more broadly the special regulatory framework dictating OAT delivery (e.g., 
OTPs).  
Beyond federal regulations, policies created by non-governmental organizations 
could influence care. Organizations such as the Joint Commission may enhance or deter 
hospital OAT delivery through the creation of policies. In 2008, the Joint Commission 
received funding to develop, specify, and test performance measures addressing alcohol 
screening and pharmacotherapy for persons with SUDs, including OUD (Joint 
Commission, 2015). The Joint Commission has the authority to mandate the inclusion of 
these measures or the requirement of addiction trained staff as part of hospital 




external organizations to mandate hospitals to deliver OAT (e.g., the Joint Commission 
mandating delivery of OAT in the hospital setting).  
Another important policy domain is the third-party payer coverage policies that 
increase barriers to OAT access in the community setting and that potentially constrain 
hospital care. Public and private payers commonly impose pharmacy benefit 
management strategies on OAT and, as is the case for methadone, more commonly do 
not provide reimbursement (Hartung et al., 2019; Reif et al., 2016; SAMHSA, 2014). 
External market forces may also influence hospital OAT delivery. Interestingly, 
from a supply-demand perspective, OAT is a service that promotes the best value for 
the patient (i.e., the demand) but it is still largely unavailable in the hospital setting (i.e. 
the supply). A mismatch between supply and demand means that OAT is an 
economically inefficient good because neither the supplier (e.g., the hospital) nor the 
demander (e.g., the patient) fully benefits. This discrepancy may be due to hospital 
reliance on contracts with external third-party payers that do not financially reward 
hospitals for OAT delivery.  
2.14.4. Summary. The final product of this chapter is the conceptual framework 
(see Figure 2.1), which depicts the complex nature of hospital OAT delivery between the 
supply-side (i.e., the hospital, the broader environment) and the demand-side (i.e., 
patient demographics). The conceptual framework supported the study’s rationale, 









Section 2.15. Conclusion 
In an era of increased OUD prevalence and care delivery in the hospital, there is 
an urgency to study and improve care delivery in this setting as part of the broader 
pathway for persons with OUD. The literature review described, summarized, and 
synthesized an interdisciplinary body of literature to support the research on hospital 
OAT delivery, and how this phenomenon is likely influenced by complex interrelated 
internal and external attributes. In the next chapter, Chapter 3, the study methodology 





Chapter 3: Methods 
Parts of this chapter were published in a peer-reviewed journal: Priest, K.C., & 
McCarty, D. (2018). Role of the hospital in the 21st Century opioid overdose 
epidemic: The addiction medicine consult service. Journal of Addiction Medicine, 
Advance online publication. doi: 10.1097/ADM.0000000000000496.  
 Chapter 3 describes the research approach used for exploring how supply-side 
attributes are associated with hospital opioid agonist therapy (OAT) delivery for patients 
with opioid use disorder (OUD). Complex social phenomena, such as health services 
delivery, required a mixed methods approach, using both qualitative and quantitative 
data and analyses to illuminate relationships and balance methodologic limitations. The 
chapter is organized in six sections: 
1. Section 3.1 restates and operationalizes the elements within the core 
research question. 
2. Section 3.2 outlines the three specific aims, the 16 research sub-questions, 
and study design. 
3. Section 3.3 justifies the research approach and outlines the study 
assumptions.  
4. Section 3.4 provides an overview of the human subjects protections.  
5. Section 3.5 describes the qualitative analytic approach for Aim 1. 
6. Section 3.6 describes the quantitative analytic approach for Aims 2 and 3. 




Section 3.1. Research Question  
 The interdisciplinary theoretical literature review and the Levesque Health Care 
Access Framework (Levesque et al., 2013) guided the creation of the study’s core 
research question: How do supply-side attributes influence hospital OAT delivery, health 
outcomes, and health services utilization for persons hospitalized with OUD?  
 Supply-side attributes refer to the contextual elements inside and outside a 
hospital that may be associated with hospital OAT delivery performance. Attributes of 
interest include hospital structural characteristics (e.g., size), social structures (e.g., 
organizational culture and values), and external attributes (e.g., local and federal 
policies, and the behavior of other hospitals). Service delivery in the hospital is 
predominantly dictated by the availability of hospital resources. For example, if a 
hospital does not have OAT on the formulary, or stocked in the inpatient pharmacy, a 
hospitalized patient cannot access OAT. The patient’s perspective on hospital OAT 
delivery was not directly addressed and is a study limitation. As proxies for patient-
informed data, the study assessed the influence of demand-side attributes using the 
qualitative and quantitative data. Key informants discussed their perceived barriers for 
patients (i.e., the demand-side), and the Veterans Health Administration (VHA) data 
included demographic information (e.g., patient age) and characteristics about the 
admission (e.g., length of stay).  
 The three categories of outcomes for this study were hospital OAT delivery (e.g., 




post-admission health services utilization (e.g., hospital readmission, emergency 
department visits, and OAT receipt). Table 3.1 defines and operationalizes the 
overarching research question and the method and data source for each element. 
Table 3.1. Primary Research Question Operationalized 
Concept Definition Method & 
Data Source 
Supply-Side Attributes 
Inside the Hospital  Social structures (e.g., hospital standards of 
care), technology and resources (e.g., hospital 
policies), patient population (e.g., OUD patient 
volume), and physical structure (e.g., 
geographic location) 
Quantitative 
Qualitative   
Outside the Hospital Social structures (e.g., behavior of other 
organizations) and technology and resources 
(e.g., treatment policies) 
Qualitative 
Outcomes 
Hospital OAT Delivery Hospital OAT delivery during an OUD-related 
admission, further specified by care delivery 
mechanism: OAT continued, OAT 
initiation/linkage; OAT sustained; OAT 
withdrawal 
Quantitative 
Admission In-hospital mortality; leaving against medical 
advice 
Quantitative 
Post-Admission Events in the 30 days after discharge: Death; 
readmission; emergency department visit; and 
OAT receipt 
Quantitative 
Section 3.2. Study Design, Specific Aims, and Research Sub-Questions 
An integrated mixed method sequential explanatory research design with three 
aims investigated the contributions of multilevel supply-side attributes on hospital OAT 
delivery. Aim 1 is the qualitative portion of the study and Aims 2 and 3 rely upon the 




A directed content analysis (Aim 1) of 17 key informant interview transcripts 
from 16 non-VHA hospitals and a framework analysis of 25 hospital guidance documents 
from 10 non-VHA hospitals examined how addiction medicine experts and their 
hospitals delivered OAT for patients with OUD. The study concluded with analyses of 
two quantitative aims (Aims 2 and 3) using administrative data from a retrospective 
national sample of patients hospitalized with OUD within the VHA system, fiscal year 
2017. The study’s three aims and 16 research sub-questions are presented below: 
Aim 1: Examine the influence of supply-side attributes inside and outside of non-VHA 
hospitals that shape hospital OAT delivery. 
 
• Q1a: How is OAT delivered for patients with OUD in the hospital setting?  
• Q1b: Which internal and external environmental supply-side elements 
facilitate hospital OAT delivery? 
• Q1c: Which internal and external environmental supply-side elements 
impede hospital OAT delivery? 
• Q1d: How do hospital policies and guidance documents inform hospital OAT 
delivery?  




Aim 2: Describe and test variation in VHA hospital OAT delivery. 
 
• Q2a: Do the characteristics of the patients who received OAT differ from 
those who did not receive OAT while hospitalized? 
• Q2b: Does non-OAT pharmacotherapy delivery differ for patients who 
received OAT and for those who did not receive OAT while hospitalized? 
• Q2c: Do outcomes differ for patients who received OAT and for those who did 
not receive OAT while hospitalized? 
• Q2d: Do the characteristics of the patients who were discontinued from OAT 
differ from those who were continued on OAT at admission? 
• Q2e: Does non-OAT pharmacotherapy delivery differ for patients who 
received OAT and for those who did not receive OAT while hospitalized? 
• Q2f: Do outcomes differ for patients who received OAT and for those who did 
not receive OAT while hospitalized? 
• Q2g: Are specific OAT care scenarios associated with hospital OAT delivery 
quartile? 
• Q2h: Which hospital attributes are associated with hospital OAT delivery? 
• Q2i: Are non-OAT pharmacotherapy services associated with hospital OAT 
delivery quartile? 





Aim 3: Test associations among patient and hospital characteristics on VHA hospital OAT 
delivery. 
 
• Q3a: How much of the variation in OAT delivery is attributable to the 
hospitals? 
• Q3b: How do patient and hospital attributes affect hospital OAT delivery? 
 The Aim 1 research questions identified supply-side attributes inside and outside 
the hospital that explain, in part, variability in hospital OAT care and the common 
practices used to enhance hospital treatment of persons with OUD. The Aim 2 research 
questions described and explored care practices and variables associated with VHA 
hospital OAT delivery variation. The Aim 3 research questions tested for the 
contributions of the multilevel attributes on OAT care variation. 
Section 3.3. Research Approach Justification and Study Assumptions 
This section discusses the use of an integrated quantitative and qualitative mixed 
methods study from paradigmatic and methodologic perspectives (Creswell & Clark, 
2011), and concludes with study assumptions. Over many years the definition of “mixed 
methods” has varied (Creswell & Clark, 2011). Mixed methods may refer to a research 
philosophy, design, or methodologic approach (Creswell & Clark, 2011). Creswell and 
Clark (2011) summarized the six core characteristics inclusive of these different 
viewpoints. In mixed methods, the researcher: 
• Mixes, integrates or links the two forms of data either concurrently, 
sequentially, or through embedding one within the other; 




• Uses both techniques in a single study; 
• Frames research techniques in a paradigm and a theoretical lens; and 
• Combines the methods into a specific research design guiding the study 
(Creswell & Clark, 2011). 
In the 1970s and 1980s, the mixed methods approach was subject to a 
philosophical debate centered on whether combining quantitative and qualitative 
approaches was possible because of their different and seemingly conflicting research 
paradigms. A research paradigm is a shared belief system among a research community 
that dictates a field’s salient questions and dominant use of research techniques (Kuhn, 
1970). During this debate, the purists held that mixing quantitative and qualitative 
paradigms was philosophically and theoretically impossible (Rossman & Wilson, 1985), 
the situationalists asserted that adaptation of research paradigms and methods for 
specific situations was possible (Creswell & Clark, 2011), and the pragmatists promoted 
the use of multiple paradigms to address a singular research problem (Rossman & 
Wilson, 1985). Thus, a pragmatic research paradigm is inclusive of other research 
worldviews such as post-positivism or constructivism to meet the needs of the research 
question (Creswell & Clark, 2011).  
3.3.1. Pragmatic research paradigm. The ontology, epistemology, axiology, and 
methodology (Creswell & Clark, 2011; Crotty, 1998) of the pragmatic research paradigm 
support the mixed methods approach used for this dissertation. A pragmatic research 




understanding of both the behavior and the beliefs that led to that outcome; thus, 
actions cannot be separated from context, actions are linked to mutable consequences, 
and actions depend on a socially shared set of beliefs (Morgan, 2014). Ontology is the 
orientation of reality, and in pragmatism, ontology holds that singular and multiple 
perspectives exist, so researchers test hypotheses and provide multiple perspectives 
(Creswell & Clark, 2011). Epistemology is the relationship between the researcher and 
the research, and in pragmatism this relationship is one of practicality, meaning that the 
researcher collects data from a “what works” approach to address the research 
question (Creswell & Clark, 2011). Axiology is the role of values in research and in 
pragmatism this includes biased and unbiased perspectives (Creswell & Clark, 2011). 
Finally, the primary methodology of a pragmatic paradigm uses a mix of quantitative 
and qualitative data collection and analyses (Creswell & Clark, 2011).  
3.3.2. Study assumptions. There were several assumptions reflected in the 
rationale, the research questions, the design, and analysis of this dissertation. The first 
assumption was that OUD is a “medical condition” even though it may be better 
understood as a complex manifestation of interacting contributory processes that exist 
at the macro and micro-levels (e.g., individual pre-disposition; social, historical, and 
cultural environment; neurobiology). A second assumption was that hospital-based OAT 
delivery is a solution to caring for persons with OUD. The third assumption was that 
demand-side attributes have a minimal contribution to hospital OAT delivery; for 




study assumed that OAT is a better treatment approach in the hospital than non-OAT 
opioids, although a direct comparison has never been studied. A fifth assumption 
posited that hospital finances, rather than patient and provider needs, drive many 
hospital decisions. 
Section 3.4. Human Subjects Protections 
On January 8, 2018, the OHSU Institutional Review Board (IRB) [IRB #18092] 
approved Aim 1 (the qualitative study), and on May 14, 2018, the Veterans Affairs (VA) 
IRB [IRB #4045] approved Aims 2 and 3 (the quantitative study). Both IRBs determined 
each of the study components to be minimal risk human subjects research. The primary 
risks for Aim 1 were minimized by using an OHSU IRB approved information sheet prior 
to interview initiation (see Appendix B), by requesting consent to participate and oral 
consent for recording the interviews, and by labeling the qualitative data with unique 
identifying codes instead of names. The primary risks for Aim 2 and 3 were minimized by 
receiving a deidentified dataset (e.g., no dates of service, birthdate, medical record 
number, social security number, or personal address) and by excluding hospitals with 
less than 25 admissions from analyses. 
Section 3.5. Aim 1: Qualitative Analyses 
 The qualitative analyses used two different, albeit similar, analytic approaches: 
directed content analysis (Hsieh & Shannon, 2005) for the key informant interview 
transcripts and a framework analysis (Ritchie & Spencer, 1994) for the hospital guidance 
documents. A directed content analysis is a primarily deductive approach effective for 




framework analysis, an approach developed for applied social policy research, has seven 
fundamental principles: 1) it is grounded or generative; 2) it is dynamic; 3) it is 
systematic; 4) it is comprehensive; 5) it is easily retrieved; 6) it allows between- and 
within-case analysis; and 7) it is accessible to others outside the study team (Ritchie & 
Spencer, 2002).  
 3.5.1. Data sources and study cohort. The Aim 1 study cohort included 17 key 
informants from 16 U.S. non-VHA hospitals. The cohort members were national hospital 
OUD experts who were professionally involved in direct care, research, or the 
development of addiction-related hospital policies, procedures, and practices for 
patients with SUD. They were addiction medicine physicians who were identified 
directly or indirectly through the publicly available 2018-2019 fellowship list from the 
Addiction Medicine Foundation (Addiction Medicine Foundation, 2018). The qualitative 
data included 17 transcribed 45-to 60-minute key informant interviews, informant 
demographic information, interview notes, and 25 hospital guidance documents from 
10 of the 16 non-VHA hospitals. 
 3.5.2. Study sample selection and recruitment. Informants were recruited in 
two waves of email sampling. The IRB approved email recruitment script is in Appendix 
C. Potential key informants received email invitations to participate a minimum of once 
and a maximum of three times. The email requested contact information for the most 




Recommendations from dissertation mentors and respondent-driven recommendations 
supplemented recruitment.  
A word search of the publicly available Addiction Medicine Foundation’s 2018 to 
2019 fellowship list (Addiction Medicine Foundation, 2018) for the word “consult” 
identified 26 fellowships that appeared to include addiction medicine consult services. 
Twenty-five of the 26 programs were contacted with an invitation to participate in the 
study; one program was excluded because the program director’s email address was not 
provided. Of the 25 programs contacted 13 individuals from 12 fellowship programs 
completed interviews.  
After exhausting the first recruitment sample, a second wave of sampling 
proceeded with the remaining 20 programs that did not have the word “consult” in the 
program description, excluding the two Canadian programs and three primarily based in 
the VHA. The Canadian and VHA programs were excluded to focus the sampling frame 
and increase the homogeneity of the types of hospitals and surrounding environments 
within the study sample. From the remaining 20 programs, 11 program directors were 
contacted based on geographic location, expert recommendation, respondent 
recommendation, and publicly available programmatic information. Of the 11 additional 
programs contacted, four additional individuals from four different institutions 




3.5.4. Data collection and study tools. The OHSU IRB approved study tools 
included: 1) the key informant demographic survey (Appendix D); and 2) the semi-
structured interview guide (Appendix E). 
3.5.4a. Key informant demographic survey. Key informants completed a 
demographic survey at the start of the interview providing basic personal and 
professional demographic information and OAT-related characteristics at the hospital of 
employment. Question examples included: “What health professional degree(s) do you 
have?” and “For how many years have you worked at your respective hospital?” 
3.5.4b. Semi-structured interview guide. The conceptual framework and the 
guidance of addiction medicine experts shaped the development of the semi-structured 
interview guide. The final interview guide probed four topics to identify external and 
hospital supply-side attributes related to hospital OAT service delivery: 1) development 
and implementation of known effective care delivery mechanisms for OUD treatment in 
the hospital setting, focused on addiction medicine consult (AMC) services; 2) OUD care 
delivery policies, procedures, and practices; 3) hospital barriers and facilitators to 
hospital OUD treatment and OAT delivery; and 4) environmental barriers and facilitators 
to hospital OUD treatment and OAT delivery.  
Informants completed 45- to 60-minute telephone interviews with the primary 
researcher. Participants did not receive a copy of the interview guide. Interviews were 




interview, a copy was requested via email after the interview to obtain electronic copies 
of the documents. Interviews were transcribed by the primary researcher. 
3.5.5. Data analysis. The data sources analyzed included: informant 
demographic survey data; key informant interview transcripts; and hospital policies.  
3.5.5a. Key informant demographic surveys. Key informant demographic 
surveys provided a professional and educational context for the perspectives of the 
informants and their current care delivery environment. Descriptive summaries, such as 
mean age of the key informants, were generated using Microsoft Excel (Microsoft, 2018) 
to contextualize the study findings. 
3.5.5b. Key informant interview transcripts. Informant interviews were coded 
using a directed content analysis approach (Hsieh & Shannon, 2005). Dedoose 
(SocioCultural Research Consultants LLC, 2016), a qualitative analysis software, was used 
to organize and manage the qualitative data and analytic process. The conceptual 
framework served informed the creation of the preliminary codebook prior to data 
collection. 
Analysis of the interviews began prior to the completion of all interviews. Each 
interview was coded and re-coded in iterative cycles. Initially the interviews were coded 
with the draft codebook (Hsieh & Shannon, 2005). Throughout the course of data 
collection and analysis, the codebook was modified to reflect emergent findings (Hsieh 




coding scheme inspired the creation of new categories and codes (Hsieh & Shannon, 
2005).  
The original codebook had five categories, with 23 codes: 1) environmental 
attributes; 2) hospital supply-side attributes; 3) demand-side attributes; 4) AMC service 
attributes; and 5) current hospital policies. The final codebook was expanded to eight 
categories, with 59 codes: 1) environmental attributes; 2) hospital supply-side 
attributes; 3) demand-side attributes; 4) AMC service attributes; 5) hospital policy and 
practice; 6) financing; 7) other models of care; and 8) care delivery topics. Changes to 
the codebook reflected the focus and the granularity of information provided during the 
interviews. Financing was added, as a single higher-level category, because it was a 
frequently described and observed to be intrinsically connected to the other categories. 
The category “hospital policies and practice” was expanded to include not only the 
discussion of documented hospital policies but also typical practices because several 
informants disclosed that their standard of care or common practices were not formally 
documented. See Appendix F for a copy of the final codebook and frequency counts of 
categories and codes.  
Upon the completion of primary coding, a second coder (the dissertation 
committee chair) reviewed the categories and codebook for all 17 coded interviews and 
provided additional coding suggestions. The primary researcher reconciled the coding 
changes and any discrepancies in codes were discussed as a research team until 




coder to identify any text that was missing a relevant code or when redundant coding 
occurred. The final themes presented in Chapter 4 were created through the 
consolidation of the eight categories from the codebook, organized around the study’s 
conceptual framework.  
3.5.5c. Hospital guidance documents. A framework analysis approach guided 
the analyses of the hospital guidance documents (Ritchie & Spencer, 2002). This 
approach begins with becoming familiar with the documents for analysis, identifying a 
thematic framework, indexing the policies, charting the policies, and completing the 
analysis and policy interpretation (Ritchie & Spencer, 2002). The preliminary thematic 
framework for this study was informed by expert opinion and a priori policy categories: 
1) OAT continuation; 2) withdrawal management; 3) OAT induction; and 4) pain 
management. The framework was modified throughout the course of data collection 
and data familiarization with the 25 policies. The thematic framework expanded to 
include five policy categories: 1) OAT continuation; 2) opioid withdrawal management; 
3) OAT induction; 4) pain management; and 5) security and behavioral management 
policy.  
During the indexing and charting processes, policies were collapsed into two 
broad policy themes comprised of eight policy sub-categories: 1) OAT management and 
2) security and behavioral management. Qualitative tables were created to summarize 




text summarized the policies and supported the policy indexing and charting processes. 
This documentation may be requested from the primary researcher. 
3.5.6. Linking Aim 1 to Aims 2 and 3. The qualitative findings presented in 
Chapter 4 provided the rationale for continuing to explore care delivery practice, 
patterns, and organizational processes for hospitalized patients with OUD. The 
qualitative findings also informed the subsequent coding of hospital OAT in the VHA 
quantitative dataset, and the analyses of Aims 2 and 3 (reported in Chapter 5). 
Section 3.6. Aims 2 and 3: Quantitative Analyses 
The exploration of the Aims 2 and 3 research questions occurred through the use 
of pre-specified statistical analytic techniques. The rationale for the use of these 
techniques was based on the evidence presented in the Chapter 2 literature review 
including previously conducted research on hospital care variation (Safavi et al., 2014). 
The Aim 2 analytic techniques included descriptive statistics (e.g., frequency, range, 
median, interquartile range [IQR]) and bivariate statistical tests to assess for differences 
among groups of patients and hospital OAT delivery quartiles (e.g., Pearson chi-square 
and Mann-Whitney U tests). The Aim 3 analytic technique used multilevel and 
multivariable logistic regression models, justified both theoretically and statistically 
(Luke, 2004). Two data analysis programs were used: 1) RStudio (RStudio Team, 2015) 
for data management, coding, and for bivariate statistical tests; and 2) Stata (StataCorp, 




Appendix G (Dinno, 2017; Fox & Weisberg, 2011; Revelle, 2018; Wasey, 2018; Wickham, 
2011, 2017).  
3.6.1. Data sources and study cohort. A retrospective sample of VHA patients 
was obtained from the VHA Corporate Data Warehouse. The VHA Corporate Data 
Warehouse is a collection of databases accessed securely through the VHA Informatics 
and Computing Infrastructure Workspace. This data source provides real-time 
demographic, medical, and pharmacy health services utilization data for veterans who 
receive care in the VHA system. In these databases patient data are linked across 
multiple tables (e.g., diagnoses, outpatient visits, inpatient admissions, outpatient 
prescription, methadone clinics) through a unique numeric identifier.  
Each case was a unique patient admission in the VHA system. Patients were 
included in this study if they had an OUD diagnosis (see Appendix H) from any source, 
inpatient or outpatient, between October 1, 2015 and October 1, 2017, in the year 
preceding the admission date of the index hospitalization as defined below. This 
included clinical scenarios in which an OUD diagnosis occurred during the index 
hospitalization. Eligible OUD diagnoses could be primary diagnoses coded when OUD 
was the main reason for the clinical encounter, or as a secondary diagnosis. The 
admitting facilities were restricted to “acute care hospitals” which was defined as 
facilities that had at least 500 acute bed days of care during the study year.  
Study validity was enhanced through the refinement of the study cohort. Each 




Appendix I which included the removal of: 1) hospitals and admissions outside the 
continental U.S. (hospitals = 1; cases = 134); 2) facilities with bed category discrepancies 
(hospitals = 6; cases = 141); 3) admissions with non-hospital places of admission (cases = 
7) or missing the place of admission (cases = 2); 4) admissions missing a primary or 
secondary admission code (cases = 271); 5) admissions with an inconsistent death code 
(hospitals = 1, cases  = 4); 6) admissions with a cancer flag (cases = 2,062), as defined by 
the Elixhauser flags (AHRQ, 2018), including cases with a solid tumor without metastasis, 
metastatic cancer, or lymphoma present on admission; 7) admissions with a length of 
stay in the 99th percentile (hospitals = 1; cases = 130); and 8) hospitals with less than 25 
admissions (hospitals =21; cases = 262). The final dataset included 12,407 admissions 
from 109 unique VHA hospitals within the continental U.S. There were no facilities 
located in New Hampshire or Nebraska. Appendix J has additional details on the study 
cohort definitions. 
3.6.2. Quantitative variables. Variable selection was informed by the existing 
literature, the data available from the VHA data source, and results of the qualitative 
portion of the study. There were three time points of interest in this study: 1) 30 days 
prior to index hospitalization (“pre-admission”); 2) index hospitalization (“admission”); 
and 3) 30 days post index hospitalization (“post-admission”). 
3.6.2a. Index hospitalization definition. The definition of an index hospital 
admission was the first hospital admission during the 2017 VHA fiscal year (October 1 




diagnosis code (Appendix H) as an inpatient or outpatient, or within the FEE BASIS care 
setting within the previous 12 months from the index hospital admission date, which 
could include a diagnosis during index admission. FEE BASIS care refers to non-VHA 
clinical care paid for by VHA on a veteran’s behalf, typically due to the service not being 
offered by VHA or because the geographic distance from the patient to the VHA service 
presents a barrier to access services. 
3.6.2b. Patient and admission variables. The patient and admission variables were 
either present upon data receipt or constructed and coded from the data; see Table 3.2 
for summarized definitions. Appendix K includes additional details on variable 
construction and Appendix L is the list of ICD-10 codes queried for co-occurring mental 




Table 3.2. Patient and Admission Variables 
Variable Type Definition 
Patient Characteristics 





1) Adjustment Disorder Other; 2) Anxiety Disorder; 3) Mood Disorder; 






1) Alcohol Use Disorder; 2) Cannabis Use Disorder; 3) Cocaine Use 
Disorder; 4) Hallucinogen Use Disorder; 5) Nicotine Dependence; 6) 
Other Psychoactive Use Disorders; 7) Other Stimulant Related 
Disorders; 8) Other Substance Use Disorder; 9) Sedative Hypnotic 
Disorders; codes in Appendix L 
Gender Binary Male or Female 











1) Endocarditis; 2) Candida Endocarditis; 3) Osteomyelitis; 4) 
Bacteremia; 5) Discitis; 6) Septic Arthritis; 7) Brain Abscess; 8) Joint 
Infection; 9) Necrotizing Fasciitis; 10) Empyema; and 11) Lung Abscess; 








Categorical The primary ICD-10 admission diagnosis code for index hospitalization 
Race Categorical 1) American Indian or Alaska Native; 2) Asian; 3) Black or African 
American; 4) White; 5) Native Hawaiian or Other Pacific Islander; 6) 
Unknown/Decline to Answer 
Secondary 
Diagnosis2 





Categorical Point of admission for the index hospitalization: 1) Outpatient 
Treatment; 2) Other Direct admission; 3) Other 
ICU Service Binary Use of ICU services during index hospitalization  
Length of Stay Continuous  Length of time (days) of the index hospitalization 
Surgical Service Binary Use of surgical services during index hospitalization 
Table Notes. 1Present on admission = identified within prior 365 days; 2Occurred during admission;  
PTSD = Post Traumatic Stress Disorder. 
3.6.2c. Non-OAT pharmacotherapy variables. Pharmacotherapy variables were 
coded for the three study time periods: 1) pre-admission, which included filled 
prescriptions or medication procedure codes; 2) admission, which included 
administered medication, filled prescriptions (<1 % of data points), or medication 




medication procedure codes. If a medication was used more than once in a study time 
period, it was only counted once. See Table 3.3 for definitions and Appendix N for 
additional details.  
Table 3.3. Non-OAT Pharmacotherapy Variables1 
Variable Definition 
Pre-Admission 
Benzodiazepine Prescription filled for any Benzodiazepine 
Concurrent Opioid/Benzodiazepine Prescription filled for any Opioid and any Benzodiazepine 
Gabapentin/Pregabalin Prescription filled for Gabapentin or Pregabalin  
Naloxone Prescription filled for Naloxone 
Naltrexone Prescription filled or HCPCS code for Naltrexone 
Opioid  Prescription filled for any Non-OAT Opioids, not including 
Methadone or Buprenorphine 
Admission2 
Benzodiazepine Administration of Benzodiazepine 
Gabapentin/Pregabalin Administration of Gabapentin or Pregabalin 
Naltrexone Administration of Naltrexone 
No Opioid and No OAT No administration of an Opioid and OAT 
Opioid  Administration of any Non-OAT Opioid, did not include 
Methadone or Buprenorphine formulations for pain 
First-Line Withdrawal Adjuvant Administration of Clonidine 
Second-Line Withdrawal Adjuvant3 Administration of any second-line adjuvant: Baclofen or 
Gabapentin or Pregabalin or Tizanidine 
Any Withdrawal Adjuvants Administration of any of the adjuvants: Baclofen or 
Clonidine or Gabapentin or Pregabalin or Tizanidine 
Post-Admission 
Benzodiazepine Prescription filled for any Benzodiazepine 
Concurrent Opioid/Benzodiazepine Prescription filled for any Opioid and any Benzodiazepine 
Gabapentin/Pregabalin Prescription filled for Gabapentin or Pregabalin  
Naloxone Prescription filled for Naloxone 
Naltrexone Prescription filled or HCPCS code for Naltrexone 
Table Notes. 1Appendix N describes variable construction; 2during admission <1% of pharmaceutical 
data points were prescribed; 3Second line adjuvants are medications recommended for use by VHA 
Opioid Taper Tool (U.S. Department of Veterans Affairs, 2016b); HCPCS = Healthcare Common 
Procedure Coding System is a specific procedure billing code for medication administration. 
3.6.2d. OAT pharmacotherapy variables. OAT pharmacotherapy variables were 
created for the three study time periods. The pre-and post-admission OAT variables 
included filled buprenorphine prescriptions, procedure codes for methadone 




any OAT admission variable included all formulations of buprenorphine and methadone 
and any OAT-related procedure codes. The decision to include non-FDA approved OAT 
formulations (e.g., injectable methadone) was based on the findings from Aim 1 and the 
federal rules that allow this practice. Table 3.4 provides a summary of the OAT variable 
definitions and Appendix O provides additional details.  
Table 3.4. OAT Variables1 
Variable Definition Pharmacotherapy 
Pre-Admission   
Any OAT  Binary/ 
Categorical 
Prescription filled for FDA-approved OAT or OAT 
Procedure Code or OTP Visit 
Admission   
Any OAT Binary/ 
Categorical 
Administration of Any OAT 
OAT Continuation Binary OAT delivered during pre-admission and 
admission, but not post-admission 
OAT Initiation & Linkage to Care Binary OAT delivered during admission and post-
admission, but not pre-admission 
OAT Sustained Binary OAT delivered pre-admission, during admission 
and post-admission 
OAT Withdrawal Binary OAT delivered during admission, but not pre or 
post-admission 
OAT with Adjuvant Binary Administration of OAT and  
an any adjuvant during admission 
OAT with First-line Adjuvant  Binary Administration of OAT and  
a first-line adjuvant during admission 
OAT with Second-line Adjuvant  Binary Administration of OAT and  
a second-line adjuvant during admission 
OAT with Opioid Binary Administration of OAT and  
an any Non-OAT Opioid during admission 
OAT with Naltrexone Binary Administration of OAT and  
naltrexone during admission 
Post-Admission   
Any OAT Binary Prescription filled for FDA-approved OAT  
or OAT Procedure Code or OTP Visit 





 3.6.2e. Patient health and utilization variables. Patient health and services 
utilization variables were queried either directly from the VHA data or constructed from 
the data through coding. Definitions are provided in Table 3.5 and additional details are 
in Appendix P.  
Table 3.5. VHA Patient Health and Utilization Variables1 
Variable Type Definition 
In-Hospital Mortality Binary/Categorical Death during admission 
Left Against Medical Advice Binary/Categorical Leaving against medical advice during 
admission 
Death Binary Death within the post-admission time 
period  
Emergency Department Visit Binary VHA emergency department visit within 
the post-admission time period 
Hospital Readmission Binary VHA acute care visit within the post-
admission time period 
Table Notes. 1Appendix P describes variable construction. 
3.6.2f. Hospital characteristic variables. Hospital characteristic variables were 
queried either directly from the VHA data or constructed through coding. Definitions are 
provided in Table 3.6 and additional details are in Appendix Q.  
Table 3.6. VHA Hospital Characteristic Variables1 
Variable Type Definition 
Acute OUD Diagnosis Volume Binary The proportion of index admissions in a 
facility with an acute OUD diagnosis (OUD-
infection or OUD diagnosis) 
Admission Volume Continuous The number of admissions in a facility  
Hospital Region Categorical U.S. Census categories: 1) Northeast; 2) 
Midwest; 3) South; 4) West 
Hospital Size Categorical 1) Small: 1 to 49 beds; 2) Medium: 50 to 99 
beds; 3) Large: 100+ 
Table Notes. 1Appendix Q describes variable construction. 
 3.6.3. Descriptive and bivariate analyses. Frequencies and percentages were 
calculated for hospital (admission volume, size, and location), patient (age, gender, race, 




characteristics across the study cohort population (n = 12,407). The frequency of patient 
health-related characteristics was also calculated for OUD-related infection diagnosis, 
acute OUD-related diagnosis, the top 10 most common primary ICD-10 diagnosis codes, 
top 10 most common secondary ICD-10 diagnosis codes, co-occurring mental health 
conditions, and co-occurring SUDs. Pharmacotherapy frequency for the entire study 
cohort was described for non-OAT and OAT in all three study time periods. Additional 
system-wide descriptions of hospital OAT delivery across the study cohort and all 
facilities were conducted for any OAT delivery (frequency, median, range, IQR, skew, 
and kurtosis) and the four OAT scenarios: 1) OAT continued; 2) OAT initiation and 
linkage to care; 3) OAT sustained; and 4) OAT withdrawal management.  
Bivariate analyses compared sub-groups within the study cohort using Pearson 
chi-square, Pearson chi-square with Yates’ continuity correction, and Mann-Whitney U 
tests. Sub-group comparisons were made between patients who received OAT and 
those who did not receive OAT during admission, and patients who were on OAT prior 
to admission and discontinued with those who were continued on OAT during 
admission. Differences were assessed for characteristics present on admission, 
admission characteristics, non-OAT pharmacotherapy delivery during admission, and 
health and utilization outcomes.  
 3.6.4. Hospital performance analyses. Hospitals were assigned to one of four 
hospital OAT delivery performance categories dependent on the proportion of admitted 




hospitals had the lowest relative proportion of OAT delivered and Quartile 4 had the 
highest. Quartiles were described using measures for any OAT delivered including 
frequency, median, range, IQR, skew, and kurtosis. Differences across and between 
quartiles were assessed for OAT and non-OAT pharmacotherapy delivery using the 
Kruskal-Wallis and Dunn’s tests. Quartiles were assessed for differences in 
characteristics and health and utilization outcomes using Dunn’s, Kruskal-Wallis, and 
Fisher’s Exact tests.  
3.6.5. Multilevel analyses. Using Stata statistical analysis software (StataCorp, 
2017), multivariable logistic regression models were constructed to study the 
association (alpha value 0.05) of multilevel attributes on patient OAT receipt during 
hospitalization.  
3.6.5a. Dependent and independent variables. The dependent variable (level 1) 
was OAT receipt (yes/no) during hospitalization. The independent variables were 
continuous, binary, or categorical variables categorized as level 1 (i.e. patient) or level 2 
(i.e., hospital). Independent variable inclusion was based on the literature review, 
expert opinion, prior study aims, and model fit. Level 1 and level 2 independent 





Table 3.7. Independent Variables 
Level 1: Patient and Admission Characteristics Level 2: Hospital Characteristics 
Demographics 1. Admission Volume 
1. Age (continuous) 2. Acute OUD Diagnoses Relative Volume  
2. Male (ref. female) 3. Hospital Size-Medium (ref. small) 
3. Race: Non-white (ref. white) 4. Hospital Size-Large (ref. small) 
4. Race: Unknown (ref white) 5. Census Region Midwest (ref. South) 
5. Ethnicity: Hispanic (ref. non-Hispanic)  6. Census Region Northeast (ref. South) 
6. Ethnicity: Unknown (ref. non-Hispanic) 7. Census Region West (ref. South) 
7. Acute OUD diagnosis/infection (yes/no)  
8. Co-occurring SUD (yes/no)  
9. Co-occurring Mental Health disorder (yes/no)  
Admission  
10. Unintentional Overdose (yes/no)  
11. Opioid Withdrawal (yes/no)  
12. Length of Stay (continuous)  
13. ICU Services Received (yes/no)  
14. Surgical Services Received (yes/no)  
15. Admission Source: Other (ref. outpatient)  
16. Admission Source: Direct (ref. outpatient)  
17. Opioid Received (yes/no)  
18. Adjuvant Received (yes/no)  
19. Benzodiazepine Received (yes/no)  
20. Naltrexone Received (yes/no)  
Pre-Admission  
21. OAT Received (yes/no)  
22. Opioid Received (yes/no)  
23. Benzodiazepine Received (yes/no)  
24. Naltrexone Received (yes/no)  
25. Gabapentin/Pregabalin Received (yes/no)  
3.6.5b. Model preparation. Model preparation began with assessments for 
multicollinearity among covariates using variance inflation factors (VIFs), the conditional 
index, and Pearson correlation. Covariates included in the models were below 
collinearity thresholds—VIF (< 10), conditional index (< 30) (Hair, Tatham, Anderson, & 
Black, 1998), variance-decomposition matrix (< 0.9) (Hair et al., 1998), Pearson’s 
correlation coefficient (< 0.8) (Midi, Sarkar, & Rana, 2010)—except for one covariate 
with an elevated conditional index (> 30; = 33.5). 
3.6.5c. Model building. Model building occurred in a stepwise approach from 




3.2 and the purpose of each of model and the equation elements are described below.
 
Figure 3.2. Multilevel Modeling Equations 
The purpose of Model 1, the variance component model, was to describe 
hospital-specific random effects (Austin & Merlo, 2017) for patient OAT receipt: 
• i = the individual admission; 
•  j = the specific hospital in which the admission occurred; 
• !"#$%	("(()	!*+*!	1	"-%."/*)12  = the dependent variable (patient OAT receipt); 
• 344  = the level 2 intercept; and  
• -42  = the variance between hospitals (i.e., the random intercept component). 
 The purpose of Model 2, the intermediate model, was to test for associations 
between patient characteristics and patient OAT receipt, and to describe the hospital-
specific random effects (Austin & Merlo, 2017):  
• 354  is the effect of the level 1 covariate on the group specific intercept. 
 The purpose of Model 3, the final model, was to test for associations between 
patient and hospital characteristics on patient OAT receipt and to describe the hospital-
specific random effects (Austin & Merlo, 2017): 





• 345  is the effect of the group level covariate on the group specific intercept. 
Comparative model fit testing, for the nested models (Model 1 vs. Model 2 vs. 
Model 3), used log-likelihood ratio test, the Akaike Information Criteria (AIC), and the 
Bayesian Information Criteria (BIC). Regression coefficients, standard errors, odds ratios 
with 95% confidence intervals, and the intraclass correlation coefficient (ICC)2 were also 
calculated and reported for all three models. 
3.6.5d. Sensitivity analysis. A sensitivity analysis was conducted to discern 
whether using a narrower OAT administration definition (i.e., the exclusion of injectable 
forms of methadone/buprenorphine) would change study findings. The results of this 
analysis are presented in Chapter 5 (Section 5.6.4c and Appendix R). 
Section 3.7. Conclusion 
A mixed methods study, based on a pragmatic research paradigm, informed the 
design, approach, and analyses crafted to address the three study aims of this 
dissertation. The next three chapters present the study findings: Chapter 4 the 
qualitative findings, Chapter 5 the quantitative findings, and Chapter 6 the synthesis and 
integration of the qualitative and quantitative findings. 
 
                                                        
2










Chapter 4: Presentation and Analysis of Qualitative Data 
Parts of this chapter were published in a peer-reviewed journal: Priest, K.C., & 
McCarty, D. (2018). Role of the hospital in the 21st Century opioid overdose 
epidemic: The addiction medicine consult service. Journal of Addiction Medicine, 
Advance online publication. doi: 10.1097/ADM.0000000000000496. 
The purpose of Aim 1 was to identify environmental and hospital supply-side 
attributes that may explain, in part, the variation in care and limited use of OAT for 
hospitalized patients with OUD. Four research sub-questions guided this portion of the 
study:  
• Q1a: How is OAT delivered for patients with OUD in the hospital setting? 
• Q1b: Which internal and external environmental supply-side elements 
facilitate hospital OAT delivery? 
• Q1c: Which internal and external environmental supply-side elements 
impede hospital OAT delivery? 
• Q1d: How do hospital policies and guidance documents inform hospital OAT 
delivery?  
The conceptual framework, described in Chapter 2, informed Chapter 4 analyses 
and the presentation of findings. Of particular note, the perspective that hospitals and 
the activities within them exist is because of dynamic and complex interactions among 
continuously evolving economic, cultural, political, and socially normative structures and 





1. Section 4.1 describes the study cohort—17 key informants from 16 non-VHA 
hospitals—to provide the professional and environmental context for study 
findings.  
2. Section 4.2. examines the shared and different organizational characteristics of 
the nine established hospital AMC services. 
3. Section 4.3 explores the supply-side attributes (inside and outside the hospital) 
that facilitate the development and implementation of AMC services for the 
nine hospitals with established services and the five hospitals with plans to 
implement AMC services.  
4. Section 4.4 describes the barriers (inside and outside the hospital) for the 
development and implementation of AMC services and hospital OAT delivery 
for all 16 hospitals.  
5. Section 4.5 briefly explores the demand-side attributes (i.e., patient attributes) 
that emerged during key informant interviews, although the focus of this study 
was primarily on the supply-side contributions to care.  
6. Section 4.6 outlines six specific emergent supply-side actions beyond the AMC 
service to improve and enhance OUD-related services in the hospital context.  
7. Section 4.7 summarizes hospital guidance document analyses (n = 25), which 
describe the current OAT practices in non-VHA hospitals.  





Section 4.1. Study Cohort 
4.1.1. Participant demographics. Interviews were completed with 17 physicians 
affiliated with 16 U.S. hospitals or health systems. Participants were found through the 
publicly available Addiction Medicine Fellowship program list (Addiction Medicine 
Foundation, 2018). Key informants were board-certified (n = 16) or board-eligible (n = 1) 
addiction medicine physicians (medical or osteopathic doctorate) from five sub-
specialties—family medicine, internal medicine, obstetrics and gynecology, pediatrics, 
and psychiatry. The key informant mean age was 47 years. The 9 women and 8 men 
were predominantly white (n = 16) and Non-Hispanic or Latino (n = 15), and most had 
worked or trained in their hospital of employment for more than five years (n = 13).  
4.1.2. Hospital characteristics. Hospitals were located in the West (n = 4), 
Midwest (n = 4), Northeast (n = 5), and South (n = 3), and most were located in states 
with Affordable Care Act Medicaid expansion (n = 12). OAT products were on all hospital 
formularies for the treatment of OUD except for one, with some restrictions. Most 
hospitals (n = 10) had affiliated or onsite addiction related services, such as opioid 
treatment programs (OTPs) and “detox” beds. Three hospitals had OTPs and dedicated 
“detox” beds, three hospitals had only OTPs, four hospitals had only dedicated detox 
beds, and six hospitals had neither. Interestingly, the two hospitals without an AMC 
service or plans to start one either had an affiliated OTP or “detox” beds, potentially 
indicating that the types of addiction-related resources (AMC service vs. OTP vs. “detox” 





role of the AMC service, as both an input and output of service delivery, was an 
emergent and important finding that is articulated throughout this chapter.  
AMC services functioned as a key care delivery mechanism for persons with 
OUD. The presentation of results, therefore, begins with an assessment of the status of 
AMC services (established, planning to start, or not established/no plans to start). Over 
half of the hospitals, 9 of 16, had established AMC services, five hospitals planned to 
start an AMC, and two hospitals had no AMC service and no plans to start one. See 
Table 4.1 for a summary of hospital characteristics by region and available services.  
Table 4.1. Hospital Characteristics 
Hospital Type Region Affiliated/Onsite Services 
MW NE S W OTP Detox Both Neither 
Established AMC 
Service 
3 3 1 2 1 2 2 4 
Starting AMC 
Service 
0 1 2 2 1 1 1 2 
No AMC Service 1 1 0 0 1 1 0 0 
Total  4 5 3 4 3 4 3 6 
Table Notes. MW = Midwest; NE = Northeast; S = South; W = West; OTP = opioid treatment 
program; Detox = dedicated hospital beds for detoxification from substances; Both = OTP and 
dedicated hospital beds for detoxification from substances. 
The following sections integrate and synthesize the evidence provided by key 
informants in the interviews and from the hospital guidance documents. The 
culmination of these findings provides a first glimpse into an otherwise previously 
limitedly described care delivery scenario. 
Section 4.2. AMC Service Design and Operations 
 This section describes shared practices and differences in AMC service design 
and operations to address research sub-question 1a: How is OAT delivered for patients 





conceptual framework, which focused on technology and resources (e.g., staffing, 
financing) and social structures. AMC service shared practices and differences emerged 
across four domains: 1) availability and coverage; 2) home department and team 
composition; 3) responsibility and scope; and 4) financing. Eight of the nine established 
AMC services had a dedicated consult service staffed with addiction medicine physicians 
and one service was a part of the psychiatry consultation liaison service. AMC services 
varied in design, specifically the availability and coverage within the hospital, team 
composition, scope and responsibility of the service, and financing. The barriers and 
facilitators to AMC implementation, however, were similar across programs. 
4.2.1. Availability and coverage. The AMC services varied with access to 
resources and staffing, because of local supply-side attributes (e.g., financing and social 
structures). At the same time, many operational characteristics and challenges across 
the nine services were similar. Most established AMC services (n = 8) provided in-person 
consultation only during weekdays and a third of services (n = 3) provided consultation 
in the emergency department. The single program with weekend service availability was 
staffed by trainees who worked on the psychiatry consultation liaison service. Generally, 
the limited weekday availability frustrated key informants; they felt that patients who 
were admitted or discharged on weekends were not receiving life-saving addiction-
related services. As a result, care was sometimes rationed on the weekdays because of 






The counselors came in with 26 consult orders yesterday, on a Monday, so they 
don't have time to do the assessments and to help actually find treatment beds 
for patients. So, they have to prioritize it to the highest needs, people who are 
directly transferring to treatment. (I1) 
 
Key informants linked staffing constraints to limited financial resources. Staffing 
deficits led to work-around clinical processes, such as taking home call or consultations 
via pager. These approaches, however, did not mitigate the heavy patient caseload on 
Monday mornings. Limited financing for clinical staff also constrained physically where 
AMC consultation could occur (e.g., the emergency department). Key informants 
believed that to be a fully operational consult service it was essential to provide services 
in the emergency department. 
4.2.2. Home department and team composition. The home department and 
AMC service team composition varied, reflecting local social structures within each 
hospital. In some programs, the AMC service was established through the departments 
of family medicine or internal medicine, and in one hospital, the AMC service based in 
the psychiatry and medicine departments. Eight of the nine established AMC services 
were staffed with addiction medicine physicians, although physician staffing resources 
varied. One well-established consult service had over 10 board-certified addiction 
medicine physicians; in contrast, others were limited to one physician. Eight of the nine 
consult services comprised of interprofessional teams. The most common non-physician 
team members were nurse practitioners (n = 4) and social workers (n = 4) and less 
common were alcohol and drug counselors (n = 2), physician assistants (n = 2), 





Although not commonly a part of the AMC services, informants sought to add 
peer support providers (i.e., trained persons with lived addiction experience; “peers”) to 
the team. At the time of interview, only one hospital had peers on their service. The 
primary responsibilities of the peer were to “…help patients stay in the hospital and help 
engage them” (deidentified3) and to provide conflict de-escalation. The key informant 
shared that the outcome most important to peers, which differed from the rest of the 
care team, was: “relationship[s]” (deidentified). The informant noted that the inclusion 
of peers on the team made other clinical staff in the hospital uncomfortable. The 
informant posited that this was because peers challenged the traditional hierarchy of 
clinical roles in the hospital. 
In contrast to peers, medical trainees (e.g., addiction medicine fellows, resident 
physicians, and medical students) were common AMC service team members. 
Informants reported that trainees were a critical resource for both the standard work of 
the service (e.g., trainees see the patient first) and as a mechanism for extending their 
clinical staffing resources (e.g., fellows staff the consult service).  
Table 4.2. Addiction Medicine Consult Service Design (n = 9) 
Availability & Coverage Non-Physician Team Members 
Weekend ED NP Peer Physician 
Assistant 
Psychologist Social  
Worker 
Alcohol & Drug 
Counselors 
11%  
(n = 1)  
38%  
(n = 3)  
50%  
(n = 4)  
11%    
   (n = 1)  
25%     
  (n = 2)  
25%     
  (n = 2)  
50%  
(n = 4)  
25%     
  (n = 2)  
Table Notes. ED = emergency department; NP = nurse practitioner. 
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4.2.3. Responsibilities and scope of practice. AMC service responsibility and 
scope of practice existed in three categories: 1) the provision of SUD-related education 
to trainees, providers, and hospital staff; 2) the delivery of psychosocial and medical 
services (e.g., motivational interviewing, pharmacotherapy, linkage to care); and 3) 
hospital guidance document development (e.g., order sets, guidelines, and protocols). 
4.2.3a. Education. Hospital-wide education related to SUD treatment was an 
important responsibility of the AMC service:  
We teach an addiction mini-course in the second-year medical student 
curriculum. It is a required course at our university. It is not a long course…but we 
are one of the few medical schools who do that from my understanding…[our] 
residential treatment facility and detox center…is a clinical training site for third 
year medical students, as well as psychiatry residents…we have a Project 
Echo…and we do a lot of addiction medicine education to primary care, 
psychiatrists, case managers and counselors. (M1) 
 
 Further, the AMC services sought to inspire hospital culture change through their 
educational initiatives. The presence of the AMC service, moreover, enhanced 
understanding among hospital staff about the need to address OUD within the medical 
context. Informants perceived that the AMC service provided other benefits such as 
decreasing provider burnout, decreasing provider stigma, and improving the culture and 
the clinical practice for SUDs: “By having the right teams in place in the hospital we can 
really change the hospital experience not just for patients but for the providers” (A2) 
and “I think there is a morale booster, both for us and our colleagues. And then it just 






4.2.3b. Service delivery. Generally, AMC services were responsible for five core 
services: 1) mental health and SUD assessments; 2) psychosocial intervention; 3) the 
medical management of SUDs (e.g., clinical activities related to OAT initiation, 
continuation, and discontinuation, the management of benzodiazepine and alcohol 
withdrawal); 4) the medical management of pain; and 5) linkage to care (e.g., referrals 
to treatment, bridge scripts, care pathways). Variation in team composition was 
associated with the different psychosocial techniques used by the service (i.e., brief 
intervention; cognitive behavioral therapy; dialectal behavioral therapy; and 
motivational interviewing) and harm reduction interventions (i.e., naloxone kit 
distribution; overdose education; counseling on syringe exchange; and allowing patients 
to smoke).  
Informants emphasized that linkage to care was an essential and distinctive AMC 
service responsibility and they described four linkage to care modalities: 1) writing a 
bridge script; 2) referring to community-based services; 3) admitting to a transition 
program; and 4) transferring to another health system’s bridge clinic. Bridge scripts 
were the most common linkage approach and occurred when an inpatient physician 
wrote a prescription for buprenorphine/naloxone to “bridge” the patient until they 
established care with a community-based provider. Other linkage to care approaches 
included providing referral to community-based services (e.g., direct transitions into 






Other less commonly used linkage approaches were the use of transition 
programs and bridge clinics. Informants described transition programs as “rapid access” 
and “reach-in” interventions, meaning that a community-based provider visited patients 
during hospitalization to prepare them for direct discharge to their outpatient program. 
Further, only one hospital had an operational bridge clinic at the time of interview. The 
bridge clinic transitioned patients, over a two-week window, to an outpatient 
community-based OAT provider. Both types of programs, transition and bridge clinics, 
were developed in collaboration with external partners.  
AMC service standard work was hospital specific; however, two services shared a 
similar consultation process based on the different types of providers on the team. At 
their hospitals, staff could request either a consult from the service’s behavioral health 
provider (e.g., social worker) or from a clinical provider (e.g., physician).  
4.2.3c. Policy development. The final category of AMC service responsibility, led 
by physicians on the team, was the creation of hospital guidance documents; 
specifically, the creation and implementation of order sets, guidelines, and protocols 
related hospital-based services for patients with OUD and other SUDs. Hospital guidance 
document creation was a common responsibility and the content of those polices is 
explored and described further in Section 4.7 of this chapter. Typically, the AMC service 
leadership worked closely with pharmacy and therapeutics (P&T) committee to ensure 
that OAT was available on the hospital formulary and that standard procedures were in 





partnering with the P&T committee to make sure we had access to buprenorphine, 
extended-release naltrexone, and methadone, on the floors. [We] wrote protocols for 
how those medications are used” (A1). 
4.2.4. Financing. A common concern and activity across all services was planning 
for and acquiring financial resources, which consistently constrained or facilitated AMC 
service existence and operation. The fiscal environment for the services was complex 
and tumultuous. Informants described service financial solvency dependent on a 
patchwork of monetary streams, including: in-house financing; third-party payer 
revenue; grant funding; state funding; and fellowship program funding. 
Many services received in-house funding for the salaries of the clinical staff and 
salaries for the addiction medicine fellows. The services procured these funds from 
either a specific department (e.g., medicine or psychiatry) or from hospital operations. 
In addition, some operating funds came through third-party payer billing. One informant 
stated that they billed “just like any other consultant” (L1) and, other informants were 
acutely aware of their reimbursement return rates: “We also do our own billing for 
patients…[our] reimbursement return rate is only about 25% though, because the vast 
majority of patients that we see are Medicaid or uninsured” (J1) and “Our recovery rate 
was 28%, so we get paid about 28% of what we bill… When we add it all up, if a nurse is 
billing at the right volume they actually pay for a lot of their salary” (K1). 
Some AMC services operated as pilot programs through grant funding from the 





how a local managed health care organization was funding the salary, for a limited 
duration of time, of specific service team members—the physician assistant and alcohol 
and drug counselor. Informants shared that state funding for the service came from 
state health care reform funds (e.g., accountable care organizations) or dedicated 
indigent funds in the states that opted out of Medicaid expansion.  
4.2.5. Summary. To date, prior research has not described the shared and 
different organizational elements of more than one AMC service. Common design and 
operational practices included weekday only service availability, the use of 
interprofessional teams, the use of medical trainees, and three domains of responsibility 
(i.e., education, delivery of psychosocial and medical services, and policy development). 
AMC services varied by home department, the professional composition of the team, 
day-to-day operations, and how the services were financed. 
These analyses suggest three important conclusions. First, AMC service 
responsibilities included two non-medical domains: 1) education; and 2) policy 
development. This finding is not surprising because of the interprofessional nature of 
the AMC service and because of the complexity of the external treatment environment 
(e.g., policies and regulations). Second, the AMC service was not only a mechanism for 
OAT delivery, but an intervention for shaping and changing hospitals’ social structures 
through diverse responsibilities (i.e., education and policy development). Third, two 
supply-side attributes influenced and mediated the AMC service design and operation—





Section 4.3. Facilitators for AMC Service Implementation 
 Prior to this study, little was known about the facilitative attributes for the 
creation of hospital-based addiction technologies and delivery of care for patients with 
OUD. This section explores research sub-question 1b: Which internal and external 
environmental supply-side elements facilitate hospital OAT delivery? A primary finding 
from the qualitative aim of this study was that the AMC service was a key mechanism 
for hospital OAT delivery and other OUD-related services. The service promoted and 
increased the use of evidence-based services in the hospital and also catalyzed the 
development of other organizational technologies, such as standard practice 
documents. This section describes the hospital and environmental attributes that 
facilitated AMC service establishment in 9 hospitals (n = 10) and the soon to be 
established services in the 5 hospitals (n = 5). These elements existed within and outside 
the hospital environment and as demand-side attributes (i.e., patient characteristics). 
4.3.1. Facilitative attributes within the hospital. In the hospital environment, 
AMC service development was only possible within the context of positive social 
structures and appropriate technology and resources (i.e., staffing). Evidence of positive 
social structures included: 1) a history of caring for persons with addiction within that 
hospital or health system; 2) designated financial and clinical resources for addiction 
treatment; 3) addiction medicine clinical training programs; 4) normative treatment 






 4.3.1a. Historical support and practice. Informants noted that an institutional 
history of addiction related initiatives facilitated AMC service design and operations. 
Informants described prior practice as positively contributing to contemporary care 
delivery environments: “I worked in the hospital where one of the founders of 
Alcoholics Anonymous worked so the hospital has a long history of detox and treatment 
of substance use disorder (L1)” and “A neurologist who had become interested in 
addiction in the 1990s established a consult service and then there was an internal 
medicine doctor who took it over…it was in many ways…almost like a labor of love” (F1). 
Informants described three types of prior clinical practices that influenced service 
establishment: 1) ad hoc consults; 2) “curbside consults” (M1); and 3) a buprenorphine 
pager. Ad hoc consultation was the most common, present in several hospitals prior to 
AMC service existence. This type of practice occurred when an addiction medicine 
physician provided an informal consult on a SUD patient as a favor to a colleague: 
One of my colleagues and I started doing ad hoc addiction medicine consultations 
five years ago and that grew into the AMC service…We had so many patients on 
the internal medicine and surgical wards with addiction issues that were really 
going untreated, people knew that my colleague and I prescribed buprenorphine 
and so they thought that we might be able to help…they would call us and we 
would leave whatever we were doing and go do a consult. (A1) 
 
The “curbside consult” approach, used in one hospital, occurred when an addiction 
medicine physician provided informal consultation for the psychiatry consult service:  
Basically, I just assist in education and curbside consult for the psychiatry consult 
team. I am not billing for consults myself the psychiatry consult team is, but if he 







 The third approach, at another hospital, was a dedicated buprenorphine pager 
staffed by a family medicine inpatient team that provided remote support on 
buprenorphine initiation. The informant shared that “we kind of just do that on our time 
on the side, to help coach providers who are interested in prescribing buprenorphine 
but aren't sure how to for their hospitalized patients” (C1). The guiding philosophy 
across all three strategies was the dedication of the addiction medicine physicians to the 
ethical treatment and care for people with SUDs in the hospital, regardless of 
compensation. 
4.3.1b. Financial and clinical resources. Financial and clinical resources were 
essential to AMC service establishment. Existing treatment services and research 
programming for addiction often facilitated the creation of a service. From a clinical 
perspective, in hospitals with addiction-related services already in existence, clinical 
leaders could argue that AMC service creation was filling a gap in the SUD care 
continuum. These additional services differed among hospitals and health systems, but 
included established outpatient addiction medicine clinics, dedicated hospital units for 
managing SUD withdrawal, intensive outpatient programming, affiliated or onsite OTPs, 
and a residential halfway house. One informant commented that because of the already 
in existence robust institutional addiction research program that hospital leadership 
viewed addiction-issues with familiarity and positivity. In addition to physical resources, 
such as clinics, dedicated beds, and research programs, informants described the 





physicians. Some of the informants shared that they were recruited to their institution 
to start a service or fellowship program: “I was hired with the intent that I would build 
this consult service and get it up and running” (I1). 
4.3.1c. Clinical training programs. Finally, unsurprisingly, addiction-related 
education programs and training activities facilitated an addiction-friendly hospital 
environment. Informants described how the financing for their addiction medicine 
fellowship was crucial for establishing a service. More than one informant described this 
explicit financial connection between the service and the fellowship: 
We kind of put a pitch together where we would ask for funding for the 
fellowship slot and then use that for our consult service… the chair of the 
department of medicine agreed to fund a fellowship slot and half of a nurse and 
then we would staff it with attendings who would bill for services. (K1) 
 
Trainee champions were another supportive element to service development. 
Residents, in particular, became champions within the hospital for improving OUD-
related services: 
The initial pilot program for buprenorphine induction in the hospital was the idea 
of residents. And they really have taken this on. And asked to be trained, to be X-
waivered…All of the residents are being trained in buprenorphine prescribing. It 
has been exciting to see how the educational aspect of this hospital has moved 
things forward for everyone not just the folks who are currently in training. (C1) 
 
These findings compliment observations from the prior section on the important 
contributions of medical trainees for AMC service operation. 
4.3.1d. Normative practice. AMC service development was facilitated by care 
standards for SUD services within the hospital and health system. One informant 





was that all providers from all services must “be able to provide methadone 
maintenance. It is just routine standard of care.” (C1). At another hospital, this practice 
was a requirement for all trainees: “We require that all our incoming interns…during 
new intern orientation get buprenorphine waived” (O1).  
4.3.1e. Administrative and clinical leadership. Supportive hospital 
administrators, with guidance from addiction medicine clinical champions, drove AMC 
service establishment. However, hospital administrators varied in their reasons for 
supporting the service. Some administrators believed that addiction was a medical and 
public health issue, some administrators had relevant clinical experience, but nearly all 
were perceived to be moved to action by the “business case.” Addiction medicine 
physicians were key leaders in developing and presenting the business case to garner 
hospital administrative support. The approaches used to engage hospital administrators 
included producing data on service needs and demands, including: 1) how the hospital 
census had an elevated SUD prevalence; 2) how untreated SUD negatively impacts 
hospital finances; 3) how other hospitals are benefiting from service implementation; 
and 4) why the hospital addiction treatment gap is a care quality issue. Each of these 
approaches are addressed in turn. 
 4.3.1e.1. Elevated SUD prevalence. Addiction medicine leaders presented either 
national public health data or internal census data on the prevalence of SUD-related 





have some co-occurring substance use problem and the inpatient [setting] is an 
opportune time to try and tackle those problems” (E1). Informants shared: 
We were able to collect data…we presented that to administration...they didn’t 
have the awareness of the saturation of the problem and we were really able to 
get buy-in from the president of the university…We basically just showed them 
the data. (M1) 
 
 4.3.1e.2. Negative financial impacts. Addiction medicine leaders also presented 
data illustrating how patients with untreated SUD in the hospital had increased resource 
utilization and how that was negatively impacting hospital revenue. Informants noted 
that readmission penalties and increased lengths of stay were persuasive arguments for 
service establishment: “What we ended up doing was basically through that needs 
assessment building a pretty strong business case around length of stay reduction and 
also building a business case around readmission reductions” (A2). At one hospital, 
administrators were convinced to implement a service because untreated SUD patients 
had longer lengths of stay which was inhibiting patient flow between the emergency 
department to the inpatient wards: “The emergency department was getting a lot of 
pressure from the hospital to move patients quicker, lots of patients were lingering in 
the emergency department that should have either been discharged or been moved to 
beds on the floor” (O1). 
4.3.1e.3. Success at other hospitals. Addiction medicine champions strategically 
leveraged the success of other prestigious institutions that were already providing 





In addition to the data that we had collected, it was honestly some healthy 
competition. I was saying look [institution A] has one of these, [institution B] has 
one of these, [institution C] has one of these, New York City is creating a city-wide 
service through the health and hospitals program. It is really silly that we don't 
have one. That caught their ear and they were able to look at the data a little 
more. (O1) 
 
Another informant shared how the positive press at a competing hospital pressured 
hospital leadership to move more swiftly in implementing their AMC service: “The 
neighboring institution started a service…a year before we did…and you know they had 
positive press coverage…my hospital had fashioned itself as a leader in addiction and it 
really prodded them and was useful external pressure.” (K1) 
4.3.1e.4. Care quality. Informants identified and shared with leaders how 
untreated SUD in the hospital setting was a care quality issue and why this issue fell 
under hospital purview. One informant stated that they “had to show that the volume 
of the service is really high [if] we are going to justify it [the AMC service]” (K1). Only 
one informant described presenting patient care preferences to hospital administrators 
when making the AMC service business case.  
4.3.1f. Stakeholders. Internal stakeholders also supported AMC service 
establishment (e.g., physician-based consultation services, nursing, hospital security, 
and the P&T committee). Informants affiliated with large academic health centers had 
access to other consult services. At some of the hospitals these other internal services 
were either supportive or were an impediment to AMC service formation. The 
supportive services varied and included the psychiatry consultation service, the pain 





with psychiatric consultation services were common and the services actively worked 
together to delineate responsibilities, to collaborate on care for shared patients, and 
produce educational activities. One informant described an uncommon collaborator—
the cardiovascular surgical service. The surgical service became involved in the 
development of the AMC service at one hospital because the surgeons had decided that 
they were no longer going to conduct valve transplants on patients who injected drugs. 
The surgeons’ refusal to care for these patients resulted in a joint medical ethics 
conference with the addiction medicine physicians, and this event inspired the surgeons 
to become vocal supporters of improving care for patients with OUD, they helped to 
lobby hospital administrators to launch the service. 
Another informant shared the importance of working with hospital security staff 
and officers, to help them better understand SUDs, because many of the service’s 
patients were either currently involved with the criminal-justice system or were 
participating in illegal activities while hospitalized: 
The consult service slowly over time has been able to navigate that conversation 
with hospital security, and use more conflict de-escalation approaches and 
behavioral agreements to managing some of those behaviors with the goal of 
keeping people in the hospital to complete their treatment and then engaging 
them in the community for treatment afterwards rather than transitioning to jail. 
(A1) 
 
Internal collaborators (e.g., hospital administrators, the P&T committee, nursing 
staff, clinicians in other departments) further bolstered the creation of other hospital-
based technologies to promote evidence-based delivery of services for patients with 





have support from multiple different department. The support of the obstetrics team, 
our anesthesiology team, and our pharmacy” (C1). 
4.3.2. Facilitative attributes outside the hospital. The external environment, 
outside the hospital, positively mediated AMC service creation. Facilitative 
environmental influencers included: 1) non-clinical stakeholders; 2) clinical 
stakeholders; 3) a robust community-based treatment network; 4) media coverage on 
the opioid overdose epidemic; 5) policies and regulations; 6) politics and political action; 
and 7) financing. 
4.3.2a. Non-clinical stakeholders. Non-clinical stakeholders contributed to the 
introduction of and support for AMC services. Stakeholders helped by: 1) generating 
new normative expectations and behaviors related to hospital addiction care; and 2) 
pressuring hospital leadership to address the issue. The non-clinical organizations of 
influence included the Association of American Medical Colleges (AAMC), the Office of 
National Drug Control Policy (ONDCP), local governments, and the state Medicaid 
programs. 
4.3.2b. Clinical stakeholders. Key informants recognized the value of formal and 
informal partnerships with community-based clinical providers and other local 
institutions. One informant noted that: “There is no doubt that without pathways to 
treatment in the community we would be hamstrung” (A2). Informants described 





based agency. Support from colleagues at a nearby hospital facilitated service training 
and development: 
We are very friendly with them [the providers at another hospital] …. Our clinics 
talk together the most…more than our consult services, but the…clinics are really 
extensions of the consult services…The other institution is starting a fellowship so 
we plan on including them in our multiprogram case conference…We are all 
friends. (K1) 
 
4.3.2c. Robust community-based treatment network. Access to community-
based treatment resources facilitated AMC service establishment in some communities. 
Although the majority of informants indicated a dearth of community-based treatment 
services available to their patients, a few informants perceived that their community-
based treatment network was readily accessible for their patients upon discharge: 
In our state, different counties have mental health and recovery boards and 
funding to support treatment for people, and the county where we are located is 
very very good, they have a lot of treatment facilities and options where they pay 
for people to go to treatment. So, they were very helpful to us because they 
offered us pipeline warm hand off essentially for people who were seen in 
consultation to be able to transition after they got out. (L1) 
 
4.3.2d. Awareness generation through media coverage. Public awareness of the 
opioid overdose epidemic, occurring primarily through local and national media 
coverage, supported service creation. General awareness about the opioid overdose 
crisis among hospital leadership created pressure for leadership to start a service. An 
informant stated that: “What really opened up the door was the opioid epidemic. Now 
hospital leaders have been paying attention” (E1), and another noted that they believed 
“it has been all the attention on the opioid crisis has been getting in popular media and 





other providers within the hospital about the challenges of the opioid overdose 
epidemic in their local community: “I think all of the news media coverage of the opioid 
epidemic. Our providers are seeing the reality of that on the streets of our city. It has 
been hugely helpful” (C1).  
4.3.2e. Policies and regulations. External policies and regulations generally were 
predominantly unsupportive of AMC service establishment. Despite this, informants 
noted four external policies and regulations that helped: 1) the American College of 
Surgeons’ trauma certification requirements; 2) Medicaid expansion; 3) the changing 
telehealth laws; and 4) Medicaid coverage for SUD treatment. One informant 
elaborated further:  
One big positive is our state signed up for Medicaid expansion. A lot of these 
patients are covered [by Medicaid] …When I talk to people in North Carolina, 
they don't have that. It is hard for me to imagine you know how they can help 
patients. In that regard we are fortunate that many of our patients can access 
health insurance and that provides them with access to good treatment. (D1) 
 
4.3.2f. Supportive politics and political leadership. Local political leaders 
contributed to AMC service implementation. In some jurisdictions, local city leadership 
explicitly called upon hospitals to act. One informant reported that: “The health 
commissioner here has encouraged hospitals to get more involved” (D1). In a different 
city, the leadership of the city health department scaled up the city-wide hospital opioid 






 4.3.2g. Financing. Overall, the financial landscape constrained AMC service 
implementation and operations, however, in certain contexts, financing promoted 
service formation. One informant shared how quality metrics and financial incentives 
and penalties linked to hospital benchmarks helped to support the business case for the 
existence of an AMC service. In some local contexts, state and regional capitation-based 
insurance programs and their payment policies tied to readmission rates indirectly 
drove hospitals to improve services for persons with SUDs, who were commonly 
readmitted. 
4.3.3. Summary. The synthesis of these findings helps to answer why a simple 
supply-demand model is insufficient to explain AMC service development: “It is [the] 
convergence of funding opportunities…greater awareness, and grassroots advocacy by 
me and my colleagues here at the institution....” (E1). These analyses suggest that the 
contributions of internal and external supply-side attributes were influential for 
inspiring hospital innovation and creation of new care delivery mechanisms for persons 
with OUD and SUD. Support attributes within the hospital context included positive 
social structures for addiction-related services, historical practice, previous clinical and 
resource investments in addiction related care, especially addiction medicine training 
programs, normative treatment practices, and supportive internal stakeholders. 
Partnerships with clinical and non-clinical stakeholders further supported service 





providers, normative practices related to addiction treatment, policies and regulations, 
financing, and media coverage and awareness of the problem.  
Section 4.4. AMC Service Implementation Barriers 
This next section explores research sub-question 1c: Which internal and external 
environmental supply-side elements impede hospital OAT delivery? Informants from all 
16 hospitals (n = 17) furthered the understanding of barriers to AMC service 
development and hospital OAT delivery. These constraining elements existed within and 
outside the hospital, providing insight as to: 1) why hospital AMC services are a relative 
new mechanism of care; 2) why adoption of AMC services across the U.S. is slow; 3) why 
the hospital OAT delivery is underused; and 4) the potential leverage points to decrease 
barriers.  
4.4.1. Barriers within the hospital. Key informants from all 16 hospitals 
described internal barriers to service establishment, service planning, and the delivery 
of OUD-related services. Six interdependent organizational barriers emerged: 1) 
restrictive policies and regulations; 2) existence of bureaucratic processes; 3) limited 
hospital-based staffing and resources related to addiction service delivery; 4) internal 
stakeholders; 5) stigmatizing behavior and training gaps perpetuated by hospital staff 
and administration; and 6) financial instability. 
4.4.1a. Restrictive policies and regulations. In some hospitals, the inpatient 
pharmacy and P&T committee would create internal policies that inhibited OAT access: 





hospital” (L1). One hospital did not have mono-product buprenorphine and only stocked 
combo-product (buprenorphine/naloxone), thereby creating issues for treating 
pregnant women because first-line treatment is mono-product. In another hospital, 
conversely, the hospital formulary only included the mono-product buprenorphine, 
requiring patients using the buprenorphine/naloxone combination product to switch or 
discontinue during the admission. Another informant gave up trying to get the 
buprenorphine implant added to the hospital formulary, stating that: “[the hospital] will 
road block anything” (G1). Other internal formulary and prescribing restrictions included 
limitations on when providers could prescribe buprenorphine/naloxone. One hospital, 
for example, restricted buprenorphine/naloxone administration only to prescribers with 
a federal buprenorphine waiver. Notably, this was one of the two hospitals without an 
AMC service or plans to start one. 
4.4.1b. Bureaucratic processes. Barriers to service development were related to 
the bureaucratic properties of large hospitals: size, staff turnover, and slow and complex 
decision-making. The large size of teaching hospitals created challenges for service 
development because the newly forming AMC service was just one of many 
consultation services: “[there are] only so many hours in the day for you to get in front 
of people's eyes” (H1). Further, more than one informant described staff turnover as 
operationally problematic, creating confusion related to the service’s roles and 
responsibilities. Finally, the slow, formal, and hierarchal decision-making process slowed 





hospital system or university. If you present a procedure it has to go through formal 
processes, formal committees, policy committee, and up to the top” (M1), and: 
As far as rolling something out you got to get it cleared by a million different 
people, there is like, it is like dealing with the federal government basically, you 
can't just get everyone in a room really quick and here's what we are going to do. 
Our size works against us. (H1) 
 
4.4.1c. Limited staffing and resources. Limited clinical staff with addiction 
medicine expertise was a common barrier for service development and operations: “We 
haven't had enough qualified faculty to be able to [start the service] until recently” (N1). 
In the two hospitals without an AMC service or the plans to start one, informants shared 
that the primary cause was a lack of resources, stating that: “Manpower is number one” 
(G1) and “It is mostly been for lack of personnel… [to] have the bandwidth to do it” (B1). 
Even for those with an established AMC service, after launching, more than one 
informant described issues related to access to physical resources and staffing: “I still 
have no office. I still have no dedicated land line. I don't have an admin” (P1). When 
asked about dedicated individual time to the AMC service one key informant responded: 
“I have about 20% FTE which is not nearly enough” (J1).  
4.4.1d. Unsupportive internal stakeholders. Another common barrier to service 
development and operations was resistance from other hospital stakeholders. An 
informant noted: “There…[are] certain individuals who are going to slow that process 
down...They have some personal biases” (M1). Psychiatry consultation services were 
frequently responsible for creating roadblocks. More than one informant described the 





threatened the psychiatric consultation liaison service because of the other service’s low 
volume: “Ironically it is the psychiatrists here who aren't as enthusiastic. It has been kind 
of a funny turf war. People get their thing going at a hospital and they see other services 
as competition” (E1). Informants also believed that the psychiatrists were reluctant to 
deliver evidence-based OUD services because of stigma and limited training experience 
in caring for persons with SUDs. 
Hospital leadership also impeded service and addiction treatment resource 
development. One informant, without a service, described how leaders at their hospital 
had “no foresight” (G1) when it came to issues related to addiction. This informant 
believed that unless outside forces intervened, such as an external mandate requiring 
evidence-based service delivery for OUD, or for reimbursement, that hospital leadership 
would never address the issue. Hospital leaders also had concerns about starting a 
service without explicitly identified connections to care upon discharge:  
I think there was also a lot of concern from our hospital leadership around 
making sure that patients were connected to outpatient care on discharge. 
Which is a complex issue because there are some patients who may or may not, 
as I was saying, connect to care on discharge. (C1) 
 
4.4.1e. Stigmatizing provider behavior and training gaps. A consistent barrier to 
hospital OAT delivery across hospitals was a lack of provider education and training. This 







Stigma is about lack of education...and the personal experience of the person 
who is stigmatizing the patient...I encourage [other clinical providers] to 
understand [addiction] through the chronic disease model and [I] just listen... 
Many times, it turns out...it is a lack of information and once I provide 
information the stigma sort of just melts [away]. (P1)  
 
 Limited education and training on the treatment of SUDs is based on historic and 
contemporary social structures within undergraduate and graduate medical education 
training programs and further enforced through other supply-side attributes (e.g., 
reimbursement and financing policies, undergraduate and graduate medical education 
accrediting bodies). The confluence of these elements informed hospital cultural-
cognitive social structures and in turn, likely negatively impacted the care of persons 
with OUD and other SUDs within the hospital. Informants frequently observed 
stigmatizing and discriminatory behavior by other providers and recognized that these 
actions reflected the failure of medical education to train physicians properly in 
addiction: 
Historically, the medical profession really has not viewed the treatment of 
addiction as part of what they do. At best, people would get a referral at the end 
of their hospitalization for rehab. And there would be no attempts to initiate 
treatment within the hospital. Obviously, that has not worked very well. Even 
when the primary reason for hospitalization was related to their substance use. 
(A1) 
 
Further, informants observed other hospital providers as having historically antiquated 
and uninformed ideas about addiction: 
In this area of the country there is still the perception by many people that 
addiction is not an illness, but it is a spiritual deficit, or a personal, or personality 
deficit. We have a lot of barriers just in terms of educating our staff to not treat 
these people differently than they would treat an individual who comes in with 





Even more alarming was the observation that providers who interfaced most 
frequently with SUD patients, orthopedic surgeons and emergency department 
physicians, were particularly uninformed on OUD and SUD treatment best practices. An 
informant described how the orthopedic surgical team had a culture of “just treat ‘em 
and street ‘em” (H1). In the emergency department, one informant shared how she 
believed that emergency services were re-traumatizing SUD patients and that it was a 
missed opportunity for care. Further, another informant explained that emergency 
department services were deficient because of “Ignorance...you know the kind that 
many of us in the health care field have been raised with. Modeling is often…not often 
very consistent...and non-therapeutic” (G1). This informant perceived that the origin of 
the challenges in the emergency department was due to the department’s externally 
contracted physician staffing model that resulted in limited incentives to improve care. 
Another informant shared how emergency department physicians at their hospital 
believed it to be illegal to provide methadone for withdrawal: “I am going to talk at the 
[emergency] department meeting and explain that it is in fact legal and humane to treat 
withdrawal and that is how you can do it safely. There are really big gaps in knowledge” 
(A2).  
Provider misunderstanding and confusion regarding OAT policies and regulations 
was common across all hospitals, and not only an issue specific to the emergency 





misinterpreting OAT regulations and subsequently not providing care. Providers and 
administrators believed it was illegal to administer OAT in the hospital:  
There is still the perception on the part of many providers that somehow it is 
illegal to engage in that practice [administer methadone in the hospital] …. [the] 
pharmacy has been a barrier, when Suboxone® or methadone-based 
maintenance and taper regimen gets ordered and the pharmacist says you can't 
do that, that is illegal. (J1)  
 
I know that because we are not certified as an OTP that there is much hesitance 
around this [administering methadone]. I know that there is as you know, the 72-
hour rule, so you can manage withdrawal on inpatients, but it is not practiced. I 
would say that generally our legal department is very conservative when it comes 
to things like that. (B1) 
 
Hospital providers, not trained in addiction medicine, often believed they had to 
have a special wavier to administer OAT during hospitalization: “The perception is that a 
provider making the order, even in the hospital setting, needs to have the DATA waiver 
to prescribe administer a buprenorphine product for that indication” (J1). Beyond legal 
confusion, informants observed that other providers had a limited understanding of 
OAT efficacy. It was common in one hospital that non-addiction trained providers 
believed that OAT was “substituting one drug for another” (C1).  
In addition to the confusion about legality and efficacy, informants observed 
more subtle forms of stigma—apathy. This was most commonly perpetuated by hospital 
leadership who decided against supporting or investing AMC service resources: 
They start with all the reasons it can't be done and stop there…you know people 
don't want to say out loud things like "well we don't to be known for that kind of 
thing." I think again that maybe they feel we don't want to draw attention to 







 Hospital leadership also held AMC services to a higher productivity standard than 
other services. An informant noted the hypocrisy of how the AMC service had to justify 
its existence by proving financial sustainability, while other non-revenue generating 
services continued to operate without the that expectation:  
I think there is still a lot of embedded stigma. It is structural. To assume that 
there is a good reason for why the addiction consult service is held to a different 
standard than established consult services than you know...we are only going to 
do it if it is good for our business. Number one public health issue that the 
community is facing. Ebola didn't generate a lot of revenue but it cost a shit load 
for the hospital even though we didn't have one single patient. (K1)  
 
 Finally, and importantly, an informant observed that language used within the 
addiction medicine community may perpetuate stigma and mythology around the 
complexity of the medical management of OUD: 
The term induction is something that I don't really like a lot. I don't actually use it 
myself. I just say I am starting treatment. It makes it seem like this fancy 
procedure that we are doing and we are just starting someone on treatment. I 
don't really see it as any different than starting any other treatment… I think 
calling it induction is a barrier to starting treatment. (D1) 
 
4.4.1f. Limited internal financing. Securing and sustaining internal financing for 
the AMC service was the “the biggest barrier” (A1) and “the hardest thing” (M1). The 
complex financial landscape created multiple barriers to planning, establishing, and 
delivering inpatient evidence-based AMC services. First, most AMC services operated 
from a cost savings model versus a revenue-generating model, making it challenging to 
articulate the fiscal value of the service to hospital leadership: “No matter what…we 
operate at a loss…there is not enough billing, our billing does not support the breadth of 





closed their previous AMC services because of funding issues, because of these internal 
constraints, informants had to look outside the hospital for funding: 
We are currently applying for grant funding to do a pilot. To get a couple [of] 
years’ worth of funding to attempt to have a consult service with the hope that 
the hospital will see that it is useful to them and take over funding in the future. 
(C1) 
 
4.4.2. Barriers outside the hospital. Key informants described four external 
supply-side constraints to establishing an AMC service and for delivering OAT: 1) limited 
access to community-based treatment resources; 2) restrictive and limiting policies and 
regulations; 3) unsupportive local politics; and 4) unstable financing.  
4.4.2a. Limited community-based treatment network. Informants identified that 
a limited community-based treatment network constrained service delivery and design 
within the hospital because of issues related to hospital discharge and transitions to 
care. Informants described five barriers that could prevent a patient from successfully 
transitioning: 1) the location of the resources or facilities in relation to where the 
patient lives; 2) the capacity of the treatment programs (e.g., number of beds, number 
buprenorphine providers, number of clinicians); 3) discriminatory organizational 
practices and policies; 4) insurance barriers (e.g. programs not accepting Medicaid); and 
5) a limited range of programs with the appropriate intensity of services. 
The community-based treatment programs such as skilled nursing facilities and 
social service and housing programs used discriminatory practices and policies to deny 
admission to patients discharged from the hospital on OAT. These policies and practices 





not wanting or having the resources to support the patient in continuing their OAT 
medication. One informant shared that the skilled nursing facilities in her community 
always happened to be full whenever their team tried to discharge a patient there who 
had history of injection drug use. Another informant observed that treatment centers 
were unwilling to invest in resources to care for persons with intravenous antibiotic 
needs, resulting in patients “sitting here in the hospital for 6 weeks because no 
treatment center is able to take someone with a PICC line...” (I1).  
4.4.2b. Restrictive policies and regulations. Additional challenges for delivering 
evidence-based services to persons with OUD in the hospital setting were related to 
policies and regulations created and enforced by non-governmental (e.g., Accreditation 
Council for Graduate Medical Education [ACGME]) and governmental (e.g., local, state, 
and federal) bodies. Many of the described regulatory barriers were connected to OTPs. 
One informant shared how state-mandated clinical assessments that had to be 
completed prior to OTP placement limited the number of patients that the service could 
see because they did not have enough staff to complete the multi-hour assessments for 
all qualified patients. Further, federal regulations allowed OTPs to create their own 
organizational policies, which can result in discriminatory practice. An OTP in one 
community, for example, discharged patients from its treatment program if the patient 
had a positive urine drug screen for methamphetamine. Moreover, informants 





limits and the strict regulations imposed by pharmacy boards, the DEA, and third-party 
payers. 
Forthcoming changes (academic year 2019) to educational policies may also 
constrain hospital-based OAT delivery. Recently, some addiction medicine fellowship 
programs were approved for accreditation through the ACGME. ACGME fellows, 
however, are not allowed to bill for patient visits independently, in turn likely changing 
the supervision and staffing requirements of some of the AMC services. 
4.4.2c. Unsupportive politics and political leadership. Key informants discussed 
the challenges of delivering evidence-based services in the hospital setting because of 
an unsupportive political environment: “It is all personality, logistics, and politics 
honestly” (M1). An informant practicing in a politically conservative community 
described OAT barriers as existing because of a lack of political will: “We are at the 
mercy of the legislature here...and so you know they are willing to spend money on the 
unborn but not on anybody at birth unfortunately...we are trying to make headway 
there” (N1). Further, political leaders in this jurisdiction had other uninformed opinions 
about evidence-based OAT: 
[The state Medicaid program does not pay for methadone]. People who are on 
methadone have to pay private facilities cash in order to get methadone…I can 
speculate but I think it is political. There is this stigma. They think these people 
are enjoying themselves on methadone. They do not see it as therapeutic. (N1)  
 
4.4.2d. Limited financing. Informants identified multiple financial barriers to 





I think really the biggest obstacle is the money. You just got to follow the money. 
If you just follow the money. I think people culturally are willing to accept that 
addiction is a disease and to treat it is such. But they aren't going to do it out of 
the goodness of their heart. You have to find a way to pay them. (E1)  
 
Third-party payers imposed five external financial barriers for the AMC services: 
1) a lack of reimbursement for interprofessional teams; 2) the incentivization of non-
evidence-based services (e.g., funding detox beds); 3) reimbursement restrictions; 4) 
prior authorizations and utilization review; and 5) limited financial incentives for 
delivering evidence-based care. An informant noted that: “The hospital is not going to 
turn off that revenue stream [for detox beds] just because they don't think it is the best 
idea for the patient” (H1). A source of deep frustration among informants were the 
third-party payer pharmacy benefit management strategies for OAT such as prior 
authorizations, quantity limits, and formulary restrictions:  
[Our state] requires essentially a prior authorization before basically anyone can 
write Suboxone®, and each insurance company, and even each Medicaid plan. 
We have [multiple] managed Medicaid plans in the state. Each one has different 
guidelines on what you are allowed to write… and of course quantity limits… That 
is going to be a huge barrier to doing this in the emergency room. (B1)  
 
If we induce them in the hospital…it is always unclear to me if the insurance 
company is going to approve the films or the tablets? Are they going to approve 
the tablet size? Are they going to have a problem with that? I end up re-writing 
prescriptions quite a bit in the hospital just to get the prior authorization 
approved for a couple of days. (I1) 
 
Another complicating financial element was third-party payer contracting. Most 
hospitals in the U.S. participate in the diagnostic related grouping (DRG) billing system, 
which is a contractually agreed upon payment for a specific condition or treatment 





to the interprofessional and comprehensive management of drug use disorders 
secondary to the primary reason for admission; thus, hospitals cannot be rewarded for 
comprehensively caring for patients with SUDs under this contractual structure. One 
informant noted that billing barriers may also exist in the emergency department and 
were told by administrators that they were prohibited from billing consultation services 
in the emergency department. It is unclear if this is either a jurisdiction or hospital policy 
specific issue. Finally, key informants described issues related to pharmaceutical pricing 
as influencing accessibility to OAT in the hospital context. At one hospital, the hospital 
only purchased mono-product, and did not stock combination-product because of costs. 
 4.4.3. Summary. The external supply-side barriers to AMC service establishment 
and the delivery of evidence-based OUD services were extensive and prohibitive. The 
socio-economic-regulatory environment in which hospitals exist was described as 
inhospitable for AMC service establishment and for the effective delivery of OAT. 
Barriers within the hospital setting included policies and regulations, bureaucratic 
processes, limited staffing and resources, internal stakeholders, stigmatizing provider 
behavior and training gaps, and limited financial resources. In the external setting, the 
barriers were access to community-based resources upon discharge, external 
educational and care delivery policies and regulations, and third-party financing (e.g., 





Section 4.5. The Contribution of Demand-Side Attributes 
Although the focus of this research, in theory and design, was on the facilitative 
and constraining supply-side elements related to AMC service development and hospital 
OAT delivery, informants also described contributions to care from the demand-side 
(i.e., patient attributes). Informants perceived demand-side elements as primarily 
increasing barriers to evidence-based services. Patients with OUD who injected drugs 
were particularly challenging to serve in the hospital because of their complex medical 
and social sequalae including serious infections (e.g., endocarditis), concurrent stimulant 
use disorder, homelessness, criminal justice involvement, or a lack of health insurance. 
Insurance status and third-party payer coverage policies also created barriers to patients 
getting timely access to OAT or other OUD-related therapeutics: 
Sometimes insurance can be an issue for patients getting rapid access. We may 
be able to give them extended release naltrexone while in the hospital, but to 
give that when they leave, it typically requires an onerous prior authorization 
process, we sometimes run into the same issue with buprenorphine and can 
result in gaps in treatment. (A1) 
 
Finally, patients had their own internalized stigma about OAT: 
Unfortunately, there are many patients that are not interested in maintenance 
treatment and so unfortunately a lot of people end up requesting tapers and they 
don't always appreciate the efficacy or understand the gravity of their problem…I 
think part of it is the stigma about medication assisted treatment. I think a lot of 
patients fear medication assisted treatment, they don't want to be “hooked” on 
something, they don't want to be dependent on something, and I think 
particularly around hospitalization many people view that as this important 
moment, I am finally going to get clean. Unfortunately, they view being on 






In contrast, the only facilitative demand-side attribute described by the 
informants was pregnancy. Pregnant women were a frequent focus of efforts for 
providing timely evidence-based protocol driven hospital-based services supported with 
linkage to care. This model population exemplified how people with SUDs could 
effectively receive care in the hospital: “Pregnancy was probably the place where all this 
was standardized first...anyone who presents to the emergency department pregnant 
and in withdrawal is supposed to come up the labor floor and if they want to, they get 
induced and stabilized” (F1). It is possible that the consistency around care for pregnant 
women with an OUD is primarily driven by the desire to decrease complications during 
pregnancy, in particular premature birth, and to improve outcomes when neonates are 
born to minimize the harms, and length of stay, as it relates to neonatal opioid 
withdrawal syndrome. 
Section 4.6. Beyond the AMC Service: Emergent Supply-Side Elements 
Beyond the development and implementation of AMC services, informants 
described six emergent supply-side actions to enhance OUD-related hospital services: 1) 
incentivize evidence-based care; 2) increase addiction-related training requirement; 3) 
create treatment organizations or programs to enhance continuity of care; 4) deliver 
care through a trauma-informed and harm reduction approaches; 5) reframe the opioid 
problem; and 6) review and improve treatment policies.  
Informants recommended creating financial incentives for high-quality evidence-





Informants also recommended that third-party payers should not reimburse ineffective 
services, such as only offering opioid withdrawal services (“detox” protocols) and that 
third-party payers (i.e., CMS) should develop value-based reimbursement mechanisms 
to create external financial incentives: 
I think if there were more clear incentives, financial incentives, in terms of 
reimbursement structure that would be the best way to mobilize doctors to pay 
attention to this problem and invest in making changes systematically to help 
people with substance use problems in the hospital. That is the type of thing that 
requires CMS to really take the lead. (E1)  
 
Informants recognized education as an important element for improving hospital 
services for patient with OUD. An informant noted that one approach to increase the 
number of hospital AMC services across the U.S. could be to require AMC service 
rotation as a part of ACGME internal medicine accreditation.  
Another suggestion to improve hospital services for patients with SUD was to 
create dedicated healing spaces for patients to go upon discharge, such as a skilled 
nursing facility with addiction medicine services. Informants reflected on the 
traumatization of hospitalization and the need for trauma-informed training among 
hospital staff: “I don't think I fully appreciate the amount trauma that hospitalization 
really...it is so traumatizing. I think. In the power and the hierarchy…it is really intense” 
(A2). Further, informants noted that internal hospital policies, such as a no smoking 
policy, were not effective for supporting people with SUDs during hospitalization:  
There is a policy about smoking…People aren't allowed to smoke. They aren't 
allowed to even walk outside to go to smoke…There is no smoking allowed either 
in or around the hospital.  Sometimes people want to leave to go smoke and 





One of the things I have had to learn. Is to prioritize our goals…You want to make 
sure somebody isn't going to die of a heroin [over] dose when they leave, you 
want to make sure they complete their antibiotic course for endocarditis. So, we 
really focus on those things. And sometimes that means letting smoking slide. If 
for example the thing that is keeping them in the hospital is going out and 
smoking every day, you let them go out and smoke. (A1) 
 
 Informants generally perceived that hospital leadership and, subsequently, 
hospital-based initiatives, overly focused on opioid delivery with not enough emphasis 
on OUD treatment. In general, hospital administrators and the broader non-clinical staff 
had narrowly constructed assumptions about the problem of opioid overdose and the 
responsibilities of the medical community to address the opioid overdose epidemic. The 
rationale was that if access to opioids is severed in the health care setting, people will 
stop using prescription opioids, and the opioid overdose epidemic will end. This type of 
rationale places opioids and opioid use in the category of deviant behavior, and 
discredits the clinical utility of opioids as an analgesic: “Just because they have an opioid 
use disorder does not mean we need to take all opioids away from them. We still need 
to adequately treat their pain and do it in as safe a way as possible” (C1).  
 Informants suggested that policymakers interested in enhancing SUD service 
delivery in the hospital, review the treatment policy barriers associated with transitions 
to care, particularly for OTPs, SNFs, and the criminal justice system. One potential 
intervention to improve hospital transitions to care, as discussed by informants, was to 
open hospital-affiliated OTPs. An informant, however, noted how challenging this would 
be: “The limitations with [OTPs] are massive. There are both state laws and city specific 





new OTP” (F1). Decreasing barriers to care through the elimination or revision of 
existing policies in the external setting could enhance the provision of hospital services. 
 Informants described a range of issues relevant to improving and enhancing the 
delivery of services for patients with SUD, and particular those with OUD. They 
recognized the power of money in the health system, calling for the development of 
reimbursement programs that financially reward hospitals for providing evidence-based 
services and penalizing hospitals that provide non-evidenced based services to patients 
with SUD. Informants noted the benefits and harms of addiction medicine specialization 
and also noted the constraints of community-based OUD treatment policies for 
delivering effective services for patients with OUD during hospitalization and upon 
discharge. Informants also described a need for creating community-based treatment 
programs to enhance continuity of care and the need to provide education to hospital 
providers on trauma-informed care. Finally, more broadly, informants articulated that 
hospital leadership had a narrow conceptualization of the opioid overdose epidemic and 
that reframing the issue around treatment could be a helpful approach for designing 
effective hospital-based services. 
Section 4.7. Hospital Guidance Documents and Standards of Care 
 This next section explores research sub-question 1d: How do hospital policies 
inform OAT delivery? This was assessed through the analysis of 25 OUD-treatment 
related hospital guidance documents (i.e., policies, procedures, protocols, guidelines, 





interviews. Hospital guidance documents, a type of organizational technology, are both 
an output of addiction related technologies and resources within an organization (e.g., 
addition trained clinical staff) and a reflection of social structures within the hospital, 
specifically cultural-cognitive structures, which are the beliefs of people within an 
organization (Scott, 2003). The findings from this section provide a preliminary 
understanding of how hospital OAT delivery is conceptualized and potentially practiced 
in well-resourced, non-VHA hospitals; and supports prior findings that an output of the 
AMC service includes the development of other hospital technologies, such as hospital 
guidance documents. 
 4.7.1. Guidance document domains. Two overarching policy domains, 
comprised of eight policy sub-domains, were observed across guidance documents: 1) 
OAT management and 2) security and behavioral management (see Table 4.4). The most 
common policies were in the OAT management policy domain, specifically for opioid 
withdrawal (n = 6), and the second most common was OAT continuation (n = 4). Of the 
nine hospitals with an established AMC service, seven (Hospitals A, D, F, H, I, J, and K) 
provided documents related to the care of persons with OUD. Policies were not 
provided by Hospitals E, G, L, M, O, or P. The policy summaries (33 pages of text) may be 





Table 4.3. Hospital Guidance Documents: By Title 
Hospital AMC Status Guidance Document Titles 
A Established 1. Preoperative and Postoperative Pain Management 
Practice Guideline  
2. Misalignment of Care Guideline 
3. Safety Agreement Policy 
4. PICC Policy 
5. PICC Assessment Tool 
B None 6. Aberrant Drug Use Policy  
C Planned 7. Acute Pain Management Guideline  
8. Inpatient Methadone Guideline 
9. Inpatient Buprenorphine Guideline 
10. Methadone Order Set 
11. Buprenorphine Order Set 
12. Methadone Quick Reference Guide 
13. Buprenorphine Quick Reference Guide 
D Established 14. Withdrawal Management Protocol 
15. Methadone Protocol 
F Established 16. Withdrawal Management Protocol 
H Established 17. Withdrawal Management Order Set 
I Established 18. OAT Guideline 
J Established 19. Aberrant Drug Use Policy 
20. Withdrawal Management Order Set 
K Established 21. Leaving Against Medical Advice Policy 
22. Preoperative and Postoperative Pain Guideline  
23. OAT Management During Pregnancy Guideline 
24. OAT Management in Non-Pregnant Adults Guideline 
N Planned 25. Withdrawal Management Protocol 
Table Notes. PICC = peripherally inserted central catheter; OAT = opioid agonist therapy. 
 
Table 4.4. Hospital Guidance Documents: Content Areasa 
 
Hospital 











AMA Safety  PICC 
Line 
A* X . . . . X X X 
B1 . . . . X . X X 
C2 X X X . . . . . 
D* . X . X . . . . 
F* . . . X . . . . 
H* . . . X . . . . 
I* . X . X . . . . 
J* . . . X X . X . 
K* X X X . . X . . 
N2 . . . X . . . . 
Table Notes. aGuidance documents could be categorized into more than one policy domain; *Established 
AMC service; 1No AMC service without plans to start one; 2AMC service being planned; AMA= leaving the 
hospital against medical advice; PICC = peripherally inserted central catheter; OAT = opioid agonist 
therapy; Cont. = continuation. 





 4.7.1. Domain 1: OAT management. Informants from all hospitals provided or 
described hospital-based policies and practices related to OAT management. Four OAT 
policy and practice sub-domains emerged: 1) acute pain and perioperative 
management; 2) OAT continuation; 3) opioid withdrawal management; and 4) OAT 
initiation. 
 4.7.1a. Acute pain and perioperative treatment: Guidance documents. Three 
hospital guidance documents (Hospitals A, C, and K) explicitly addressed OUD-related 
acute pain and perioperative management approaches. The documents, all hospital 
guidelines, recommended the same general practice—OAT continuation for all patients 
who had previously established OAT in the outpatient setting. Hospital K differed from 
the others by recommending that pregnant patients on buprenorphine, in need of 
additional opioid agonists, be discontinued from buprenorphine when additional opioids 
were required for pain control. Hospital C and K included recommendations for 
buprenorphine and methadone, and Hospital A recommendations were for 
buprenorphine only. All the guidelines recommended the use of non-opioid adjuvants to 
manage pain in the pre-operative and post-operative period.  
 All three guidelines recommended the use of opioid agonists for breakthrough 
and severe pain. Recommendations (Hospital C and K) explicitly noted that opioid dosing 
would likely be higher due to tolerance. All three guidelines suggested alternative OAT 
dosing approaches to manage pain. Two guidelines (Hospital A and Hospital K) 





recommended increasing OAT dosing frequency. All three guidelines included action 
related to discharge planning to ensure continuity of OUD treatment. Table 4.5 (after 
Section 4.7.1b) summarizes and compares the care policy domains (i.e., continuation of 
OAT, the use of non-opioid adjuvants, the use of opioids, alternative OAT approaches, 
and discharge planning).  
 4.7.1b. Acute pain and perioperative treatment: Interviews. Informants that did 
not have or provide analyzable documents described routine practice and care 
considerations for acute pain management and perioperative management for patients 
with OUD. There was a consensus among informants that daily OAT should be continued 
during hospitalization and that the buprenorphine dose could be increased or split to 
manage pain: “With methadone typically, we will just continue it and use a full agonist 
on top of it…. I think in general we find that just continuing it [buprenorphine] is the 
best policy. That is generally what we recommend” (D1) and: 
We do not have an official procedure or guideline but our consult service 
recommendations would vary if the patient was on methadone or buprenorphine. 
For methadone we keep it on and have them add pain medication. For 
buprenorphine we may keep it on and split it, or slightly increase the dose, or 
hold it and just give more pain meds and then help advise them when to restart 
it. (I1)  
 








We treat every case individually. The degree of the pain the person is in, how 
long we expect them to be in pain, what their goals are. I had a consult with a 
woman with septic arthritis of her hip and severe pain. Her long-term goal was to 
be on methadone maintenance which she had been on before but was not 
currently on. We treated her pain with methadone in divided doses and she 
needed six weeks of intravenous antibiotics. So, she went to a nursing home on 
methadone for her pain and her addiction treatment. It really depends. I had 
another patient with more minor pain…so we gave him buprenorphine he was 
happy with that and he followed up with me in clinic. It depends on the patient. 
(D1)  
 
Informants commented that managing this clinical scenario, continuing OAT through 
surgery or pain, frequently required a phone consultation or in-person consultation with 
an addiction medicine expert or the AMC service:  
They tend to consult us pretty frequently for that...I think there is...from the 
perspective of addiction medicine we tend to recommend continuing their basal 
opioid requirement and treating acute pain on top of that. I do not think that is 
universally recognized way to do things and so often times they will appreciate 
getting our input on that issue. (J1)  
 
Challenges to effective pain management for patients on OAT were related to either the 
limited evidence base or the limited knowledge base about OAT among hospital staff: 
I think the biggest barrier is we do not have great evidence to say this is the best 
way to do it. If there were great studies that we could point out that shows 
definitively that this the right thing to do for this patient. We rely more on a 
combination of clinical experience, observational studies, general knowledge of 
pharmacology…It is hard to convince somebody this is the right way to do it when 
I do not have evidence to back me up…I think that creates a lot of confusion in 






Table 4.5. Guidance Document Recommendations: Pain Managementa 









Acetaminophen; NSAIDs; gabapentin 
 
Intra-Operative 
Regional anesthesia; continuous infusion 




Ketamine, lidocaine, or dexmedetomidine 
infusion 
Post-Operative 






dose or divide 
daily dose to 
every 6 to 8-
hours 
Continue inpatient pain 
management and coordinate 
follow-up with outpatient 
buprenorphine provider  
C Pre-Operative 
Ibuprofen, acetaminophen, or topical 
analgesics; gabapentin; tricyclic 
antidepressants; serotonin and norepinephrine 
reuptake inhibitors; tizanidine, baclofen, or 
cyclobenzaprine; sedating serotonin reuptake 
inhibitors; ketamine or dexmedetomidine; 
neuraxial, regional, and local anesthesia 
 
Post-Operative 
Use multiple modalities 
Pre-Operative 
Increase opioids and consult the 
pain service. If opioids are needed 
will likely need to provide higher 
dose and monitor closely 
 
Post-Operative 
Manage similar to routine 
postoperative care but may need 




dose or dose 
methadone 
three times a 
day 
Coordinate care. Specific 
accommodations for skilled 
nursing facility, outpatient living 
situations, and coordination with 
OTP or outpatient buprenorphine 
provider. Including writing a 
discharge bridge script for 
buprenorphine  
K Pre-Operative 
Multimodal management with non-opioids 
(NSAIDs, acetaminophen, epidural/spinal 
analgesics, and nerve blocks)  
Post-Operative 
If opioids are required, will likely 
need higher doses and they should 
use patient-controlled analgesia 




dose or increase 
buprenorphine 
dose 
The patient should receive a 
letter for OTP. The discharge case 
manager and patient may need to 
arrange for home methadone 
doses with OTP if they cannot 
receive on their day of discharge 
Table Notes. aAll hospitals recommend OAT continuation; All hospitals included recommendations for pregnant and non-pregnant patients (not 





  4.7.1c. OAT continuation: Guidance documents. Informants from four hospitals 
(Hospitals C, D, I, and K) provided OAT continuation guidance documents. Hospitals C, I, 
and K provided recommendations for buprenorphine and methadone, and Hospital D 
provided methadone recommendations. The consensus of the four guidance documents 
was that OAT should be continued and providers should consult with either the AMC 
service or addiction experts as needed. 
 Policies typically required dose verification for patients taking buprenorphine. All 
three guidance documents described steps for completing this task, including contacting 
the pharmacy (Hospital C), reviewing the electronic health record (Hospitals C and K), 
checking the prescription drug monitoring program (PDMP) (Hospitals C, I, and K), 
contacting the outpatient clinic (Hospital I), and contacting the outpatient provider 
(Hospital K). Two of the hospitals provided recommendations for OAT continuation 
(Hospitals C and K) and two of the documents addressed pain management (Hospitals C 
and K). The other care delivery recommendation domains inconsistently articulated 
among the guidelines were approaches to missed doses, linkage to care, and legal 
reminders. See Table 4.6 (following Section 4.7.1d) for a summary of these findings. 
 All four methadone continuation guidelines recommended dose verification by 
contacting the patient’s OTP. One guideline recommended use of the prescription bottle 
to verify dose (Hospital I). Three of the documents addressed pain management 
(Hospitals C, D, and K) in particular to provide additional opioids for pain as needed. 





injectable) (Hospitals D, I, and K), and two of those hospitals (Hospitals D and K) 
described the OAT conversion to intramuscular injection. Three hospitals described 
linkage to care processes (Hospitals D, I, and K) including the operational limits of OTP 
and how to ensure communication with the OTP on the last dose received. Three 
hospitals provided legal reminders (Hospitals C, I and K) about methadone (e.g., do not 
write an outpatient prescription for methadone). The other care delivery 
recommendation domains not consistently described across the guidelines were how to 
address missed doses and naloxone orders. See Table 4.7 (following Section 4.7.1d) for a 
summary of these findings. 
 4.7.1d. OAT continuation: Interviews. Informants that did not have or provide 
analyzable documents described OAT continuation practice as similar to the provided 
and reviewed hospital policies. The most common approach was OAT continuation 
without restrictions upon dose verification from the outside provider: “We continue it 
absolutely it is an ethical and legal obligation” (H1) and “We get confirmation from their 
current providers and as long as we get confirmation about their dose and that the 
provider plans to continue to follow them and then we continue it [for both types of 
OAT]” (L1). Dose verification was completed by different members of the team (e.g., 
nursing or pharmacy) and involved using different verification sources depending on 
OAT—for buprenorphine (PDMP) or for methadone (OTP or the state substance abuse 





buprenorphine verification, because methadone is not in the state PDMP; however, one 
informant cautioned against trusting the PDMP for buprenorphine dose verification. 
Key informants described OAT continuation, specifically for buprenorphine, as 
being dependent on the hospital formulary. One hospital switched patients from 
Suboxone® (the combination product) to Subutex® (the mono product) because of the 
formulary limitations and another hospital did the opposite, switching patients arriving 
on Subutex® to Suboxone®. Some key informants were unsure about general hospital 
practice for this clinical scenario, stating that they did not “think there are policies right 
now [stating] that we have to do certain medication protocols. As far as I know it is 
physician discretion” (M1). Further, an informant noted that fear among the providers 
drove discontinuation of outside methadone because providers did not understand 
federal treatment regulations: 
The majority of the time [patients on methadone are discontinued while 
hospitalized]. Unless they have a reason, pain. I have had these discussions with 
docs. They are nervous about using it for non-pain services and they are worried 
that they are doing something illegal. (M1) 
 
Another key informant described how anyone admitted to the hospital on OAT triggers 
a consultation from the AMC service: 
There is almost a sort of automatic trigger finger type response for most of the 
hospitals to call addiction medicine for anything. If somebody comes in on 
buprenorphine or methadone it is almost guaranteed they will consult us. If they 





Table 4.6. Guidance Document Recommendations: Buprenorphine Continuationa 
















• Contact pharmacy 
 
• Review electronic 
health record 
 
• Check PDMP 
•If a patient has not used 
opioids in the interim, 
provider may order full 
outpatient dose 
 
•If a patient has used 





Not described Not described 
I Not described •Contact clinic  
 
•Check PDMP 
Not described Not described Not described Not described 






• Check electronic health 
record 
 
Outside Clinic  
• Contact provider 
• Check PDMP 











































C Contact OTP 
 
• Discuss with OTP 
provider 
• If OTP cannot be reached 
give full dose if 1-2 days 
are missed, half dose if 3-
4 days are missed, and 
restart if ³ 5 days are 
missed 
Short-acting 












D Contact OTP Not described Do not 
withhold with 
opioids and do 
not subsite as 
analgesic 






• Direct questions about 
addiction treatment to OTP   
• Prior to discharge notify 
OTP of last dose amount 
and date/time  
• Write note for patient to 








• Do not attempt to make 
up missed dose 
• If >3 days of dosing 
missed decrease verified 
daily dose by 10% or 10 
mg for each day missed  








• OTPs are closed on holidays 
and Sundays. 
• OTP should be notified 
when admitted and should 

















Yes At discharge provide letter 
for OTP with admission dates 
and date/amount of last 
dose, names and dose of 
other opioids given  
Do not write 
outpatient 
prescription 





 4.7.1e. Opioid withdrawal management: Guidance documents. Withdrawal 
management policies were received from six hospitals (Hospitals D, F, H, I, J, and N). 
Similarities and differences among the protocols were observed among the 
recommendations for first-line therapy, the protocol type, the protocol initiation 
threshold, and the 24-hour maximum dose. Four of the six protocols specified the first-
line medication for withdrawal management as one or both types of OAT. One hospital 
protocol was restricted to non-OAT pharmacotherapy symptom management (i.e., 
clonidine), and one hospital used a combination non-OAT pharmacotherapy (i.e., 
clonidine) and intramuscular buprenorphine injections. All of the protocols were framed 
as tapering protocols, and one protocol provided the option for OAT initiation (Hospital 
I). Each protocol had a different threshold for starting their protocol, as well as different 
total maximum doses for the first 24-hours. See Table 4.8 (following section 4.7.1f) for a 
summary of these findings. 
 4.7.1f. Interviews: Opioid withdrawal management. Informants that did not 
have or provide analyzable documents described a variety of practice approaches, which 
included the use of OAT to manage withdrawal, the use of non-opioid adjuvants for 
symptom management (i.e., clonidine), and the use of tramadol for a rapid taper. When 
queried about the distinction among induction versus withdrawal versus tapering, some 
informants emphasized that their approach was focused on “maintenance therapy” 
(A1). Other informants shared that there was variation across their respective hospital 





that those admitted to the hospital detoxification unit received a tapering protocol that 
was for 72 hours and patients who were admitted to the main part of the hospital 
received a 72-hour to 120-hour tapering protocol. Another informant described little to 
no management for opioid withdrawal across their institution. 





Starting Dose 24-Hour Maximum 
Dose 
D Sublingual  
BUP-NX 
COWS ³ 8 4 mg  Not described 
F Sublingual  
BUP-NX 
COWS ³ 13 Sublingual BUP-NX  
4 mg/ 1 mg  
 
Oral or IV Methadone  
5 mg (COWS 13 to 24) and 
10 mg (COWS 25 to 36) 
Sublingual BUP-NX  
8 mg 
 
Oral or IV Methadone  
40 mg oral or 20 mg IV 
H Sublingual  
BUP-NX or 
Methadone 
COWS ³ 12 Sublingual BUP-NX  
4 mg/ 1 mg  
 
Oral Methadone  
15 mg  
Sublingual BUP-NX  
8 mg (10 mg severe) 
 
Oral Methadone  
30 mg (35 mg severe) 




Oral Methadone  
5 to 10 mg  
Oral Methadone  
40 mg 
J Clonidine Not 
described 
Clonidine Standard  
0.2mg  
 
Clonidine Reduced  
0.1 mg 
 
Clonidine Lowest  
0.05 mg  






COWS ³ 5 Clonidine 





1.2 mg (max 0.4 mg 
dose every 8 hours) 
 
IM Buprenorphine 
1.5 mg (0.3 mg x 3, plus 
0.6 mg dose) 
Table Notes. BUP-NX = buprenorphine/naloxone; COWS = Clinical Opiated Withdrawal Scale is a tool for 
assessing the severity of withdrawal symptoms using an 11-item assessment administered in either the 





 4.7.1g. OAT initiation: Guidance documents. Two hospitals (Hospital C and K) 
provided OAT initiation hospital guidance documents in the form of guidelines, 
protocols, and order sets. There were few common recommendations across the two 
guidelines. For buprenorphine initiation, Hospital C and Hospital K had different 
protocol initiation thresholds with differences in Clinical Opiate Withdrawal Scale 
(COWS) score thresholds to initiate OAT and allowable maximum daily doses (16 mg 
versus 12 mg). The first day dosing protocols were also different, in timing, dosing, and 
COWS score threshold.  
 Hospitals C and K also had different methadone protocols including the 
threshold for protocol initiation, the maximum daily dose during hospitalization (60 mg 
versus 40 mg), and the first day dosing protocol. The common recommendation was the 
maximum total daily dose of methadone on day 1 of the protocol, 40 mg. See Table 4.9 
(following section 4.7.1h) for a summary of these findings. 
 4.7.1h. Interviews: OAT initiation. Informants that did not have or provide 
analyzable documents disclosed a range of practice behaviors related to OAT initiation. 
At some institutions the delivery environment focused on OAT initiation versus 
withdrawal management: 
Methadone or buprenorphine can be initiated during hospitalization, in 
consultation with an addiction medicine specialist, if the patient will be detoxed 
off during hospitalization or there is a clear documented plan for continuation of 
OAT in the outpatient setting. (O1)  
 
In contrast, some hospital environments were described as underdeveloped in this 





hospital policies [on this topic]” (M1). One informant described extreme frustration that 
OAT initiation was not happening for hospitalized patients: 
No! No! No! That pisses me off!!… So what is happening is that people are 
getting withdrawal management, tapered, and then sent to a clinic, where I re-
induce them…It is a source of frustration. (F1)  
 
 Informants provided insight into some of the barriers to hospital OAT initiation, 
which included: 1) OTPs requiring QTc interval testing; 2) internalized stigma of patients; 
and 3) providers not trained in administering OAT. OAT initiation in many hospitals was 
described as primarily the responsibility of the consult service: 
What I would say around that is that it is quite rare [for physicians to do 
buprenorphine inductions]. I think there are some family medicine providers that 
do inductions in the outpatient setting and that will do them without our consult 
service. Other than that, I have not seen it. (A2)  
 
Occasionally [physicians who are not addiction medicine specialist will induct 
patients on OAT and] there will be some miscommunications and people get 
started on methadone and all of a sudden, they are being discharged and how 
are they going to get connected with the methadone clinic. Sometimes surgical 
teams will start buprenorphine for patients, and not involve us, which is fine, but 
I think it just leaves some potential for gaps in their treatment, like what if they 
don't have that Suboxone® at home anymore because they missed their 
appointment because they were in the hospital, should they be back on the same 
dose or not? So just stuff like that will occasionally get missed. (I1) 
 
Some informants described a preference for providing different types of OAT in the 
hospital. One informant emphasized their preference for starting buprenorphine over 
methadone in the hospital context: “I really prefer buprenorphine” (P1). Other 
informants discussed trying to use different non-OAT opioid formulations, such as 






Table 4.9. Guidance Document Recommendations: OAT Initiation 
Hospital Protocol Initiation 
COWS Score1 
Max Total 
Dose Day 1 
Max Daily Dose 
During Admission 
First Day  
Dose Protocol 
Buprenorphine  




No opioid use in the 
prior 5 days: COWS = 0 
 
All Others 
COWS ³ 8 
16 mg for 
both types 
of patients 
24 mg for both 
types of patients  
Abstinent 
• Dose 1 is 2 mg 
• COWS score to be reassessed after 2 hours  
• If cravings persist add another 2 mg. This may be repeated on day 1 
until max is reached  
 
All Others  
• For patients with COWS < 8 or no objective withdrawal, the COWS 
should be administered every 2 hours until COWS is ³ 8  
• When COWS ³ 8, administer 4 mg and assess COWS in 1 hour. If 
COWS is < 8 at that time, reassess every 6 hours 
• Provider may give 4 mg if COWS ³ 8 at any point 
K • COWS ³ 5 OR; 
• The presence of 
signs/symptoms of 
withdrawal 
12 mg   16 mg  • Regardless of the historic amount of opioid use start with 
buprenorphine/naloxone sublingual 4/1 mg for dose 1 
• Reevaluate the patient every 2 to 3 hours 
• Give additional dose increments of 4/1 mg every 2 to 3 hours until 
withdrawal abates (COWS < 5) 
Methadone  
C Not described 40 mg 60 mg The initial dose selection should start anywhere from 10 to 30 mg 




40 mg 40 mg • Regardless of the historic amount of opioid use start with 
methadone 20 mg solution by mouth for dose 1  
• Reevaluate the patient every two to three hours 
• Give additional doses increments of 5 to 10 mg every 2 to 3 hours 
until withdrawal abates (COWS <5) 





 4.7.2. Policy and practice domain 2: Security and behavior management. This 
policy and practice domain addressed security and behavior management of patients 
with OUD and other SUDs. Informants from Hospitals A, B, J, and K provided hospital 
guidance documents in this policy domain. Specific protocols addressed the 
management of aberrant drug use, decision-making around peripherally inserted central 
catheter (PICC) lines, and patient safety and security assessment and interventions. The 
hospital guidance documents emphasized interprofessional collaboration to ensure 
patient safety; however, because the guidance documents varied in focus, most of the 
documents were difficult to compare, except for the aberrant drug use policies, which 
had enough shared properties for analysis. 
  4.7.2a. Guidance documents: Aberrant drug use. Aberrant drug use was defined 
as the use of drugs (illegal or prescribed) in a manner or route that was incongruent 
with appropriate or safe use. The policies on this topic from Hospitals B and J were 
similarly structured. Recommendations advised conducting a risk assessment for 
aberrant drug use; documentation of behavior and interventions protocols; 
interventions for medication administration; interventions for securing the 
environment; behavioral requirements for patients leaving the unit and for patient 
visitors; the use of urine drug screens; the use of patient sitters; and the involvement of 
campus safety. In Hospital B, the guideline was created because of a patient’s poor 
outcome. Another issue related to aberrant drug use, which came up in the Hospital J 





that there had been discussions about using video to monitor patients with drug use 
disorders: 
This was a discussion [we had] quite recently because of increasing opioid related 
admissions. We have had more of this kind of issue [aberrant drug use] … in the 
hospital or people being found with paraphernalia on them and the guidance at 
this point is essentially been assigning a sitter for those individuals. To observe. 
There has been a discussion to use video because sitters are a finite resource and 
there was getting to be issue with a little more frequency with some concern that 
there may not be enough sitter availability. (J1)  
 
At present, according to the guideline, the use of video monitoring for this patient 


































• Convert pills to 
liquida  
• Crush pillsa 




• Oral checka 
 
Yesa Yesb • Remove sharps 
container from 
roomb 
• Move patient 
room close to 
nursing station 
• Leave door 
openb 
• Application of 
tamper 
prevention 
seals on all IV 
portsb 

















• Direct observation  
• Check for 
swallowing 
• Crush medication 
and put it in 
pudding 
• Limit IV access  
Yes Yes • Remove sharps 
container from 
room 
• Do not leave 
needles/syringe
s in the room  
• Re-search the 
room if there is 
evidence of 
“contraband” 
Yes Yes  • Security should be 
informed of any 
substances or 
paraphernalia found  
• Security will 
determine if police 
involvement is 
necessary 
• Security and nursing 
may search room 
including patient 
belongings 
Table Notes.1There were two categories of intervention: primary and secondary. Primary is indicated with superscript a and secondary is indicated with 





 The other hospital guidance documents comprising this domain were on topics 
related to decision-making for patient discharge with PICC lines and patient safety and 
security assessments and interventions. Hospital A provided several hospital guidance 
documents related to PICC lines and aberrant drug use, including a PICC line policy and 
PICC assessment tool, an internal and externally facing behavior agreement policy, and 
a care misalignment document. An informant from Hospital A described the 
involvement of the hospital AMC service when behavioral issues arose, in particular for 
the misuse of drugs in the hospital setting: 
[This is] part of the consult services task. We incorporate that into the behavioral 
agreement. It is one of the areas of culture change. Previously that had been a 
deal beaker for staying in the hospital. Because we are willing to engage with the 
patient…The truth is. If someone is on appropriate dosing of buprenorphine and 
methadone they are not going to want to use. They use in the hospital because 
they are in pain or on the wrong dose…We do not kick people out because they 
use. (A1) 
 
The Hospital A PICC Policy and PICC Assessment Tool standardized PICC related 
discharge decision-making for high risk patients. The PICC Policy stated that PICC 
placement is a medical decision to be determined by a physician and informed by 
previous risk factors.  
The Hospital A Safety Agreement Policy was an internally facing (for staff) and 
externally facing (for patients) policy. The internal component addressed how to identify 
a patient at risk for care misalignment, elopement, or harm to self or others; how to 
prepare and implement a safety plan; how to document the plan; how to handle 





communicated both behavioral expectations (e.g., no drug use) and care delivery 
expectations while in the hospital (e.g., understand the role of nursing).  
The Hospital A Misalignment of Care Guideline was a tool designed to support 
interprofessional care plan meetings to facilitate care for patients at risk for 
misalignment in their care goals or the use of force. It outlined the steps to be taken to 
facilitate and implement a plan to keep at-risk patients safe. 
Hospital K’s Against Medical Advice (AMA) Policy provided a clear set of steps for 
action when patients leave the hospital AMA. Four steps were recommended when a 
patient says they are going to leave AMA: 1) discourage leaving and explain why it is 
important to stay; 2) inform the primary team; 3) if the patient still chooses to leave, 
staff ask the patient to sign the AMA form and document this conversation in the 
medical record; and 4) the event is documented in the patient record and filed in a 
reporting system. The guidance documents from Hospital A and Hospital K were not 
included in the comparison table because they were non-comparable, standalone 
protocols. A full summary of each set of recommendations is available by request from 
the primary researcher. 
4.7.2b. Interviews: Security and behavior management. Similar to the findings 
observed in the hospital guidance documents, key informants who did not provide 
guidance documents from this policy domain described care scenarios and practice 





4.7.2b.1. Aberrant drug use. Informants shared that it was the role and 
responsibility of addiction medicine and the interprofessional teams when there is 
ongoing aberrant drug use during hospitalization: “It certainly comes up. I get called 
about it sometimes. I get providers who are concerned about it sometimes and we will 
talk through it” (C1); “We get calls about people who smuggle in opioids and use them 
in the shower and have taken fentanyl or something that they have smuggled in” (M1); 
and “But this is another reason we sometimes we get consulted. Somebody has been 
hoarding medications and then crushing their oxy and injecting it through their port. Um 
friends bringing in their benzos from home” (F1). 
Many informants, when asked about protocols and standard practice on 
aberrant drug use, indicated that there was limited hospital-wide understanding on 
what to do in these scenarios: “I am not personally aware of protocols around that. I do 
know that, I have seen certain situations of patients who have used in the hospital and 
they aren't automatically discharged or anything like that” (C1) and “No. No real policy. 
A lot of consternation” (N1). In contrast, other informants described a no-tolerance 
policy related to on-campus drug use that involved campus security: 
Yeah it is obviously not allowed and security gets involved and you know it is 
pretty bad. I don't think they are looking to call the police but cognizant of the 
fact that this is illegal and can't go on...I think a lot of people will just AMA [leave 
against medical advice]. And leave. We have had a couple of situations where it 
is obvious they have called a drug dealer or something and they usually find 








We discourage it. I think there have been times were people caught using 
intravenous drugs in the hospital and you know, generally, security is sort of put 
outside their room and visitors are restricted and their belongings are generally 
searched. That is only if they are caught doing it. (L1)  
 
4.7.2b.2. PICC lines. Informants discussed the role and responsibility of addiction 
medicine providers to support decision-making related to PICC line insertion or removal: 
“A common genre of consults is somebody with a PICC line” (F1). Hospital clinical staff 
would request that the AMC service conduct a risk assessment prior to discharging a 
patient with a PICC line and a history of intravenous drug use. General practice around 
PICC lines included efforts to discourage patients with intravenous drug use history from 
leaving the hospital with a PICC line: “No, we try not to let them leave the hospital with 
a PICC line if they have a history of intravenous use. Again, I think the nurses are kind of 
trained to be more vigilant in those cases” (L1).  
Informants noted that addiction medicine experts were responsible for 
navigating the challenges of patient placement upon discharge because a patient had an 
active OUD, a need for OAT, and a PICC line: 
We cannot discharge patients often times...[because] we can't get nurses to go 
into a home if there is a history of substance use...and they wouldn't be 
discharging a patient with a PICC line if there is a history [of use] ...I have a huge 
problem with nursing homes that will subtly discriminate against patients on 
methadone. This is a big issue. A big issue, right? I am just screaming for a 
lawsuit from somebody. (G1)  
 
Any patient who needs a PICC line gets a PICC line. If patient requires long-term 
antibiotics (e.g., endocarditis, osteomyelitis) then patient is discharged to SNF for 
duration of antibiotics. Can be challenging if patient is on OAT –however we have 
worked with several area SNF who will accept patients who inject drugs with a 






Related to PICC line placement, one informant described the tension between 
patient autonomy and hospital interventions: 
There seems to be a profound concern among the PICC line insertion team that 
people are going to go and use their PICC line to get high, and I was like, so 
what? I mean it is their human right. It is a terrible idea and we can message 
them that is a really dangerous and really bad…my sense of their concern [the 
PICC line insertion team] was that they viewed the lines as their property and 
god-forbid the patient ran out and used with their IV in. I was just like patients 
have agency here and they are allowed to make horrible choices… we certainly 
put PICCs in OUD patients, but to be honest, I am sure they are mistreated, I 
know people judge them, I know people probably make remarks, probably not 
even behind their back right around them, oh he is going to do something with 
his PICC. Heck a PICC is safer than doing it yourself. (H1)  
 
Informants also described other stigmatizing, and likely traumatizing behavioral 
management practices (e.g., no visitors allowed policies and searching patient’s 
belongings): 
I initiated a policy that when I am involved [in care] there is a no visitors policy for 
patients. And I say to them you cannot have visitors. I basically get their consent 
to put that in place. I explain to them you are sick and I do not want someone to 
bring something in to you it could put you in jeopardy and it can put the hospital 
staff in jeopardy. And many times, we have security sitting outside the door…but 
it is really not a problem people get it. (P1)  
 
Behavioral issues were so common that one hospital created an 
interprofessional consult service to de-escalate patients with behavioral issues. 
4.7.3. Interviews: Non-evidence-based care. Throughout the interviews, 
informants described a variety of non-evidence-based care practices for patients 
hospitalized with OUD. These care scenarios included patients receiving no treatment 





uncommon care delivery modalities. The informants associated with these delivery 
scenarios have been deidentified.  
 4.7.3a. No treatment. One informant shared how the standard of care on the 
medical and surgical services at their hospital was to not provide any OUD-related 
care—even symptom management for withdrawal, referring to a patient with 
endocarditis secondary to intravenous drug use: 
At the very least we will…treat their pain…But you know what we struggle with 
the most is these people who have endocarditis or are septic and have to have 6 
weeks of antibiotics and they are not receiving anything for withdrawal...on 
some services maybe someone would write you something for pain...but that 
wouldn't necessarily be for withdrawal. They could give some clonidine. 
(deidentified) 
 
4.7.3b. Incorrect or outdated care. Evidence supports the use of continued OAT 
in the outpatient setting to decrease return to substance use and death (Clark et.al, 
2011). Despite this, informants described the provision of OUD-related services in their 
respective hospitals as focused on “detox” (i.e., withdrawing patients from opioids 
instead of initiating and continuing OAT upon discharge): “We have what we call a 
chemical opiate withdrawal protocol that we have been using for a number of years” 
(deidentified); “Generally they will use clonidine for detoxification purposes” 
(deidentified); and: 
They come in, they get consulted by addiction medicine…[and] now, our 
policy/procedure is to utilize tramadol to detox along with as needed medications 
for all the symptoms, clonidine, muscle relaxer, something for nausea ease, 
Vistaril for anxiety things like that. We generally don't use buprenorphine or 







4.7.3c. Uncommon care delivery modalities. Informants described unique 
withdrawal management protocols. The protocols do not appear to be supported by 
evidence, yet there is little third-party oversight in the hospital setting to ensure the use 
of validated treatment protocols. One of the protocols was a rapid 72-hour taper using 
tramadol, and the other was an injectable buprenorphine taper protocol. The informant 
rationalized the use of the rapid tramadol taper approach because of the 72-hour rule. 
She described that prior to the implementation of the tramadol protocol they had used 
Suboxone® on their detoxification unit, and the consult service. She said that once 
patients realized that they could only receive the medication for 72-hours they would 
leave AMA, she said it created a “revolving door, they would come and get a couple of 
days’ worth [of Suboxone®] and leave and come back to get more” (deidentified). She 
shared that using tramadol has minimized this effect. 
 4.7.4. Summary. The hospital guidance documents addressed similar clinical 
domains, but differences were observed within the policy sub-domains. Informants and 
guidance document recommendations related to acute pain management agreed; 
patients on OAT prior to admission should be continued on OAT during hospitalization. 
For withdrawal management, however, there was substantial variation among the 
guidance documents across almost all practice domains (i.e., first-line therapy, protocol 
initiation threshold, starting dose, and 24-hour maximum dose). This variation was also 
reflected in the key informant descriptions of care practices. For OAT initiation, again as 





domains (i.e., protocol initiation threshold, maximum day 1 dose, maximum total daily 
dose, and first day dose protocol), and generally informants were unsure about the 
existence of common practices for OAT initiation in their institutions. The variation 
among the hospital guidance documents provide additional evidence of the novelty of 
this practice within hospitals, that there is limited standardization because few hospitals 
are doing it; thus, a national standard does not exist yet.  
 It was challenging to draw conclusions from the security and behavioral 
management sub-policy domains because the guidance documents varied in focus. They 
emphasized interprofessional collaboration to ensure patient safety. The two aberrant 
drug use policies had similar recommendations for assessments, documentation, 
interventions, patient and visitor requirements, the use of urine drug screening, and 
campus safety involvement. However, less consistency was observed in disclosed care 
practices related to aberrant drug use—most informants indicated limited hospital-wide 
understanding in addressing aberrant drug use. Less common, though highly 
problematic, was the existence of guidance documents and disclosures from informants 
during the interviews of the delivery of non-evidenced based care to persons with OUD. 
These non-evidence-based care scenarios included patients receiving no treatment for 
their OUD, patients receiving incorrect or outdated care, or receiving uncommon and 
untested protocols.  
 The findings from this section provide additional evidence to support the 





of hospitalized patients with OUD, and that the existence of said policies and normative 
practices reflect specific supply-side attributes within and outside of the local hospital 
environment. The variation and care discrepancy existed within the context of 16 
hospitals that are well-resourced for the delivery of addiction-related services in 
contrast with the average U.S. hospital without addiction medicine experts or addiction 
medicine training programs.  
 Finally, based on the evidence presented in the previous sections, triangulated 
with the observations from this section, AMC service existence is a conduit for OAT 
management policy creation and implementation. Seventy-eight percent of hospitals 
with established AMC services in this study had OAT management policies (n = 7) as 
compared with 0% of hospitals without an AMC service and the plans to start one. 
Further, 40% of hospitals with the plans to start an AMC service (n = 2) had OAT 
management guidance documents. 
Section 4.8. Linking Qualitative Findings to Quantitative Approach 
 The analyses presented in this chapter provide the conceptual rationale and 
justification for continuing to explore care delivery practice, patterns, and organizational 
processes for patients with OUD in Aims 2 and 3. The findings from Chapter 4 identified 
care delivery patterns for the treatment of persons with OUD during hospitalization that 
appear to be suboptimal and not evidence-based. Informants described care variation 
within and between hospitals. The collection and analyses of hospital guidance 





justification for proceeding with Aims 2 and 3 to quantitatively explore, describe, and 
assess care delivery across the largest integrated health system in the U.S.—the 
Veterans Health Administration (VHA). 
The results of this chapter illuminate gaps in fundamental knowledge as they 
relate to understanding the social and technical contributory elements that contributes 
to an addiction friendly hospital. Some of the findings from this section suggest that 
there are mutable social and technical attributes within and outside of a hospital that 
may enhance a hospital’s ability to deliver evidence-based OUD services including: 
positive social structures (i.e., behaviors, cultural-cognitive, and normative), resource 
investments in addiction-related care (e.g., addiction medicine training programs or an 
AMC service), normative treatment practices (e.g., guidelines), and supportive internal 
stakeholders. Further, findings from this chapter illustrate the power of the local 
environment to enhance or foster the internal work of the hospital such as external 
stakeholders, a robust community-based referral network, external incentives through 
policy, regulations, financing, education, and knowledge. This emphasizes the 
theoretical underpinnings of this study that hospitals, like other organizations, do not 
operate in isolation but act as dynamic, malleable structures influenced by the broader 
social and professional contexts and systems. How these internal and external 
contributions are measured, defined, and quantified warrants future exploration. 





specifically how OAT was operationalized to include all OAT formulations of OAT and 






Chapter 5: Presentation and Analysis of Quantitative Data 
Aim 2 explores the variation in hospital use of opioid agonist therapy (OAT) and 
other non-OAT pharmacotherapies for hospitalized patients with OUD in the Veterans 
Health Administration (VHA) system. A description of the study cohort opens the 
chapter and reviews patient and facility characteristics, and pharmacotherapy delivery 
patterns. The Aim 2 research sub-questions analyze care delivery patterns and examine 
OAT administration variability among hospitalized veterans. Aim 3 analyses expand 
upon the findings of Aim 2 to further understand the multilevel drivers of hospital OAT 
variation in the VHA system. Results are organized into seven sections: 
1. Section 5.1 describes the facilities, patient demographics, admission 
characteristics, patient health characteristics (present on admission and 
during admission), and pharmacotherapy delivery patterns (pre, during, and 
post-admission) of the study cohort. 
2. Section 5.2 (research sub-questions 2a, 2b, and 2c) examines the differences 
in the characteristics and outcomes of patients who do and do not receive 
OAT when hospitalized in the VHA.  
3. Section 5.3 (research sub-questions 2d, 2e, 2f) explores the differences in the 
characteristics and outcomes for patients who received OAT prior to 
admission and were subsequently continued or discontinued.  
4. Section 5.4 reviews the distribution and frequency of hospital OAT delivery 





and non-OAT delivery is broadly summarized (research sub-questions 2g). 
Second, the associations between hospital performance quartile and specific 
OAT care delivery scenarios (research sub-questions 2h) are assessed. Third, 
hospital attributes associated with hospital OAT delivery (research sub-
questions 2i) are summarized. Fourth, differences in non-OAT 
pharmacotherapy delivery associated with hospital OAT delivery quartile 
performance (research sub-questions 2j) are assessed. Finally, associations 
between health and health care utilization outcomes with hospital OAT 
delivery rank or quartile (research sub-questions 2k) are evaluated. 
5. Section 5.5 summarizes the findings from Aim 2 that frame the Aim 3 
analyses. 
6. Section 5.6 explores the multilevel contributions of patients and hospital 
level attributes that are associated with the delivery of OAT during admission 
and the delivery of OAT in the 30 days post-admission. 
7. Section 5.7 summarizes the findings of this chapter. 
Section 5.1. Patient, Admission, and Hospital Descriptive Statistics 
 This section explores the facility, patient, and admission characteristics for the 
final study cohort—12,407 unique index hospitalizations from 109 VHA hospitals in the 
continental U.S. during the 2017 fiscal year.  
5.1.1. Hospital characteristics. Most hospitals were in either the South (n = 43; 





100 beds (n = 45; 41%) or medium sized hospitals with 50 to 99 beds (n = 36; 33%). 
Cases occurred most commonly in large hospitals (n = 7,234; 58%) and in the South 
(39%; n = 4,867). The number of patients with OUD admitted per hospital ranged from 
26 to 430 with a median of 98 (IQR = 97) (see Table 5.1). 
Table 5.1. VHA Hospital Characteristics 
Variable Number of Facilities 
(n = 109) 
Patient Frequency 
(n = 12,407) 
Admissions (count) Median, 98; Mean, 114.0                       Range 26 - 430; IQR 97 
Number of Beds    
Small: 1 to 49 beds 28 12.5% (1551) 
Medium: 50 to 99 beds 36 29.2% (3622) 
Large: 100+ beds 45 58.3% (7234) 
Census Region    
Midwest 25 22.1% (2742) 
Northeast 18 16.4% (2035) 
South 43 39.2% (4867) 
West 23 22.3% (2763) 
5.1.2. Patient characteristics. Patient characteristics across the study cohort 
were similar. Most patients were male (n = 11,543; 93%), white (n = 8,880; 72%), and 
non-Hispanic or Latino (n = 11,476; 93%). The median patient age was 61 years (range 












Table 5.2. VHA Patient Characteristics 
Variable Frequency %, Count (n = 12,407) 
Age Median 61, Mean 58.5 (21 to 90) 
Gender  
Male  93.0% (11543) 
Female 6.8% (864) 
Race  
American Indian or Alaska Native 1.2% (147) 
Asian < 1% (43) 
Black or African American 21.8% (2706) 
Native Hawaiian or Pacific Islander < 1% (106) 
White 71.6% (8880) 
Unknown/Declined to Answer 4.2% (525) 
Ethnicity  
Hispanic or Latino 4.8% (595) 
Non-Hispanic or Latino 92.5% (11476) 
Unknown 2.7% (336) 
5.1.3. Admission characteristics. Admission-related characteristics were also 
homogenous. The median length of stay was 5 days ranging from 1 to 50 days. Most 
hospital admission sources were either direct admission (n = 5,616; 45%) or from 
outpatient treatment (n = 6,095; 49%). One in five patients (n = 2,303; 19%) received 
services in the intensive care unit (ICU) and 6% (n = 779) received surgical services 
during their admission (see Table 5.3). 
Table 5.3. Admission Characteristics 
Variable Frequency %, Count (n = 12,407) 
Length of Stay Median, 5; Mean 6.6 (1 - 50) 
Admission Source 
Outpatient Treatment 49.1% (6095) 
Other Direct Admission 45.3% (5616) 
Other 4.9% (696) 
Service Acuity 
ICU Services 18.6% (2303) 
Surgical Services 6.3% (779) 
5.1.4. Health characteristics during admission. Health-related characteristics 
during admission and present on admission were heterogenous. The prevalence of 





unique primary ICD-10 codes and 1,875 unique secondary ICD-10 codes in the study 
cohort. The top ten primary ICD-10 codes, which accounted for approximately 18% of 
admissions, included: 1) alcohol dependence (4%); 2) chronic obstructive pulmonary 
disease with (acute) exacerbation (2%); 3) opioid dependence with withdrawal (2%); 4) 
sepsis, unspecified organism (2%); 5) kidney failure, unspecified (1%); 6) alcohol 
dependence with intoxication, unspecified (1%); 7) other chest pain (1%); 8) pneumonia, 
unspecified organism (1%); 9) cellulitis of right lower limb (1%); and 10) unilateral 
primary osteoarthritis, right knee (1%). 
The top ten secondary ICD-10 codes accounted for approximately 26% of unique 
admissions: 1) opioid dependence, uncomplicated (7%); 2) acute kidney failure, 
unspecified (4%); 3) suicidal ideations (4%); 4) essential (primary) hypertension (2%); 5) 
pneumonia, unspecified organism (2%); 6) end stage renal disease (2%); 7) human 
immunodeficiency virus disease (2%); 8) hypoosmolality and hyponatremia (1%); 9) 
opioid dependence, with withdrawal (1%); and 10) chronic obstructive pulmonary 
disease with acute exacerbations (1%). 
OUD-related infections occurred in 5.5% of admissions. The top two OUD-related 
infections were osteomyelitis (2%) and bacteremia (1%). Acute OUD-related admission 
diagnoses occurred in 6% of primary diagnoses, 10% of secondary diagnoses, and 15% 
for either primary and/or secondary. Further, 20% of cases in the cohort had either an 






Table 5.4. Health-Related Characteristics: During Admission 
Variable                   Frequency %, Count (n = 12, 407) 
Any Acute OUD Infectiona 5.5% (691) 
1. Osteomyelitis (M86.X) 2.2% (274) 
2. Bacteremia (R78.81) 1.3% (158) 
3. Epidural Abscess/ Diskitis (M46.4; M51.9; M50.X; M51.8) <1% (112) 
4. Septic Arthritis (M00.) <1% (71) 
5. Prosthetic Joint Infection (T84.5x) <1% (57) 
6. Endocarditis (I33.X) <1% (46) 
7. Brain Abscess (G06.X) <1% (45) 
8. Lung Abscess (J85) <1% (38) 
9. Empyema (J86) <1% (24) 
10. Candida Endocarditis (B37.6) <1% (3) 
Any OUD-Related Diagnosis Primary or Secondaryb 14.9% (1848) 
Primary 5.7% (707) 
Secondary 9.5% (1181) 
Any OUD-Related Diagnosis or Any Acute OUD Infection 20.1% (2491) 
Top 10 Primary ICD-10 Diagnosis Codes   
1. Alcohol Dependence (F10.239) 4.4% (551) 
2. Chronic Obstructive Pulmonary Disease with (acute) 
Exacerbation (J44.1) 
2.3% (289) 
3. Opioid Dependence with Withdrawal (F11.23) 2.3% (281) 
4. Sepsis, Unspecified Organism (A41.9) 1.7% (213) 
5. Acute Kidney Failure, Unspecified (N17.9) 1.4% (174) 
6. Alcohol Dependence with Intoxication, Unspecified (F10.229) 1.4% (173) 
7. Other Chest Pain (R07.89) 1.3% (165 
8. Pneumonia, Unspecified Organism (J18.9) 1.2% (151) 
9. Cellulitis of Right Lower Limb (L03.115) 1.1% (133) 
10. Unilateral Primary Osteoarthritis, Right Knee (M17.11) 1.0% (122) 
Top 10 Secondary ICD-10 Diagnosis Codes   
1. Opioid Dependence, Uncomplicated (F11.20) 6.8% (842) 
2. Acute Kidney Failure, Unspecified (N17.9) 4.2% (526) 
3. Suicidal Ideations (R45.851) 4.1% (508) 
4. Essential (Primary) Hypertension (I10.) 2.1% (257) 
5. Pneumonia, Unspecified Organism (J18.9) 1.6% (193) 
6. End Stage Renal Disease (N18.6) 1.5% (191) 
7. Human Immunodeficiency Virus [HIV] Disease (B20) 1.5% (185) 
8. Hypo-Osmolality and Hyponatremia (E87.1) 1.3% (162) 
9. Opioid Dependence with Withdrawal (F11.23) 1.3% (159) 
10. Chronic Obstructive Pulmonary Disease with (Acute) 
Exacerbation (J44.1) 
1.2% (147) 
Table Notes. aNecrotizing fasciitis was queried but not present; bSee Appendix H for queried 
codes. 
5.1.5. Co-occurring conditions present on admission. Co-occurring diagnoses 
occurred within 365 days prior to the index hospitalization. Patients with chronic 





because of the common clinical practice of prescribing opioids for this population 
(Caraceni et al., 2012). Co-occurring mental health and SUD were present in more than 
half of the study cohort—64% of cases had a mental health diagnosis and 49% had 
another SUD diagnosis. The most common mental health disorders present on 
admission were mood disorders (50%), PTSD (31%), and anxiety (28%). The most 
common SUD diagnoses were alcohol use disorder (36%), other psychoactive use 
disorders (17%), and cannabis use disorder (16%) (see Table 5.5). 
Table 5.5. Health-Related Characteristics: Present on Admission 
Variable                Frequency %, Count (n = 12,407) 
Co-Occurring Mental Healtha  65.2% (8094) 
1. Mood Disorder 50.8% (6306) 
2. PTSD 31.8% (3951) 
3. Anxiety Disorder 28.7% (3560) 
4. Non-Mood Psychotic Disorder 7.7% (957) 
5. Adjustment Disorder Other 3.2% (402) 
6. Self-Harm 2.9% (358) 
Co-Occurring Substance Use Disordersa 48.6% (6024) 
1. Alcohol Use Disorder 37.4% (4641) 
2. Other Psychoactive Use Disorder 17.3% (2147) 
3. Cannabis Use Disorder 16.5% (2045) 
4. Stimulant Use Disorder `9.5% (1172) 
5. Cocaine Use Disorder 6.2% (769) 
6. Nicotine Dependence 3.5% (434) 
7. Sedative Use Disorder 2.9% (354) 
8. Other Substance Use Disorders 1.9% (241) 
9. Hallucinogen Use Disorders <1% (66) 
10. Inhalant Related Use Disorders <1% (46) 
Table Notes. aSee Appendix L for codes queried. 
5.1.6. Pharmacotherapy. The pharmacotherapy data were examined for the 
periods of 30 days pre-admission, admission, and 30 days post-admission. 
5.1.6a. Pre-admission pharmacotherapy. Nearly one in three patients (30%) 
filled at least one opioid prescription in the 30 days prior to index-hospitalization. The 





A prescription for gabapentin/pregabalin (e.g., Lyrica®) was filled in 32% of unique cases 
and benzodiazepine prescriptions were present in 9% of cases (see Table 5.6). 
Table 5.6. Pre-Admission: Non-OAT Pharmacotherapya 
Variable Frequency %, Count (n = 12,407) 
Opioidb 30.4% (3766) 
1. Oxycodone 11.8% (1462) 
2. Hydrocodone 10.1% (1256) 
3. Morphine 6.6% (822) 
4. Tramadol 5.4% (675) 
5. Fentanyl 1.3% (158) 
6. Codeine 1.1% (133) 
7. Hydromorphone <1% (109) 
8. Tapentadol <1% (3) 
9. Meperidine <1% (2) 
10. Oxymorphone <1% (1) 
11. Butorphanol <1% (1) 
Benzodiazepine 8.8% (1085) 
1. Clonazepam 3.0% (373) 
2. Lorazepam 2.2% (271) 
3. Diazepam 1.7% (212) 
4. Alprazolam 1.5% (185) 
5. Temazepam <1% (88) 
Concurrent Opioid/Benzodiazepine  4.7% (583) 
Gabapentin/Pregabalin 32.1% (3984) 
Naltrexone 2.0% (244) 
Injection <1% (38) 
Oral 1.7% (212) 
Naloxone 3.8% (477) 
Table Notes. aSub-categories of pharmaceutical groups may equal more than the collapsed category 
because patients may have received more than one drug from a given category; bDoes not include 
methadone or buprenorphine formulations for pain. 
OAT receipt occurred in 11% of cases (n = 1,325) in the pre-admission time 
period. The most common type of OAT was buprenorphine (5%; n = 625) and the second 






Table 5.7. Pre-Admission: OAT 
Variable Frequency %, Count (n = 12,407) 
Any OATa 10.7% (1325) 
Buprenorphine Onlyb 5.0% (625) 
Non-Specific Administrationc  4.7% (577) 
>1Type of OAT Receivedd <1% (112) 
Methadone Onlye <1% (11) 
Table Notes. aIncludes each of the 4 sub-categories in this table; bIncludes buprenorphine prescription 
fills and the Healthcare Common Procedure Coding System (HCPCS) codes (J0574, J0575, J0571); 
cIncludes an OTP stop code visit or the non-specific OAT administration HCPCS code (H0033); dIncludes 
any patients who received more than one type of OAT during the pre-period; eIncludes the methadone 
specific HCPCS code (S0109). 
5.1.6b. Admission pharmacotherapy. Admission data suggested frequent opioid 
administration during admission. More than half of patients (55%) had at least one 
opioid delivered during admission; oxycodone (29%) and morphine (20%) were most 
common. More than one in three admissions received gabapentin/pregabalin (37%) and 
more than one in four admissions received benzodiazepines (30%). First or second-line 
adjuvants for the symptom management of opioid withdrawal were administered in 
44% of cases. The VHA’s recommended first line adjuvant for withdrawal, clonidine, was 
only observed in 9% of cases; second-line adjuvants (i.e., baclofen, gabapentin, 






Table 5.8. Admission: Non-OAT Pharmacotherapya 
Variable Frequency %, Count (n = 12,407) 
Any Opioidb 54.5% (6765) 
1. Oxycodone 29.2% (3623) 
2. Morphine 20.4% (2525) 
3. Hydromorphone 18.0% (2635) 
4. Hydrocodone 13.3% (1645) 
5. Tramadol 8.1% (1008) 
6. Fentanyl 4.4% (551) 
7. Codeine <1% (103) 
8. Meperidine <1% (17) 
9. Belladonna <1% (11) 
10. Tapentadol <1% (2) 
11. Oxymorphone <1% (1) 
12. Butorphanol <1% (1) 
No Opioids and No OAT 35.6% (4418) 
Any adjuvants 44.4% (5502) 
First-Line Adjuvantc 8.8% (1089) 
Any Second-Line Adjuvantd 39.3% (4882) 
Any benzodiazepine 30.3% (3757) 
1. Lorazepam 21.6% (2677) 
2. Diazepam 5.3% (662) 
3. Clonazepam 3.1% (383) 
4. Alprazolam 1.9% (240) 
5. Midazolam 1.7% (214) 
6. Temazepam 1.3% (159) 
Gabapentin/Pregabalin  36.7% (4556) 
Naltrexone 1.4% (168) 
Oral Tablet 1.3% (155) 
Injectable <1% (31) 
Table Notes. aGroup sub-categories may equal more than the collapsed category because patients 
can receive more than one drug from a category; bDoes not include methadone or buprenorphine 
formulations; cFirst-line: clonidine; dSecond-line: baclofen, gabapentin, pregabalin, and tizanidine. 
OAT was administered in 15% of cases, with methadone delivery (9%) more 
common than buprenorphine (5%). Across the study population, OAT was used primarily 
to manage withdrawal symptoms (7%) (i.e., the patient did not receive OAT prior to or 
after admission, only during admission). The second most common OAT delivery 
mechanism was OAT sustained (6%) (i.e., a patient received OAT throughout the care 
continuum—in the pre, admission, and post periods). OAT initiation and linkage to care 





setting within 30›days of discharge). Very few patients received OAT continuation (1%) 
(i.e., OAT delivery in the pre-period and during admission, but not in the post-admission 
discharge period) (see Table 5.9). 
Table 5.9. Admission: OAT 
Variable Frequency %, Count (n = 12,407) 
Any OATa 15.4% (1914) 
Methadone Onlyb 8.5% (1049) 
Buprenorphine Onlyc 5.2% (639) 
>1 Type of OAT Receivedd 1.1% (136) 
Non-Specific Administration Onlye <1% (90) 
OAT by Care Delivery Scenario   
OAT Withdrawalf 6.8% (844) 
OAT Sustainedg 5.8% (722) 
OAT Initiation and Linkageh 1.6% (203) 
OAT Continuedi 1.2% (145) 
OAT Administered with Other Pharmacotherapy  
With Any Adjuvant  7.2% (893) 
With Second-Line Adjuvant  6.2% (766) 
With Opioid 5.6% (690) 
With First-Line Adjuvant: Clonidine 2.2% (271) 
With Naltrexone <1% (9) 
aIncludes each of the 4 OAT sub-categories in this table; bIncludes the methadone specific Healthcare 
Common Procedure Coding System (HCPCS) code (S0109); cIncludes buprenorphine prescription fills 
and HCPCS codes (J0574, J0575, J0571); dIncludes any patients who received more than one type of 
OAT during admission; eIncludes an OTP stop code visit or the non-specific OAT administration HCPCS 
code (H0033); fOAT received during admission, but not in pre or post period; gOAT received in the pre, 
admission, and post periods; hOAT received during admission and the post period, but not the pre 
period; iOAT received in the pre and admission periods, but not the post period. 
5.1.6c. Post-admission pharmacotherapy. Over one third of the patients (34%) 
in the study cohort filled one or more opioid-related prescriptions in the 30 days after 
hospital discharge. The most commonly filled prescriptions were oxycodone (17%) and 
hydrocodone (10%). Compared with the pre-admission data, the proportion of cases 
with gabapentin/pregabalin (26%) and benzodiazepine (8%) prescriptions was lower. 
Compared with the pre-admission data, the proportion of cases prescribed naloxone 





Table 5.10. Post-Admission: Non-OAT Pharmacotherapya 
Variable Frequency %, Count (n = 12,407) 
Any Opioidb 34.3% (4250) 
1. Oxycodone 17.0% (2112) 
2. Hydrocodone 9.9% (1229) 
3. Morphine 6.1% (759) 
4. Tramadol 5.2% (650) 
5. Hydromorphone 1.6% (196) 
6. Fentanyl 1.2% (150) 
7. Codeine <1% (108) 
8. Tapentadol <1% (2) 
9. Meperidine <1% (2)  
10. Oxymorphone <1% (1) 
11. Belladonna <1% (1) 
Any Benzodiazepine 7.7% (949) 
1. Clonazepam 2.3% (317) 
2. Lorazepam 2.2% (267) 
3. Diazepam 1.5% (188) 
4. Alprazolam 1.1% (140) 
5. Temazepam <1% (66) 
6. Midazolam <1% (3) 
Concurrent Opioid & Benzodiazepine  3.9% (483) 
Gabapentin/Pregabalin 26.3% (3263) 
Naltrexone 2.8% (341) 
Oral Tablet 2.3% (289) 
Injectable <1% (68) 
Naloxone 6.2% (765) 
Table Notes. aSub-categories of pharmaceutical groups may equal more than the collapsed 
category because patients may have received more than one drug from a given category; 
bDoes not include methadone or buprenorphine formulations for pain. 
OAT receipt during the post-admission period occurred in 11% of cases, with a 
nearly even distribution of use between buprenorphine (5%) and non-specific 





Table 5.11. Post-Admission: OAT 
Variable Frequency %, Count (n = 12,407) 
Any OATa 11.4% (1420) 
Buprenorphine Onlyb 5.1% (633) 
Non-Specific Administration Onlyc 5.1% (628) 
>1 Type of OAT Receivedd 1.1% (142) 
Methadone Onlye <1% (17) 
Table Notes. aIncludes each of the 4 sub-categories in this table; bIncludes buprenorphine prescription 
fills and the Healthcare Common Procedure Coding System (HCPCS) codes (J0574, J0575, J0571); 
cIncludes an OTP stop code visit or the non-specific OAT administration HCPCS code (H0033); dIncludes 
any patients who received more than one type of OAT during admission; eIncludes the methadone 
specific HCPCS code (S0109).  
5.1.7. Admission-related outcomes. The admission-related outcomes were 
assessed during hospitalization or within the 30 days post-admission. In-hospital 
mortality (1%), post-admission death (<1%), and leaving against medical advice (6%) 
were uncommon outcomes across the study cohort. In contrast, it was common for 
patients to need additional acute care services during the post-admission period. More 
than one quarter of patients (28%) in the sample had an emergency department visit, 
and re-admissions occurred for 13% of patients (see Table 5.12). 
Table 5.12. VHA Study Cohort Outcomes 
Variable  Frequency %, Count (n = 12,407) 
Admission  
Left Against Medical Advice 5.7% (701) 
In-Hospital Mortality  1.0% (119) 
Post-Admission  
Death <1% (112) 
Emergency Department Visit  27.7% (3436) 
Hospital Readmission  13.1% (1630) 
 5.1.8. Summary. This section explored the supply-side and demand-side 
attributes, care delivery patterns, and outcomes for the entire study cohort. The study 
cohort characteristics were homogenous for the supply-side (i.e., hospitals) and 





elderly white men, with co-occurring mental health conditions, in large hospitals. In 
contrast, the clinical reasons for admission varied among patients. Interestingly, most 
admissions were not OUD-related by primary or secondary diagnosis or by OUD-related 
infection codes. 
 These descriptive analyses begin to depict care patterns for patients with OUD 
that are potentially problematic. In all three time periods (pre, admission, post), opioid 
prescription or administration frequency was higher than OAT delivery. When OAT was 
delivered in the hospital setting, it was primarily administered for withdrawal 
management. The most effective approaches to care (i.e., OAT sustaining, continuing, 
initiating and linkage to care) occurred infrequently. An additional indicator of poor care 
or lower quality care delivery in the hospital setting was the elevated use of the 
emergency department in the post-admission period. This measure has not been 
studied in the VHA system; however, a 30-day hospital readmission rate for the VHA 
system has been reported at 18% (Vincent, Wiitala, Burns, Iwashyna, & Prescott, 2018), 
and a previous hospitalization (OR, 2.5; 95% CI [2.3, 2.7]) is associated with increased 
risk of an emergency department visit (Hastings et al., 2011). 
Section 5.2. OAT vs. No OAT Received During Admission 
To expand upon the observations of the prior section, this section explored 
potential differences between patients who received or did not receive OAT based on 
clinical and admission characteristics, care delivery patterns, and outcomes. This section 





• 2a: Do the characteristics of the patients who received OAT differ from those 
who do not receive OAT while hospitalized? 
• 2b: Does non-OAT pharmacotherapy delivery differ for patients who received 
OAT and for those who did not receive OAT while hospitalized? 
• 2c: Do outcomes differ for patients who received OAT and for those who did 
not receive OAT while hospitalized? 
5.2.1. Patient characteristics. Patients who received OAT differed statistically (p 
< 0.05) from those who did not receive OAT during admission. OAT patients were one 
year younger (mean = 57 years of age vs. 58 years of age) and were less likely to be 
women (5% vs. 7%). Patients who received OAT had a statistically significant different 
distribution of racial categories with more Black patients (27% vs. 21%) and fewer White 
patients (68% vs. 76%). Patients administered OAT during hospitalization were also 
more likely to have comorbid SUDs (51% vs. 48%) and to have mental health disorders 
(67% vs. 65%). Although the two groups differed statistically on most characteristics, the 
differences do not appear to be clinically significant; rather they reflect the study’s large 





Table 5.13. Patient Characteristics: OAT Received vs. Not Received 
Characteristics OAT Received 
(15%, 1,914) 
No OAT Received 
(85%, 10,597) 
Difference Test  
Statistic 
Age*** Median, 60.0 years  
Mean, 57.1 
(SD = 12.4; 23-90)  
Median, 61.0 years 
Mean, 58.8  
(SD = 13.4; 21-90) 
1 year W = 10675000 
p < 0.05a 
Race***     
American Indian or Alaska Native  <1% (12) 1.3% (135) »  <1% X2 = 42.56 
df = 5 
p < 0.05b 
Asian <1% (7) <1% (36) »  <1% 
Black or African American 27.0% (516) 21.0% (2190) »  6% 
Native Hawaiian or Pacific Islander <1% (12) <1% (94) »  <1% 
Unknown/Declined to Answer 3.4% (65) 4.3% (460) »  <1% 
White 68.0% (1302) 75.7% (7578) »  7%  
Ethnicity     
Hispanic or Latino 5.5% (105) 4.7% (490) »  <1% X2 = 2.3663 
df = 2 
p > 0.05  
Non-Hispanic or Latino 91.8% (1758) 92.6% (9718) »  <1% 
Unknown 2.6 % (51) 2.8% (285) »  <1% 
Gender***     
Male 95.5% (1827) 92.6% (9716) »  2% X2 19.99 
df = 1 
p < 0.05c 
Female 4.6% (87) 7.4% (777) »  3% 
Comorbidities     
SUD* 51.4% (983) 48.0% (5041) »  3% X2 = 6.9972 
df = 1 
p < 0.05c 
Mental health condition** 67.4% (1290) 64.8% (6804) » 2% X2 = 4.5472 
df = 1 
p < 0.05c 
Table Notes. aMann-Whitney U Test (Wilcoxon rank sum test with continuity correction); bPearson chi-square test; cPearson chi-square test with 





5.2.2. Admission characteristics. The two groups had statistically significant 
differences for length of stay, admission source, acuity of services received (ICU and 
surgical), OUD diagnoses, and OUD infection diagnoses. Although, again, most observed 
differences between the two groups were likely trivial, findings with substantive 
relevance were likely for three characteristics. Patients who received OAT had a longer 
length of stay (5 days vs. 4 days) and were more likely to have a primary or secondary 
OUD diagnosis (29% vs. 12%) or an OUD diagnosis/and or an OUD-related infection (37% 










No OAT Received 
(85%, 10,597) 
Difference Test  
Statistic 
Length of Stay*** Median, 5 days 
Mean, 7.53  
(SD 7.05; 1 – 50) 
Median, 4 days 
Mean, 6.44 
(SD 6.23, 1- 50) 
1 day W = 8758700 
p < 0. 05a 
Admission Source***     
Outpatient Treatment 46.0% (880) 49.7% (5215) » 4% X2 = 13.533 
df = 2 
p < 0.05b 
Other Direct Admission 49.3% (942) 44.5% (4673) » 4% 
Other 4.8% (91) 5.8% (605) » 1% 
Type of Services Received     
ICU Services** 16.3% (312) 19.0% (1991) » 3% X2 = 7.4787 
df = 1 
p < 0.05c 
Surgical Services* 5.2% (100) 6.5% (679) » <1% X2 = 4.0638 
df = 1 
p < 0.05c 
Acute OUD or Infection Diagnosis     
Acute OUD Diagnosis*** 29.0% (560) 12.3% (1288) » 17% X2 = 366.98 
df = 1 
p < 0.05c 
OUD Infection Diagnosis *** 8.3% (158) 5.1% (533) » 3% X2 = 30.434 
df = 1 
p < 0.05c 
Acute OUD or Infection Diagnosis**** 36.5% (698) 17.1% (1793) » 20% X2 = 377.7 
df = 1 
p < 0.05c 
Table Notes. aMann-Whitney U Test (Wilcoxon rank sum test with continuity correction); bPearson chi-square test; cPearson chi-square test 






5.2.3. Care delivery during admission. Care delivery processes during admission 
differed significantly for patients who received OAT and for those who did not. Patients 
who received OAT were less likely to receive opioids (36% vs. 58%), benzodiazepines 
(28% vs. 31%), or naltrexone (<1% vs. 2%). They were also more likely to receive 
withdrawal management adjuvants (48% vs. 44%), or first-line adjuvants (14% vs. 8%). 
The differences in opioid administration between the two groups were likely 
meaningful, although, generally, the remainder of the statistical differences appeared to 
have minimal clinical relevance (see Table 5.15).  
Table 5.15. Admission Non-OAT Pharmacotherapy: OAT Received vs. Not Received 




No OAT Received 
(85%, 10,597) 
Difference Test  
Statistic 
Non-OAT Opioid***  36.1% (690) 57.9% (6075) » 22% X2 = 310.67 
df = 1 
p < 0.05c 
Any Adjuvant***  48.0% (919) 43.7% (4583) » 4% X2 = 12.167 
df = 1 
p < 0.05c 
First-Line Adjuvant: 
Clonidine*** 
14.2% (271) 7.8% (818) » 7% X2 = 81.064 
df = 1 
p < 0.05c 
Second-Line Adjuvant 40.0% (766) 39.2% (4116) » <1% X2 = 0.39576 
df = 1 
p > 0.05c 
Benzodiazepine***  27.6% (528) 30.8% (3229) » 3% X2 = 7.6361 
df = 1 
p < 0.05c 
Naltrexone*** <1% (9) 1.5% (159) » 1% X2 = 12.465 
df = 1 
p < 0.05c 
Table Notes. cPearson chi-square test with Yates’ continuity correction; p < 0.05*; p < 0.01**;  
p < 0.001***. 
5.2.4. Health and utilization outcomes. Compared to patients who did not 
receive OAT, patients who received OAT were significantly less likely to leave against 





vs. 38%), benzodiazepines (5% vs. 8%), concurrent opioids and benzodiazepines (<1% vs. 
4%), and naltrexone (<1% vs. 3%). The differences were small and likely have little 
clinical importance; however, two of the differences had apparent clinical significance: 












No OAT Received 
(85%, 10,493) 
Difference Test Statistic 
Admission     
In-Hospital Mortality  <1% (15) 1.0% (104) » <1% X2 = 0.53115 
df = 1 
p > 0.0 
Left Against Medical Advice*** 
 
3.5% (68) 6.0% (633) » 2% X2 = 18.211 
df = 1 
p < 0.05  
Post-Admission     
Death <1% (18) <1% (94) » <1% X2 = 0.00343 
df = 1 
p > 0.05 
Emergency Department Visit  26.1% (499) 28.0% (2937) » 2% X2 = 2.8819 
df = 1 
p > 0.05 
Hospital Readmission  12.8% (245) 13.2% (1385) » <1% X2 = 0.19206 
df = 1 
p > 0.05 
Non-OAT Opioid***  16.3% (312) 37.5% (3938) » 22% X2 = 322.98 
df = 1  
p < 0.05 
Benzodiazepine ***  5.4% (103) 8.1% (846) » 3% X2 = 16.095 
df = 1 
p < 0.05 
Naloxone***  11.2% (214) 5.3% (551) » 6% X2 = 97.351 
df = 1 
 p < 0.05 
Gabapentin/Pregabalin  25.8% (493) 26.4% (2770) » <1% X2 = 0.31084 
df = 1 
p > 0.05 
Naltrexone*** <1% (17) 3.2% (324) » 3% X2 = 28.483 
df = 1 
p < 0.05 
Concurrent Opioid/ 
Benzodiazepine*** 
<1% (34) 4.3% (449) » 4% X2 = 26.562 
df = 1 
p < 0.05 
OAT*** 48.3% (925) 4.7% (495) » 43% X2 = 3033.3 
df = 1 
p < 0.05 
Table Notes. bPearson chi-square test; p < 0.05*; p < 0.01**; p < 0.001***; Post-admission event within 






5.2.5. Summary. Most of the statistically significant findings were based on small 
relative differences that were likely not clinically significant but reflected the large study 
sample size. Four findings from this section stood out and warrant further discussion 
and exploration. First, patients who received OAT were more likely to have an OUD 
diagnosis and/or an OUD-related infection. This suggests that treatment processes and 
services differed between patients with an acute OUD-related issue during admission as 
compared with patients with a chronic OUD presentation. Second, patients who 
received OAT had a lower frequency of opioid administration during hospitalization. 
Determining whether this is appropriate or inappropriate care is challenging without 
further granularity on each case. The qualitative analyses in Chapter 4 suggested that 
patients who received OAT in the hospital setting may require additional opioids to 
manage pain when OAT administration alone is insufficient to manage moderate to 
severe pain. Lower opioid administration for this patient population during 
hospitalization, therefore, may be inappropriate. Third, patients who received OAT had 
less post-admission opioid prescriptions filled suggesting that prescribers may be 
assessing opioid risk more carefully among patients who received OAT. However, 16% of 
these patients were still receiving non-OAT opioids in the post-admission period. Fourth, 
patients who received OAT were more likely to receive OAT in the 30-day discharge 
period suggesting that OAT delivery in the hospital setting is part of a broader pathway 





Section 5.3. OAT Discontinuation vs. OAT Continuation Upon Admission 
There were 1,325 patients in the sample receiving OAT prior to hospital 
admission. Of those patients, 65% (n = 867) continued OAT during admission, and 35% 
(n = 458) were discontinued from OAT during admission. Of the patients who continued 
OAT during admission, most (83%) were continued in the post-admission period (n = 
722; the OAT sustained variable). Of those who were discontinued upon admission, 64% 
of those patients (n = 295; the OAT discontinued with restart variable) were restarted 
upon discharge in the post-admission period. Post-hospitalization approximately 23% of 
patients (n = 308, the OAT interrupted variable) who had received OAT prior to hospital 
admission (regardless of care received during admission) had their OAT care interrupted 
by hospitalization, and did not return to OAT in the 30 days post-admission. Section 5.3 
addresses the following research sub-questions: 
• 2d: Do the characteristics of the patients who were discontinued from OAT 
differ from those who were continued on OAT at admission? 
• 2e: Does non-OAT pharmacotherapy delivery differ for patients who received 
OAT and for those who did not receive OAT while hospitalized? 
• 2f: Do outcomes differ for patients who received OAT and for those who did 
not receive OAT while hospitalized? 
5.3.1. Patient characteristics. Patients who were discontinued on OAT upon 
admission (n = 458) and patients who continued OAT during admission (n = 867) 





of age) and more likely to be women (9% vs. 4%). The observed differences were not 
large, and are not clearly clinically significant, but may reflect some combined 
demographics or a sub-population not otherwise discernable in the bivariate analysis 






Table 5.17. Patient Characteristics: OAT Continued vs. Discontinued 
Characteristics OAT Discontinued 
(n = 458) 
OAT Continued 
(n = 867) 
Difference Test  
Statistic 
Age** Median, 59.0 years  
Mean, 54.0 
(SD = 13.2; 24 -81)  
Median, 60.0 years 
Mean, 56.2  
(SD = 12.4; 23-87) 
1 year W = 216700 
p < 0.05a 
Race     
American Indian/Alaska Native  <1% (1) <1% (3) » <1% X2 = 6.108 
df = 5 
p > 0.05b 
Asian <1% (2) <1% (3) » <1% 
Black/African American 22.3% (102) 28.1% (244) » 6% 
Native Hawaiian/Pacific Islander <1% (2) <1% (6) » <1% 
Unknown/Declined to Answer 2.8% (13) 2.8% (24) No diff. 
White 73.8% (338) 67.7% (587) » 6%  
Ethnicity     
Hispanic or Latino 4.6% (21) 5.7% (49) » 1% X2 = 0.68579 
df = 2 
p > 0.05  
Non-Hispanic or Latino 92.8% (425) 91.7% (795) » 1% 
Unknown 2.6 % (12) 2.7% (23) » <1% 
Gender***     
Male 91.3% (418) 96.0% (832) » 5% X2 = 11.516 
df = 1 
p < 0.05c 
Female 8.7% (40) 4.0% (35) » 5% 
Comorbidities     
Co-Occurring Substance Use Disorder 58.1% (266) 61.7% (535) » 3% X2 = 1.5021 
df = 1 
p > 0.05c 
 
Co-Occurring Mental Health 74.2% (340) 76.4% (662) » 2% X2 = 0.61981  
df = 1 
p > 0.05c 
Table Notes. aMann-Whitney U Test (Wilcoxon rank sum test with continuity correction); b Pearson chi-square test; cPearson chi-square test with 





5.3.2. Admission characteristics. The OAT-discontinued and OAT-continued 
groups differed on two admission-related characteristics: length of stay and receipt of 
surgical service. Length of stay was likely the only clinically meaningful difference. 
Discontinued OAT patients had a median stay of three days while OAT-continued 
patients had a median stay of five days. There were also important similarities between 
the groups, specifically: 1) the two groups did not differ on source of admission; 2) 
patients did not differ in acuity of services (e.g., ICU use); and 3) there were no 
differences in frequency of acute OUD diagnoses and or/OUD-related infections (see 
Table 5.18). These findings suggest other unmeasured sources were contributing to the 





Table 5.18. Admission-Related Patient Characteristics: OAT Continued vs. Discontinued 
Characteristics OAT Discontinued 
(n = 458) 
OAT Continued 
(n = 867) 
Difference  Test  
Statistic 
Length of Stay*** Median, 3 days 
Mean, 4.46  
(SD 4.84; 1 – 43) 
Median, 5 days 
Mean, 6.65 
(SD 5.88, 1- 47) 
2 days  W = 266920 
p < 0. 05a 
Admission Source 
Outpatient Treatment 48.0% (220) 45.6% (395) » 2%  X2 = 1.6934 
df = 2 
p > 0.05b 
Other Direct Admission 46.5% (213) 49.9% (433) » 2%  
Other 5.4% (25) 4.5% (39) » 1%  
Type of Services Received 
ICU Services  15.9% (73) 15.9% (138) No diff.  X2 = 7.2 X 10-30  
df = 1 
p =1c 
Surgical Services** 10.3% (47) 5.4% (47) » 5%  X2 = 9.934  
df = 1 
 p < 0.05c 
OUD or Infection Diagnosis 
Primary or Secondary OUD Diagnosis 26.6% (122) 27.2% (236) » <1%  X2 = 0.026289  
df = 1 
p > 0.05c 
OUD Infection Diagnosis 5.0% (23) 6.3% (55) » 1%  X2 = 0.72166 
df = 1 
p > 0.05c 
OUD Diagnosis or Infection Diagnosis 31.2% (143) 32.9% (285) » 2%  X2 = 0.30117  
df = 1 
p > 0.05c 
Table Notes. aMann-Whitney U Test (Wilcoxon rank sum test with continuity correction); bPearson chi-square test; cPearson chi-square test with 






5.3.3. Care delivery during admission. Medications provided during admission 
differed statistically for patients who discontinued or continued OAT for opioid 
administration, any adjuvant administration, and second-line adjuvant administration. 
Of these observed differences, only one of the care delivery processes was likely 
clinically meaningful: OAT discontinued patients were more likely to receive non-OAT 
opioids during admission (44% vs. 26%) (see Table 5.19).  




(n = 458) 
OAT Continued 
(n = 867) 
Difference Test  
Statistic 
Non-OAT Opioid***  43.9% (201) 26.2% (227) » 18% X2 = 42.15 
df = 1 
p < 0.05c 
Any Adjuvant*  37.3% (171) 43.7% (379) » 7% X2 = 4.7615 
df = 1 
p < 0.05c 
First-Line  
Adjuvant: Clonidine 
10.3% (47) 9.7% (84) 
 
» <1% X2 = 0.055607 
df = 1 
p > 0.05c 
Second-Line  
Adjuvant** 
31.2% (143) 39.1% (339) » 8% X2 = 7.6988 
df = 1 
p < 0.05c 
Benzodiazepine  23.6% (108) 23.5% (204) » <1% X2 = 5.5 X 10-29 
df = 1 
p = 1c 
Naltrexone <1% (2) <1% (2) » <1% X2 = 0.01527 
df = 1 
p > 0.05c 
Table Notes. cPearson chi-square test with Yates’ continuity correction; p < 0.05*; p < 0.01**; 
 p < 0.001***. 
5.3.4. Outcome characteristics. Compared with the OAT discontinued patients, 
the OAT continued patients were statistically less likely to leave the hospital against 
medical advice (3% vs. 10%), less likely to receive post-admission opioid prescriptions 
(12% vs. 27%), and were more likely to receive OAT upon discharge in the post-





Table 5.20. Outcomes: OAT Continued vs. Discontinued 
Characteristics OAT  
Discontinued 
(n = 458) 
OAT Continued 
(n = 867) 
Difference Test  
Statistic 
Admission     
In-Hospital Mortality  <1% (1) 1.0% (5) » <1% X2 = 0.24386 
df = 1 
p > 0.05 
Left Against Medical 
Advice*** 
10.0% (46) 3.0% (26) » 7% X2 = 27.589 
df = 1 
p < 0.05  
Post-Admission     
Death 10.0% (5) 3.0% (7) » 7% X2 = 0.046088 
df = 1 
p > 0.05 
Emergency  
Department Visit  
29.5% (135) 26.2% (227) » 4% X2 = 1.4757 
df = 1 
p > 0.05 
Hospital Readmission  12.9% (59) 11.8% (102) » 1% X2 = 0.25637 
df = 1 
p > 0.05 
Non-OAT Opioid***  26.9% (123) 12.0% (104) » 15% X2 = 45.576 
df = 1  
p < 0.05 
Benzodiazepine  6.3% (29) 4.7% (41) » 1% X2 = 1.2352 
df = 1 
p > 0.05 
Naloxone 8.1% (37) 8.7% (75) » <1% X2 = 0.063547 
df = 1 
 p > 0.05 
Gabapentin/Pregabalin  28.8% (132) 26.3% (228) » 2% X2 = 0.84105 
df = 1 
p > 0.05 
Naltrexone  2.0% (9) <1% (6) » 2% X2 = 3.2764 
df = 1 
p > 0.05 
Concurrent Opioid & 
Benzodiazepine  
2.0% (9) 1.2% (10) » 1% X2 = 0.88162 
df = 1 
p > 0.05 
OAT*** 64.4% (295) 83.3% (722) » 19% X2 = 58.272 
df = 1 
p < 0.05 
Table Notes. bPearson chi-square test; cPearson chi-square test with Yates’ continuity correction;  






5.3.5. Summary. This section provides insights about a special subset of patients 
from the study cohort—patients receiving OAT in the 30 days prior to their hospital 
admission. Several findings stand out. First the difference in OAT receipt during the 30 
days after hospital discharge (i.e., the post-admission period) for patients who were 
either continued (83%) or discontinued (64%) on OAT during the admission was 
significant. This difference illustrates the importance of hospital-based continuation of 
OAT. Further, this suggests that care pathways or care transition plans may exist for 
patients in the VHA system who are on OAT prior to admission. 
Second, there were differences in patient-and admission-related characteristics. 
Patients discontinued from OAT had substantially shorter lengths of stay (3 days vs. 5 
days) suggesting that something may be characteristically different about this patient 
population, and the primary reason for their hospitalization. The causes of a shorter 
length of stay cannot be explicitly determined and there are a variety of factors that 
could explain this difference. One explanation is that shorter stays are related to a 
higher occurrence of leaving against medical advice (AMA) in the discontinuation 
population (10% vs. 3%). Another explanation is that because the patient has a shorter 
length of stay, due to non-OUD related factors, it is possible that a patient’s withdrawal 
symptoms were not identified. This misidentification could be due to withdrawal 
masking because non-OAT opioids were administered during admission. OAT 
discontinued patients were more likely to receive non-OAT opioids (44% vs. 26%). The 





withdrawal and the use of non-FDA approved opioids to manage withdrawal. Short-
acting opioids in this patient population were frequently continued post-admission. 
Patients discontinued from OAT had increased opioid use post-admission (27% vs. 12%), 
suggesting that discontinuing OAT in the hospital setting increases the opportunity for 
OUD treatment disruption and the propagation of non-evidence-based care.  
There were important non-statistically significant findings from this sub-group 
analysis. First, the two sub-groups did not differ in hospitalization acuity (ICU services) 
or types of services received (surgery). These are both potential clinical reasons as to 
why a patient could be discontinued from OAT. Second, there were no differences 
between the two groups in the frequency of acute OUD diagnoses and or/OUD-related 
infections. This is a relevant finding because patients with an acute OUD diagnosis may 
have more obvious needs for OAT continuation. These non-significant findings indicate 
that the differences in OAT continuation may be explained by other unmeasurable 
elements, such as the care delivery environment.  
Section 5.4. Hospital OAT Delivery Distribution and Performance Quartiles 
To expand upon previous observations that patient and hospital characteristics 
may contribute to hospital OAT delivery variation, this section further investigates 
hospital OAT care variation across the VHA system. This section addresses the following 
research sub-questions: 
• 2f: Do outcomes differ for patients who received OAT and for those who did not 





• 2g: Are specific OAT care scenarios associated with hospital OAT delivery 
quartile? 
• 2h: Which hospital attributes associated with hospital OAT delivery? 
• 2i: Are non-OAT pharmacotherapy services associated with hospital OAT delivery 
quartile? 
• 2j. Were outcomes associated with hospital OAT delivery performance?  
The relative OAT delivery frequency (the number of admissions with OAT 
delivered divided by total number of admissions at that facility) was calculated for each 
facility (n = 109). The median relative frequency was 11%, with a standard deviation of 
0.10, and a range from 0% to 43%, confirming variation in hospital OAT delivery across 
the VHA system. An assessment of specific OAT delivery mechanisms found that the 
most common OAT delivery scenarios were withdrawal management (39%) and OAT 
sustained (33%); OAT initiation and linkage to care (9%) and OAT continuation (7%) were 
uncommon (see Table 5.21 and Figure 5.1).  
Table 5.21. Hospital OAT Delivery Mechanisms 




Median Range IQR Skew Kurtosis 
Any OAT  
(n = 1914) 
100%  0.12 0, 0.43 0.11 1.10 0.77 
Withdrawal Managementa  
 (n = 844) 
38.6 0.05 0.0, 0.39 0.06 1.32 1.99 
OAT Sustainedb    
(n = 722) 
33.0%  0.04 0.0, 0.23 0.06 1.38 -1.24 
OAT Initiation & Linkagec  
(n = 203) 
9.2%  0.005 0.0, 0.08 0.02 1.77 3.13 
OAT Continuedd  
(n = 145) 
6.6%  0.006 0..0, 0.06 0.02 1.38 1.37 
Table Notes. aOAT received during admission period, but not in pre or post period; bOAT received 
in the pre, admission, and post periods; cOAT received during admission and the post period, but 





Figure 5.1. Relative OAT Frequency for Each Hospital by Quartile 





Based on the relative OAT delivery frequency (of any OAT delivery scenario), 
facilities were categorized into hospital OAT delivery performance quartiles: Q1 (0 to 
6.0%), Q2 (7.0 to 11.0%), Q3 (12.0 to 18.0%), and Q4 (18.1 to 42.0%). The data had a 
non-normal distribution skewed towards lower performance (see Table 5.22 and Figure 
5.2.). 
Table 5.22. Any OAT Received: By OAT Performance Quartilea 
Performance 
Quartile 
No. of  
Obs. 
Median Range IQR Skew Kurtosis 
All  (n = 109) 12,407 0.12 0.0, 0.43 0.11 1.05 0.73 
Q4  (n = 28) 3,944 0.27 0.18, 0.43 0.12 0.51 -0.97 
Q3  (n = 26) 2,767 0.15 0.12, 0.18 0.03 0.21 -1.28 
Q2  (n = 28) 2,836 0.10 0.07, 0.12 0.03 -0.05 -1.57 
Q1  (n = 27) 2,860 0.05 0 .0, 0.07 0.03 -0.78 -0.33 
Table Notes. aQ4 is the highest performing group and Q1 is the lowest performing group; No. of Obs 
= The total number of cases in each quartile with and without OAT delivered. 




































5.4.1. Performance quartiles: OAT delivery. Hospital OAT performance delivery 
quartiles differed for all OAT care delivery scenarios. For any OAT received, each quartile 
differed statistically from each other (alpha = 0.05), indicating that quartiles provided a 
meaningful distinction of OAT performance. Generally, facilities in Quartile 4 were more 
likely to use OAT to manage withdrawal symptoms, to sustain OAT through the care 
delivery continuum, to continue OAT, and to initiate OAT and link patients to care. The 
median delivery of OAT in this quartile (27%), however, suggests that most patients, 
even in the highest performing hospitals, did not receive OAT. Even the highest perform 
OAT hospitals in the VHA did not appear to meet current standards of care for 












































f,h,i » 22% X2 = 101.24 
df = 3 















 » 8% X2 = 53.051 
df = 3 
p < 0.05c 
OAT Sustained*** 4% 











 » 8% X2 = 54.929 
df = 3 













 » 2% X2 = 18.467 
df = 3 
p < 0.05c  
OAT Initiation and 
Linkage*** 
<1%  









 » 3% X2 = 38.2776 
df = 3 
p < 0.05c  
Table Notes.  aHospitals were categorized into OAT delivery performance quartiles based on the proportion of cases at a hospital with OAT 
during admission. Q1 hospitals were the lowest performers and Q4 the highest; bKruskal-Wallis Test; cDunn’s Test; dDunn’s Test results: 
difference between Q1 and Q2; eDunn’s Test results: difference between Q1 and Q3; fDunn’s Test results: difference between Q1 and Q4; 
gDunn’s Test results: difference between Q2 and Q3; hDunn’s Test results: difference between Q3 and Q4; iDunn’s Test results: difference 





5.4.2. Performance quartiles: Hospital characteristics. Next, relationships 
among hospital OAT performance quartile and supply-side characteristics (i.e., size and 
region) were assessed. OAT performance delivery quartiles differed on the number of 
hospital beds and the geographic location of the facility, but not for hospital volume of 
acute OUD diagnoses and/or OUD-related infections. Meaningful differences appeared 
to exist between Quartile 4 (highest performer) and Quartile 1 (lowest performer). 
Quartile 4 included fewer small hospitals (4% vs. 26%), more large hospitals (57% vs. 
37%), and a different geographic distribution of facilities. Quartile 4 included more 
hospitals in the Midwest (25% vs. 15%), Northeast (32% vs. 7%), and the West (21% vs. 






Table 5.24. Hospital Characteristics by VHA Hospital OAT Delivery Performance Quartilea,b 
Characteristics All 
(n = 109) 
Quartile 1 
(n = 27) 
Quartile 2 
(n = 28) 
Quartile 3 
(n = 26) 
Quartile 4 






















0.6 X2 = 3.818 
df = 3 
p > 0.05d 
 















58 X2 = 5.206 
df = 3 
p > 0.05d 
Hospital Size* 
Small  25.7% (28) 25.9% (7) 39.3% (11) 23.1% (6) 3.6% (1) » 22% p < 0.05c 
Medium 33.0% (36) 37.0% (10) 25.0% (7) 30.8 (8) 39.3% (11) » 2% 
Large 41.3% (45) 37.0% (10) 35.7% (10) 46.2% (12) 57.1% (16) » 20% 
U.S. Region** 
Midwest 22.9% (25) 14.8% (4) 28.6% (8) 23.1% (6) 25.0% (7) » 10% p < 0.05c 
Northeast 16.5% (18) 7.4% (2) 10.7% (3) 15.4% (4) 32.1% (9) » 25% 
South 39.4% (43) 74.1% (20) 25.0% (7) 38.5% (10) 21.4% (6) » 52% 
West 21.1% (23) 3.7% (1) 35.7% (10) 23.1% (6) 21.4% (6) » 17% 
Table Notes aHospitals were categorized into OAT delivery performance quartiles based on the proportion of cases at a hospital with OAT during 
admission. Q1 hospitals were the lowest performers and Q4 the highest; bQuartile percentages were calculated by row; cFisher’s Exact Test was used 
because some of the cell values were less than 5; dKruskal-Wallis Rank Sum Test; Small hospital = 1-49 beds; Medium hospital = 50-99 beds;  





5.4.3. Performance quartiles: Non-OAT pharmacotherapy. OAT performance 
quartiles differed statistically for the delivery of non-OAT opioids, any withdrawal 
management adjuvant, and second-line adjuvant. Quartile 4 facilities were significantly 
less likely to administer opioids compared with the other OAT performance quartiles 
(Q1, Q2, and Q3). Quartile 4 hospitals also had lower use of adjuvant and second-line 
adjuvant administration versus the bottom quartile (Q1). There were no statistically 
significant differences among quartiles for use of benzodiazepines, which across the 
study population was relatively high (median – 32%; range 13% to 83% of admissions), 
and for naltrexone which across the study population was relatively low (median <1%; 













(n = 27) 
Prop., Median % 
Q2  
(n = 28) 
Prop., Median % 
Q3  
(n = 26) 
Prop., Median % 
Q4  
(n = 28) 





Opioid** 53.8%  
(0.2, 0.83) 
56.5%f 59.3%i 54.1%h 46.8%f,h,i » 10% X2 = 15.556 
df = 3 





48.5%e,f 45.2%  42.9%e 41.6%f » 6% X2 = 12.085 
df = 3 
p < 0.05 c 
First-Line1 7.7%   
(0.0, 0.40) 
7.7%  7.7% 8.2% 6.9% » <1% X2 = 
0.21976 
df = 3 





44.7%e,f 41.4%  36.2%e 36.8%f » 8% X2 = 16.12 
df = 3 





34.0% 33.2% 29.3% 28.2% » 6% X2 = 0.2818 
df = 3 
p > 0.05c 
Naltrexone  <1%  
(0.0, 0.08) 
1.2% <1% 1.2% 1.1% » <1% X2 = 5.1653 
df = 3 
p > 0.05 
aHospitals were categorized into OAT delivery performance quartiles based on the proportion of cases at a hospital with OAT during admission. Q1 
hospitals were the lowest performers and Q4 the highest; bKruskal-Wallis Test; cDunn’s Test calculated; dDunn’s Test results: difference between 
Q1 and Q2; eDunn’s Test results: difference between Q1 and Q3; fDunn’s Test results: difference between Q1 and Q4; gDunn’s Test results: 
difference between Q2 and Q3; hDunn’s Test results: difference between Q3 and Q4; iDunn’s Test results: difference between Q2 and Q4; 






5.4.4. Performance quartiles: Outcomes. Of the ten health care utilization 
measures, three differed statistically by OAT quartile. Opioid prescriptions in the 30 days 
post-admission were less common in Quartile 4 (28%) as compared to the other 
quartiles (Q1, 37%; Q2, 41%; Q3, 34%). Gabapentin/pregabalin prescriptions in the post-
admission period were higher in Quartile 1 (29%) versus Quartile 3 (25%) and Quartile 4 
(24%). Post-admission OAT receipt differed among each of the quartiles: Q1, 4%; Q2, 
7%; Q3, 10%; and Q4, 19%. The frequency of post-admission emergency department 
visits (median, 29%; range: 0% to 50%) was noteworthy but did not differ significantly. 
Also, the two mortality measures (in-hospital mortality and post-admission death) were 












(n = 27) 
Q21 
(n = 28) 
Q31 
(n = 26) 
Q41 











<1% <1% <1% 1.1% » <1% X2 = 2.1073 
df = 3 






5.3% 5.7% 5.3% 5.1% » <1% X2 = 0.31675 
df = 3 
p > 0.05  
Post-Admission 
Death 0%  
(0.0 -0.05) 
1.2% <1% <1% <1% » <1% X2 = 0.83801 
df = 3 






25.9% 29.6% 29.9% 27.0% » 1% X2 = 1.5277 
df = 3 





12.0% 13.2% 12.8% 13.8% » 2% X2 = 1.1666 
df = 3 
p > 0.05 
Opioid*** 36.4%  
(0.1 -0.69) 
36.6%f 41.2%i 34.0%h 28.2%f,h,i » 8% X2 = 16.707 
df = 3 





7.1% 8.8% 7.3% 7.6% » <1% X2 = 5.9958 
df = 3 
p > 0.05 
Naloxone  5.0%  
(0.0 - 0.31) 
6.4% 4.1% 5.3% 6.8% » <1% X2 = 4.2447 
df = 3 





28.2%e,f 26.2% 24.5%e 23.9%f » 4% X2 = 10.161 
df = 3 
p < 0.05c 
Naltrexone <1%  
(0.0 -0. 08) 
1.2% <1% 1.2% 1.1% » <1% X2 = 5.1653 
df = 3 







4.0% 4.2% 3.9% 3.4% » <1% X2 = 3.3905 
df = 3 
p > 0.05 
OAT*** 8.4%  
(0.0-0.38) 
3.5%d,e,f 6.8%d,g,i 10.3%e,g,h 18.5%f,h,i » 15% X2 = 55.252 
df = 3 
p < 0.05c 
Table Notes. 1Median proportion in percent per quartile; aHospitals were categorized into OAT delivery 
performance quartiles based on the proportion of cases at a hospital with OAT during admission; bKruskal-
Wallis Test; cDunn’s Test; dDunn’s Test results: difference between Q1 and Q2; eDunn’s Test results: 
difference between Q1 and Q3; fDunn’s Test results: difference between Q1 and Q4; gDunn’s Test results: 
difference between Q2 and Q3; hDunn’s Test results: difference between Q3 and Q4; iDunn’s Test results: 





5.4.5. Summary. OAT delivery in the hospital setting varied across the VHA 
system, with statistically significant differences observed across hospital performance 
quartiles. Underperformance across the system was consistent. The highest performing 
hospitals, in Quartile 4, provided OAT to less than half of their patients with a current or 
prior OUD diagnosis. The most common OAT delivery scenarios across the VHA system 
were withdrawal management and sustaining OAT through the VHA care continuum. 
Hospital OAT performance quartiles differed statistically by the number of hospital beds 
and the geographic location of the facility, but not for hospital volume of acute OUD 
diagnoses or OUD-related infections. Hospitals also differed among quartile 
performance for the delivery of non-OAT opioids, withdrawal management adjuvants, 
and second-line adjuvants. Finally, of the ten outcome measures, only three differed 
statistically by OAT quartile: 30-day opioid prescription fills (lowest in Q4), 30-day 
gabapentin/pregabalin prescription fills (highest in Q1 and lowest in Q4), and 30-day 
OAT receipt (highest in Q4 and lowest in Q1). The remaining seven health care 
utilization outcome measures did not differ by quartile. These preliminary and 
exploratory analyses suggest that contextual attributes within the hospital or the local 
environment influence OAT and non-OAT care delivery performance and subsequent 
outcomes for discharged patients. 
Section 5.5. Aim 3 Justification 
 The findings from Aim 2 support continuing to explore these phenomena 





multilevel attributes and the delivery of OAT during admission for patients hospitalized 
with OUD-related diagnoses in VHA hospitals. 
Aim 2 analyses suggested potentially problematic care patterns for patients with 
OUD across the VHA system, specifically, that patients frequently received opioids and 
gabapentin/pregabalin, and not OAT. In all three time periods (pre, admission, post), 
opioid prescription or administration frequency was higher than OAT delivery. 
Withdrawal management was the predominant OAT delivery mechanism, which is not 
the most effective way to treat OUD and not the current standard of care. Additionally, 
although 21st century harm reduction practices recommend co-prescribing of naloxone 
with opioid prescriptions or for patients with OUD, few VHA patients received naloxone. 
It is possible that patients had already been prescribed naloxone 31 days prior to 
admission and thus already had naloxone in their possession. 
Although the study cohort was homogenous for many demand-side attributes 
(i.e., patient characteristics), the clinical reasons for hospital admission varied. Most 
admissions were not OUD related (by primary or secondary diagnosis or by OUD-related 
infection codes). A comparison of those who received and did not receive OAT during 
admission found that more patients who received OAT had an acute OUD diagnosis and 
OUD-related infections. However, overall, 60% of patients who received OAT did not 
have a primary or secondary OUD diagnosis or an OUD-related infection suggesting 





 Finally, a wide range of OAT administration during hospitalization persisted—
some hospitals delivered no OAT (n = 2) and some hospitals delivered OAT to 43% of 
their patients with OUD (n = 2). The frequency of the type of OAT mechanism varied 
across hospital OAT performance quartile, suggesting that measured (hospital size, 
geographic location, and hospital OAT performance quartile) and unmeasured supply-
side attributes influenced OAT care delivery and performance. Observed differences 
existed for hospital size, geographic location, and OAT performance quartile, but not for 
acute OUD case volume. Other elements may drive care delivery variation. Differences 
existed among hospital OAT performance quartiles for non-OAT care delivery 
mechanisms, specifically, opioid delivery during and in the 30 days after hospital 
discharge. Although statistical differences did not exist for most outcomes, one non-
significant finding stands out: nearly one third of patients received services in the 
emergency department within 30 days of hospitalization which suggests unresolved 
care issues post-hospitalization for this patient population. 
 The Aim 2 descriptive and bivariate analyses justify the continued exploration 
and understanding of OAT delivery for exploration of Aim 3. Proceeding with Aim 3 is 
warranted because the current care delivery practices were observed to be sub-optimal, 
demand-side (patient) and supply-side (hospital) attributes were associated with the 
receipt of OAT, and hospital OAT delivery varied significantly across the VHA system. 





receive OAT when hospitalized in the VHA system and the contributions of patient and 
hospital-level attributes to OAT delivery using multilevel models.  
Section 5.6. Multilevel Model Output 
This section explores the associations of patient and hospital attributes on the 
receipt of OAT during hospitalization through multilevel modeling. The multilevel model 
uses the same study cohort as Aim 2, with 12,407 unique index hospitalizations from 
109 VHA hospitals within the continental U.S. during the 2017 fiscal year. This section 
addressed research sub-questions: 
• 3a: How much of the variation in OAT delivery is attributable to the 
hospitals?  
• 3b: How do level 1 and level 2 attributes affect hospital OAT delivery? 
5.6.4. Multilevel logistic regression model. A multilevel logistic regression model 
was used to test for associations at the 0.05 alpha value in this study cohort. A patient 
hospitalized in an average VHA hospital, without controlling for patient-level or hospital-
level covariates, had a 12% chance of OAT administration.4 
5.6.4a. Testing for hospital variation. The first model, Model 1, was the variance 
component model. This model did not include any covariates and only included the 
intercept. The intraclass correlation statistic (ICC) for Model 1 was 0.14, meaning that 
approximately 14% of the variability of receiving OAT during admission was explained by 
                                                        
4 The probability of receiving OAT in an 'average' VHA facility were estimated as exp(-1.97) = 





between-hospital differences (e.g., hospital level characteristics). Subsequently, within-
hospital differences (e.g., patient level characteristics) explained the other 86% of the 
variability for receiving OAT during admission (see Table 5.27). 
The second model, Model 2, was the level 1 intermediate model. This model 
included the intercept and the patient covariates. In this model, there was a decrease in 
the ICC from Model 1, going from 0.14 to 0.10, suggesting that some of the variation in 
OAT delivery across the study cohort may be due to the differences in patient 
population characteristics among hospitals (e.g., differences in average age or gender 
distribution). In this model, level 1 covariates collectively accounted for 4% of OAT 
delivery variation (see Table 5.27). 
The third model, Model 3, was the final model, which included the intercept, 
patient characteristics, and hospital covariates. When compared with Model 2, the ICC 
statistic in this Model decreased from 0.10 to less than 0.06, respectively, indicating that 
the inclusion of the available and selected hospital level variables, in part, explained 
variation between hospitals. However, with an additional 6% still unexplained by the 
model, this suggests that additional unexplored or unmeasured level 2 covariates may 
further explain variation hospital OAT delivery in the VHA system (see Table 5.27). 
Table 5.27. Testing for Variation in Hospital OAT Delivery Across the VHA 
 Model 1: Without 
Covariates 
Model 2: Patient 
Covariates 
Model 3: Patient and 
Hospital Covariates 
B SE 95% CI B SE 95% CI B SE 95% CI 
Constant 0.52 0.09 0.37, 0.72 0.38 0.07 0.26, 0.56 0.02 0.05 0.13, 0.34 






 5.6.4b. Testing for associations among covariates and OAT delivery. In Model 2, 
the model with only patient characteristics, 12 covariates were associated with either 
increased or decreased odds of OAT delivery during admission. Six covariates increased 
the odds of OAT delivery, while holding the other level 1 covariates constant: 1) pre-
admission OAT receipt (OR [Odds Ratio] 15.3; 95% CI [13.2, 17.8]); 2) the presence of an 
OUD diagnosis or infection (OR 2.30; 95% CI [1.99, 2.67]); 3) male gender (OR 1.52; 95% 
CI [1.15, 2.00]); 4) an opioid withdrawal diagnosis (OR 1.46; 95% CI [1.12, 1.91]); 5) 
admission adjuvant receipt (OR 1.53; 95% CI [1.33, 1.76]); and 6) an increased length of 
stay (OR 1.04; 95% CI [1.04, 1.05]) (see Table 5.28). 
Six covariates were associated with decreased odds of OAT delivery during 
hospitalization, while holding the other level 1 covariates constant: 1) pre-admission 
naltrexone receipt (OR 0.27; 95% CI [0.13, 0.57]); 2) unintentional overdose diagnosis 
(OR 0.29; 95% CI [0.16, 0.52]); 3) admission naltrexone receipt (OR 0.30; 95% CI [0.14, 
0.65]); 4) pre-admission non-OAT opioid receipt (OR 0.49; 95% CI [0.41, 0.58]); 5) 
admission non-OAT opioid receipt (OR 0.53; 95 CI [0.46, 0.61]); and 6) co-occurring SUD 
diagnosis (OR 0.77; 95% CI [0.67, 0.88]) (see Table 5.28). 
In Model 3, which included both patient and hospital characteristics, the 12 
patient covariates associated with either increased or decreased odds of hospitalized 
OAT delivery in Model 2 did not qualitatively change with regard to direction or 
statistical significance. One hospital covariate decreased the odds of OAT delivery 





0.99]). Four of the hospital-level covariates increased the odds of OAT delivery: size and 
location. The medium (OR 1.90; 95% CI [1.33, 2.70) and large sized hospitals (OR 2.04; 
95% CI [1.39, 3.00]) had increased odds of OAT delivery during admission compared to 
small hospitals. Hospitals located in the Northeast (OR 1.80; 95% CI [1.30, 2.49]) and 
West (OR 1.62; 95% CI [1.19, 2.22]) had increased odds of OAT receipt compared to 
hospitals located in the South (see Table 5.28). 
5.6.4c. OAT sensitivity analysis definition. A sensitivity analysis examined if 
there were differences in the study results if the definition of hospital OAT delivery was 
narrowed (Definition 2). The two definitions were: 1) Definition 1: Any type of OAT 
regardless of FDA-approval of that formulation (e.g., intramuscular/intravenous 
methadone or buprenorphine); 2) Definition 2: Only FDA-approved formulations of OAT 
(e.g. oral/sublingual methadone and buprenorphine). When comparing results of the 
two models, there was only one difference observed for one of the 18 statistically 
significant covariates. In the model built with Definition 2, the narrower OAT definition, 
the variable surgical services (a patient covariate) was no longer statistically significant. 
Otherwise, there were no observed differences in the statistical significance of any of 
the other 17 covariates or the directionality of the parameters. This suggests that the 
findings from Aim 1 that non-FDA approved versions of buprenorphine/methadone are 
used in the hospital setting, may be true. See Appendix R for additional details. 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.6.5. Summary. The multilevel model provided another perspective of how OAT 
delivery varied across the VHA system with two primary findings. First, unexplained 
variation was attributable to both the differences between hospitals (14%) and 
differences within hospitals (86%). In the final model, the between-hospital difference 
dropped to 6%, but not 0%, indicating that the patient and hospital characteristics 
included in the model did not fully explain between-hospital variation. Second, as 
hypothesized, several patient and hospital covariates were associated with differing 
odds of OAT receipt during admission. These findings reveal mutable and nonmutable 
characteristics for future exploration for patients, hospitals, and health systems. Patient 
receipt of OAT prior to hospitalization enhanced the odds of OAT during hospitalization 
indicating the importance of establishing OAT care in the outpatient setting prior to 
hospitalization and further, establishing care transition processes that enhanced care 
coordination for patients with OUD across the care delivery continuum. Specific 
immutable characteristics about the hospital, such as the geographic location and the 
size, likely reflected other unmeasurable attributes or resources within each respective 
hospital that influence the delivery of OAT. 
A perplexing finding was that patients with acute opioid overdose diagnoses had 
lower odds of receiving OAT. One reason commonly used to explain the undertreatment 
of OUD in certain care delivery contexts is under diagnosis. In this study, however, 
patients with a primary or secondary overdose diagnosis had decreased odds of 





acute OUD issue; thus, the reasons for not providing OAT must be explained by 
something else (e.g., resources, training, culture, stigma).  
Section 5.7. Conclusion 
The primary hypotheses of this study, explored through qualitative methods and 
further addressed through quantitative approaches, were that care variation would exist 
for OAT delivery during hospital admission and that multilevel attributes (patient and 
hospital) would contribute to OAT delivery and OAT delivery variation between and 
within hospitals. Overall, the findings from Aim 2 and Aim 3 supported and extended the 
qualitative findings from Aim 1: 1) variability in OAT delivery existed in an integrated 
health system; 2) a severe care deficit existed for this patient population; and 3) 
mutable and nonmutable characteristics of patients and hospitals contribute to the 
delivery of OAT in the hospital setting. The final chapter, Chapter 6, presents an 






Chapter 6. Discussion, Health System and Policy Implications, and Conclusions 
Parts of this chapter were published in a peer-reviewed journal: Priest, K.C., & 
McCarty, D. (2018). Role of the hospital in the 21st Century opioid overdose 
epidemic: The addiction medicine consult service. Journal of Addiction Medicine, 
Advance online publication. doi: 10.1097/ADM.0000000000000496. 
 The final chapter of this dissertation integrates the results from the analysis of 
the data supporting the three study aims with the overarching purpose of informing 
future research, practice, and policy. The study findings are timely and relevant as the 
U.S. struggles with the 21st century opioid overdose epidemic. Prior to this dissertation, 
analyses describing care delivery for patients with an opioid use disorder (OUD) in the 
hospital were limited and there were no multi-site or system-wide assessments of the 
delivery patterns and practices for hospitalized patients with OUD. This study provides 
the first description of system-wide opioid agonist therapy (OAT) delivery and an 
exploration of the contextual attributes, inside and outside the hospital, associated with 
the delivery of services for hospitalized patients with OUD. The research question for 
this study asked: How do supply-side attributes influence hospital OAT delivery, health 
outcomes, and health services utilization for persons hospitalized with OUD?   
To answer questions about complex social phenomena, such as hospital OAT 
delivery, the analysis drew on a diverse and complementary array of scholarship from 
the domains of public health, health policy, sociology, organizational behavior, systems 
science, and economics. The mixed methods study, grounded in a pragmatic research 
philosophy, addressed multiple OUD-related care delivery issues. The study provides a 





services (n = 109 hospitals; n = 12,407 patients) and a multisite qualitative assessment of 
non-VHA hospitals (n = 16 non-VHA hospitals; n = 17 addiction medicine physicians) on 
the topic of hospital-based services for patients with OUD. 
This final chapter includes a synopsis of the seven primary study findings, a 
presentation of the modified study conceptual framework, a discussion of research 
limitations, final conclusions, and the implications for health systems and policy: 
1. Section 6.1 integrates the qualitative and quantitative results and concludes 
that OAT is underused in the hospital (Finding 1). 
2. Section 6.2 outlines the evidence from the three study aims suggesting that 
OAT delivery varies across hospitals and health systems (Finding 2). 
3. Section 6.3 describes how OAT is ineffectively used (e.g., withdrawal 
management) in hospitals inside and outside the VHA (Finding 3). 
4. Section 6.4 illustrates how and which non-OAT modalities (e.g., short-acting 
opioid substitutes) are inappropriately used during and after hospitalization 
(Finding 4). 
5. Section 6.5 provides evidence of specific attributes inside and outside the 
hospital facilitating or impeding AMC service development and OAT delivery 
(Finding 5). 






7. Section 6.7 asserts, with evidence from this study, that the hospital is an 
important part of the OUD care continuum (Finding 7).  
8. Section 6.8 presents the modified and updated study conceptual framework, 
based upon the study findings. 
9. Section 6.9 outlines the limitations associated with the qualitative, 
quantitative, and integrative approaches. 
10. Section 6.10 proposes health system and policy interventions related to 
education and service delivery to promote OAT use for hospitalized patients 
with OUD, and the removal of policies creating barriers to OAT access. 
11. Section 6.11 outlines future research and policy questions. 
12. Section 6.12 states the dissertation’s final conclusions. 
Section 6.1. Finding 1: OAT is Underused in the Hospital 
 Hospital OAT delivery for patients with OUD is essentially undescribed in the 
peer-reviewed literature; in contrast, OAT delivery in the community setting is well-
studied, and it is established that OAT is underused in that context (Knudsen & Roman, 
2012). The studies describing the hospital care delivery environment use discharge 
prescribing and referral data to assert potential hospital OAT underuse (Ali & Mutter, 
2016; Frazier et al., 2017; Naeger, Ali, et al., 2016; Rosenthal et al., 2015). To date, a 
multi-site or system-wide study has not been conducted to assess hospital OAT delivery. 
The findings from this study, therefore, are a novel contribution, confirming and 





 6.1.1. Qualitative evidence. Semi-structured interviews with 17 addiction 
medicine physicians, in non-VHA hospitals, documented OAT underutilization even in 
the hospitals with addiction medicine-related resources (e.g., addiction medicine 
trained physicians, or AMC services, or addiction medicine fellowships). OAT initiation 
(i.e., starting a patient on OAT who was not already on it prior to hospitalization), as 
federal guidance suggests (SAMHSA, 2018), should be offered by medical staff as the 
first-line treatment option for patients not already on OAT. In this study, informants 
perceived this practice, outside the AMC services, to be either uncommon or not 
occurring in non-VHA hospitals. One informant stated that their non-VHA hospital 
typically did not provide any OUD-related care, including symptom management for 
withdrawal.  
6.1.2. Quantitative evidence. Across the VHA study cohort (n = 12,407) the vast 
majority of patients did not receive OAT during admission (85%) or in the 30 days post 
admission (89%). In this study cohort, a patient with an OUD who was hospitalized in a 
VHA hospital had a 12% chance of OAT administration during hospitalization, without 
controlling for patient or hospital characteristics. Hospital care practices across the VHA 
system reflected a lower than desired performance even in the highest performing 
hospitals. On average, less than one third of patients with OUD received OAT when 
treated in the highest OAT performing hospitals.  
6.1.3. Summary. Evidence from the qualitative and quantitative analyses 





perspectives of expert addiction medicine physicians in non-VHA hospitals and from the 
VHA health care administrative data. Further, there is outside evidence to suggest that 
the VHA system has enhanced hospital care quality as compared with non-VHA 
hospitals. VHA hospitals out-performed non-VHA hospitals on 14 of 15 care quality 
metrics (Weeks & West, 2018). This may suggest that non-VHA hospitals have worse 
performance in this care delivery domain. 
Section 6.2. Finding 2: OAT Delivery Varies Across Hospitals and Health Systems 
 There is a long-standing interest in identifying and explaining variation in health 
services delivery across communities (Glover, 1938). Low variation in health services 
delivery should occur for highly effective and inexpensive treatments (Chandra & 
Skinner, 2012; Skinner, 2011; Wennberg et al., 2002), such as OAT. Variation in OAT use 
in the community setting, however, is associated with a variety of patient and structural 
elements (Ducharme, Knudsen, & Roman, 2006; Mark, Lubran, McCance-Katz, Chalk, & 
Richardson, 2015). Within the VHA system, in previous research, decreased OAT access 
was associated with older age, urban residence, and race (Manhapra, Quinones, & 
Rosenheck, 2016). Variation in hospital OAT delivery within, among, or across health 
systems has not been assessed. 
 6.2.1. Qualitative evidence. Analysis of the hospital guidance documents 
received from the study’s informants revealed variation in OAT delivery approaches 
across hospital contexts with modest similarities in practice. The withdrawal 





which medication was first-line (i.e., methadone vs. buprenorphine vs. clonidine); 
severity of withdrawal symptoms (e.g., COWS score ³ 5 or ³ 8 or ³ 12 or ³ 13); initial 
dose (e.g., methadone 5 mg, 10 mg, or 15 mg); and the 24-hour maximum dose (e.g., 30 
mg or 40 mg of methadone). Similarly, variation was observed in the OAT initiation 
guidance documents (e.g., protocol initiation threshold, maximum total daily dose). In 
contrast, there was clear practice consensus for the acute management and non-acute 
pain management for patients on OAT prior to hospitalization. This was reflected in the 
guidance documents and the informant interviews. The consensus was that, in most 
circumstances, daily OAT should be continued in the hospital and that buprenorphine 
doses could be increased or split to help manage pain.  
 6.2.2. Quantitative evidence. The quantitative findings echo the qualitative 
findings. OAT delivery performance varied across the VHA health system. Hospital OAT 
delivery in this integrated health system ranged from 0% of admissions, in the lowest 
performing hospitals, to 43% of admissions, in the highest performing hospital. Hospital 
OAT delivery performance differed significantly across four hospital performance 
quartiles (Q4, Q3, Q2, and Q1). The median performance in the highest performing 
quartile (Q4) was 27% and the lowest performing quartile was 5%, a five-fold difference 
in median care practices between the highest and lowest quartiles.  
 6.2.3. Summary. Evidence from the qualitative and quantitative analyses 
suggests that OAT delivery varies across hospitals and health systems in well-resourced 





variation within the VHA system is not surprising as it reflects previous OAT delivery 
research in the VHA’s community-based treatment system (Finlay et al., 2018). In 2017, 
the overall rate for OUD pharmacotherapy delivery across the VHA was 41% (n = 
22,179), with facility performance varying between 2% to 76% (Finlay et al., 2018); in 
this study, the median delivery across hospitals was 12%, with hospital performance 
varying between 0% to 43% (n = 109 hospitals; n = 12,407 patients). It is possible that 
hospitals and health systems outside this study sample have OAT delivery variation, in 
particular low resourced hospitals (e.g., no addiction medicine physicians) and hospitals 
not affiliated with an integrated health system. 
Section 6.3. Finding 3: Less Effective OAT Approaches Are Used 
 To date, the peer-reviewed literature has not described or distinguished the 
different types of OAT delivery scenarios that could occur during hospitalization. This 
dissertation provides the first description and assessment of different types of hospital 
OAT scenarios, specifically: OAT continued; OAT initiation and linkage to care; OAT 
withdrawal management; and OAT sustained.  
 6.3.1. Qualitative evidence. The non-VHA key informants described OAT delivery 
in their respective hospitals as broadly focused on “detox” (i.e., withdrawing patients 
from opioids instead of initiating or continuing OAT) outside the care delivered by AMC 
services. The focus of OUD-related hospital technologies (e.g., hospital guidance 
documents) on withdrawal management in non-VHA hospitals supported this finding. 





contrast, only three had OAT initiation guidance documents and four had OAT 
continuation guidance. One non-VHA hospital protocol was restricted to adjuvant 
symptom-only management (i.e., clonidine to minimize the severity of opioid 
withdrawal). This suggests that across non-VHA hospitals, even in the presence of 
addiction medicine experts, there may be a need for education on how to most 
effectively care for people with OUD during hospitalization to match contemporary 
research and federal guidance (SAMHSA, 2018). Medical withdrawal, unless it is patient 
preference, is contrary to known best practices for OUD treatment (Clark, Samnaliev, 
Baxter, & Leung, 2011). Federal guidance suggests “offering maintenance therapy with 
medication, not short-term medically supervised withdrawal” (SAMHSA, 2018, pp. 3-44) 
and states that it is “essential for the patient to continue receiving OUD medication 
while hospitalized” (SAMHSA, 2018, pp. 3-101). Federal guidance further recommends 
that providers should not “force patients to withdraw from opioid agonist therapy in the 
hospital” (SAMHSA, 2018, pp. 3-104). 
 6.3.2. Quantitative evidence. The VHA quantitative findings corroborate the 
non-VHA qualitative findings that articulated the common use of withdrawal 
management. When OAT delivery occurred in the VHA system (in only 15% of hospital 
admissions), it was most commonly delivered as withdrawal management (39%), which 
is not the recommended first-line approach to OUD management (SAMHSA, 2018). 
When separated into high and low OAT performance quartiles, the highest performing 





OAT delivery approaches (e.g., OAT continued, OAT initiation and linkage, and OAT 
sustained). Nonetheless, the occurrence of these approaches was still infrequent in the 
Quartile 4 hospitals. Median performance in Quartile 4 was 10% for OAT sustained, 3% 
for OAT initiated and linkage to care, and 2%, for OAT continued.  
 6.3.3. Summary. Evidence from the qualitative and quantitative analyses of this 
study suggests that less effective OAT approaches are used during hospitalization. This 
dissertation is the first study to attempt to distinguish four different hospital-based OAT 
delivery care scenarios: 1) OAT continued; 2) OAT initiated and linkage; 3) OAT 
sustained; and 4) OAT withdrawal management. It is possible that there are other OAT 
scenarios not captured in this study. These designations may serve as the beginning of a 
foundational conversation about hospital OAT delivery quality. 
Section 6.4. Finding 4: Non-OAT Pharmacotherapies are Used 
 An additional care delivery concern related to the treatment of patients with 
OUD in the hospital is the possibility that other less effective non-OAT 
pharmacotherapies (e.g., short-acting non-OAT opioids) are used as a substitute for 
OAT. Research does not exist describing this explicit concern. Prior research, however, 
suggests that prescription non-OAT opioid use and other non-OAT medications (e.g., 
benzodiazepine) post-hospital discharge are common for patients with OUD (Larochelle 
et al., 2016; Naeger, Ali, et al., 2016). This study confirms these previously established 
findings and expands upon a literature gap to describe the frequent use of non-OAT 





 6.4.1. Qualitative evidence. Since all of the key informants were addiction 
medicine experts, the use of non-OAT modalities as substitutes for OAT was not 
commonly described. Two informants, however, shared that their hospital withdrawal 
management protocols used non-OAT approved opioids, specifically: a rapid 72-hour 
taper using tramadol and an injectable buprenorphine taper protocol. 
 6.4.2. Quantitative evidence. Three findings from the VHA cohort suggest the 
potential use of non-OAT pharmacotherapies for the treatment of OUD. First, non-OAT 
opioid prescription or administration occurred more often than OAT delivery in all three 
time periods: 30 days prior to index hospitalization (30% vs. 11%); during index 
hospitalization (55% vs. 15%); and 30 days post-hospital admission (34% vs. 11%). 
Second, patients who were discontinued from their OAT during hospitalization were 
more likely to receive non-OAT opioids during admission (44% vs. 26%) and at discharge 
(27% vs. 12%) when compared with patients who were continued on their pre-OAT 
during hospitalization. Discontinuing OAT during hospitalization not only disrupted OUD 
treatment but appeared to promote the use of non-evidence-based care (i.e., the 
substitution of non-OAT opioids). Third, there were other potentially problematic 
prescribing trends post-admission, including: gabapentin/pregabalin (26%), 
benzodiazepine (8%), and concurrent benzodiazepine and opioid prescribing (4%).  
 6.4.3. Summary. Evidence primarily from the quantitative analyses suggest that 
non-OAT pharmacotherapies, specifically, non-OAT opioids, may be administered and 





frequency in the VHA cohort was higher (34%) than previously reported findings within 
a non-VHA population, which had 22% of patients (n = 8,225) fill a non-OAT opioid 
prescription in the 30 days after hospital discharge (Naeger, Ali, et al., 2016). These 
findings suggest either clinician misidentification of patients with an OUD or provider 
training deficits. In most clinical scenarios, patients with OUD should not receive non-
OAT opioid prescriptions upon discharge because non-OAT opioid continuation after a 
hospitalization is associated with higher risk for a subsequent overdose (Larochelle et 
al., 2016). 
Section 6.5. Finding 5: Contextual Hospital Attributes Inform OUD-Related Services  
Hospitals are socially constructed entities comprised of physical, technological, 
cultural, and social milieu (Scott, 2003). The internal social structures of organizations 
are comprised of normative, patterned, formal and informal interactions (Scott, 2003). 
Social structures within an organization impart explicit and implicit values, norms, and 
role expectations (Davis, 1949; Scott, 2003). These expectations are promulgated 
through reward systems for specific behavior and enacted through socialization, 
mentoring, group dynamics, decision-making, communication, influence, and leadership 
(Kinicki & Kreitner, 2009; Ostroff et al., 2003). Organizations exist as coordinated 
systems embedded within broad complex networks (Meyer & Rowan, 1977), dependent 
on external relationships (Scott, 2003).  
In the health care context, a hospital exists as a functional unit within the nested 





units (patients, units, divisions, departments) (Ferlie & Shortell, 2001; Perrow, 1986). A 
product of this phenomenon is the continuous evolution and interaction within each 
level of the nested context and the influence of external factors, such as other hospitals 
(DiMaggio & Powell, 1983), the prior training and socialization of hospital employees 
(Scott, 2003), financial incentives or disincentives promoted through external contracts 
(Alchian & Demsetz, 1972; Eisenhardt, 1989; Jensen & Meckling, 1976; Zeckhauser & 
Pratt, 1985), or the enforcement of contracts (North, 1990; Zeckhauser & Pratt, 1985). 
This theoretical foundation provides the rationale and justification for exploring how 
attributes within and outside the hospital influence and shape the delivery of evidence-
based OUD services. This study is the first to explore the attributes that facilitate or 
impede care for patients hospitalized with OUD.  
 6.5.1. Qualitative evidence. The analysis of the non-VHA key informant 
interviews found six internal facilitators, six internal barriers, seven external facilitators, 
and four external barriers to AMC service establishment and hospital OAT delivery. A 
primary finding was that the AMC service, a hospital characteristic, was both an output 
of a supportive hospital environment and a modifier for service delivery and the 
development of other addiction-related technologies. A supportive hospital 
environment was generated through positive social structures and technology and 
resources allocated to addiction-related service activities. Fifteen key informants 
described six supports provided at the 14 non-VHA hospitals with established or 





• Historic precedent and investment in addiction service delivery, education, 
and research; 
• Dedicated resources for addiction services, research, and education; 
• Creation or existence of an addiction medicine clinical training program; 
• Use of evidence-based addiction treatment practices; 
• Leadership supportive of addiction treatment; and 
• Internal stakeholders supportive of addiction treatment. 
 Key informants (n = 17) from all 16 non-VHA hospitals described AMC 
establishment and hospital OAT service delivery barriers. Informants most commonly 
cited barriers related to resources and staffing, social structures, and financing: 
• Restrictive hospital policies and regulations that inhibited or prevented 
hospital OAT delivery; 
• Bureaucratic processes slowing AMC service development, OUD-service 
delivery, and education; 
• Limited staffing and resources for addiction-related treatment and 
education; 
• Unsupportive internal stakeholders; 
• Knowledge gaps within hospital leadership and clinical staff that 
promulgated discriminatory behavior towards patients with OUD; and 






 Each of the internal barriers and facilitators to AMC service and OAT delivery, 
except for historic precedent, are mutable properties of a hospital or health services 
delivery organization that could be changed through strategic interventions. 
 Key informants in hospitals with established or planned AMC services described 
seven external influencers that positively mediated AMC service establishment and 
subsequently enhanced OAT delivery: 
• Elevation and prioritization of this issue by non-clinical stakeholders; 
• Development of formal and informal partnerships with external clinical 
stakeholders; 
• Access to a robust community-based treatment network; 
• Media coverage of the opioid overdose epidemic; 
• Policies and regulations enhancing OAT access; 
• Supportive political leadership and political action; and 
• Supportive financial incentives. 
Four external barriers were also described by informants: 
• A limited community-based treatment network; 
• Policies and regulations impeding OAT access;  
• Unsupportive political leadership and political action; and 
• Financing and funding limitations.  
 These external facilitators and barriers were all mutable. Unlike interventions 





control and influence to change these external elements. Changing, removing, 
increasing, promoting, or enhancing external elements is possible but likely a more 
challenging and long-term endeavor. 
 6.5.2. Quantitative evidence. The quantitative analyses did not support a 
nuanced assessment of organizational characteristics or the external hospital 
environments. Each hospital’s OAT delivery performance, however, was compared to 
the other hospitals within the VHA system (n = 109) to discern hospital-level 
characteristics contributing to variation. The characteristics observed to enhance OAT 
delivery included hospital size and geographic location. An impediment to OAT delivery 
was an elevated rate of acute OUD admissions in the hospital. Statistically significant 
differences in hospital size and region were also observed among the hospital OAT 
performance quartiles. There were more small hospitals (26%; n = 7) in the lowest 
performing quartile as compared with the hospitals in the highest performing quartile 
(3%; n = 1). Most hospitals (74%; n = 20) in the lowest performing quartile were in the 
South as compared with the highest performing quartile (21%; n = 6).  
 Further, when patient and hospital characteristics were controlled for in the 
multilevel logistic regression model, specific hospital characteristics increased the odds 
of patient OAT receipt during admission: the medium (OR 1.90; 95% CI [1.33, 2.70]) and 
large hospital sizes (OR 2.04; 95% CI [1.39, 3.00]), as compared to the small hospitals, 
and hospitals located in the Northeast (OR 1.80; 95% CI [1.30, 2.49]) or the West (OR 





diagnosis volume in a hospital decreased the odds of individual OAT receipt (OR 0.98; 
95% CI [0.97, 0.99]). Although the size or location of a VHA hospital is essentially 
immutable, these characteristics likely represent potentially modifiable organizational 
and environmental characteristics. The fully specified multilevel model accounted for 
only 6% (ICC value) of the contributions to performance variation in the VHA dataset. 
This suggests that there were other unmeasured organizational attributes contributing 
to OAT delivery variation within the VHA system. 
 6.5.3. Summary. Evidence from this study’s qualitative and quantitative analyses 
suggests that internal and external supply-side elements likely influence both the 
establishment of AMC services and hospital OAT delivery. Research in the outpatient 
and community-based settings suggests a variety of reasons for OAT underuse (e.g., 
financial, regulatory, geographic, and health care professional attitudinal factors) 
(Sharma et al., 2017). This study is the first to describe these phenomena in the hospital 
setting. 
Section 6.6. Finding 6: Patient Attributes Facilitate or Deter Hospital OAT Delivery 
 There is a limited evidence base suggesting that patients who are hospitalized 
with OUD or SUD would like to receive treatment for their drug use disorder. A 
qualitative analysis of 32 hospitalized adults with SUD, the majority of whom had 
moderate-to-high-risk use of opioids (65%), concluded that current hospitals practice 
was not meeting their needs and that care could be greatly improved if life stressors, 





for supported, coordinated, and timely care upon hospital discharge (Velez et al., 2017). 
Studies of patient attributes that enhance or deter hospital OAT delivery have not been 
reported. This study builds on the findings that patient attributes contribute to hospital 
OAT delivery.  
 6.6.1. Qualitative evidence. In the interviews from non-VHA hospitals, 
informants perceived specific patient characteristics that were an impediment to OAT 
access. Informants described patients with OUD who inject drugs as particularly 
challenging to serve in the hospital because of their complex psychosocial 
characteristics (e.g., uninsured, homeless, criminal justice involvement) and ongoing 
medical issues (e.g., serious infections, polysubstance use). Patients with these 
challenges, specifically those with a need for long-term antibiotics, were also generally 
not accepted in transitional and lower acuity facilities, creating barriers for discharge. 
The common barriers to OAT, from this perspective, included insurance status, care 
disruption by the criminal justice system, the creation of a non-therapeutic atmosphere 
with law enforcement involvement, and the patient’s own internalized stigma about 
OAT. In contrast, only one specific demographic characteristic emerged qualitatively to 
enhance OAT delivery—pregnancy. Pregnant patients had enhanced access to 
treatment because hospitals’ efforts focused on providing protocol driven hospital-






 6.6.2. Quantitative evidence. Associations between patient characteristics and 
hospital OAT delivery were observed in the VHA. The findings from the fully-specified 
multilevel logistic regression showed that patient demographics and the receipt of 
specific types of care before and during admission, were either positively or negatively 
associated with hospital OAT delivery. The positively associated patient characteristics 
included: 
• An OUD diagnosis or infection during admission (OR 2.30; 95% CI [1.99, 
2.66]);  
• Male gender (OR 1.52; 95% CI [1.16, 2.01]); and 
• An opioid withdrawal diagnosis (OR 1.47; 95% CI [1.12, 1.92]). 
The other care delivery scenarios positively associated with hospital OAT delivery 
included: 
• Pre-admission OAT receipt (OR 15.3; 95% CI [13.2, 17.7]); 
• Admission adjuvant receipt (OR 1.52; 95% CI [1.32, 1.75]); and 
• An increased length of hospital stay (OR 1.04; 95% CI [1.03, 1.05]). 
The negatively associated patient characteristics included: 
• An unintentional overdose diagnosis (OR: 0.29; 95% CI [0.16, 0.52]); and 
• Having a co-occurring SUD diagnosis during admission (OR: 0.77; 95% CI 
[0.67, 0.88]). 






• Pre-admission non-OAT opioid receipt (OR 0.49; 95% CI [0.41, 0.58]); 
• Admission non-OAT opioid receipt (OR 0.53; 95 CI [0.46, 0.61]); 
• Pre-admission naltrexone receipt (OR 0.26; 95% CI [0.12, 0.56]); and 
• Admission naltrexone receipt (OR 0.31; 95% CI [0.14, 0.66]). 
 6.6.3. Summary. Evidence from this study’s qualitative and quantitative analyses 
confirms and expands upon previous findings (Velez et al., 2017) that specific patient 
characteristics may facilitate or deter hospital-based OAT access. Demographic 
characteristics described as relevant to OAT access in the qualitative findings were 
either not assessed (e.g., criminal justice involvement, homelessness), not relevant to 
the veteran patient population (e.g., insurance status), or not common among patients 
in the VHA (e.g., pregnancy). 
Section 6.7. Finding 7: The Hospital has an Important Role in the OUD Care Continuum 
 There is a growing evidence base exploring the influence of hospital service 
delivery on patient outcomes upon discharge. Retrospective analyses of AMC services 
(Nordeck et al., 2018; Suzuki, 2016), prospective single-site studies (Trowbridge et al., 
2017; Wakeman et al., 2017), and one randomized control trial (Liebschutz et al., 2014) 
suggest the provision of OUD-related services in the hospital context is associated with 
either discontinued or continued OAT upon discharge. Further, a recent study by 
Moreno et al. (2019) observed that 30-day and 90-day hospital readmissions were 





suggesting that care in the inpatient setting has implications post-discharge. The 
findings from this study build and expand on these previous findings. 
6.7.1. Qualitative evidence. Data from the semi-structured interviews suggest 
that hospitals had a role in either disrupting, starting, or continuing care for patients 
with OUD. Hospital involvement was dependent on the existence of addiction-related 
resources, specifically the AMC service. Key informants, from non-VHA hospitals, shared 
that the AMC services were primarily responsible for OAT initiation. They observed that, 
when OAT initiation was managed by non-AMC providers, treatment gaps frequently 
occurred because of the providers’ limited knowledge of how to link patients to care 
upon discharge. Care disruption was also attributed to restrictive internal policies 
related to OAT delivery and provider training gaps and confusion about OAT federal 
regulations. Providers and administrators commonly believed it was illegal to administer 
OAT in the hospital or that a provider had to have a special wavier. 
6.7.2. Quantitative evidence. The VHA dataset illustrates how hospitals serve an 
important role in the broader OUD care continuum. There were 1,325 patients in the 
study cohort who received OAT prior to hospital admission, two-thirds (65%; n = 867) of 
these patients were continued on OAT during admission. This is a positive finding but 
also reflects room for improvement, as OAT discontinuation in the hospital setting 
should be a rare occurrence (e.g., patient preference). Of the 1,325 patients who 
received OAT prior to admission, 23% (n = 308) did not receive OAT within 30 days of 





patients whose OAT engagement was interrupted post-hospitalization, 53% had their 
OAT discontinued upon admission (n = 163), and 47% had their OAT continued during 
admission (n = 145). Further, patients who were continued on OAT were statistically less 
likely to leave the hospital against medical advice (3%; n = 26) as compared to those 
who were discontinued on their OAT (10%; n = 46). Further, for patients who received 
any type of OAT during admission were statistically more likely than those who did not 
receive any OAT during hospitalization to receive OAT in the post-admission period (48% 
vs. 5%; p < 0.05). These observations suggest that hospitalization disrupts ongoing 
outpatient OAT delivery, inpatient medical management of the patient’s primary issue, 
and OAT receipt upon hospital discharge.  
 6.7.3. Summary. Evidence from the study’s qualitative and quantitative findings 
suggests that hospitals play an important organizational role in the OUD care 
continuum, either disrupting, starting, or continuing care. This perspective is reflected in 
the efforts of leadership at the Centers for Medicare & Medicaid Services [CMS]). CMS 
requires the use of the ASAM levels of care (ASAM. 2018b) for §1115 waivers to address 
the opioid overdose epidemic (CMS, 2017), emphasizing care coordination among the 
different ASAM levels of care, including acute care hospitals (Level 4.0).  
Section 6.8. Modified Conceptual Framework. 
 The original study conceptual framework, presented in Chapter 2 (Figure 2.1), 
guided research design, and analysis, through the integrated conceptualization of the 





influence the delivery of hospital-based OAT. Based on the results of the dissertation, 
the conceptual framework was updated and refined (see Figure 6.1). The most 
substantial modifications include: 1) visualizing the hospitalization of the patient as a 
dynamic interaction and exchange; 2) drawing attention to an organizational outcome—
the establishment of an AMC service—that influences the OUD-related care delivered 
during hospitalization; 3) distinguishing different types of service delivery for patients 
with OUD; and 4) refining the broader categories of the contextual attributes.  
 In addition to these changes, the modified conceptual framework became more 
granular through the incorporation of the specific findings from this study (i.e., how the 
hospital, the events of hospitalization, the patient demand-side attributes, and the 
external environment influence hospital OAT delivery, and AMC service establishment). 
The modified conceptual framework may help researchers and policymakers visualize 
the complex and interdependent contributions affecting the production and delivery of 
evidence-based services for hospitalized patients with OUD. The positive and negative 
contributions are included in the updated conceptual model. The (+) symbol identifies 
variables that enhance OAT delivery and support AMC services, and the (-) symbol 
reflects elements that inhibit OAT delivery and development of AMC services. The 
elements written in italics were quantitative findings and the non-italicized words were 
the qualitative findings. It is possible for an element to have both facilitative and 











Section 6.9. Research Limitations  
 The interpretation and conclusions generated from the findings of this 
dissertation are limited because of the study focus and the qualitative and quantitative 
methodological approaches.  
6.9.1. Study scope limitations. This study was focused primarily on 
understanding and exploring supply-side contributions (i.e., the hospital) and not the 
demand-side contributions (i.e., the patient). This is a study finding limitation because 
health care access and delivery occurs through the dynamic interaction of the supply-
side and demand-side (Levesque et al., 2013). The qualitative and quantitative datasets 
were limited to primarily exploring supply-side factors, aside from patient 
demographics. This was due to the choices made on how to reasonably scope this study, 
which included deciding on who to include in the qualitative study cohort. The study 
was limited to querying addiction medicine physician experts to ensure a narrower and 
more focused sampling frame to ensure timely completion of the dissertation. The 
inclusion of the patient perspective would have complicated the study design and 
methods (e.g., creation of patient survey, different sampling approach).  
 6.9.1. Qualitative limitations. The main limitation of this study was 
transferability, which is inherent to findings from qualitative research. Findings from the 
interviews with addiction medicine experts in large well-resourced institutions may not 
be applicable to hospitals with more limited resources (e.g., the organizational and 





delivery). This study does not provide an understanding of the challenges faced in 
lower-resourced hospitals. Indeed, the proposed solution—the creation of AMC 
services—may not be possible in these contexts. Sixteen of the 17 informants were from 
hospitals not affiliated with an integrated delivery system, meaning that the 
organizational challenges particularly around care continuation differ from those 
working in a VHA type system. Further, this study cohort included perspectives from 
addiction medicine physicians at relatively well-resourced hospital with regards to 
addiction-related services.  
 Another limitation in this study was the variation in the amount of involvement 
that the key informants had with establishing or running their respective AMC 
services—some informants were observers, some were creators, and some worked on 
the service. This was a limitation because systems may be perceived differently based 
on the positionality of “the perceiver” (Lendaris, 1986). However, the quantitative 
analyses provided additional perspectives on the use of OAT among hospitalized 
patients that could more broadly translate to larger and smaller hospitals in rural and 
urban communities that serve a spectrum of patients. Finally, and importantly, this 
study did not include the patient perspective, which would have strengthened the study 
because patients would have identified relevant practice and policy issues unobserved 
in this study. 
 6.9.2. Quantitative limitations. There are also inherent limitations associated 





observational retrospective cohort study, causal relationships cannot be established. 
Second, there were limitations to the generalizability of the results because of the study 
cohort (veterans) and the health services system design (the VHA). This was a study of 
VHA administrative data, and primarily applicable to the U.S. veteran population (older, 
white, and male). Further, the VHA is an integrated health payer and health system; 
thus, its linkages to care and organizational facilitators and barriers may differ from non-
VHA hospitals, as was reflected in the sustained OAT data analyses. This is an important 
point because it means that third-party health insurance, the revenue generated 
through billing, and the formulary, which is the same across the VHA system, are not the 
external and internal environmental attributes contributing to deficiencies and 
variations in hospital OAT. Rather, other factors were contributing to variation in the 
VHA. In addition, patient inclusion criteria for quantitative aims included an OUD 
diagnosis in the year prior to (and including) index hospitalization. However, OUD may 
not have been a focus of treatment during hospitalization. Care practices may vary from 
what was observed in the current study when OUD-related complications are the 
primary reason for hospitalization. Finally, the study data are from the year 2017, a 
specific moment in time, and do not capture potential changes in practice over time. 
Nevertheless, the qualitative interviews with addiction medicine experts in non-VHA 
hospitals help balance the limitations in the quantitative analysis. The interviews offer 
insight into emerging standards of care and provide detail on how and why OAT is used 





The study cohort was also limited by the true denominator prevalence issue as 
described by Harris (2016). When using a diagnosis-based denominator—the number of 
persons hospitalized with OUD—to compare hospital delivery performance, it is possible 
that hospital delivery performance differences may be a result of a hospital’s and clinical 
staff’s ability to identify, diagnose, and document OUD. The findings from this study 
suggest that the contributions from these phenomena are likely minimal. Differences 
were not observed in the bivariate analyses of acute OUD diagnosis volume and OUD 
admission volume among hospital OAT performance quartiles. The true denominator 
prevalence issue is most problematic when the denominator affects performance 
measures. Selective identification of patients can enhance or suppress measures of 
hospital performance. The measures used in the quantitative analysis were not being 
used as quality measures and have no affect on hospital finances. 
Another limitation is related to the construction of study variables, specifically, 
the health services utilization variables. The study was restricted to a 30-day period of 
observation post-index hospitalization. Previous research on opioid overdose deaths 
post-hospitalization used a time period longer than 30 days (Larochelle et al., 2018; 
Larochelle et al., 2016). A longer-term observation period (> 30 days) may provide 
additional information about risks of hospitalization and the OAT care delivery 
continuum. It is also possible that this study has underreported acute care delivery 
utilization in the 30-day period post-index hospitalization, as the 30-day ED and 





study was likely underpowered to effectively assess the impact of infrequently occurring 
outcomes (e.g., 30-day death rate and in-hospital mortality).  
6.9.3. Mixed methods integration limitations. There were several limitations to 
integrating the qualitative and quantitative findings for this mixed methods study. Key 
informants, and hospital guidance documents, were all from outside the VHA system. 
The quantitative data were from the VHA system. However, OAT care practice 
approaches outside the VHA informed the design of OAT practice variables and 
informed the selection of covariates included in the quantitative data. Unfortunately, 
data on the existence of AMC services or the presence of addiction-related hospital-
based services were not available for the VHA facilities, limiting the ability to connect 
VHA outcomes to VHA addiction-related hospital services. Nevertheless, mixing 
quantitative and qualitative data strengthened the conclusions of this research study. 
The final presentation and synthesis of study findings were enhanced because of the 
mixed methods approach used in this study. Importantly, the qualitative findings 
contextualized the quantitative findings, providing richer and policy and practice 
relevant applications. Further, the two sets of data were complimentary, confirmatory, 
and also provided insights that would not have emerged in isolation.  
Section 6.10. Health Systems and Policy Implications 
This section explores potential policy tools and health systems interventions that 
could enhance and promote health system and hospital services for patients with OUD. 





suggests that OAT is not reaching the majority of hospitalized patients with an OUD and 
that systems-level attributes and policies inhibit hospital OAT delivery. This section 
proposes interventions for policymakers, health system and hospital leaders, clinicians, 
and researchers who are interested in improving services for patients hospitalized with 
OUD. 
Policy tools are incentives or rules (Stone, 2011) that promote regulative or 
allocative action on policy targets (Dunn, 2012). Regulative policy action ensures 
compliance with certain standards or procedures, and allocative policy actions require 
the input of time, money, personnel, and equipment (Dunn, 2012). Policy tools may be 
distributive or redistributive (Lowi, 1964) and may target different actors responsible for 
action within a system. Health and social service policies are supposed to promote the 
non-punitive treatment for persons with SUDs (Babor et al., 2010). These policies affect 
treatment access through planning, financing, developing the professional workforce, 
and shaping the structural resources available to treat SUDs (e.g., number of facilities) 
(Klingemann et al., 1993; Klingemann & Klingemann, 1999).  
The findings from this study could inspire policy interventions inside and outside 
the hospital targeting a variety of actors to address OAT underuse, including: variation 
of OAT delivery across systems; the use of less effective treatment approaches; the 
frequent use of non-OAT modalities; the mutable internal and external environmental 
attributes impeding or facilitating hospital OAT delivery; the specific patient attributes 





important component in the OUD care continuum. The suggested policy and health 
system interventions fall into three broad domains: 1) education; 2) service delivery; 
and 3) policy modifications. 
6.10.1. Education interventions. An important observation from the non-VHA 
hospital informant interviews was the consensus across the study cohort that most 
hospital providers, in particular physicians, had knowledge gaps in their understanding 
of how to care for patients with OUD. Knowledge gaps included a lack of awareness of 
evidence-based practices for OUD treatment, misconceptions and discriminatory beliefs 
about people with SUDs, and a misunderstanding of federal OAT policies. There are at 
least two education-related strategies that may support the amelioration of knowledge 
gaps related to OUD and OAT service delivery: 1) targeted educational campaigns; and 
2) educational requirements. 
 6.10.1a. Strategy 1: Targeted OAT educational campaigns. To reduce confusion 
related to federal OAT policies in the hospital setting, stakeholders could engage in 
educational initiatives to debunk common myths and to increase awareness about the 
legality and efficacy of providing OAT to hospitalized patients with OUD. SAMHSA could 
include specific information about these policies in its buprenorphine waiver training 
courses or create a special training and educational platform for hospital-based 
providers. Further, the DEA could improve messaging about the legality of treating 
patients with OAT during hospitalization and include this information in any 





 Specific groups of providers could be targeted for intervention. Medical 
societies, in particular ASAM, could partner with the Society of Hospital Medicine and 
the American Hospital Association (AHA) to launch an educational campaign for 
hospital-based physicians. Further, orthopedic surgeons and emergency medicine 
physicians were particularly noted as having challenges in caring for patients with OUD. 
These specific groups could be a direct focus for policy initiatives and educational 
campaigns led by their respective medical societies: The American Board of Orthopaedic 
Surgeons and the American Academy of Emergency Medicine. 
 6.10.1b. Strategy 2: Educational requirements. There may also be opportunities 
for medical education regulatory and accrediting bodies (e.g., Association of American 
Medical Colleges, the Liaison Committee for Medical Education, Commission on 
Osteopathic College Accreditation, the American Osteopathic Association, and the 
Accreditation Council for Graduate Medical Education [ACGME]) to mandate evidence-
based addictions training for both undergraduate and graduate medical education. The 
groups could incorporate training in addiction services into the learning competency 
requirements at each stage of medical training, and reinforce this learning with the 
inclusion of addiction medicine related questions in national medical licensing 
examinations. 
 Moreover, ACGME and physician specialty boards could leverage and expand 
upon programmatic requirements. Internal medicine residents, for example, are 





means that general medical consult services must exist in hospitals that seek to employ 
internal medicine residents. Similarly, all internal medicine residents could be required 
to rotate on an AMC service. Another leverage point could be to require residents and 
medical students to obtain a buprenorphine waiver as a graduation requirement. This is 
being tested at the Brown University School of Medicine with support from state 
legislation (Arditi, 2017). This will likely become more common because the federal 
2018 SUPPORT for Patients and Communities Act created a pathway for medical 
trainees to obtain a waiver to prescribe buprenorphine immediately upon entering 
practice (J. W. Frank, Wakeman, & Gordon, 2018). 
 6.10.2. Service delivery interventions. There are at least four potential 
strategies to guide and enhance initiatives to improve OUD care in health systems and 
hospital settings: 1) guidance documents; 2) regulatory requirements; 3) statutory 
requirements; and 4) financial incentives. 
 6.10.2a. Strategy 1: Guidance documents. First, health systems and hospitals 
could implement standardized guidance documents to promote and enhance care 
delivery standards for hospital OAT delivery. Organizations can use guidance documents 
to address care variation to support standard practice in clinical scenarios with high 
levels of certainty, clinical agreement, and definitive science (Institute of Medicine 
Committee on Quality of Health Care in America, 2001). This intervention is proposed 
because significant variation was found in the quantitative and qualitative analyses. The 





share these documents nationwide. AHA and ASAM could partner as initiative leaders to 
either create new materials or endorse the use of other materials already existence, 
such as the Project Support for Hospital Opioid Use Treatment (SHOUT) tools (Project 
SHOUT, 2018) or the recently published federal treatment guidance documents 
(Substance Abuse and Mental Health Services Administration, 2018). It is likely that the 
voluntary adoption of these guidance documents will be limited to the innovators and 
early adopters (Rogers, 2003); thus, the use of external coercive policies to adopt these 
guidelines may be necessary through the Joint Commission (see strategy 2 below).  
 6.10.2b. Strategy 2: Regulatory requirements. A second strategy to enhance 
OAT delivery may include the use of external coercive policies to require hospitals to 
deliver OAT by leveraging the power of hospital-related accrediting and professional 
regulatory bodies (e.g., the Joint Commission or American College of Surgeons [ACS]). 
The Joint Commission designates hospital accreditation requirements and ensures 
hospitals are meeting those standards. At present, there are no requirements related to 
the care of persons with OUD and SUDs in the hospital context. In 2008, the Joint 
Commission created optional performance metrics for alcohol screening and 
pharmacotherapy for persons with SUDs, including OUD (Joint Commission, 2015). It is 
within the authority of the Joint Commission to require reporting and performance 
measurement for OAT and mandate addiction-related technologies for hospital 





 ACS is another regulatory body with the power to influence hospital practice, 
particularly at large tertiary care centers, or any hospital that strives to maintain or 
become trauma center certified. ACS specifically requires that all trauma patients 
admitted for more than 24 hours must be screened for alcohol use disorders (American 
College of Surgeons, 2018). The current policy could be expanded to include other SUDs 
or could be modified to require a consultation with a board-certified addiction medicine 
physician, which would require hospitals to have trained addiction medicine physicians 
on staff. 
 6.10.2c. Strategy 3: Statutory requirements. Third, local jurisdictions could enact 
coercive policies to improve hospital practices. An excellent example of this occurred 
recently in Massachusetts. In August 2018, the Massachusetts legislature passed House 
Bill 4866, Prevention and Access to Appropriate Care and Treatment of Addiction, 
comprehensive legislation focused on addressing the opioid overdose epidemic (WBUR 
News & Wire Services, 2018). The legislation requires Massachusetts’s emergency 
departments to offer and provide OAT for patients with an opioid overdose, and to link 
them to care upon discharge (WBUR News & Wire Services, 2018). Similar legislation in 
other states could be proposed and expanded to require offering of OAT during hospital 
admission. Garnering the support necessary to pass this type of legislation would likely 
entail the creation of a broad coalition of patients, health care professionals, and 





in how the statute is implemented and enforced in different jurisdictions, dependent on 
local governance structures among state health, mental health, and SUD agencies.  
6.10.2d. Strategy 4: Financial incentives and penalties. Another strategy may be 
to create financial motivators for hospital performance related to OUD service delivery. 
Public payers, such as Medicaid, could incentivize appropriate hospital care through the 
Delivery System Reform Incentive Payment (DSRIP) program through the §1115 waiver 
mechanism (MACPAC, 2018). Through this program mechanism, policymakers could test 
reimbursement strategies, the design of interprofessional teams, penalties for delivering 
non-evidence-based services (e.g., funding detox beds), and financial incentives for 
evidence-based services. To make this a reality, CMS would need to explicitly outline 
these approaches in program notices for future demonstration opportunities. 
Cities are also investing local dollars to create hospital AMC services. New York 
City Health & Hospitals launched the Consult for Addiction Treatment and Care in 
Hospitals Program (CATCH). Funded in part by more than $7.5 million from Mayor de 
Blasio’s Healing NYC Initiative, the CATCH program is implementing AMC services at six 
New York public hospitals over the next one and a half years (NYC Health & Hospitals, 
2018). Replicating this citywide initiative in other jurisdictions is likely possible with the 
right coalition and project champions; however, similar to the variation in state law 
implementation and enforcement, a one-size-fits-all strategy might not be possible 
because of local differences in city and county health agency relationships, operations, 





Finally, the delivery of hospital-based OAT could be included in CMS pay-for-
performance hospital programming such as Medicare’s Hospital Value-Based Purchasing 
Program. This program uses value-based purchasing to redistribute funds to 
participating hospitals based on performance (CMS, 2018b) The metrics for this program 
could be updated to include care processes related to OAT delivery. Another potential 
CMS program that could incentivize OAT delivery during hospitalization is the Hospital 
Readmission Reduction Program (CMS, 2018a), which reduces hospital payments based 
on excessive readmissions. Conditions that are currently tracked do not include OUD 
and or OUD-related infection, and these could be added to the program. Summaries of 
the education and service delivery policy interventions are provided in Table 6.1, on the 





Table 6.1. Interventions to Enhance OUD Services During Hospitalization 









Targeted OAT educational 
campaigns  




Mandate addiction medicine 
training as a core clinical 
competency 
Regulative UME regulatory 
bodies1; GME 
regulatory bodies2 
UME and GME 
programs  
Mandate addiction medicine 
exam questions into licensing 
exams 
Regulative NBME Medical trainees 
Mandate rotation on an AMC 
service 







for medical trainees 
Regulative UME regulatory 
bodies1; GME 
regulatory bodies 2 
Medical trainees 
Service Delivery 
Create national hospital OAT 
guidance documents and 
mandate adoption  
Regulative  ASAM, AHA, Project 





Mandate AMC service existence Regulative Joint Commission; ACS Health systems 
and hospitals 
Mandate hospital OUD care 
quality reporting  
Regulative Joint Commission; ACS Health systems  
and hospitals 
Mandate hospital OAT provision  Regulative State or local public 
health department 
Health systems  
and hospitals 
Include OAT in the Hospital Value-
Based Purchasing Program 
Allocative CMS Health systems 
 and hospitals 
Include OUD in the Hospital 
Readmission Reduction Program 
Allocative CMS Health systems  
and hospitals 
Incentivize hospital OUD 
treatment innovation with DSRIP 
and §1115 waiver mechanism  
Allocative CMS State Medicaid 
program 
Allocate local funds to pay for 
AMC service 
Allocative Local jurisdictions Health systems  
and hospitals 
Table Notes. SAMHSA = Substance Abuse and Mental Health Service Administration; DEA = Drug 
Enforcement Administration; UME = undergraduate medical education; GME = graduate medical 
education; NBME = National Board of Medical Examiners; AMC = addiction medicine consult service; 
ASAM = American Society of Addiction Medicine; AHA = American Hospital Association; ACS = 
American College of Surgeons; CMS = Centers for Medicare and Medicaid Services; DSRIP = Delivery 
System Reform Incentive Payment; 1American Association of Medical Colleges, the Liaison Committee 
on Medical Education, the American Osteopathic Association; 2Accreditation Council for Graduate 






 6.10.3. Policy reform. Treatment policies, inside and outside non-VHA hospitals, 
were identified by key informants as creating OAT delivery barriers. Within the hospital, 
informants observed internal policies creating barriers through hospital formulary 
limitations, restrictive OAT prescribing and administering policies, and the absence of 
hospital-wide guidance documents for OUD-related services. The absence of guidance 
documents was perceived to complicate OUD care management issues because hospital 
standards of care for this patient population were unknown.  
 Policies creating barriers to hospital OAT access were created by third-party 
payers (e.g., coverage policies), OTPs (e.g., state assessment requirements), and federal 
drug treatment regulators (e.g., buprenorphine patient panel limits). Frequently, these 
policies negatively constrained outpatient OAT access, which in turn influenced the 
potential care delivery options in the hospital setting. Informants believed that 
streamlined access to outpatient services was necessary for establishing an AMC service 
(see Table 6.2).  
Table 6.2. Policies for Reform Suggested by Informants 
Hospital  Outside the hospital  
• Formulary restrictions on OAT 
• Only allowing providers with DATA 
waivers to prescribe 
buprenorphine/naloxone 
Third-Party Payer Polices 
• No methadone coverage 
• Prior authorization for buprenorphine 
• Utilization review for buprenorphine 
• Formulary restrictions for buprenorphine 
OTP Policies 
• State assessment requirements prior to placement 
• Disallow concurrent polysubstance use 
Federal Drug Treatment Policies 






 In addition to the suggestions for policy revision from informants, hospital 
policies such as behavioral management, visitor and room searches, and smoking 
policies could become more trauma-informed. Further, the removal of the 72-hour rule, 
which limits the use of OAT for three days for patients admitted with opioid withdrawal, 
may eliminate much of the confusion held by hospital providers on the legality of 
providing OAT in the hospital. More broadly, policymakers could consider removing the 
special regulatory oversight system currently governing OAT, specifically the OTP 
regulations and buprenorphine/naloxone wavier system (Fiscella, Wakeman, & Beletsky, 
2018; J. W. Frank et al., 2018). Canada, for example, has discontinued its federal waiver 
and provider enrollment requirements for methadone to decrease administrative 
barriers to care (Priest et al., 2019). Despite decreasing federal government 
involvement, all the provinces still require or strongly suggest that providers who 
prescribe OAT participate in additional training (CRISM-ICRAS, 2018), which may still 
create barriers to OAT prescribing. Another international model with considerable 
success in increasing OAT access is the French system, which since 1996 has allowed 
providers to prescribe buprenorphine without any additional training or registration 
requirements (Auriacombe, Fatséas, Dubernet, Daulouede, & Tignol, 2004). The U.S. 
could implement one of these approaches or a hybrid approach, either shifting 
responsibility to states or using the already existing federal regulatory system that 
oversees the distribution and prescription of scheduled pharmaceutical products (i.e., 





Section 6.11. Future Research Questions and Areas for Exploration 
 Several future research questions and areas for exploration were generated from 
study findings. Potential lines of inquiry include: extending and expanding upon this 
study; confirming the study’s quantitative findings in non-VHA health systems and 
hospitals; confirming the study’s qualitative findings in hospitals and health systems 
without an addiction medicine fellowship or in rural hospitals; operationalizing hospital 
OAT care quality; exploring barriers to provider knowledge; exploring demand-side 
issues from the patient perspective; and continuing research on AMC service design and 
operations. 
 6.11.1. Continue research with VHA hospitals. Future research could explore 
why hospital OAT variation exists across the VHA system. These explorations could 
include the addition of other information not in the original dataset, such as the 
existence of VHA affiliated community-based addiction-related services. Questions from 
this line of inquiry could include: 
• What are the organizational or environmental (i.e., policy, regulatory, other 
organizations) factors that contribute to high performing VHA hospitals? 
• What are the organizational or environmental (i.e., policy, regulatory, other 
organizations) factors that contribute to low performing VHA hospitals? 
Additional areas for exploration could involve a chart review to better understand why 
some patients were sustained or discontinued on OAT during hospitalization. This 





sustaining OAT through a hospitalization. Another approach would be to see if different 
findings exist when the study population is narrowed to only patients hospitalized with 
opioid overdose or other OUD-related complications. Finally, different outcome 
measures related to OAT administration could be assessed through multilevel modeling 
including: in-hospital mortality, 30-day readmission, 30-day emergency department 
visit, 30-day death, and leaving the hospital against medical advice. 
6.11.2. Confirm and expand study findings in non-VHA hospitals. The 
quantitative findings from this study could be confirmed outside the non-VHA system, 
specifically: Do the study’s findings of OAT underuse, OAT variation, and the use of non-
OAT pharmacotherapies persist in non-VHA hospitals and health systems, both in the 
U.S. or internationally? To answer this question, policymakers and researchers need to 
explore data access issues. One of the primary challenges to studying hospital OAT 
delivery is the widespread use of diagnosis-related groupings (DRG) in hospital billing. 
The DRG billing system allows hospitals to bill payers through a bundled payment 
algorithm to account for illness acuity (Quinn, 2008). Although DRG billing minimizes 
administrative billing processes, it unfortunately masks the ability for researchers and 
payers to determine if OAT was delivered during hospitalization, a conundrum for 
studying most pharmacotherapy administered during hospitalization. Another potential 
line of inquiry that bypasses the DRG billing complication could be to assess OAT 





other care contexts or in other domestic integrated health systems (e.g., Kaiser 
Permanente).  
6.11.3. Confirm and expand study findings in hospitals without addiction 
medicine fellowships. The qualitative findings, in particular the barriers to AMC service 
establishment and the delivery of evidence-based care, could be confirmed in hospitals 
without addiction medicine fellowship affiliation and hospitals in rural settings. 
Questions for this avenue of research could include: 
• Are there different contextual attributes that facilitate or impede AMC 
service establishment and OAT delivery in hospitals without an addiction 
medicine fellowship? Or in rural hospitals? 
• Are the OAT and non-OAT practices different in hospitals without an 
addiction medicine fellowship? Or in rural hospitals? 
 6.11.3. Operationalize hospital OAT care quality. The findings from this study 
could lead to future lines of inquiry about how hospital OAT delivery quality could be 
defined and measured from a care quality perspective. Future questions could ask:  
• Is the delivery of OAT during hospitalization enough or does linkage to care need 
to happen? What about patients who are already on OAT? 
 6.11.4. Explore barriers to provider knowledge. The findings from this study also 
inspire questions related to the knowledge base and training of health care 
professionals, in particular physicians. Future research could focus on exploring hospital 





regulations. A specific question that could be explored in the VHA setting is to assess 
why patients on OAT prior to hospitalization are being discontinued from OAT and being 
managed on short-acting opioid agonists. As was described in the qualitative findings, 
the continuation of OAT supplemented with short-acting opioids is the recommended 
approach to managing pain for patients with OUD (SAMHSA, 2018). 
6.11.5. Explore demand-side perspectives. This study was designed to focus on 
supply-side barriers and facilitators; as such, future research could focus on the barriers 
to patient access to hospital OAT. This could be done by inviting the patient’s 
perspective. Further, research could include and consider patient-informed harm 
reduction approaches and the impacts of hospitalization trauma. Recent research on 
hospitalized patients, not specific to patients with SUDs, suggests that the trauma of 
hospitalization itself is associated with increased access to acute care delivery services 
(ED visits and 30-day readmission) in the 30 days post discharge (Rawal et al., 2018). 
Based on the findings of this study and prior research (Velez et al., 2017), the trauma of 
hospitalization could disproportionately impact patients hosptialized with SUDs.  
6.11.6. Continue research on AMC service design and operations. Beyond this 
study, little is known about the design and operations of AMC services. Future research 
could build on study findings by developing an AMC service design survey that could be 
administered by the AHA. This survey could further quantify the potential barriers to 





AMC services (e.g., does your hospital have an AMC service), and design elements (e.g., 
availability and coverage). 
Section 6.12. Study Conclusions and Future Challenges 
Addictions cannot be understood as merely the behavior patterns of individuals, 
as if they were the product of personal choices or personality characteristics 
alone, but also must be conceptualized as collective probabilities that are woven 
into the social fabric. (Reinarman & Granfield, 2014, p. 16) 
 
 This study began the process of describing and exploring the dynamic, evolving, 
organizational and socio-economic phenomena influencing the delivery of hospital-
based services for patients with OUD. There are seven primary findings from this mixed 
methods study that confirm and expand upon prior research and also provide novel 
contributions. The quality of care for this patient population appears to be suboptimal 
(Findings 1, 2, 3, and 4). This study provides the first description of specific contextual 
attributes inside and outside the hospital that facilitate or impede AMC service 
development and hospital OAT delivery (Finding 5). This study builds upon a growing 
evidence base suggesting that patient attributes impede or facilitate hospital OAT 
delivery (Finding 6), and also provides a first look into the important role of the hospital 
in the broader OUD care continuum (Finding 7). The findings from this study suggest it is 
likely that many U.S. hospitals, particularly those without addiction medicine expertise, 
fail to provide adequate care for patients with OUD during hospitalization. 
 Although the study findings are primarily negative, there are a variety of ways in 
which hospitals, health systems, and policymakers may improve care for patients with 





potential to minimize harm and enhance support for people seeking treatment for their 
drug use. Resources should be allocated to these initiatives. There is, however, a 
significant challenge: the U.S. health services delivery system exists within the U.S. 
contemporary drug policy regime. The U.S. drug policy regime does not exist to 
minimize harm to persons who use drugs. It is grounded in a historical and social 
context that views persons with SUDs as morally deficient and incapable of making 
sound decisions. The construction of these views, embodied and normalized through 
over a century of policy and practice, run counter to the public health model of 
promoting human health and mitigating disease. A true public health approach to caring 
for persons with SUDs requires an overhaul of the U.S. drug policy regime. The current 
framework for addressing harmful drug use centers on the false notion that people who 
use drugs are immoral and must face criminal consequences for their behaviors. Until 
these antiquated views are stripped from federal and local policies, people with SUDs in 
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Appendix A: The DSM 5 Opioid Use Disorder Diagnostic Criteria 
From the American Psychiatric Association (2013):  
 
“A problematic pattern of opioid use leading to clinically significant impairment or distress, as 
manifested by at least two of the following, occurring within a 12-month period: 
 
1. Opioids are often taken in larger amounts or over a longer period than was intended. 
2. There is a persistent desire or unsuccessful efforts to cut down or control opioid use. 
3. A great deal of time is spent in activities necessary to obtain the opioid, use the opioid, 
or recover from its effects. 
4. Craving, or a strong desire or urge to use opioids. 
5. Recurrent opioid use resulting in a failure to fulfill major role obligations at work, school, 
or home. 
6. Continued opioid use despite having persistent or recurrent social or interpersonal 
problems caused or exacerbated by the effects of opioids. 
7. Important social, occupational, or recreational activities are given up or reduced 
because of opioid use. 
8. Recurrent opioid use in situations in which it is physically hazardous. 
9. Continued opioid use despite knowledge of having a persistent or recurrent physical or 
psychological problem that is likely to have been caused or exacerbated by the 
substance. 
10. Tolerance, as defined by either of the following: A need for markedly increased amounts 
of opioids to achieve intoxication or desired effect; or a markedly diminished effect with 
continued use of the same amount of an opioid. *This criterion is not considered to be 
met for those taking opioids solely under appropriate medical supervision. 
11. Withdrawal, as manifested by either of the following: The characteristic opioid 
withdrawal syndrome (refer to Criteria A and B of the criteria set for opioid withdrawal, 
pp. 547–548); or opioids (or a closely related substance) are taken to relieve or avoid 
withdrawal symptoms. *This criterion is not considered to be met for those individuals 
taking opioids solely under appropriate medical supervision. 
Specify if: 
In early remission: After full criteria for opioid use disorder were previously met, none of the 
criteria for opioid use disorder have been met for at least 3 months but for less than 12 months 
(with the exception that Criterion A4, “Craving, or a strong desire or urge to use opioids,” may 
be met). 
In sustained remission: After full criteria for opioid use disorder were previously met, none of 
the criteria for opioid use disorder have been met at any time during a period of 12 months or 
longer (with the exception that Criterion A4, “Craving, or a strong desire or urge to use opioids,” 
may be met). 
On maintenance therapy: This additional specifier is used if the individual is taking a prescribed 





disorder have been met for that class of medication (except tolerance to, or withdrawal from, 
the agonist). This category also applies to those individuals being maintained on a partial 
agonist, an agonist/antagonist, or a full antagonist such as oral naltrexone or depot naltrexone. 
In a controlled environment: This additional specifier is used if the individual is in an 
environment where access to opioids is restricted. 
Coding based on current severity: Note for ICD-10-CM codes: If an opioid intoxication, opioid 
withdrawal, or another opioid-induced mental disorder is also present, do not use the codes 
below for opioid use disorder. Instead, the comorbid opioid use disorder is indicated in the 4th 
character of the opioid-induced disorder code (see the coding note for opioid intoxication, 
opioid withdrawal, or a specific opioid-induced mental disorder). For example, if there is 
comorbid opioid-induced depressive disorder and opioid use disorder, only the opioid-induced 
depressive disorder code is given, with the 4th character indicating whether the comorbid 
opioid use disorder is mild, moderate, or severe: F11.14 for mild opioid use disorder with opioid-
induced depressive disorder or F11.24 for a moderate or severe opioid use disorder with opioid-
induced depressive disorder. 
305.50 (F11.10) Mild: Presence of 2–3 symptoms. 
304.00 (F11.20) Moderate: Presence of 4–5 symptoms. 
304.00 (F11.20) Severe: Presence of 6 or more symptoms.” 





Appendix B: OHSU IRB Approved Informational Sheet 
TITLE: Opioid Agonist Treatment in Hospitals 
 
PRINCIPAL INVESTIGATOR: Dennis McCarty, PhD (503) 494-1177 
 
CO-INVESTIGATOR: Kelsey Priest, MPH  
 
FUNDED BY: National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) 
 
PURPOSE: 
You have been invited to be in this research study because you are either a national hospital 
addiction medicine expert (e.g., physician, pharmacist, nurse, social worker, hospital 
administrator, health services researcher, or government official), a member of a hospital 
pharmacy and therapeutics committee for at least 6 months (e.g., nursing, physician, 
pharmacist, hospital administrator), or a health professional  (e.g., nursing, physician, 
pharmacist, hospital administrator) who works on a hospital addiction consult service. 
 
The purpose of this interview is to explore your perspectives about your organization’s hospital 
opioid use disorder care delivery policies, procedures, and practice, specifically:  
 
1. Hospital OUD care delivery policies, procedures, and practice. 
2. Barriers and facilitators to hospital OUD treatment and OAT delivery. 
3. Ideas or solutions for enhancing hospital OUD treatment and OAT delivery. 
 
PROCEDURES: 
This study requires one 45-to 60-minute telephone (or in-person) audio recorded interview. If 
you mention a specific hospital policy during the course of the interview I will request a copy 
and I may follow-up with clarifying questions.  
 
We are recruiting approximately 30 key informants to participate in this study who are 
professionals identified from across the United States as hospital-based OUD treatment experts.  
 
The recordings of the interviews will be professionally transcribed (meaning that what is said 
will be written down exactly as stated), reviewed, summarized, and entered into a software 
program that is designed to facilitate analysis of the interviews.  Notes will be taken during the 
interviews and entered into the same software program.  All data from the interviews will be de-
identified and coded with a special number when entered and stored in the software program.  
 
If you have any questions, concerns or complaints regarding this study now or in the future, or 
you think you may have been injured or harmed by the study, contact Dr. Dennis McCarty (503) 










Although we have made every effort to protect your identity, there is a minimal risk of loss of 
confidentiality. The recording of the interview will be stored on OHSU encrypted and password-
protected servers for no longer than 3 years after study completion. Access to the data will be 
granted only to the study researchers. All of the data kept in notes, recordings, and 
transcriptions related to the research will be destroyed as soon as the research is complete.    
 
BENEFITS: 
You will not benefit from being in this study. However, by serving as a participant, you may help 
us learn how to benefit patients with opioid use disorder in the future. 
 
CONFIDENTIALITY: 
We will take steps to keep your personal information confidential, but we cannot guarantee 
total privacy. All NIDA sponsored studies have an automatic federal certificate of confidentiality 
to help protect the confidentiality of the data. 
 
PARTICIPATION: 
This research is being overseen by an Institutional Review Board (“IRB”). You may talk to the 
OHSU IRB at (503) 494-7887 or irb@ohsu.edu if: 
• Your questions, concerns, or complaints are not being answered by the research team. 
• You want to talk to someone besides the research team. 
• You have questions about your rights as a research subject. 
• You want to get more information or provide input about this research. 
 
You may also submit a report to the OHSU Integrity Hotline online at 
https://secure.ethicspoint.com/domain/media/en/gui/18915/index.html or by calling toll-free 
(877) 733-8313 (anonymous and available 24 hours a day, 7 days a week). 
 
You do not have to join this or any research study.  If you do join, and later change your mind, 
you may quit at any time.  If you refuse to join, or withdraw early from the study, there will be 






Appendix C: OHSU IRB Approved Email Recruitment Script 
Subject Line: OHSU Research Study: Opportunity for Participation  
 
Email Primary Contact 
“Dear ___________, 
My name is Kelsey Priest, and I am a fourth year MD/PhD student at Oregon Health & Science 
University (OHSU) and a doctoral student at OHSU-Portland State University School of Public 
Health in the Health Systems and Policy program. I am contacting you in connection with a 
research study (OHSU IRB approval #STUDY00018092) that I am conducting as part of my 
dissertation, under the supervision of Dr. Dennis McCarty who is the chair of my dissertation 
committee. This project seeks to learn more about the health care service patterns of opioid 
agonist therapy (OAT) delivery in the hospital setting for persons with opioid use disorder.  
 
I am seeking to speak with an expert from your hospital on hospital-based practices and policies 
related to the treatment of persons with opioid use disorder. Preferably this will be someone 
who has worked on opioid use disorder related initiatives for several years and/or has seen the 
implementation of programs, like an addiction consult services over time. The purpose of the 
interview is to capture this expert’s perspectives about your organization’s hospital opioid use 
disorder care delivery policies, procedures, and practice, specifically:  
 
1. Hospital OUD care delivery policies, procedures, and practice. 
2. Barriers and facilitators to hospital OUD treatment and OAT delivery. 
3. Ideas or solutions for enhancing hospital OUD treatment and OAT delivery. 
 
I am emailing to see if you would be interested in participating as a key informant in our 
research study or if you could refer me to someone at your hospital who you think would be 
better able to answer these questions. 
 
In either case, please respond to this email with either your recommended contact or indicate 
whether or not you are interested in participating.  
 
If you are interested in participating, I will arrange a time over email for us to have a 45 to 60-
minute confidential phone interview (or in-person meeting) to talk at your convenience.  
 
If you are recommending a colleague, I will reach out to them directly. 
 
If you have concerns about this research please contact Dr. Dennis McCarty at (503) 494-1177 
and mccartyd@ohsu.edu.If you have questions about your rights as a research subject or 
research-related injuries, you can call the OHSU Research Integrity Office at 503-494-7887. 
 
Email Secondary Contact 
“Dear ___________, 
My name is Kelsey Priest, and I am a fourth year MD/PhD student at Oregon Health& Science 
University (OHSU) and a doctoral student at OHSU-Portland State University School of Public 





research study (OHSU IRB approval #STUDY00018092) that I am conducting as part of my 
dissertation, under the supervision of Dr. Dennis McCarty who is the chair of my dissertation 
committee. This project seeks to learn more about the health care service patterns of opioid 
agonist therapy (OAT) delivery in the hospital setting for persons with opioid use disorder.  
 
I am seeking to speak with an expert from your hospital on hospital-based practices and policies 
related to the treatment of persons with opioid use disorder. Preferably this will be someone 
who has worked on opioid use disorder related initiatives for several years and/or has seen the 
implementation of programs, like an addiction consult services over time. The purpose of the 
interview is to capture this expert’s perspectives about your organization’s hospital opioid use 
disorder care delivery policies, procedures, and practice, specifically:  
 
1. Hospital OUD care delivery policies, procedures, and practice. 
2. Barriers and facilitators to hospital OUD treatment and OAT delivery. 
3. Ideas or solutions for enhancing hospital OUD treatment and OAT delivery. 
 
You have been identified by [references name] as an expert in hospital-based practices and 
policies related to the treatment of persons with opioid use disorder at your hospital.  
 
I am emailing to see if you would be interested in participating as a key informant in our 
research study. If you are interested please respond to this email, and I will arrange a time for us 
to have a 45 to 60-minute confidential phone interview (or in-person meeting) to talk at your 
convenience.  
 
If you have concerns about this research please contact Dr. Dennis McCarty at (503) 494-1177 
and mccartyd@ohsu.edu.  
 
If you have questions about your rights as a research subject or research-related injuries, you 






Appendix D: OHSU IRB Approved Key Informant Demographic Survey 











• 70 or older 
•  
With what gender do you identity?  
• Woman 
• Man  
• Other __ 
• Decline to Answer 
 
How do you racially identify?  
• American Indian/Alaska Native 
• Asian 
• Native Hawaiian or Other Pacific Islander 
• Black or African American 
• White 
• More than one race 
• Decline to Answer 
 
What ethnicity best describes you? [pick one] 
• Hispanic or Latino 
• Not Hispanic or Latino 
• Decline to Answer 
 
What health professional degree(s) do you have? And what year did you graduate from each 
program(s)? 
 
Which profession best describes your current work? 
• Hospital administrator/manager 
• Nurse 
• Pharmacist 






o Addiction Medicine Board Certification? (y/n)  
• Social worker 
• Behavioral health specialist 
• Legal counsel 
• Other___ 
 




• more than 5 
 




• more than 5 
 




• more than 5 
 
Does your hospital have methadone on the formulary for treatment of OUD?  
• Yes 
• No 
• Unknown  
 
Does your hospital have buprenorphine on the formulary for treatment of OUD? 
• Yes 
• No 






Appendix E: OHSU IRB Approved Semi-Structured Interview Guide 
 
ID #:           Date:   
 
Introduction 
My name is Kelsey Priest, and I am a fourth year MD/PhD student at Oregon Health & Science 
University (OHSU) and a doctoral student at OHSU-Portland State University School of Public 
Health in the Health Systems and Policy program. As part of the requirements of the doctoral 
program, I am conducting dissertation research to study the treatment of persons with opioid 
use disorder (OUD) in the hospital setting. As the [position of research participant] for the 
[hospital name], you have been identified as knowledgeable about the treatment of persons 
with opioid use disorder at [hospital name].  
 
This project is an opportunity to learn more about the health care service patterns of opioid 
agonist therapy (OAT) delivery in the hospital setting for persons with opioid use disorder. The 
purpose of this interview is to capture your perspectives about your organization’s hospital 
opioid use disorder care delivery policies, procedures, and practice, specifically:  
 
1. Hospital OUD care delivery policies, procedures, and practice. 
2. Barriers and facilitators to hospital OUD treatment and OAT delivery. 
3. Ideas or solutions for enhancing hospital OUD treatment and OAT delivery. 
 
The interview will last between 45 and 60 minutes, depending on the length of your answers. If 
you describe any hospital-based policies during the interview I will follow-up via email after the 
interview with a request to see them with your permission and I may also follow up with 
additional clarifying questions.   
 
Consent 
I have provided the consent form ahead of time, and I want to ensure that you are clear on the 
expectations of participation. I assume that your presence here today indicates you have read 
the consent form. Do you have any questions about your participation in this research study? I 
would now like to receive verbal consent to participate from you.  
 
<Obtain verbal consent> 
 
Audio Recording Instructions 
With your permission, I will take notes and record the interview. Your participation in this 
interview is voluntary; you do not have to answer any question that you do not want to answer 
and you may stop the interview at any time. All individual responses will be kept confidential.  
 
The recording and my notes will help me to accurately represent our discussion; no one else will 
ever hear the recordings or see the written transcripts. If there are things that you tell me that 
you do not wish repeated, please indicate this so that I do not include those comments in any 






Similarly, if at any time you would like me to stop recording, please indicate this and I will turn 
off the recorder. Findings will be reported in the aggregate with larger themes identified within 
and across hospitals. Quotes will be selected to illustrate these broader themes and will be 
presented without attribution to individuals. Do I have your permission to record this interview?  
 
<Obtain verbal consent, and turn on the recording device> 
 
At this time, do you have any other questions or concerns? 
 
<After addressing any questions and/or concerns> 
 
Then let us begin. 
 
Questions 
1. We will start with a brief demographic survey.  
 
<Reads questions from key informant demographic survey> 
 
2. Role and Introductions. Please tell me briefly about your role at your institution and 
within the hospital. 
 
3. Responsibility of Care. Who (what service) within the hospital is responsible for the 
clinical management of an OUD during hospitalization?  
a. Probe: Dependent on clinical scenario (e.g., surgical vs. non-surgical or acuity). 
 
4. Care Delivery Mechanisms. Does your hospital have an addiction consult service? 
a. If yes, when did the service start? What was the context or catalyst for this 
change? 
i. Probe: Since that time, what shifts in culture and/or stigma of persons 
with OUD or other addictive disorders have occurred?  
ii. Probe: How have hospital policies, procedures, or guidelines changed 
over time related to care for persons with OUD since the establishment 
of the service? 
iii. Probe: What were the facilitators for starting the service? 
1. Probe: Within the organization? 
2. Probe: Outside the organization? 
iv. Probe: What were the barriers to starting the service? 
1. Probe: Within the organization? 
2. Probe: Outside the organization? 
b. If no, is this something that is being considered? If not, why do you think that is? 
 
5. Addiction Consult Service Structure and Design. What is the current design of the 
addiction consult service? 






b. Probe: Describe the services provided by the consult service (e.g., medication 
management, pain consultation, harm reduction). 
c. Probe: Describe the availability of the service (e.g., weekdays only, 24-7 
coverage). 
 
6. Current Policies. What are your hospital’s current policies and procedures (e.g., 
guidelines) for OUD management and/or withdrawal?  
a. Probe: Specifically, does your hospital have policies or procedures on the 
continuation of methadone or buprenorphine for OUD treatment during 
hospitalization?   
i. If so, please describe the policies. 
ii. Have these changed over time? If yes, how so?  
b. Probe: Does your hospital have any policies or procedures on the induction of 
methadone or buprenorphine during hospitalization?  
i. If so, please describe the policies 
ii. Have these changed over time? If yes, how so? 
c. Probe: Does your hospital have any policies or procedures on the use of 
buprenorphine or methadone to manage withdrawal?  
i. If so, please describe the policies. 
ii. Have these changed over time? If yes, how so? 
d. Probe: If applicable, do these policies or procedures reflect practice generally?  
 
7. Organizational Barriers. What do you think are some of the organizational barriers to 
implementing policies and procedures for caring for persons with OUD at your hospital? 
a. Probe: Physical environment/location? 
b. Probe: Leadership? 
c. Probe: Resources and staffing? 
d. Probe: Policy implementation process? 
e. Probe: Hospital culture and understanding of OUD? 
 
8. External Barriers. What do you think are some of the external barriers to implementing 
policies and procedures for caring for persons with OUD at your hospital? 
a. Probe: Federal or local policies? (e.g., federal regulations or insurance 
regulations) 
b. Probe: System service delivery issues (e.g., care transitions)? 
c. Probe: Other local hospitals?  
 
9. Organizational Facilitators. What do you think are some of the organizational 
facilitators for implementing policies and procedures for caring for persons with opioid 
use disorder at your hospital? 
a. Probe: Physical environment/location? 
b. Probe: Leadership? 
c. Probe: Resources and staffing? 
d. Probe: Policy implementation process? 






10. External Facilitators. What do you think are some of the external facilitators for 
implementing policies and procedures for caring for persons with opioid use disorder at 
your hospital? 
a. Probe: Federal or local policies?  
b. Probe: System? 
c. Probe: Other local hospitals? 
 
11. Is there anything else that we have not discussed about the treatment of OUD in your 
hospital? 
 
Closing the Interview 
Thank you for participating in this interview, and for your thoughtful comments, insights and 
candor. I am meeting with approximately 19 other key informants from other hospitals across 
the United States. I will be analyzing and synthesizing the key themes and issues that emerge 
over the course of the study. If you think of anything else, please contact me. Findings from the 
interviews will be included in my dissertation and read by the OHSU-PSU School of Public Health 
faculty serving on my dissertation committee. At the conclusion of the study, I would be happy 
to share a report of the aggregated findings with you. May I contact you if I have any follow up 










1. Addiction Consult Service: Elements related to AMC service 239 
2. Culture and Practice Shift 9 
3. Design 44 
4. Historical Context 77 
5. Policy Influence 2 
6. Team Composition 32 
7. Care Delivery Topics: Elements related to OUD treatment within hospital 217 
8. Criminal Justice 5 
9. Culture Change 8 
10. Education 34 
11. Electronic Health Record 8 
12. Emergency Department 30 
13. Endocarditis 11 
14. Formulary 20 
15. Harm Reduction 12 
16. Injectable Naltrexone 2 
17. Linkage to Care 63 
18. Naloxone 11 
19. Non-evidence-based care 24 
20. Nursing involvement/initiative 10 
21. Pain Consult 12 
22. Peers 19 
23. Psychiatry Consult  36 
24. Script on DX 8 
25. Security and Public Safety 5 
26. Stigma 43 
27. Stimulant Use 5 
28. Tobacco/Nicotine 4 
29. Trainees 61 
30. Trauma 2 
31. Demand-Side Attributes: Elements related to patient characteristics 27 
32. Patient Characteristics 29 
33. External Environment: Elements external to the hospital influencing care 
delivery 66 
34. External Treatment Organizations 49 
35. Media Coverage 12 
36. Normative social structure 12 
37. Policies and Regulations 19 
38. Politics and Political Leadership 24 
39. Quality Metrics 9 
40. Hospital Policy: Policy and practice related to the treatment of OUD 205 
41. Aberrant Drug Use/Behavioral Agreement 25 
42. BYOD 1 
43. Induction 43 
44. OAT continuation 23 





46. Pain Management 24 
47. Policy Frame 5 
48. Policy Process 22 
49. Pregnancy 16 
50. Security 6 
51. Withdrawal Management 47 
52. Hospital Supply-Side Attributes: Elements within the hospital influencing 
care 92 
53. Leadership 44 
54. Location/Geography 3 
55. Misunderstanding of Policy 13 
56. Normative Social Structures 18 
57. Research, Evaluation, Data 22 
58. Resources and Staffing 71 
59. Stakeholders 8 
60. Other Models of Care 62 
61. Ad Hoc Consults 13 
62. Bridge Clinic 6 
63. Detox 20 
64. Longitudinal Care (within the same institution) 4 
65. OTP 33 
66. Service or Policy Design Lever 21 
67. Financing: Elements related to financing care and delivery of services for 





Appendix G: RStudio Packages 
dunn.test 
 Dinno, A. (2017). Dunn.test: Dunn's Test of multiple comparisons using rank sums. 
Retrieved from https://CRAN.R-project.org/package=dunn.test 
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 Wasey, J. O. (2018). icd: Comorbidity calculations and tools for ICD-9 and ICD-10 codes. 
Retrieved from https://CRAN.R-project.org/package=icd 
 
plyr 
 Wickham, H. (2011). plyr: The split-apply-combine strategy for data analysis. Journal of 
Statistical Software, 40(1). doi:10.18637/jss.v040.i01  
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Appendix H: OUD Diagnosis Codes Queried 
ICD-10-CM 
Code ICD-10-CM Description 
F11.10 Opioid abuse, uncomplicated 
F11.11 Opioid abuse, in remission 
F11.120 Opioid abuse with intoxication, uncomplicated 
F11.121 Opioid abuse with intoxication delirium 
F11.122 Opioid abuse with intoxication with perceptual disturbance 
F11.129 Opioid abuse with intoxication, unspecified 
F11.14 Opioid abuse with opioid-induced mood disorder 
F11.150 Opioid abuse with opioid-induced psychotic disorder with delusions 
F11.151 Opioid abuse with opioid-induced psychotic disorder with hallucinations 
F11.159 Opioid abuse with opioid-induced psychotic disorder, unspecified 
F11.181 Opioid abuse with opioid-induced sexual dysfunction 
F11.182 Opioid abuse with opioid-induced sleep disorder 
F11.188 Opioid abuse with other opioid-induced disorder 
F11.19 Opioid abuse with unspecified opioid-induced disorder 
F11.20 Opioid dependence, uncomplicated 
F11.220 Opioid dependence with intoxication, uncomplicated 
F11.21 Opioid dependence, in remission 
F11.221 Opioid dependence with intoxication delirium 
F11.222 Opioid dependence with intoxication with perceptual disturbance 
F11.229 Opioid dependence with intoxication, unspecified 
F11.23 Opioid dependence with withdrawal 
F11.24 Opioid dependence with opioid-induced mood disorder 
F11.250 Opioid dependence with opioid-induced psychotic disorder with delusions 
F11.251 Opioid dependence with opioid-induced psychotic disorder with hallucinations 
F11.259 Opioid dependence with opioid-induced psychotic disorder, unspecified 
F11.281 Opioid dependence with opioid-induced sexual dysfunction 
F11.282 Opioid dependence with opioid-induced sleep disorder 
F11.288 Opioid dependence with other opioid-induced disorder 
F11.29 Opioid dependence with unspecified opioid-induced disorder 
F11.90 Opioid use, unspecified, uncomplicated 
F11.920 Opioid use, unspecified, with intoxication, uncomplicated 
F11.921 Opioid use, unspecified, with intoxication delirium 
F11.922 Opioid use, unspecified, with intoxication with perceptual disturbance 
F11.929 Opioid use, unspecified, with intoxication, unspecified 
F11.93 Opioid use, unspecified with withdrawal 
F11.94 Opioid use, unspecified with opioid-induced mood disorder 
F11.950 Opioid use, unspecified with opioid-induced psychotic disorder with delusions 
F11.951 
Opioid use, unspecified with opioid-induced psychotic disorder with 
hallucinations 





F11.981 Opioid use, unspecified with opioid-induced sexual dysfunction 
F11.982 Opioid use, unspecified with opioid-induced sleep disorder 
F11.988 Opioid use, unspecified with other opioid-induced 
F11.99 Opioid use, unspecified with unspecified opioid-induced disorder 
T40.0X1A Poisoning by opium, accidental (unintentional), initial encounter 
T40.0X1D Poisoning by opium, accidental (unintentional), subsequent encounter 
T40.0X1S Poisoning by opium, accidental (unintentional), sequelae 
T40.0X4A Poisoning by opium, undetermined, initial encounter 
T40.0X4D Poisoning by opium, undetermined, subsequent encounter 
T40.0X4S Poisoning by opium, undetermined, sequelae 
T40.0X5A Adverse effect of opium, initial encounter 
T40.0X5D Adverse effect of opium, subsequent encounter 
T40.0X5S Adverse effect of opium, sequelae 
T40.1X1A Poisoning by heroin, accidental (unintentional), initial encounter 
T40.1X1D Poisoning by heroin, accidental (unintentional), subsequent encounter 
T40.1X1S Poisoning by heroin, accidental (unintentional), sequelae 
T40.1X4A Poisoning by heroin, undetermined, initial encounter 
T40.1X4D Poisoning by heroin, undetermined, subsequent encounter 
T40.1X4S Poisoning by heroin, undetermined, sequelae 
T40.2X1A Poisoning by other opioids, accidental (unintentional), initial encounter 
T40.2X1D Poisoning by other opioids, accidental (unintentional), subsequent encounter 
T40.2X1S Poisoning by other opioids, accidental (unintentional), sequelae 
T40.2X4A Poisoning by other opioids, undetermined, initial encounter 
T40.2X4D Poisoning by other opioids, undetermined, subsequent encounter 
T40.2X4S Poisoning by other opioids, undetermined, sequelae 
T40.2X5A Adverse effect of other opioids, initial encounter 
T40.2X5D Adverse effect of other opioids, subsequent encounter 
T40.2X5S Adverse effect of other opioids, sequelae 
T40.3X1A Poisoning by methadone, accidental (unintentional), initial encounter 
T40.3X1D Poisoning by methadone, accidental (unintentional), subsequent encounter 
T40.3X1S Poisoning by methadone, accidental (unintentional), sequelae 
T40.3X4A Poisoning by methadone, undetermined, initial encounter 
T40.3X4D Poisoning by methadone, undetermined, subsequent encounter 
T40.3X4S Poisoning by methadone, undetermined, sequelae 
T40.3X5A Adverse effect of methadone, initial encounter 
T40.3X5D Adverse effect of methadone, subsequent encounter 
T40.3X5S Adverse effect of methadone, sequelae 
T40.4X1A Poisoning by synthetic narcotics, accidental (unintentional), initial encounter 
T40.4X1D 
Poisoning by synthetic narcotics, accidental (unintentional), subsequent 
encounter 
T40.4X1S Poisoning by synthetic narcotics, accidental (unintentional), sequelae 
T40.4X4A Poisoning by synthetic narcotics, undetermined, initial encounter 
T40.4X4D Poisoning by synthetic narcotics, undetermined, subsequent encounter 
T40.4X4S Poisoning by synthetic narcotics, undetermined, sequelae 





T40.4X5D Adverse effect of synthetic narcotic, subsequent encounter 
T40.4X5S Adverse effect of synthetic narcotic, sequelae 
T40.601A Poisoning by unspecified narcotics, accidental (unintentional), initial encounter 
T40.601D 
Poisoning by unspecified narcotics, accidental (unintentional), subsequent 
encounter 
T40.601S Poisoning by unspecified narcotics, accidental (unintentional), sequelae 
T40.604A Poisoning by unspecified narcotics, undetermined, initial encounter 
T40.604D Poisoning by unspecified narcotics, undetermined, subsequent encounter 
T40.604S Poisoning by unspecified narcotics, undetermined, sequelae 
T40.605A Adverse effect of unspecified narcotics, initial encounter 
T40.605D Adverse effect of unspecified narcotics, subsequent encounter 
T40.605S Adverse effect of unspecified narcotics, sequelae 
T40.691A Poisoning by other narcotics, accidental (unintentional), initial encounter 
T40.691D Poisoning by other narcotics, accidental (unintentional), subsequent encounter 
T40.691S Poisoning by other narcotics, accidental (unintentional), sequelae 
T40.694A Poisoning by other narcotics, undetermined, initial encounter 
T40.694D Poisoning by other narcotics, undetermined, subsequent encounter 
T40.694S Poisoning by other narcotics, undetermined, sequelae 
T40.695A Adverse effect of other narcotics, initial encounter 
T40.695D Adverse effect of other narcotics, subsequent encounter 




















































132 Unique Facilities  
15,136 Unique Index Hospitalizations  
109 Unique Facilities 
12,407 Unique Index Hospitalizations 
 
139 Unique Facilities  
15,420 Unique Index Hospitalizations 
Step 1. Exclude Puerto Rico facility 
(hospitals = 1; cases = 134). 
 
Step 2. Exclude facilities with bed category 
discrepancies (hospitals = 6; cases = 141). 
 
Step 3. Exclude cases with non-Hospital place 
admissions (cases = 7) or missing place of 
admission (cases = 2). 
 
 
Step 4. Exclude cases missing primary or 
secondary admission diagnosis (n = 271). 
 
Step 5. Exclude cases with inconsistent death 
variable (cases = 4); lost a facility here 
(hospitals = 1). 
 
Step 6. Exclude cases with cancer flag (see 
definition in next section) —solid tumor w/o 
metastatic, metastatic cancer, and lymphoma 
(cases = 2062). 
 
Step 7. Exclude cases with a length of stay >= 
51 days (99th percentile) (cases = 130); lost a 







Step 8. Excluded facilities based on minimum 
observations < 25 (hospitals = 21; cases = 
262). 
130 Unique Facilities 






Appendix J: Patient and Hospital Study Cohort Definitions 
Acronyms 
CDW = corporate data warehouse; VHA = Veterans Health Administration. 
 
Index Hospitalization 
Index hospitalization was defined as the first acute hospitalization per patient with an OUD 
diagnosis as defined below in the VHA 2017 fiscal year (discharge date between 10/1/2016 and 
10/1/2017). Index hospitalizations were included in the study cohort for an OUD diagnosis at the 
time of hospitalization in any of the “Present on Admission” fields or any number of the 
diagnosis fields for that hospital stay or any OUD diagnosis for any encounter outpatient or 
inpatient within the 12 months prior to index hospitalization.  
 
OUD Diagnosis  
Patients with an OUD diagnosis, from any source, inpatient or outpatient, between 10/1/2015 
and 10/1/2017 in the year preceding the discharge date of index hospitalization. This could 
include an OUD diagnosis during index hospitalization and the diagnosis could be at any of the 
24 diagnoses positions. 
 
Hospitalization fields searched 
1. Present on admission: “Inpat.PresentOnAdmission” 
2. Summary diagnoses: “Inpat.InpatientDiagnosis”  
3. Discharge diagnoses: “Inpat.InpatientDischargeDiagnosis”  
4. Diagnoses associated with patient transfer within the hospital: 
“Inpat.PatientTransferDiagnosis”  
5.  Diagnoses associated with specialty transfer within the hospital: 
“Inpat.SpecialtyTransferDiagnosis”  
6. Fee Basis inpatient diagnoses tables 
 
Outpatient fields searched 
1. Outpatient diagnosis table 
2. Fee Basis Outpatient diagnoses tables 
  
Identification of Cancer Codes: Present on Admission 
Comorbidities were identified in several sources within the CDW (Outpatient, Outpatient FEE 
BASIS, Inpatient Diagnosis, Inpatient Discharge, Inpatient Transfer Diagnosis, Inpatient Present 
on Admission, Inpatient Specialty Transfer Diagnosis, Inpatient FEE BASIS). At least one ICD10 
diagnosis was present for a patient to receive a flag. Conditions were identified within 365 days 
prior to the index admission date. The Elixhauser classification system (Agency for Healthcare 
Research and Quality, 2018) was used: LYMPH  = 'Lymphoma'; METS  = 'Metastatic cancer'; 
TUMOR   = 'Solid tumor w/out metastasis.’ 
 
Hospital Selection 
Included hospitals were restricted to “acute care hospitals” from a report produced internally at 
the VHA, which only included hospitals with at least 500 “acute” bed days of service during fiscal 








Hospital size was defined by the number of operating beds from a document downloaded from 
the VHA Support Service Center reporting portal. Operating beds were staffed and available for 
admission of patients. The operating bed count did not include unavailable beds. Occupancy 
rates were determined for each facility based on current approved operating bed levels. 
Further, the bed type was restricted to “acute” (e.g., internal medicine, surgery, neurology) and 
did not include counts for nursing beds or hospice beds (e.g., beds that cannot accommodate 
acute care patients). 
 
Hospital Identifier 
The hospital identifier, the parent facility, was created by using the VHA station number. A 






Appendix K: Patient and Admission Definitions 
Acronyms 
CDW = corporate data warehouse; VHA = Veterans Health Administration; SUD = substance use 
disorder; OUD= opioid use disorder. 
 
Age 
Calculated continuous variable for age of patient on the index hospitalization admission date. 
Values ranged from 21 to 90. Patients aged > 90 were listed at 90. 
 
Co-Occurring Mental Health Condition: Present on Admission  
Co-occurring mental health conditions were identified in several sources within the CDW 
(Outpatient, Outpatient FEE BASIS, Inpatient Diagnosis, Inpatient Discharge, Inpatient Transfer 
Diagnosis, Inpatient Present on Admission, Inpatient Specialty Transfer Diagnosis, Inpatient FEE 
BASIS). At least one ICD-10 diagnosis must have been present for a patient to receive a positive 
flag. See Appendix L for ICD-10 code list. Conditions were identified within 365 days prior to the 
index hospitalization admission date: Adjustment disorder other; anxiety disorder; mood 
disorder; non-mood psychotic disorder; post-traumatic stress disorder; and self-harm.  
 
Co-Occurring SUD: Present on Admission  
Co-occurring SUDs were identified in several sources within the CDW (Outpatient, Outpatient 
FEE BASIS, Inpatient Diagnosis, Inpatient Discharge, Inpatient Transfer Diagnosis, Inpatient 
Present on Admission, Inpatient Specialty Transfer Diagnosis, Inpatient FEE BASIS). At least one 
ICD-10 diagnosis must have been present for a patient to receive a positive flag. See Appendix L 
for ICD-10 code list. Conditions were identified within 365 days prior to the index hospitalization 
admission date: Alcohol use disorder; cannabis use disorder; cocaine use disorder; hallucinogen 
use disorder; nicotine dependence; other psychoactive use disorders; other stimulant related 
disorders; other substance use disorder; and sedative hypnotic disorder. 
 
Gender 
VHA variable for gender of the patient: male or female. 
 
Ethnicity 
VHA variable describing the patient’s ethnicity: Not Hispanic or Latino; Hispanic Or Latino; and 
Unknown. 
 
OUD-Related Infection: During Admission 
OUD-related infections during index hospitalization were captured using the following tables 
from the CDW: Inpatient Diagnosis, Inpatient Discharge, Inpatient Transfer Diagnosis, Inpatient 
Present on Admission, Inpatient Specialty Transfer Diagnosis. The presence of a least one ICD-10 
diagnosis in one of those tables must have been present during admission for a patient to 
receive a positive flag. See Appendix M for ICD-10 code list: Endocarditis; candida endocarditis; 
osteomyelitis; bacteremia; discitis; septic arthritis; brain abscess; joint infection; necrotizing 







OUD-Related Diagnosis: During Admission 
An OUD-related diagnosis during admission occurred in either the primary or secondary 
diagnosis code location for the index hospitalization from the “Inpat.InpatientDiagnosis” table. 
The ICD-10 codes were transformed using the ICD Rstudio package (Wasey, 2018). 
 
• All OUD Codes: Primary: A variable that indicates whether an F or T code for OUD was 
in the primary diagnosis position. Included codes are listed in Appendix H. 
 
• All OUD Codes: Secondary: A variable that indicates whether an F or T code for OUD 
was in the secondary. Included codes are listed in Appendix H. 
 
• Any OUD Code: A primary or secondary OUD code. Included codes are listed in 
Appendix H. 
 
Primary or Secondary Diagnosis Code: During Admission  
The primary or secondary diagnosis code captured the primary or secondary diagnosis codes for 
the index hospitalization from the “Inpat.InpatientDiagnosis” table. The ICD-10 codes were 
transformed using the ICD RStudio package (Wasey, 2018). 
 
Race 
The race variable used in this study was the “Race 1” category. The original 8 categories were 
collapsed to 6 categories: Unknown; Native American; Black; Asian; Native Islander; and White. 
 
Admission Source 
The admission source variable indicated the source for the admission. These entries come from 
VISTA, and each local health care system devises their own coding scheme and abbreviations. 
The original 18 categories were collapsed into 3 categories: outpatient treatment; other direct 
admission; and other. 
 
ICU Services Received  
The ICU variable indicated whether there was an ICU bed stay (i.e., medical, surgical, cardiac, 
neurosurgery) associated with the index hospitalization.  
 
Surgical Services Received 
The surgical services variable indicated whether there was a surgery bed stay (i.e., general 
surgery, cardiac surgery, surgical step-down, thoracic surgery, oral surgery, plastic surgery) 
associated with the index hospitalization.  
 
Length of Stay 
The length of stay variable was calculated based on the number of days of index hospitalization. 
If admitted/discharged on the same day this was represented as 1 day.  The values ranged from 






Appendix L: Co-Occurring Mental Health and Substance Use Disorder  
Diagnosis Codes Queried 
ICD10 
Code ICD10 Long Description 
F4321 Adjustment disorder with depressed mood 
F4322  Adjustment disorder with anxiety 
F4323 Adjustment disorder with mixed anxiety and depressed mood 
F4324  Adjustment disorder with disturbance of conduct 
F4325  Adjustment disorder with mixed disturbance of emotions and conduct 
F4329 Adjustment disorder with other symptoms 
F438 Other reactions to severe stress 
F439 Reaction to severe stress, unspecified 
F4320 Adjustment disorders, unspecified 
F1010 Alcohol abuse, uncomplicated 
F10120 Alcohol abuse with intoxication, uncomplicated 
F10121 Alcohol abuse with intoxication delirium 
F10129 Alcohol abuse with intoxication, unspecified 
F1014 Alcohol abuse with alcohol-induced mood disorder 
F10150 Alcohol abuse with alcohol-induced psychotic disorder with delusions 
F10151 Alcohol abuse with alcohol-induced psychotic disorder with hallucinations 
F10159 Alcohol abuse with alcohol-induced psychotic disorder, unspecified 
F10180 Alcohol abuse with alcohol-induced anxiety disorder 
F10181 Alcohol abuse with alcohol-induced sexual dysfunction 
F10182 Alcohol abuse with alcohol-induced sleep disorder 
F10188 Alcohol abuse with other alcohol-induced disorder 
F1019 Alcohol abuse with unspecified alcohol-induced disorder 
F1020 Alcohol dependence, uncomplicated 
F1021 Alcohol dependence, in remission 
F10220 Alcohol dependence with intoxication, uncomplicated 
F10221 Alcohol dependence with intoxication delirium 
F10229 Alcohol dependence with intoxication, unspecified 
F10230 Alcohol dependence with withdrawal, uncomplicated 
F10231 Alcohol dependence with withdrawal delirium 
F10232 Alcohol dependence with withdrawal with perceptual disturbance 
F10239 Alcohol dependence with withdrawal, unspecified 
F1024 Alcohol dependence with alcohol-induced mood disorder 
F10250 Alcohol dependence with alcohol-induced psychotic disorder with delusions 





F10259 Alcohol dependence with alcohol-induced psychotic disorder, unspecified 
F1026 Alcohol dependence with alcohol-induced persisting amnestic disorder 
F1027 Alcohol dependence with alcohol-induced persisting dementia 
F10280 Alcohol dependence with alcohol-induced anxiety disorder 
F10281 Alcohol dependence with alcohol-induced sexual dysfunction 
F10282 Alcohol dependence with alcohol-induced sleep disorder 
F10288 Alcohol dependence with other alcohol-induced disorder 
F1029 Alcohol dependence with unspecified alcohol-induced disorder 
F10920 Alcohol use, unspecified with intoxication, uncomplicated 
F10921 Alcohol use, unspecified with intoxication delirium 
F10929 Alcohol use, unspecified with intoxication, unspecified 
F1094 Alcohol use, unspecified with alcohol-induced mood disorder 
F10950 Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions 
F10951 Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations 
F10959 Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified 
F1096 Alcohol use, unspecified with alcohol-induced persisting amnestic disorder 
F1097 Alcohol use, unspecified with alcohol-induced persisting dementia 
F10980 Alcohol use, unspecified with alcohol-induced anxiety disorder 
F10981 Alcohol use, unspecified with alcohol-induced sexual dysfunction 
F10982 Alcohol use, unspecified with alcohol-induced sleep disorder 
F10988 Alcohol use, unspecified with other alcohol-induced disorder 
F1099 Alcohol use, unspecified with unspecified alcohol-induced disorder 
F4000 Agoraphobia, unspecified 
F4001 Agoraphobia with panic disorder 
F4002 Agoraphobia without panic disorder 
F4010 Social phobia, unspecified 
F4011 Social phobia, generalized 
F40210 Arachnophobia 
F40218 Other animal type phobia 
F40220 Fear of thunderstorms 
F40228 Other natural environment type phobia 
F40230 Fear of blood 
F40231 Fear of injections and transfusions 
F40232 Fear of other medical care 
F40233 Fear of injury 
F40240 Claustrophobia 
F40241 Acrophobia 
F40242 Fear of bridges 





F40248 Other situational type phobia 
F40290 Androphobia 
F40291 Gynephobia 
F40298 Other specified phobia 
F408 Other phobic anxiety disorders 
F409 Phobic anxiety disorder, unspecified 
F410 Panic disorder [episodic paroxysmal anxiety] without agoraphobia 
F411 Generalized anxiety disorder 
F413 Other mixed anxiety disorders 
F418 Other specified anxiety disorders 
F419 Anxiety disorder, unspecified 
F42 Obsessive-compulsive disorder 
F1210 Cannabis abuse, uncomplicated 
F12120 Cannabis abuse with intoxication, uncomplicated 
F12121 Cannabis abuse with intoxication delirium 
F12122 Cannabis abuse with intoxication with perceptual disturbance 
F12129 Cannabis abuse with intoxication, unspecified 
F12150 Cannabis abuse with psychotic disorder with delusions 
F12151 Cannabis abuse with psychotic disorder with hallucinations 
F12159 Cannabis abuse with psychotic disorder, unspecified 
F12180 Cannabis abuse with cannabis-induced anxiety disorder 
F12188 Cannabis abuse with other cannabis-induced disorder 
F1219 Cannabis abuse with unspecified cannabis-induced disorder 
F1220 Cannabis dependence, uncomplicated 
F1221 Cannabis dependence, in remission 
F12220 Cannabis dependence with intoxication, uncomplicated 
F12221 Cannabis dependence with intoxication delirium 
F12222 Cannabis dependence with intoxication with perceptual disturbance 
F12229 Cannabis dependence with intoxication, unspecified 
F12250 Cannabis dependence with psychotic disorder with delusions 
F12251 Cannabis dependence with psychotic disorder with hallucinations 
F12259 Cannabis dependence with psychotic disorder, unspecified 
F12280 Cannabis dependence with cannabis-induced anxiety disorder 
F12288 Cannabis dependence with other cannabis-induced disorder 
F1229 Cannabis dependence with unspecified cannabis-induced disorder 
F1290 Cannabis use, unspecified, uncomplicated 
F12920 Cannabis use, unspecified with intoxication, uncomplicated 
F12921 Cannabis use, unspecified with intoxication delirium 





F12929 Cannabis use, unspecified with intoxication, unspecified 
F12950 Cannabis use, unspecified with psychotic disorder with delusions 
F12951 Cannabis use, unspecified with psychotic disorder with hallucinations 
F12959 Cannabis use, unspecified with psychotic disorder, unspecified 
F12980 Cannabis use, unspecified with anxiety disorder 
F12988 Cannabis use, unspecified with other cannabis-induced disorder 
F1299 Cannabis use, unspecified with unspecified cannabis-induced disorder 
F14121 Cocaine abuse with intoxication with delirium 
F14122 Cocaine abuse with intoxication with perceptual disturbance 
F14129 Cocaine abuse with intoxication, unspecified 
F1414 Cocaine abuse with cocaine-induced mood disorder 
F14150 Cocaine abuse with cocaine-induced psychotic disorder with delusions 
F14151 Cocaine abuse with cocaine-induced psychotic disorder with hallucinations 
F14159 Cocaine abuse with cocaine-induced psychotic disorder, unspecified 
F14180 Cocaine abuse with cocaine-induced anxiety disorder 
F14181 Cocaine abuse with cocaine-induced sexual dysfunction 
F14182 Cocaine abuse with cocaine-induced sleep disorder 
F14188 Cocaine abuse with other cocaine-induced disorder 
F1419 Cocaine abuse with unspecified cocaine-induced disorder 
F14220 Cocaine dependence with intoxication, uncomplicated 
F14221 Cocaine dependence with intoxication delirium 
F14222 Cocaine dependence with intoxication with perceptual disturbance 
F14229 Cocaine dependence with intoxication, unspecified 
F1423 Cocaine dependence with withdrawal 
F1424 Cocaine dependence with cocaine-induced mood disorder 
F14250 Cocaine dependence with cocaine-induced psychotic disorder with delusions 
F14251 Cocaine dependence with cocaine-induced psychotic disorder with hallucinations 
F14259 Cocaine dependence with cocaine-induced psychotic disorder, unspecified 
F14280 Cocaine dependence with cocaine-induced anxiety disorder 
F14281 Cocaine dependence with cocaine-induced sexual dysfunction 
F14282 Cocaine dependence with cocaine-induced sleep disorder 
F14288 Cocaine dependence with other cocaine-induced disorder 
F1429 Cocaine dependence with unspecified cocaine-induced disorder 
F14920 Cocaine use, unspecified with intoxication, uncomplicated 
F14921 Cocaine use, unspecified with intoxication delirium 
F14922 Cocaine use, unspecified with intoxication with perceptual disturbance 
F14929 Cocaine use, unspecified with intoxication, unspecified 
F1494 Cocaine use, unspecified with cocaine-induced mood disorder 





F14951 Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations 
F14959 Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified 
F14980 Cocaine use, unspecified with cocaine-induced anxiety disorder 
F14981 Cocaine use, unspecified with cocaine-induced sexual dysfunction 
F14982 Cocaine use, unspecified with cocaine-induced sleep disorder 
F14988 Cocaine use, unspecified with other cocaine-induced disorder 
F1499 Cocaine use, unspecified with unspecified cocaine-induced disorder 
F1610 Hallucinogen abuse, uncomplicated 
F16120 Hallucinogen abuse with intoxication, uncomplicated 
F16121 Hallucinogen abuse with intoxication with delirium 
F16122 Hallucinogen abuse with intoxication with perceptual disturbance 
F16129 Hallucinogen abuse with intoxication, unspecified 
F1614 Hallucinogen abuse with hallucinogen-induced mood disorder 
F16150 Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions 
F16151 Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations 
F16159 Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified 
F16180 Hallucinogen abuse with hallucinogen-induced anxiety disorder 
F16183 Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks) 
F16188 Hallucinogen abuse with other hallucinogen-induced disorder 
F1619 Hallucinogen abuse with unspecified hallucinogen-induced disorder 
F1620 Hallucinogen dependence, uncomplicated 
F1621 Hallucinogen dependence, in remission 
F16220 Hallucinogen dependence with intoxication, uncomplicated 
F16221 Hallucinogen dependence with intoxication with delirium 
F16229 Hallucinogen dependence with intoxication, unspecified 
F1624 Hallucinogen dependence with hallucinogen-induced mood disorder 
F16250 Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions 
F16251 Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations 
F16259 Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified 
F16280 Hallucinogen dependence with hallucinogen-induced anxiety disorder 
F16283 Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks) 
F16288 Hallucinogen dependence with other hallucinogen-induced disorder 
F1629 Hallucinogen dependence with unspecified hallucinogen-induced disorder 
F1690 Hallucinogen use, unspecified, uncomplicated 
F16920 Hallucinogen use, unspecified with intoxication, uncomplicated 
F16921 Hallucinogen use, unspecified with intoxication with delirium 
F16929 Hallucinogen use, unspecified with intoxication, unspecified 
F1694 Hallucinogen use, unspecified with hallucinogen-induced mood disorder 






Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with 
hallucinations 
F16959 Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified 
F16980 Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder 
F16983 Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks) 
F16988 Hallucinogen use, unspecified with other hallucinogen-induced disorder 
F1699 Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder 
F18121 Inhalant abuse with intoxication delirium 
F18129 Inhalant abuse with intoxication, unspecified 
F1814 Inhalant abuse with inhalant-induced mood disorder 
F18150 Inhalant abuse with inhalant-induced psychotic disorder with delusions 
F18151 Inhalant abuse with inhalant-induced psychotic disorder with hallucinations 
F18159 Inhalant abuse with inhalant-induced psychotic disorder, unspecified 
F1817 Inhalant abuse with inhalant-induced dementia 
F18180 Inhalant abuse with inhalant-induced anxiety disorder 
F18188 Inhalant abuse with other inhalant-induced disorder 
F1819 Inhalant abuse with unspecified inhalant-induced disorder 
F1824 Inhalant dependence with inhalant-induced mood disorder 
F18250 Inhalant dependence with inhalant-induced psychotic disorder with delusions 
F18251 Inhalant dependence with inhalant-induced psychotic disorder with hallucinations 
F18259 Inhalant dependence with inhalant-induced psychotic disorder, unspecified 
F1827 Inhalant dependence with inhalant-induced dementia 
F18280 Inhalant dependence with inhalant-induced anxiety disorder 
F18288 Inhalant dependence with other inhalant-induced disorder 
F1829 Inhalant dependence with unspecified inhalant-induced disorder 
F18920 Inhalant use, unspecified with intoxication, uncomplicated 
F18921 Inhalant use, unspecified with intoxication with delirium 
F18929 Inhalant use, unspecified with intoxication, unspecified 
F1894 Inhalant use, unspecified with inhalant-induced mood disorder 
F18950 Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions 
F18951 Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations 
F18959 Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified 
F1897 Inhalant use, unspecified with inhalant-induced persisting dementia 
F18980 Inhalant use, unspecified with inhalant-induced anxiety disorder 
F18988 Inhalant use, unspecified with other inhalant-induced disorder 
F1899 Inhalant use, unspecified with unspecified inhalant-induced disorder 
F1810 Inhalant abuse, uncomplicated 
F18120 Inhalant abuse with intoxication, uncomplicated 
F1820 Inhalant dependence, uncomplicated 





F18220 Inhalant dependence with intoxication, uncomplicated 
F18221 Inhalant dependence with intoxication delirium 
F18229 Inhalant dependence with intoxication, unspecified 
F1890 Inhalant use, unspecified, uncomplicated 
F3010 Manic episode without psychotic symptoms, unspecified 
F3011 Manic episode without psychotic symptoms, mild 
F3012 Manic episode without psychotic symptoms, moderate 
F3013 Manic episode, severe, without psychotic symptoms 
F302 Manic episode, severe with psychotic symptoms 
F303 Manic episode in partial remission 
F304 Manic episode in full remission 
F308 Other manic episodes 
F309 Manic episode, unspecified 
F310 Bipolar disorder, current episode hypomanic 
F3110 Bipolar disorder, current episode manic without psychotic features, unspecified 
F3111 Bipolar disorder, current episode manic without psychotic features, mild 
F3112 Bipolar disorder, current episode manic without psychotic features, moderate 
F3113 Bipolar disorder, current episode manic without psychotic features, severe 
F312 Bipolar disorder, current episode manic severe with psychotic features 
F3130 Bipolar disorder, current episode depressed, mild or moderate severity, unspecified 
F3131 Bipolar disorder, current episode depressed, mild 
F3132 Bipolar disorder, current episode depressed, moderate 
F314 Bipolar disorder, current episode depressed, severe, without psychotic features 
F315 Bipolar disorder, current episode depressed, severe, with psychotic features 
F3160 Bipolar disorder, current episode mixed, unspecified 
F3161 Bipolar disorder, current episode mixed, mild 
F3162 Bipolar disorder, current episode mixed, moderate 
F3163 Bipolar disorder, current episode mixed, severe, without psychotic features 
F3164 Bipolar disorder, current episode mixed, severe, with psychotic features 
F3170 Bipolar disorder, currently in remission, most recent episode unspecified 
F3171 Bipolar disorder, in partial remission, most recent episode hypomanic 
F3172 Bipolar disorder, in full remission, most recent episode hypomanic 
F3173 Bipolar disorder, in partial remission, most recent episode manic 
F3174 Bipolar disorder, in full remission, most recent episode manic 
F3175 Bipolar disorder, in partial remission, most recent episode depressed 
F3176 Bipolar disorder, in full remission, most recent episode depressed 
F3177 Bipolar disorder, in partial remission, most recent episode mixed 
F3178 Bipolar disorder, in full remission, most recent episode mixed 





F3189 Other bipolar disorder 
F319 Bipolar disorder, unspecified 
F320 Major depressive disorder, single episode, mild 
F321 Major depressive disorder, single episode, moderate 
F322 Major depressive disorder, single episode, severe without psychotic features 
F323 Major depressive disorder, single episode, severe with psychotic features 
F324 Major depressive disorder, single episode, in partial remission 
F325 Major depressive disorder, single episode, in full remission 
F328 Other depressive episodes 
F329 Major depressive disorder, single episode, unspecified 
F330 Major depressive disorder, recurrent, mild 
F331 Major depressive disorder, recurrent, moderate 
F332 Major depressive disorder, recurrent severe without psychotic features 
F333 Major depressive disorder, recurrent, severe with psychotic symptoms 
F3340 Major depressive disorder, recurrent, in remission, unspecified 
F3341 Major depressive disorder, recurrent, in partial remission 
F3342 Major depressive disorder, recurrent, in full remission 
F339 Major depressive disorder, recurrent, unspecified 
F341 Dysthymic disorder 
F390 Unspecified mood [affective] disorder 
F17203 Nicotine dependence unspecified, with withdrawal 
F17208 Nicotine dependence, unspecified, with other nicotine-induced disorders 
F17209 Nicotine dependence, unspecified, with unspecified nicotine-induced disorders 
F17213 Nicotine dependence, cigarettes, with withdrawal 
F17218 Nicotine dependence, cigarettes, with other nicotine-induced disorders 
F17219 Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders 
F17223 Nicotine dependence, chewing tobacco, with withdrawal 
F17228 Nicotine dependence, chewing tobacco, with other nicotine-induced disorders 
F17229 Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders 
F17293 Nicotine dependence, other tobacco product, with withdrawal 
F17298 Nicotine dependence, other tobacco product, with other nicotine-induced disorders 
F17299 Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders 
F200 Paranoid schizophrenia 
F201 Disorganized schizophrenia 
F202 Catatonic schizophrenia 
F203 Undifferentiated schizophrenia 
F205 Residual schizophrenia 
F2081 Schizophreniform disorder 





F209 Schizophrenia, unspecified 
F22 Delusional disorders 
F23 Brief psychotic disorder 
F24 Shared psychotic disorder 
F250 Schizoaffective disorder, bipolar type 
F251 Schizoaffective disorder, depressive type 
F258 Other schizoaffective disorders 
F259 Schizoaffective disorder, unspecified 
F28 Other psychotic disorder not due to a substance or known physiological condition 
F29 Unspecified psychosis not due to a substance or known physiological condition 
F4489 Other dissociative and conversion disorders 
F1910 Other psychoactive substance abuse, uncomplicated 
F19120 Other psychoactive substance abuse with intoxication, uncomplicated 
F19121 Other psychoactive substance abuse with intoxication delirium 
F19122 Other psychoactive substance abuse with intoxication with perceptual disturbances 
F19129 Other psychoactive substance abuse with intoxication, unspecified 
F1914 Other psychoactive substance abuse with psychoactive substance-induced mood disorder 
F19150 
Other psychoactive substance abuse with psychoactive substance-induced psychotic 
disorder with delusions 
F19151 
Other psychoactive substance abuse with psychoactive substance-induced psychotic 
disorder with hallucinations 
F19159 
Other psychoactive substance abuse with psychoactive substance-induced psychotic 
disorder, unspecified 
F1916 
Other psychoactive substance abuse with psychoactive substance-induced persisting 
amnestic disorder 
F1917 
Other psychoactive substance abuse with psychoactive substance-induced persisting 
dementia 
F19180 Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder 
F19181 
Other psychoactive substance abuse with psychoactive substance-induced sexual 
dysfunction 
F19182 Other psychoactive substance abuse with psychoactive substance-induced sleep disorder 
F19188 Other psychoactive substance abuse with other psychoactive substance-induced disorder 
F1919 
Other psychoactive substance abuse with unspecified psychoactive substance-induced 
disorder 
F1920 Other psychoactive substance dependence, uncomplicated 
F1921 Other psychoactive substance dependence, in remission 
F19220 Other psychoactive substance dependence with intoxication, uncomplicated 
F19221 Other psychoactive substance dependence with intoxication delirium 
F19222 Other psychoactive substance dependence with intoxication with perceptual disturbance 
F19229 Other psychoactive substance dependence with intoxication, unspecified 
F19230 Other psychoactive substance dependence with withdrawal, uncomplicated 
F19231 Other psychoactive substance dependence with withdrawal delirium 





F19239 Other psychoactive substance dependence with withdrawal, unspecified 
F1924 
Other psychoactive substance dependence with psychoactive substance-induced mood 
disorder 
F19250 
Other psychoactive substance dependence with psychoactive substance-induced psychotic 
disorder with delusions 
F19251 
Other psychoactive substance dependence with psychoactive substance-induced psychotic 
disorder with hallucinations 
F19259 
Other psychoactive substance dependence with psychoactive substance-induced psychotic 
disorder, unspecified 
F1926 
Other psychoactive substance dependence with psychoactive substance-induced persisting 
amnestic disorder 
F1927 
Other psychoactive substance dependence with psychoactive substance-induced persisting 
dementia 
F19280 
Other psychoactive substance dependence with psychoactive substance-induced anxiety 
disorder 
F19281 
Other psychoactive substance dependence with psychoactive substance-induced sexual 
dysfunction 
F19282 
Other psychoactive substance dependence with psychoactive substance-induced sleep 
disorder 
F19288 
Other psychoactive substance dependence with other psychoactive substance-induced 
disorder 
F1929 
Other psychoactive substance dependence with unspecified psychoactive substance-
induced disorder 
F1990 Other psychoactive substance use, unspecified, uncomplicated 
F19920 Other psychoactive substance use, unspecified with intoxication, uncomplicated 
F19921 Other psychoactive substance use, unspecified with intoxication with delirium 
F19922 
Other psychoactive substance use, unspecified with intoxication with perceptual 
disturbance 
F19929 Other psychoactive substance use, unspecified with intoxication, unspecified 
F19930 Other psychoactive substance use, unspecified with withdrawal, uncomplicated 
F19931 Other psychoactive substance use, unspecified with withdrawal delirium 
F19932 Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance 
F19939 Other psychoactive substance use, unspecified with withdrawal, unspecified 
F1994 
Other psychoactive substance use, unspecified with psychoactive substance-induced mood 
disorder 
F19950 
Other psychoactive substance use, unspecified with psychoactive substance-induced 
psychotic disorder with delusions 
F19951 
Other psychoactive substance use, unspecified with psychoactive substance-induced 
psychotic disorder with hallucinations 
F19959 
Other psychoactive substance use, unspecified with psychoactive substance-induced 
psychotic disorder, unspecified 
F1996 
Other psychoactive substance use, unspecified with psychoactive substance-induced 
persisting amnestic disorder 
F1997 
Other psychoactive substance use, unspecified with psychoactive substance-induced 
persisting dementia 
F19980 
Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety 
disorder 
F19981 







Other psychoactive substance use, unspecified with psychoactive substance-induced sleep 
disorder 
F19988 
Other psychoactive substance use, unspecified with other psychoactive substance-induced 
disorder 
F1999 
Other psychoactive substance use, unspecified with unspecified psychoactive substance-
induced disorder 
F1510 Other stimulant abuse, uncomplicated 
F15120 Other stimulant abuse with intoxication, uncomplicated 
F15121 Other stimulant abuse with intoxication delirium 
F15122 Other stimulant abuse with intoxication with perceptual disturbance 
F15129 Other stimulant abuse with intoxication, unspecified 
F1514 Other stimulant abuse with stimulant-induced mood disorder 
F15150 Other stimulant abuse with stimulant-induced psychotic disorder with delusions 
F15151 Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations 
F15159 Other stimulant abuse with stimulant-induced psychotic disorder, unspecified 
F15180 Other stimulant abuse with stimulant-induced anxiety disorder 
F15181 Other stimulant abuse with stimulant-induced sexual dysfunction 
F15182 Other stimulant abuse with stimulant-induced sleep disorder 
F15188 Other stimulant abuse with other stimulant-induced disorder 
F1519 Other stimulant abuse with unspecified stimulant-induced disorder 
F1520 Other stimulant dependence, uncomplicated 
F1521 Other stimulant dependence, in remission 
F15220 Other stimulant dependence with intoxication, uncomplicated 
F15221 Other stimulant dependence with intoxication delirium 
F15222 Other stimulant dependence with intoxication with perceptual disturbance 
F15229 Other stimulant dependence with intoxication, unspecified 
F1523 Other stimulant dependence with withdrawal 
F1524 Other stimulant dependence with stimulant-induced mood disorder 
F15250 Other stimulant dependence with stimulant-induced psychotic disorder with delusions 
F15251 Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations 
F15259 Other stimulant dependence with stimulant-induced psychotic disorder, unspecified 
F15280 Other stimulant dependence with stimulant-induced anxiety disorder 
F15281 Other stimulant dependence with stimulant-induced sexual dysfunction 
F15282 Other stimulant dependence with stimulant-induced sleep disorder 
F15288 Other stimulant dependence with other stimulant-induced disorder 
F1529 Other stimulant dependence with unspecified stimulant-induced disorder 
F1590 Other stimulant use, unspecified, uncomplicated 
F15920 Other stimulant use, unspecified with intoxication, uncomplicated 
F15921 Other stimulant use, unspecified with intoxication delirium 
F15922 Other stimulant use, unspecified with intoxication with perceptual disturbance 





F1593 Other stimulant use, unspecified with withdrawal 
F1594 Other stimulant use, unspecified with stimulant-induced mood disorder 
F15950 Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions 
F15951 
Other stimulant use, unspecified with stimulant-induced psychotic disorder with 
hallucinations 
F15959 Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified 
F15980 Other stimulant use, unspecified with stimulant-induced anxiety disorder 
F15981 Other stimulant use, unspecified with stimulant-induced sexual dysfunction 
F15982 Other stimulant use, unspecified with stimulant-induced sleep disorder 
F15988 Other stimulant use, unspecified with other stimulant-induced disorder 
F1599 Other stimulant use, unspecified with unspecified stimulant-induced disorder 
F550 Abuse of antacids 
F551 Abuse of herbal or folk remedies 
F552 Abuse of laxatives 
F553 Abuse of steroids or hormones 
F554 Abuse of vitamins 
F558 Abuse of other non-psychoactive substances 
O99320 Drug use complicating pregnancy, unspecified trimester 
O99321 Drug use complicating pregnancy, first trimester 
O99322 Drug use complicating pregnancy, second trimester 
O99323 Drug use complicating pregnancy, third trimester 
O99324 Drug use complicating childbirth 
O99325 Drug use complicating the puerperium 
F4310 Post-traumatic stress disorder, unspecified 
F4311 Post-traumatic stress disorder, acute 
F4312 Post-traumatic stress disorder, chronic 
F13121 Sedative, hypnotic or anxiolytic abuse with intoxication delirium 
F13129 Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified 
F1314 
Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood 
disorder 
F13150 
Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced 
psychotic disorder with delusions 
F13151 
Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced 
psychotic disorder with hallucinations 
F13159 
Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced 
psychotic disorder, unspecified 
F13180 
Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety 
disorder 
F13181 
Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual 
dysfunction 
F13182 
Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep 
disorder 
F13188 







Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-
induced disorder 
F13220 Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated 
F13221 Sedative, hypnotic or anxiolytic dependence with intoxication delirium 
F13229 Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified 
F13230 Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated 
F13231 Sedative, hypnotic or anxiolytic dependence with withdrawal delirium 
F13232 Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance 
F13239 Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified 
F1324 
Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced 
mood disorder 
F13250 
Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced 
psychotic disorder with delusions 
F13251 
Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced 
psychotic disorder with hallucinations 
F13259 
Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced 
psychotic disorder, unspecified 
F1326 
Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced 
persisting amnestic disorder 
F1327 
Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced 
persisting dementia 
F13280 
Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced 
anxiety disorder 
F13281 
Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced 
sexual dysfunction 
F13282 
Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced 
sleep disorder 
F13288 
Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-
induced disorder 
F1329 
Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or 
anxiolytic-induced disorder 
F13920 Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated 
F13921 Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium 
F13929 Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified 
F13930 Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated 
F13931 Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium 
F13932 
Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual 
disturbances 
F13939 Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified 
F1394 
Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-
induced mood disorder 
F13950 
Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-
induced psychotic disorder with delusions 
F13951 
Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-
induced psychotic disorder with hallucinations 
F13959 
Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-






Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-
induced persisting amnestic disorder 
F1397 
Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-
induced persisting dementia 
F13980 
Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-
induced anxiety disorder 
F13981 
Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-
induced sexual dysfunction 
F13982 
Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-
induced sleep disorder 
F13988 
Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-
induced disorder 
F1399 
Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or 
anxiolytic-induced disorder 
T1491 Suicide attempt 
T1491XA Suicide attempt, initial encounter 
T1491XD Suicide attempt, subsequent encounter 
T1491XS Suicide attempt, sequelae 
T39012A Poisoning by aspirin, intentional self-harm, initial encounter 
T39012D Poisoning by aspirin, intentional self-harm, subsequent encounter 
T39012S Poisoning by aspirin, intentional self-harm, sequelae 
T39092A Poisoning by salicylates, intentional self-harm, initial encounter 
T39092D Poisoning by salicylates, intentional self-harm, subsequent encounter 
T39092S Poisoning by salicylates, intentional self-harm, sequelae 
T391X2A Poisoning by 4-Aminophenol derivatives, intentional self-harm, initial encounter 
T391X2D Poisoning by 4-Aminophenol derivatives, intentional self-harm, subsequent encounter 
T391X2S Poisoning by 4-Aminophenol derivatives, intentional self-harm, sequelae 
T392X2A Poisoning by pyrazolone derivatives, intentional self-harm, initial encounter 
T392X2D Poisoning by pyrazolone derivatives, intentional self-harm, subsequent encounter 
T392X2S Poisoning by pyrazolone derivatives, intentional self-harm, sequelae 
T39312A Poisoning by propionic acid derivatives, intentional self-harm, initial encounter 
T39312D Poisoning by propionic acid derivatives, intentional self-harm, subsequent encounter 
T39312S Poisoning by propionic acid derivatives, intentional self-harm, sequelae 
T39392A 
Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, 
initial encounter 
T39392D 
Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, 
subsequent encounter 
T39392S 
Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, 
sequelae 
T394X2A 
Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, initial 
encounter 
T394X2D 
Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, subsequent 
encounter 






Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, 
intentional self-harm, initial encounter 
T398X2D 
Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, 
intentional self-harm, subsequent encounter 
T398X2S 
Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, 
intentional self-harm, sequelae 
T3992XA 
Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional 
self-harm, initial encounter 
T3992XD 
Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional 
self-harm, subsequent encounter 
T3992XS 
Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional 
self-harm, sequelae 
T400X2A Poisoning by opium, intentional self-harm, initial encounter 
T400X2D Poisoning by opium, intentional self-harm, subsequent encounter 
T400X2S Poisoning by opium, intentional self-harm, sequelae 
T401X2A Poisoning by heroin, intentional self-harm, initial encounter 
T401X2D Poisoning by heroin, intentional self-harm, subsequent encounter 
T401X2S Poisoning by heroin, intentional self-harm, sequelae 
T402X2A Poisoning by other opioids, intentional self-harm, initial encounter 
T402X2D Poisoning by other opioids, intentional self-harm, subsequent encounter 
T402X2S Poisoning by other opioids, intentional self-harm, sequelae 
T403X2A Poisoning by methadone, intentional self-harm, initial encounter 
T403X2D Poisoning by methadone, intentional self-harm, subsequent encounter 
T403X2S Poisoning by methadone, intentional self-harm, sequelae 
T404X2A Poisoning by other synthetic narcotics, intentional self-harm, initial encounter 
T404X2D Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter 
T404X2S Poisoning by other synthetic narcotics, intentional self-harm, sequelae 
T405X2A Poisoning by cocaine, intentional self-harm, initial encounter 
T405X2D Poisoning by cocaine, intentional self-harm, subsequent encounter 
T405X2S Poisoning by cocaine, intentional self-harm, sequelae 
T40602A Poisoning by unspecified narcotics, intentional self-harm, initial encounter 
T40602D Poisoning by unspecified narcotics, intentional self-harm, subsequent encounter 
T40602S Poisoning by unspecified narcotics, intentional self-harm, sequelae 
T40692A Poisoning by other narcotics, intentional self-harm, initial encounter 
T40692D Poisoning by other narcotics, intentional self-harm, subsequent encounter 
T40692S Poisoning by other narcotics, intentional self-harm, sequelae 
T407X2A Poisoning by cannabis (derivatives), intentional self-harm, initial encounter 
T407X2D Poisoning by cannabis (derivatives), intentional self-harm, subsequent encounter 
T407X2S Poisoning by cannabis (derivatives), intentional self-harm, sequelae 
T408X2A Poisoning by lysergide [LSD], intentional self-harm, initial encounter 
T408X2D Poisoning by lysergide [LSD], intentional self-harm, subsequent encounter 






Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, initial 
encounter 
T40902D 
Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, 
subsequent encounter 
T40902S Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, sequelae 
T40992A Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, initial encounter 
T40992D 
Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, subsequent 
encounter 
T40992S Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, sequelae 
T423X2A Poisoning by barbiturates, intentional self-harm, initial encounter 
T423X2D Poisoning by barbiturates, intentional self-harm, subsequent encounter 
T423X2S Poisoning by barbiturates, intentional self-harm, sequelae 
T424X2A Poisoning by benzodiazepines, intentional self-harm, initial encounter 
T424X2D Poisoning by benzodiazepines, intentional self-harm, subsequent encounter 
T424X2S Poisoning by benzodiazepines, intentional self-harm, sequelae 
T4272XA 
Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, 
initial encounter 
T4272XD 
Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, 
subsequent encounter 
T4272XS 
Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, 
sequela 
T43012A Poisoning by tricyclic antidepressants, intentional self-harm, initial encounter 
T43012D Poisoning by tricyclic antidepressants, intentional self-harm, subsequent encounter 
T43012S Poisoning by tricyclic antidepressants, intentional self-harm, sequelae 
T43022A Poisoning by tetracyclic antidepressants, intentional self-harm, initial encounter 
T43022D Poisoning by tetracyclic antidepressants, intentional self-harm, subsequent encounter 
T43022S Poisoning by tetracyclic antidepressants, intentional self-harm, sequelae 
T431X2A 
Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, initial 
encounter 
T431X2D 
Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, 
subsequent encounter 
T431X2S Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, sequela 
T43202A Poisoning by unspecified antidepressants, intentional self-harm, initial encounter 
T43202D Poisoning by unspecified antidepressants, intentional self-harm, subsequent encounter 
T43202S Poisoning by unspecified antidepressants, intentional self-harm, sequelae 
T43212A 
Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-
harm, initial encounter 
T43212D 
Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-
harm, subsequent encounter 
T43212S 
Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-
harm, sequela 
T43222A Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, initial encounter 
T43222D 
Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, subsequent 
encounter 





T43292A Poisoning by other antidepressants, intentional self-harm, initial encounter 
T43292D Poisoning by other antidepressants, intentional self-harm, subsequent encounter 
T43292S Poisoning by other antidepressants, intentional self-harm, sequelae 
T433X2A 
Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, initial 
encounter 
T433X2D 
Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, 
subsequent encounter 
T433X2S Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, sequelae 
T434X2A 
Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, initial 
encounter 
T434X2D 
Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, 
subsequent encounter 
T434X2S Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, sequelae 
T43502A 
Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, initial 
encounter 
T43502D 
Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, subsequent 
encounter 
T43502S Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, sequelae 
T43592A Poisoning by other antipsychotics and neuroleptics, intentional self-harm, initial encounter 
T43592D 
Poisoning by other antipsychotics and neuroleptics, intentional self-harm, subsequent 
encounter 
T43592S Poisoning by other antipsychotics and neuroleptics, intentional self-harm, sequelae 
T43602A Poisoning by unspecified psychostimulants, intentional self-harm, initial encounter 
T43602D Poisoning by unspecified psychostimulants, intentional self-harm, subsequent encounter 
T43602S Poisoning by unspecified psychostimulants, intentional self-harm, sequelae 
T43612A Poisoning by caffeine, intentional self-harm, initial encounter 
T43612D Poisoning by caffeine, intentional self-harm, subsequent encounter 
T43612S Poisoning by caffeine, intentional self-harm, sequelae 
T43622A Poisoning by amphetamines, intentional self-harm, initial encounter 
T43622D Poisoning by amphetamines, intentional self-harm, subsequent encounter 
T43622S Poisoning by amphetamines, intentional self-harm, sequelae 
T43632A Poisoning by methylphenidate, intentional self-harm, initial encounter 
T43632D Poisoning by methylphenidate, intentional self-harm, subsequent encounter 
T43632S Poisoning by methylphenidate, intentional self-harm, sequelae 
T43692A Poisoning by other psychostimulants, intentional self-harm, initial encounter 
T43692D Poisoning by other psychostimulants, intentional self-harm, subsequent encounter 
T43692S Poisoning by other psychostimulants, intentional self-harm, sequelae 
T438X2A Poisoning by other psychotropic drugs, intentional self-harm, initial encounter 
T438X2D Poisoning by other psychotropic drugs, intentional self-harm, subsequent encounter 
T438X2S Poisoning by other psychotropic drugs, intentional self-harm, sequelae 
T4392XA Poisoning by unspecified psychotropic drug, intentional self-harm, initial encounter 
T4392XD Poisoning by unspecified psychotropic drug, intentional self-harm, subsequent encounter 






Poisoning by unspecified drugs, medicaments and biological substances, intentional self-
harm, initial encounter 
T50902D 
Poisoning by unspecified drugs, medicaments and biological substances, intentional self-
harm, subsequent encounter 
T50902S 
Poisoning by unspecified drugs, medicaments and biological substances, intentional self-
harm, sequelae 
T50992A 
Poisoning by other drugs, medicaments and biological substances, intentional self-harm, 
initial encounter 
T50992D 
Poisoning by other drugs, medicaments and biological substances, intentional self-harm, 
subsequent encounter 
T50992S 
Poisoning by other drugs, medicaments and biological substances, intentional self-harm, 
sequelae 
T5802XA 
Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, initial 
encounter 
T5802XD 
Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, 
subsequent encounter 
T5802XS 
Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, 
sequelae 
T5812XA Toxic effect of carbon monoxide from utility gas, intentional self-harm, initial encounter 
T5812XD 
Toxic effect of carbon monoxide from utility gas, intentional self-harm, subsequent 
encounter 
T5812XS Toxic effect of carbon monoxide from utility gas, intentional self-harm, sequelae 
T582X2A 
Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, 
intentional self-harm, initial encounter 
T582X2D 
Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, 
intentional self-harm, subsequent encounter 
T582X2S 
Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, 
intentional self-harm, sequelae 
T588X2A Toxic effect of carbon monoxide from other source, intentional self-harm, initial encounter 
T588X2D 
Toxic effect of carbon monoxide from other source, intentional self-harm, subsequent 
encounter 
T588X2S Toxic effect of carbon monoxide from other source, intentional self-harm, sequelae 
T5892XA 
Toxic effect of carbon monoxide from unspecified source, intentional self-harm, initial 
encounter 
T5892XD 
Toxic effect of carbon monoxide from unspecified source, intentional self-harm, subsequent 
encounter 
T5892XS Toxic effect of carbon monoxide from unspecified source, intentional self-harm, sequelae 
X710XXA Intentional self-harm by drowning and submersion while in bathtub, initial encounter 
X710XXD Intentional self-harm by drowning and submersion while in bathtub, subsequent encounter 
X710XXS Intentional self-harm by drowning and submersion while in bathtub, sequelae 
X711XXA Intentional self-harm by drowning and submersion while in swimming pool, initial encounter 
X711XXD 
Intentional self-harm by drowning and submersion while in swimming pool, subsequent 
encounter 
X711XXS Intentional self-harm by drowning and submersion while in swimming pool, sequelae 
X712XXA 
Intentional self-harm by drowning and submersion after jump into swimming pool, initial 
encounter 
X712XXD 






X712XXS Intentional self-harm by drowning and submersion after jump into swimming pool, sequela 
X713XXA Intentional self-harm by drowning and submersion in natural water, initial encounter 
X713XXD Intentional self-harm by drowning and submersion in natural water, subsequent encounter 
X713XXS Intentional self-harm by drowning and submersion in natural water, sequelae 
X718XXA Other intentional self-harm by drowning and submersion, initial encounter 
X718XXD Other intentional self-harm by drowning and submersion, subsequent encounter 
X718XXS Other intentional self-harm by drowning and submersion, sequelae 
X719XXA Intentional self-harm by drowning and submersion, unspecified, initial encounter 
X719XXD Intentional self-harm by drowning and submersion, unspecified, subsequent encounter 
X719XXS Intentional self-harm by drowning and submersion, unspecified, sequelae 
X72XXXA Intentional self-harm by handgun discharge, initial encounter 
X72XXXD Intentional self-harm by handgun discharge, subsequent encounter 
X72XXXS Intentional self-harm by handgun discharge, sequelae 
X730XXA Intentional self-harm by shotgun discharge, initial encounter 
X730XXD Intentional self-harm by shotgun discharge, subsequent encounter 
X730XXS Intentional self-harm by shotgun discharge, sequelae 
X731XXA Intentional self-harm by hunting rifle discharge, initial encounter 
X731XXD Intentional self-harm by hunting rifle discharge, subsequent encounter 
X731XXS Intentional self-harm by hunting rifle discharge, sequelae 
X732XXA Intentional self-harm by machine gun discharge, initial encounter 
X732XXD Intentional self-harm by machine gun discharge, subsequent encounter 
X732XXS Intentional self-harm by machine gun discharge, sequelae 
X738XXA Intentional self-harm by other larger firearm discharge, initial encounter 
X738XXD Intentional self-harm by other larger firearm discharge, subsequent encounter 
X738XXS Intentional self-harm by other larger firearm discharge, sequelae 
X739XXA Intentional self-harm by unspecified larger firearm discharge, initial encounter 
X739XXD Intentional self-harm by unspecified larger firearm discharge, subsequent encounter 
X739XXS Intentional self-harm by unspecified larger firearm discharge, sequelae 
X7401XA Intentional self-harm by airgun, initial encounter 
X7401XD Intentional self-harm by airgun, subsequent encounter 
X7401XS Intentional self-harm by airgun, sequelae 
X7402XA Intentional self-harm by paintball gun, initial encounter 
X7402XD Intentional self-harm by paintball gun, subsequent encounter 
X7402XS Intentional self-harm by paintball gun, sequelae 
X7409XA Intentional self-harm by other gas, air or spring-operated gun, initial encounter 
X7409XD Intentional self-harm by other gas, air or spring-operated gun, subsequent encounter 
X7409XS Intentional self-harm by other gas, air or spring-operated gun, sequelae 
X748XXA Intentional self-harm by other firearm discharge, initial encounter 
X748XXD Intentional self-harm by other firearm discharge, subsequent encounter 





X749XXA Intentional self-harm by unspecified firearm discharge, initial encounter 
X749XXD Intentional self-harm by unspecified firearm discharge, subsequent encounter 
X749XXS Intentional self-harm by unspecified firearm discharge, sequelae 
X75XXXA Intentional self-harm by explosive material, initial encounter 
X75XXXD Intentional self-harm by explosive material, subsequent encounter 
X75XXXS Intentional self-harm by explosive material, sequelae 
X76XXXA Intentional self-harm by smoke, fire and flames, initial encounter 
X76XXXD Intentional self-harm by smoke, fire and flames, subsequent encounter 
X76XXXS Intentional self-harm by smoke, fire and flames, sequelae 
X770XXA Intentional self-harm by steam or hot vapors, initial encounter 
X770XXD Intentional self-harm by steam or hot vapors, subsequent encounter 
X770XXS Intentional self-harm by steam or hot vapors, sequelae 
X771XXA Intentional self-harm by hot tap water, initial encounter 
X771XXD Intentional self-harm by hot tap water, subsequent encounter 
X771XXS Intentional self-harm by hot tap water, sequelae 
X772XXA Intentional self-harm by other hot fluids, initial encounter 
X772XXD Intentional self-harm by other hot fluids, subsequent encounter 
X772XXS Intentional self-harm by other hot fluids, sequelae 
X773XXA Intentional self-harm by hot household appliances, initial encounter 
X773XXD Intentional self-harm by hot household appliances, subsequent encounter 
X773XXS Intentional self-harm by hot household appliances, sequelae 
X778XXA Intentional self-harm by other hot objects, initial encounter 
X778XXD Intentional self-harm by other hot objects, subsequent encounter 
X778XXS Intentional self-harm by other hot objects,  sequelae 
X779XXA Intentional self-harm by unspecified hot objects, initial encounter 
X779XXD Intentional self-harm by unspecified hot objects, subsequent encounter 
X779XXS Intentional self-harm by unspecified hot objects, sequelae 
X780XXA Intentional self-harm by sharp glass, initial encounter 
X780XXD Intentional self-harm by sharp glass, subsequent encounter 
X780XXS Intentional self-harm by sharp glass, sequelae 
X781XXA Intentional self-harm by knife, initial encounter 
X781XXD Intentional self-harm by knife, subsequent encounter 
X781XXS Intentional self-harm by knife, sequelae 
X782XXA Intentional self-harm by sword or dagger, initial encounter 
X782XXD Intentional self-harm by sword or dagger, subsequent encounter 
X782XXS Intentional self-harm by sword or dagger, sequelae 
X788XXA Intentional self-harm by other sharp object, initial encounter 
X788XXD Intentional self-harm by other sharp object, subsequent encounter 





X789XXA Intentional self-harm by unspecified sharp object, initial encounter 
X789XXD Intentional self-harm by unspecified sharp object, subsequent encounter 
X789XXS Intentional self-harm by unspecified sharp object, sequelae 
X79XXXA Intentional self-harm by blunt object, initial encounter 
X79XXXD Intentional self-harm by blunt object, subsequent encounter 
X79XXXS Intentional self-harm by blunt object, sequelae 
X80XXXA Intentional self-harm by jumping from a high place, initial encounter 
X80XXXD Intentional self-harm by jumping from a high place, subsequent encounter 
X80XXXS Intentional self-harm by jumping from a high place, sequelae 
X810XXA Intentional self-harm by jumping or lying in front of motor vehicle, initial encounter 
X810XXD Intentional self-harm by jumping or lying in front of motor vehicle, subsequent encounter 
X810XXS Intentional self-harm by jumping or lying in front of motor vehicle, sequelae 
X811XXA Intentional self-harm by jumping or lying in front of (subway) train, initial encounter 
X811XXD Intentional self-harm by jumping or lying in front of (subway) train, subsequent encounter 
X811XXS Intentional self-harm by jumping or lying in front of (subway) train, sequelae 
X818XXA Intentional self-harm by jumping or lying in front of other moving object, initial encounter 
X818XXD 
Intentional self-harm by jumping or lying in front of other moving object, subsequent 
encounter 
X818XXS Intentional self-harm by jumping or lying in front of other moving object, sequelae 
X820XXA Intentional collision of motor vehicle with other motor vehicle, initial encounter 
X820XXD Intentional collision of motor vehicle with other motor vehicle, subsequent encounter 
X820XXS Intentional collision of motor vehicle with other motor vehicle, sequelae 
X821XXA Intentional collision of motor vehicle with train, initial encounter 
X821XXD Intentional collision of motor vehicle with train, subsequent encounter 
X821XXS Intentional collision of motor vehicle with train, sequelae 
X822XXA Intentional collision of motor vehicle with tree, initial encounter 
X822XXD Intentional collision of motor vehicle with tree, subsequent encounter 
X822XXS Intentional collision of motor vehicle with tree, sequelae 
X828XXA Other intentional self-harm by crashing of motor vehicle, initial encounter 
X828XXD Other intentional self-harm by crashing of motor vehicle, subsequent encounter 
X828XXS Other intentional self-harm by crashing of motor vehicle, sequelae 
X830XXA Intentional self-harm by crashing of aircraft, initial encounter 
X830XXD Intentional self-harm by crashing of aircraft, subsequent encounter 
X830XXS Intentional self-harm by crashing of aircraft, sequelae 
X831XXA Intentional self-harm by electrocution, initial encounter 
X831XXD Intentional self-harm by electrocution, subsequent encounter 
X831XXS Intentional self-harm by electrocution, sequelae 
X832XXA Intentional self-harm by exposure to extremes of cold, initial encounter 
X832XXD Intentional self-harm by exposure to extremes of cold, subsequent encounter 
X832XXS Intentional self-harm by exposure to extremes of cold, sequelae 
X838XXA Intentional self-harm by other specified means, initial encounter 
X838XXD Intentional self-harm by other specified means, subsequent encounter 







Appendix M: OUD-Related Infection Codes Queried 
Infection Related to  
Intravenous Drug Use 
ICD-10 
Endocarditis  I33.x 
Candida endocarditis b37.6 
Osteomyelitis m86.x 
Bacteremia R78.81 
Epidural Abscess/ Discitis m46.4; m51.9; m50.x; m51.8 
Septic Arthritis m00. 
Brain Abscess g06.x 
Prosthetic Joint Infection t84.5x  
Necrotizing fasciitis  m72.6 
Empyema  j86 
Lung Abscess  j85 
 






Appendix N: Non-OAT Pharmacotherapy Definitions 
Acronyms 




All formularies and routes of administration were included as present in the dataset. The pre-
opioid variable included the presence of one of these medications: acetaminophen/codeine, 
acetaminophen/hydrocodone, acetaminophen/oxycodone, belladonna/opium, 
chlorpheniramine/hydrocodone, codeine, fentanyl, hydromorphone, meperidine, morphine, 
oxycodone, oxymorphone, tapentadol, and tramadol.  
 
Pre-Benzodiazepine 
All formularies and routes of administration were included as present in the dataset. The pre-
benzodiazepine variable included the presence of one of these medications: alprazolam, 
clonazepam, diazepam, temazepam, and lorazepam. 
 
Pre-Gabapentin/Pregabalin 
All formularies and routes of administration were included as present in the dataset. The 
variable included the presence of one of these medications: gabapentin or pregabalin. 
 
Pre-Naltrexone 
All formularies and routes of administration were included as present in the dataset. The 
variable included the presence of the tablet or injectable or HCPCS code J2315. 
 
Pre-Concurrent Opioid and Benzodiazepine 
Cases with both an opioid and benzodiazepine fill in the time period. 
 
Pre-Naloxone 
All formularies and routes of administration were included as present in the dataset (i.e., 
injection solution, kit, solution nasal spray).  
 
Admission  
Admission Pharmacotherapy  
The majority of inpatient medications reported in this study came from the “Bar Code 
Medication Administration” table. Outpatient appointments are possible during admission; thus, 
resulting in an outpatient pharmacy prescription. In this cohort less than 1% (5,861 of 715,277) 
of medications received during hospitalization were recorded as outpatient prescriptions rather 
than medication administered. 
 
Admission-Opioid 
All formularies and routes of administration were included as present in the dataset (e.g., tablet, 
oral solution, injection, suppository, nasal spray). The admission opioid variable included the 





acetaminophen/oxycodone, belladonna/opium, butorphanol, bupivacaine/fentanyl, codeine, 
fentanyl, hydromorphone, meperidine, morphine, oxycodone, oxymorphone, tapentadol, and 
tramadol.  
 
Any Adjuvant Therapy 
The presence of a first line withdrawal management adjuvant or a second-line adjuvant as 
defined below. 
 
First-Line Adjuvant: Clonidine 
The first-line variable included the presence of clonidine. Patch or tablet formularies were 
included in the query for the dataset. 
 
Second-Line Adjuvant 
The second-line adjuvant was defined using the VHA recommendations for withdrawal 
management for OUD (U.S. Department of Veterans Affairs, 2016b). All formularies and routes 
of administration were included as present in the dataset. The variable included the presence of 
one of these medications: baclofen, gabapentin, pregabalin, and tizanidine. 
 
Admission-Gabapentin/Pregabalin 
All formularies and routes of administration were included as present in the dataset. The 
variable included the presence of one of these medications: gabapentin or pregabalin. 
 
Admission-Benzodiazepine 
All formularies and routes of administration were included as present in the dataset. The 
admission-benzodiazepine variable included the presence of one of these medications: 
alprazolam, clonazepam, diazepam, midazolam, temazepam, and lorazepam. 
 
Admission-Naltrexone 
All formularies and routes of administration (tablet and injectable) were included as present in 
the dataset. HCPCS code J2315 was queried but not present in dataset. 
 
Admission-No Opioid and No OAT 




All formularies and routes of administration (e.g., suppository vs. oral) were included as present 
in the dataset. The post-opioid variable included the presence of one of these medications: 
belladonna/opium, chlorpheniramine/hydrocodone, codeine, fentanyl, hydromorphone, 
meperidine, morphine, oxycodone, oxymorphone, tapentadol, and tramadol. 
 
Post-Gabapentin/Pregabalin 
All formularies and routes of administration were included as present in the dataset. The 










All formularies and routes of administration were included as present in the dataset. The post-
benzodiazepine variable included the presence of one of these medications: alprazolam, 
clonazepam, diazepam, midazolam, temazepam, and lorazepam. 
 
Post-Naltrexone 
All formularies and routes of administration were included as present in the dataset. The 
variable included the presence of the tablet or injectable or HCPCS code J2315. 
 
Post-Naloxone 
All formularies and routes of administration were included as present in the dataset (i.e., 
injection solution, kit, solution nasal spray).  
 
Post-Concurrent Opioid and Benzodiazepine 






Appendix O: OAT Pharmacotherapy Definitions 
Pre-Admission OAT 
Pre-admission OAT included a visit to an VHA OTP (counted by VHA stop code) or Healthcare 
Common Procedure Coding System (HCPCS) codes (H0033: non-specific oral medication direct 
observation; J0574: buprenorphine/naloxone 6.1-10 mg; J0575: buprenorphine/naloxone > 
10mg; J0571: oral buprenorphine 1 mg; S0109: methadone oral 5 mg) or outpatient 
buprenorphine filled prescriptions (only FDA-approved OAT formularies and routes of 
administration were included: buprenorphine film buccal; buprenorphine sublingual tablet; 
buprenorphine/naloxone film sublingual; buprenorphine/naloxone sublingual tablet). 
 
Admission OAT 
Admission OAT was defined as a visit to an VHA OTP (counted by VHA stop code) or HCPCS 
codes (H0033: non-specific oral medication direct observation; J0571: oral buprenorphine 1 mg ; 
S0109: methadone oral 5 mg) or any formulation of buprenorphine or methadone administered 
during admission: buprenorphine sublingual tablet; buprenorphine/naloxone sublingual film; 
buprenorphine/naloxone sublingual tablet; buprenorphine injection; buprenorphine patch; 
methadone injection; methadone solution concentrate; methadone solution oral; methadone 
tablet; methadone tablet effervescent; and methadone unknown formulation. 
 
Post-Admission OAT 
Post-admission OAT included a visit to an VHA OTP (counted by VHA stop code) or HCPCS codes 
(H0033: non-specific oral medication direct observation; J0574: buprenorphine/naloxone 6.1-10 
mg; J0575: buprenorphine/naloxone > 10 mg; J0571: oral buprenorphine 1 mg; S0109: 
methadone oral 5 mg) or outpatient buprenorphine filled prescriptions (only FDA-approved OAT 
formularies and routes of administration were included: buprenorphine film buccal; 
buprenorphine sublingual tablet; buprenorphine/naloxone film sublingual; and 
buprenorphine/naloxone sublingual tablet).  
 
Specific Admission OAT Scenarios 
Using the definitions in this appendix for pre, admission, and post OAT. 
 
• OAT Continuation: OAT delivery in the 30-days prior to and during admission, but not 
after. 
 
• OAT Initiation & Linkage to Care: OAT delivery during admission and post-admission, 
but not prior to admission. 
 
• OAT Sustained: OAT delivery before admission, during admission, and post-admission. 
 






Appendix P: Patient Health & Utilization Definitions 
In-Hospital Mortality 
In-hospital mortality was constructed using the VHA disposition variables (#6 and #7): death 
with autopsy or death without autopsy during index hospitalization.  
 
Left Against Medical Advice 
Left against medical advice was constructed from VHA disposition variables (#2 and #4): 
irregular or NBC or While ASIH (Absent Sick in Hospital).  
 
30-Day Death 
30-day death from index hospitalization discharge was captured from the VHA death data 
sources: died during care provided by the VHA, BIRLS (i.e., national cemetery database), CMS, 
Social Security Administration, VHA Benefits Division, and FEE Basis Care. This does not include 
cases that were registered as having a death but health care resources were utilized post-death.  
 
30-Day Hospital Readmission 
30-day hospital readmission was captured when a patient was re-admitted to a VHA facility for 
acute care within 30 days after the index hospitalization. 
 
30-Day Emergency Department Visit 
30-day emergency department visit was captured when a patient was seen in a VHA Emergency 






Appendix Q: Hospital Characteristic Definitions 
Admission Volume 
The number of admissions in that facility with the study cohort population. 
 
Acute OUD Diagnosis Volume  
The percentage of admissions out of all admissions in that facility with an acute OUD diagnosis. 
As defined in Appendix M as either an OUD-related infection or any OUD diagnosis in the 
primary or secondary admission diagnosis spot.  
 
Hospital Census Region 
Using the hospital state location hospitals were labeled as existing in one of the four U.S. 
Geographic Census Regions (U.S. Census Bureau, 2015): Northeast; Midwest; South; and West. 
 
Hospital Size 
Bed counts for “acute care hospitals” (an additional report produced internally at the VHA) 
included hospitals that had at least 500 acute bed days of care during the year. Bed size was 
collapsed from four categories (1 to 49 beds; 50 to 99 beds; 100 to 199 beds; ³ 200 beds) to 




Appendix R: Sensitivity Analysis: OAT Definition 
The models were re-run using a narrower OAT definition for admission delivery; specifically, 
excluding any non-FDA approved versions of OAT (i.e., injectable formulations of methadone 
and buprenorphine). There were no differences in OAT quartile cut-offs during data preparation. 
 
Model 1: The Variance Component Model. Meaningful differences were not observed for the 
narrower OAT definition. The coefficient was the same (and same direction), as were the 
random effects (ICC: 0.13 vs. 0.13). 
 
Model 2: The Intermediate Model with Level 1 Covariates. There were no differences in the 
intermediate model (Model 2) with regards to covariate direction or statistically significant 
associations; except for the surgical variable. Which was statistically significant in the model 
with the broader OAT definition. There was no difference in the ICC between the two models 
(0.10 vs. 0.10).  
 
Model 3: The Full Model with Level 1 and Level 2 Covariates. There were no differences in the 
final model (Model 3) with regards to covariate direction or statistically significant associations; 
except for, the surgical variable. Which was statistically significant in the model with the broader 




Narrow OAT Definition OR SE Z P 95% CI  
admit_age 1.000299 0.002539 0.12 0.9060 1.00 1.01 
male_dum 1.503346 0.2121659 2.89 0.0040 1.14 1.98 
racecollapse_nonwhite_dum 0.9459724 0.0738042 -0.71 0.4770 0.81 1.10 
racecollapse_unk2_dum 0.8397542 0.149254 -0.98 0.3260 0.59 1.19 
ethnicity_hisp_dum 0.9842062 0.1419715 -0.11 0.9120 0.74 1.31 
ethnicity_unk_dum 1.201423 0.24997 0.88 0.3780 0.80 1.81 
_Ioud_dxinf_1 2.298961 0.1720454 11.12 0.0000 1.99 2.66 
_Icosud_all_1 0.7782597 0.0543631 -3.59 0.0000 0.68 0.89 
_Icomentalh_1 0.9536874 0.0677582 -0.67 0.5050 0.83 1.10 
_Iunintent__1 0.2717729 0.0836167 -4.23 0.0000 0.15 0.50 
_Iwd_codes_1 1.50842 0.206946 3 0.0030 1.15 1.97 
index_los 1.043432 0.0045775 9.69 0.0000 1.03 1.05 
_Iicu_flag_1 0.8893198 0.0745036 -1.4 0.1610 0.75 1.05 
_Isurgery_f_1 0.766244 0.1058284 -1.93 0.0540 0.58 1.00 
admitsource_other_dum 0.8804784 0.1260072 -0.89 0.3740 0.67 1.17 
admitsource_direct_dum 0.9829147 0.0771065 -0.22 0.8260 0.84 1.15 
_Ianyopioid_1 0.5408422 0.0376208 -8.84 0.0000 0.47 0.62 
_Ianyadj_co_1 1.51515 0.1087461 5.79 0.0000 1.32 1.74 
_Ibenzo_1 0.9098837 0.06681 -1.29 0.1980 0.79 1.05 
_Inaltrexon_1 0.3129734 0.1215771 -2.99 0.0030 0.15 0.67 
_Ipre_anyoa_1 15.04093 1.143896 35.64 0.0000 12.96 17.46 
_Ipre_anyop_1 0.482209 0.0418063 -8.41 0.0000 0.41 0.57 
_Ipre_benzo_1 0.9870739 0.1243564 -0.1 0.9180 0.77 1.26 
_Ipre_naltr_1 0.2692671 0.1035082 -3.41 0.0010 0.13 0.57 
_Ipre_gaba_1 0.8937247 0.0687118 -1.46 0.1440 0.77 1.04 
oud_dxinf_rel_vol_percent 0.9824978 0.0069802 -2.49 0.0130 0.97 1.00 
bed_cat_collapse_med_dum 1.89009 0.3410116 3.53 0.0000 1.33 2.69 
 
 381 
bed_cat_collapse_large_dum 1.905646 0.3767839 3.26 0.0010 1.29 2.81 
census_reg_mw_dum 1.25838 0.1970601 1.47 0.1420 0.93 1.71 
census_reg_ne_dum 1.600228 0.2682119 2.81 0.0050 1.15 2.22 
census_reg_w_dum 1.626464 0.2603606 3.04 0.0020 1.19 2.23 
admissions 0.9989553 0.0010102 -1.03 0.3010 1.00 1.00 
_cons 0.0599586 0.0234484 -7.2 0.0000 0.03 0.13 
fac_study_id: var (cons) 0.2176029 0.0507659 - - 1.00 1.01 
 
Output: 
Broader OAT Definition OR SE Z P 95% CI  
admit_age 1.00 0.0025329 0.17 0.86800 1.00 1.01 
male_dum 1.52 0.2151393 2.98 0.00300 1.16 2.01 
racecollapse_nonwhite_dum 0.95 0.0738871 -0.65 0.51600 0.82 1.11 
racecollapse_unk2_dum 0.84 0.1484017 -1 0.31700 0.59 1.19 
ethnicity_hisp_dum 1.02 0.1444581 0.13 0.89700 0.77 1.34 
ethnicity_unk_dum 1.20 0.250349 0.88 0.37700 0.80 1.81 
_Ioud_dxinf_1 2.30 0.1719125 11.170 0.00000 1.99 2.66 
_Icosud_all_1 0.77 0.0537238 -3.730 0.00000 0.67 0.88 
_Icomentalh_1 0.97 0.0684419 -0.49 0.62100 0.84 1.11 
_Iunintent__1 0.29 0.0871154 -4.120 0.00000 0.16 0.52 
_Iwd_codes_1 1.47 0.2013285 2.79 0.00500 1.12 1.92 
index_los 1.04 0.0045693 9.760 0.00000 1.03 1.05 
_Iicu_flag_1 0.88 0.0732433 -1.58 0.11500 0.74 1.03 
_Isurgery_f_1 0.75 0.1041471 -2.06 0.04000 0.57 0.99 
admitsource_other_dum 0.88 0.1255941 -0.92 0.36000 0.66 1.16 
admitsource_direct_dum 0.99 0.0773472 -0.16 0.87600 0.85 1.15 
_Ianyopioid_1 0.53 0.0367234 -9.1700 0.00000 0.46 0.61 
_Ianyadj_co_1 1.52 0.1089526 5.8600 0.00000 1.32 1.75 
_Ibenzo_1 0.92 0.0672824 -1.15 0.24900 0.80 1.06 
_Inaltrexon_1 0.31 0.120364 -3.02 0.00300 0.14 0.66 
_Ipre_anyoa_1 15.26 1.164097 35.720 0.00000 13.14 17.72 
_Ipre_anyop_1 0.49 0.0420021 -8.350 0.00000 0.41 0.58 
_Ipre_benzo_1 1.03 0.1280635 0.25 0.80400 0.81 1.32 
_Ipre_naltr_1 0.26 0.1017697 -3.46 0.00100 0.12 0.56 
_Ipre_gaba_1 0.89 0.0683887 -1.5 0.13300 0.77 1.04 
oud_dxinf_rel_vol_percent 0.98 0.0069608 -2.7 0.00700 0.97 0.99 
bed_cat_collapse_med_dum 1.90 0.3416866 3.560000 0.00000 1.33 2.70 
bed_cat_collapse_large_dum 2.04 0.4020263 3.62 0.00000 1.39 3.00 
census_reg_mw_dum 1.27 0.1978938 1.5 0.13300 0.93 1.72 
census_reg_ne_dum 1.80 0.2990432 3.52 0.00000 1.30 2.49 
census_reg_w_dum 1.62 0.259615 3.03 0.00200 1.19 2.22 
admissions 1.00 0.0010067 -1.47 0.14300 1.00 1.00 
_cons 0.06 0.0243274 -7.11000 0.00000 0.03 0.13 
fac_study_id: var (cons) 0.22 0.05 -- -- 0.14 0.34 
 
